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This thesis is dedicated to my father, Peter McCreery. 
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mine dad. 




“My father gave the greatest gift anyone could give another person, 
he believed in me.” 






Effective rehabilitation strategies are paramount to improve physiological and 
psychological health in pulmonary disease. The aim of this thesis was to 
investigate traditional and alternative pulmonary rehabilitation strategies in 
those with chronic respiratory disease. 
Chapter Four found that traditional pulmonary rehabilitation (PR) was 
physiologically and psychologically effective, regardless of respiratory 
disease, with socioeconomic status being a key determinant of adherence. 
Chapter Five investigated the feasibility and acceptability of IMT. Children 
aged 10.8 ± 0.8 years with Cystic Fibrosis (CF) enjoyed the IMT intervention, 
perceiving improvements in their physical ability and psychosocial health. The 
care team highlighted that future interventions needed to be longer and to 
monitor engagement and adherence. Chapter Six assessed the effectiveness of 
an alternative rehabilitation strategy, using a four-week inspiratory muscle 
training (IMT) intervention, on lung function and heart rate variability in 
children with CF aged 10.8 ± 1.1 years. There were significant and clinically 
meaningful increases in respiratory muscle strength, a clinically meaningful 
decrease in sympathetic modulation, and decreases in respiratory symptoms. 
Subsequently, utilising the formative, physiological and psychological 
findings derived from Chapters Five and Six, an eight-week IMT intervention 
with live biofeedback, performed at 80% maximal inspiratory pressure, three 
times a week was implemented, with an eight-week optional IMT top-up. 
Overall, Chapter Seven found that eight weeks of IMT elicited significant 
increases in respiratory muscle strength, aerobic capacity and in CF-specific 
questionnaire domains in children (11.0 ± 2.2 years) with CF, which were 
maintained following the eight-week top-up period. Chapter Eight 
demonstrated significant improvements in inspiratory muscle strength and 
endurance after eight weeks, with sustained improvements in physiological 
health after 16-weeks in adults with bronchiectasis (64.5 ± 10.3 years). CF and 
bronchiectasis participants demonstrated high levels of adherence and reported 
competency and autonomy. Overall, IMT may be an effective and feasible 
alternative to pulmonary rehabilitation.  
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Respiratory diseases impose a significant health problem across the world, with more 
than 1 billion people worldwide suffering from either acute or chronic respiratory 
conditions (WHO, 2012). Whilst, globally, approximately 4 million people die 
prematurely from chronic respiratory diseases annually (Ferkol & Schraufnagel, 2014; 
WHO, 2014), the United Kingdom (UK) has the highest mortality rate from 
respiratory diseases in Europe (Salciccioli et al., 2018). Respiratory disease therefore 
represents a significant burden to individuals, to society and to the health service; it 
was recently estimated that respiratory diseases cost the NHS £11.1 billion annually 
(Trueman, Woodcock, & Hancock, 2017).  
Chronic respiratory conditions can be separated into two categories; obstructive or 
restrictive lung disease (Figure 1.1). Obstructive lung diseases are characterised by 
increased airway resistance, airway secretions and ventilatory demand, dynamic 
hyperinflation, abnormalities of gas exchange and cardiovascular dysfunction (Dhand, 
2005; Figure 1.1, A). Examples of obstructive lung disease include chronic obstructive 
pulmonary disease (COPD), asthma, bronchiectasis and cystic fibrosis (CF). 
Conversely, restrictive lung diseases, such as interstitial lung disease, sarcoidosis, 
pulmonary fibrosis and silicosis typically present as dyspnoeic with an increased 
respiratory centre drive resulting from decreased lung elasticity (Dimarco, Kelsen, 
Cherniack, & Gothe, 1983; Renzi, Milic-Emili, & Grassino, 1982; Figure 1.1, B). 
Despite having inherently different pathophysiologies, both obstructive and restrictive 
lung disease share a number of common manifestations, such as dyspnoea, coughing, 
fatigue and physical inactivity (Varadi & Goldstein, 2010). Additionally, those with 
chronic respiratory disease often experience secondary peripheral muscular, as well as 
cardiac, nutritional and psychologic impairments, which both individually and in 
combination with the primary respiratory condition can further limit exercise capacity 
and health-related quality of life (HRQoL; Varadi & Goldstein, 2010). This 
subsequently impacts on personal and family health, as well as necessitating increased 




Figure 1.1 Example of A) obstructive and B) restrictive disease flow volume loops. 
Bronchiectasis is a chronic airway disease characterised by permanent destruction and 
dilation of large airways, bronchi and bronchioles (Cohen & Sahn, 1999; Martínez-
García, Soler-Cataluña, Perpiñá-Tordera, Román-Sánchez, & Soriano, 2007). A 
vicious cycle of persistent bacterial colonisation, chronic inflammation of the 
bronchial mucosa and progressive tissue destruction is evident due to the dysfunction 
of mucociliary clearance (Barker, 2002). Impaired lung function in bronchiectasis 
leads to chronic airflow obstruction (Barker, 2002; Martínez-García, Perpiñá-Tordera, 
Román-Sánchez, & Soler-Cataluña, 2005; Wilson, Jones, O’Leary, Cole, & Wilson, 
1997), with the degree of hyperinflation and lung diffusion capacity being independent 
predictors of mortality in this population (Loebinger et al., 2009). It has been reported 
that the presence of bronchiectasis worsens underlying disease prognosis and 
accelerates loss of pulmonary function (King et al., 2005; Mannino & Davis, 2006), 
with frequent exacerbations associated with a rapid decline in lung function (Martinez-
Garcia, Soler-Cataluña, Perpiñá-Tordera, Roman-Sanchez, & Soriano, 2007), 
increased mortality and significantly reduced quality of life (Martínez-García et al., 
2005; Martińez-García et al., 2013). There is an urgent need to identify long-term 
therapies that retard, or ameliorate, this decline in lung function and concomitant 
decrements in quality of life, as well as reduce exacerbations in those with 
bronchiectasis (Gibson, Loddenkemper, Sibille, Lundback, & Flecther, 2013). 
Bronchiectasis is a common feature of a variety of pulmonary diseases, with CF being 
the major inherited disease associated with bronchiectasis (Schafer et al., 2018). 
Indeed, CF is the most common cause of childhood bronchiectasis, with 50-70% of 
CF patients having computed tomography (CT) defined bronchiectasis by three to five 
years of age (Stick et al., 2009). Globally, in up to half of all cases of bronchiectasis 
A. Obstructive Lung Disease B. Restrictive Lung Disease 
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the cause cannot be identified (idiopathic; Schafer et al., 2018). These cases, in 
combination with several other known aetiologies, collectively fall under the category 
of ‘non-cystic fibrosis’ (non-CF) bronchiectasis (Boyton et al., 2016).  
CF is a multisystem genetic disease and the most common monogenetic disease in 
Caucasian populations (Rowe, Hoover, Solomon, & Sorscher, 2016). The disease is 
caused by mutations in the cystic fibrosis transmembrane conductance regulator 
(CFTR) protein, which results in abnormal ion transport (Cutting, 2015). The altered 
fluid and salt transport properties alter cell-lining fluid and mucous qualities, leading 
to chronic upper and lower respiratory tract infection, bronchiectasis and end-stage 
lung disease (Molina & Hunt, 2017; Rowe et al., 2016). The progressive decline in 
lung function in those with CF has been linked to inflammatory-mediated airflow 
obstruction, yet emerging evidence suggests that inspiratory muscle weakness plays a 
key role (Sovtic, Minic, Markovic-Sovtic, & Trajkovic, 2018). Specifically, 
mechanical disadvantage is evident in those with CF due to airflow obstruction, which 
engenders hyperinflation, leading to sub-optimal shortening of the inspiratory muscles 
(Sharma et al., 2001). Therefore, strategies to address this inspiratory muscle 
weakness and mechanical disadvantage are of vital importance to improve quality of 
life (QoL; Zemanick et al., 2010) and even life expectancy (Cohen-Cymberknoh, 
Shoseyov, & Kerem, 2011). 
Physical activity (PA) has been shown to positively impact the health and well-being 
of those with chronic respiratory conditions (Arne et al., 2009; O’Donovan et al., 
2010). Indeed, in CF, increased PA levels have been associated with slower rates of 
decline in lung function (Wilkes, Scheniderman-Walker, Corey, 2007) and, 
consequently, longer survival (Nixon, Orenstein, Kelsey, & Doershuk, 1992). 
Moreover, those with bronchiectasis who undertake PA show improved physiological 
and psychological health compared to their peer who didn’t partake (Lee, Hill, 
McDonald, & Holland, 2017; Mandal et al., 2012; Patel et al., 2019b). However, 
despite the importance of PA, there is little consensus regarding PA levels in those 
with CF, especially in children, with some reporting lower volumes of habitual PA 
(Aznar et al., 2014; Nixon, Orenstein, & Kelsey, 2001) whilst others found no 
significant differences (Jantzen et al., 2016; Mackintosh, Ridgers, Evans, & McNarry, 
2018; Selvadurai, Blimkie, Cooper, Mellis, & Van Asperen, 2004) compared to their 
healthy peers. Indeed, current PA promotion in CF is limited to informal discussion 
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and generic advice as current assessments in CF clinics are not sufficient to provide 
information about habitual PA (Shelley et al., 2018). Habitual PA levels are less 
equivocal in the bronchiectasis population who are generally reported to be largely 
inactive, with few meeting PA guidelines (Bradley et al., 2015), and a significant 
proportion showing marked decreases in exercise tolerance and PA levels (Burtin & 
Hebestreit, 2015; Pehlivan, Niksarlıoğlu, Balcı, & Kılıç, 2019). Poor engagement in 
PA in both CF and bronchiectasis could be attributed to numerous factors, including, 
but not limited to, treatment burden, which increases with age and disease severity 
(Roberts & Hubbard, 2010; Williams & Stevens, 2013). Further research is important 
as the impact of disease on mental health and well-being, with mental state shown to 
affect compliance to treatments and, eventually, morbidity and mortality (de Bruyne, 
Eg, & Thavagnanam, 2017; Quittner et al., 2014). Therefore, it is imperative to 
ascertain the views of those with CF and bronchiectasis regarding PA and their 
involvement in interventions to ensure long-term adherence. 
Perhaps one of the most widely implemented, non-pharmacological interventions for 
those with respiratory disease, pulmonary rehabilitation (PR) is a multi-faceted 
intervention incorporating education, behaviour change and exercise training 
components. Considerable research has focused on the utility of PR for those with 
respiratory diseases, with evidence regarding those with chronic obstructive 
pulmonary disease (COPD) considered relatively conclusive (Lacasse, Cates, 
McCarthy, & Welsh, 2015). However, the transferability of traditional PR 
programmes to other respiratory conditions largely remains to be elucidated. In 
bronchiectasis, PR is suggested to be associated with improvements in HRQoL, 
exercise capacity, clinical symptoms and frequency of exacerbations (Lee et al., 2017). 
In CF, PR may increase aerobic fitness (Klijn et al., 2004; Selvadurai et al., 2002), 
decrease the rate of decline, or indeed improve, lung function (Moorcroft, Dodd, 
Morris, & Webb, 2004; Schneiderman-Walker et al., 2000) and improve HRQoL 
(Selvadurai et al., 2004). However, many of these studies are characterised by 
potentially biased samples, with many patients either refusing to enrol on, or not 
completing, the PR programme (Steiner et al., 2017). Whilst the reason for this lack 
of engagement is unclear, high treatment burdens associated with CF and 
bronchiectasis may preclude patients from adhering to regular exercise and 
educational programmes (Metersky & ZuWallack, 2019). Moreover, chronic 
25 
 
respiratory diseases are highly varied, with differing aetiologies; the composition of 
PR programmes may, therefore, not be transferable from COPD. Indeed, the 
magnitude of effect in those studies that have reported beneficial effects of PR in other 
respiratory disease is, in general, considerably smaller than those elicited in COPD 
(Holland, Wadell, & Spruit, 2013). The considerable inter-study heterogeneities in PR 
composition, limits the interpretation of PR effectiveness in different respiratory 
conditions or the identification of whether the varying success is due to programme 
variations, adherence or disease-specific factors. Therefore, the acceptability and 
transferability of PR to respiratory diseases, other than COPD, is questionable. 
Alternative interventions that provide similar physiological and psychological 
benefits, whilst being time-efficient and, preferably, home-based, would be 
advantageous for these populations.  
One alternative method to PR that has received increasing attention in clinical 
populations is inspiratory muscle training (IMT), which is a low cost and time-
efficient training method (Polkey, Moxham, & Green, 2011). By utilising a restricted 
airflow breathing technique, IMT increases the load placed on the intercostal muscles 
and diaphragm, stimulating a hypertrophic response (Enright, Unnithan, Heward, 
Withnall, & Davies, 2006). Given that the force a skeletal muscle can generate 
depends on how effective it is at applying tensile force to a cross-sectional area 
(Rochester, 1988), stimulating a hypertrophic response in the inspiratory muscles and 
increasing their cross-sectional area may delay, or reverse, the complications of 
impaired inspiratory muscle function (Enright, Chatham, Ionescu, Unnithan, & Shale, 
2004). Furthermore, a reduction in lung function and increased inspiratory muscle 
fatigue has been associated with an increase in metaboreflex resulting in sympathetic 
overactivity in those with bronchiectasis and COPD, suggesting an increased 
cardiorespiratory risk (Rached et al., 2015). Previous research has hypothesised that 
improving respiratory muscle function through IMT may, potentially, increase fatigue 
resistance and lessen sympathetic outflow (Ferreira et al., 2013). Therefore, if IMT 
has the potential to improve heart rate variability (HRV), it may improve lung function 
in those with CF and bronchiectasis, or vice-versa.  
Previous research has shown equivocal results regarding the potential utility of IMT 
in both CF and bronchiectasis. Specifically, improvements in respiratory muscle 
strength and HRQoL have been reported in CF (Asher, Pardy, Coates, Thomas, & 
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Macklem, 1982; Bieli, Summermatter, Boutellier, & Moeller, 2017; De Jong, Van 
Aalderen, Kraan, Ko Ter, & Van Der Schans, 2001) and bronchiectasis (Liaw et al., 
2011; Newall, Stockley, & Hill, 2005; Ozalp et al., 2019). Furthermore, improvements 
in vital capacity have been reported in CF (Sawyer & Clanton, 1993) and 
improvements in endurance and exercise capacity have recently been found in 
bronchiectasis (Ozalp et al., 2019). Nonetheless, Bieli and colleagues (2017) recently 
concluded that regular respiratory muscle endurance training was not supported in 
children with CF, with a recent Cochrane review also highlighting that the effect of 
IMT in CF is inconclusive due to insufficient evidence (Hilton & Solis-Moya, 2018). 
However, it is pertinent to note that, despite  lung function decline on those with CF 
being manifest from early adolescence (Welsh, Robertson, & Ranganathan, 2014), 
there has been an almost exclusive focus on the effect of IMT in middle-aged 
populations with CF, with little known regarding its impact in youth. Indeed, there are 
significant physiological and age-related differences that may affect the plasticity and 
response to IMT, therefore, the current findings in adults with CF are unlikely to 
applicable to youth (Shei, Dekerlegand, Mackintosh, Lowman, & McNarry, 2019). 
In bronchiectasis, it has been reported that the beneficial effects of IMT are limited to 
improvements in inspiratory and expiratory muscle strength (Liaw et al., 2011), or 
conversely, that IMT adds no additional advantage to those obtained through PR 
(Newall, Stockley, et al., 2005). The conflicting findings regarding the effectiveness 
of IMT, and inter-disease variability, are likely to be attributable to inter-study 
differences in the type of inspiratory muscle training (strength or endurance) and the 
intensity, duration and frequency of training. Furthermore, the equivocal findings 
regarding the effectiveness of IMT are also likely to be attributable to a lack of control 
of workload (Smith, Cook, Guyatt, Madhaven, & Oxman, 1991) or the volume at 
which training is applied (Hart et al., 2001), a failure to maintain overload on the 
inspiratory muscles throughout (Chatham, Baldwin, Griffiths, Summers, & Enright, 
1999) and a lack of reporting of adherence or participant’s perceptions. Inspiratory 
muscles are morphologically and functionally skeletal muscles and therefore adopting 
general training theory, inspiratory muscle gains should be achieved at 80-90% of 
maximal inspiratory pressure (MIP) whilst strength and/or endurance gains would be 
anticipated to be elicited at 60-80% of MIP, which is comparable to high-intensity 
training regimes in systemic exercise (Kraemer et al., 2002). When these physiological 
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training principles are applied to IMT, increases in lung volume, strength, total lung 
capacity and exercise capacity have been found in adults with CF (Enright, 2001), 
however whether this applicable to children with CF or those with bronchiectasis 
remains to be elucidated. More empirical research is required to ascertain whether 
IMT is a plausible intervention for those with a chronic respiratory condition. 
 
1.1 General Aim 
 
The overarching aim of this thesis was to investigate non-pharmacological strategies 
to enhance health and well-being in those with chronic respiratory conditions. 
Specifically, the aim was to determine whether the effectiveness of conventional PR 
was dependent on respiratory condition and to determine the acceptability and 
effectiveness of inspiratory muscle training as an alternative treatment method in those 
with a chronic respiratory condition. The specific aims of the experimental chapters 
















Table 1.1 Experimental study aims 
 Aims 
Chapter 4 To investigate the effectiveness and feasibility of PR in respiratory 
diseases other than COPD. 
Chapter 5 To investigate the physiological and psychological effect of a pilot 
IMT intervention on HRV and respiratory function in children with 
CF. 
Chapter 6 To elicit the perceptions and experiences of children, adolescents, and 
their multi-disciplinary team on their experiences of an IMT 
intervention. 
Chapter 7 To investigate the physiological and psychological effects of an 8-
week high-intensity IMT intervention in children with cystic fibrosis. 
Chapter 8 To determine the physiological and psychological effects of a high-




















2.1 Introduction to Obstructive Pulmonary Diseases  
The anatomical and functional development of the respiratory system is susceptible to 
harmful infection, inflammation and trauma, as well as genetic disorders (Merkus et 
al., 2004). The potential resultant structural and/or functional damage to the lungs and 
airways is dependent on several factors, such as the timing, severity, duration of the 
damage, the host response and subsequent repair process and the effects of initial and 
chronic treatments (Merkus et al. 2004). Obstructive disease of the airways often result 
in weakness of the respiratory muscles, the advancement of which can result in 
respiratory muscle failure, which is ultimately fatal (Laghi & Tobin, 2003).  
2.1.1 Pathophysiology of Non-Cystic Fibrosis Bronchiectasis  
Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
drive the earliest pathogenic events in epithelial cells that ultimately lead to the 
emergence of bronchiectasis (Schafer et al., 2015). Bronchiectasis is a major chronic 
pulmonary disease defined by infection, inflammation and the presence of chronic 
dilation of the bronchial wall (Chandrasekaran, Aogáin, Chalmers, Elborn, & 
Chotirmall, 2018). It is characterised by mild to moderate airflow obstruction (King, 
Holdsworth, Freezer, Villanueva, & Holmes, 2006) that usually worsens over time (de 
Vries, Chang, & Marchant, 2018; Wurzel et al., 2014). Clinical features include 
shortness of breath, cough, chronic daily sputum production and recurrent respiratory 
infection leading to increased morbidity and deterioration of quality of life (QoL; 
Keistinen, Säynäjäkangas, Tuuponen, & Kivelä, 1997; Lonni et al., 2015). 
Bronchiectasis has a wide range of causes and comorbidities, including, but not limited 
to, previous severe respiratory infection, impairment of ciliary clearance, allergic 
bronchopulmonary aspergillosis, and primary or secondary immunodeficiency (Lonni 
et al., 2015). Bronchiectasis can be found in a variety of pulmonary diseases, both 
genetically caused and acquired, such as severe pulmonary infections and CF, as well 
as being a feature of chronic obstructive pulmonary diseases, severe asthma or primary 
immunodeficiencies (Chalmer et al., 2015; Sidhu et al., 2014; McShane et al., 2013). 
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In children with CF, structural damage in the lungs associated with bronchiectasis has 
been evidenced in those as young as 10 weeks of age (Mott et al., 2012; Sly et al., 
2009; Stick et al., 2009; Davis et al., 2007). In 50-70% of children with CF aged 3-5 
years, CT defined bronchiectasis is evident (Mott et al., 2012; Stick et al., 2009; 
Wainwright et al., 2011). Despite receiving the best current respiratory therapy, 
bronchiectasis persists and progresses in approximately 75% of young children (Mott 
et al., 2012).  The cause is unknown in half of all cases of bronchiectasis worldwide. 
Therefore, idiopathic cases together with other known aetiologies such as post-
infectious and allergic hypersensitivity, fall under the category of non-CF 
bronchiectasis (Boyton & Altmann, 2016). 
The most widely known model for the pathophysiology leading to bronchiectasis is 
termed “the vicious cycle hypothesis” (Cole, 1986). This model suggests that in, a 
genetically predisposed individual, an environmental insult stimulates a robust 
inflammatory response to pulmonary infection or damage, leading to subsequent 
structural damage that results in impaired muco-ciliary clearance (King, 2009). This 
subsequently leads to more infections and a cycle of progressive inflammation causing 






























Figure 2.1 Cycle of infection and inflammation in bronchiectasis. Based on the "vicious 
cycle hypothesis" described by Cole (1986). 
31 
 
Those with bronchiectasis present with respiratory muscle weakness (Liaw et al., 
2011; Moran, Piper, Elborn, & Bradley, 2010; Newall, Stockley, & Hill, 2005), the 
underlying cause of which is unknown. It has been postulated that the cause of loss in 
strength is primary and hyperinflation-related functional weakness (O’Shea, Taylor, 
& Paratz, 2004). Inspiratory muscle weakness could lead to discordance between 
muscle loading and capacity, resulting in decreased exercise tolerance, 
hypoventilation, dyspnoea, and, ultimately, respiratory failure (Ozalp et al., 2019). A 
decrease in expiratory muscle strength diminishes the effectiveness of coughing and 
decreases the removal of airway secretions (Moran et al., 2010; Troosters, Gosselink, 
& Decramer, 2005). Subsequent airway obstruction and air trapping may be 
responsible for reduced diffusion capacity (Loubeyre et al., 1996), which has been 
attributed to a reduction in forced expiratory volume in one second (FEV1; Roberts et 
al., 2000). 
Previous studies have found that women have an increased predisposition to 
developing bronchiectasis, but that the rate of lung damage progresses at the same rate 
in both sexes (Quint et al., 2016; Pasteur et al., 2000). Since 2004, the incidence of 
bronchiectasis in women has increased from 21.24 per 100,000 person-years to 35.17 
per 100,000 person-years in 2013, and from 18.19 to 26.92 per 100,000 person-years 
in men, in the UK alone (Quint et al., 2016). As the incidence of bronchiectasis 
increases (Seitz, Olivier, Adjemian, Holland, & Prevots, 2012; Weycker, Edelsberg, 
Oster, & Tino, 2005), hospital admissions (Ringshausen et al., 2013) and mortality 
(Roberts & Hubbard, 2010) continues to rise.  
2.1.2 Pathophysiology of Cystic Fibrosis   
Cystic Fibrosis (CF) is the most common autosomal recessive disease in Caucasian 
populations (Donaldson & Boucher, 2007). In 1985, the genetic defect responsible for 
CF was localised to the long arm of chromosome 7; the gene was named cystic fibrosis 
transmembrane conductance regulator (CFTR) and was subsequently identified by 
full length sequencing in 1989 (Kerem et al., 1989; Riordan et al., 1989; Rommens et 
al., 1989). To date, more than 2,023 mutations have been identified in the CFTR 
mutation database (http://www.genet.sickkids.on.ca), however, the majority of these 
mutations are rare and their pathomechanisms remain poorly understood. The most 
common mutation worldwide is the ΔF508 mutation, caused by the depletion of 
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phenylalanine in position ΔF508 (Ratjen, 2009). Within the UK, 89.5% of people with 
CF have the ΔF508 mutation; 4,789 (49.1%) and 3,882 (40.4%) of which are 
homozygous and heterozygous, retrospectively (Jeffery, Charman, Cosgriff, & Carr, 
2017).  
CFTR codes for a protein by the same name that belongs to a family of adenosine 
triphosphate (ATP) binding cassette proteins (Filbrun, Lahiri, & Ren, 2016) and is 
found in the membranes of cells that line the passageways of the lungs, liver, pancreas, 
intestines, reproductive tract and skin. CFTR’s primary role is the regulation of ion 
transport across cell membranes in mucosal surfaces (Donaldson & Boucher, 2007). 
Given CFTR’s role as a key regulator of salt and water transport across multiple 
epithelia, abnormalities in its function result in the alteration of the ion transport 
necessary for the appropriate function of the epithelial structures (Griesenbach, Pytel, 
& Alton, 2015). This alteration results in less chloride secretion out of, and less water 
transport in to, the epithelial surface layer, due to ion transport creating an osmotic 
gradient (Boucher, 2007). CF mutations are influenced by modifier genes (Collaco & 
Cutting, 2008; Cutting, 2010), environmental factors (Kopp et al., 2015) and the 
socioeconomic status of patients (Barr, Britton, Smyth, & Fogarty, 2011; Schechter, 
Shelton, Margolis, & FitzSimmons, 2001; Veit et al., 2016). CFTR mutations can be 
grouped into six distinct classes, dependent on their functional consequences on the 
CFTR within the cell 
• Class I mutations cause changes in the synthesis of CFTR by affecting the 
CFTR transcription. 
• Class II mutations involves those that affect the processing of CFTR. 
• Class III affects the regulation of CFTR, specifically the binding of ATP to the 
nucleotide binding domains (NBDs) which are required to activate CFTR. 
Mutations that affect CFTR interaction with ATP have been shown to alter this 
binding function (Drumm et al. 1991; Anderson & Welsh 1992). 
• Class IV mutations alter chloride conduction properties of CFTR, resulting in 
changes to the CFTR protein structure that forms the pore of the channel. This 
‘misshaped’ CFTR pore can restrict the movement of chloride ions (CI-




• Class V mutations result in extremely reduced amounts of normal CFTR 
protein that can be synthesised, resulting in less protein at cell surface, and is 
associated with a milder form of CF. 
• Class VI mutations destabilise the channel in post- endoplasmic reticulum  
compartments and/or plasma membrane (PM), resulting in accelerated PM and 
reduced apical PM expression (Silvis et al., 2003).  
The frequency of CFTR mutation classes varies considerably. De Boeck and 
colleagues (2014) found that 80% of those with CF in European countries had at least 
one class II mutation containing ΔF508. At least 16.4% of those with CF have at least 
one class I mutation, and 2.9%, 3.3% and 3.0% for class III, IV and V, respectively 
(De Boeck, Zolin, Cuppens, Olesen, & Viviani, 2014). Furthermore, genotypes which 
result in partial functioning CFTR (classes IV, V) are usually associated with a milder 
phenotype and, subsequently, later diagnosis (Kerem & Kerem, 1996). Over the past 
10 years, modulators of CFTR protein function have progressively transformed the 
outcome and quality of life of those with CF (Elborn, 2016). There are a number of 
modulators dependent on an individual’s genotype mutation: (i) ivacaftor for 
individuals with sequence variants associated with class III mutation; (ii) combination 
therapies in individuals homozygous for ΔF508 such as lumacaftor/ivacaftor or 
tezacaftor/ivacaftor; and (iii) a triple combination therapy (tezacaftor/ivacaftor and 
elexacaftor), which has been shown to be a highly effective modulator treatment for 
individuals with at least one ΔF508 mutation and more robust compared to 
tezacaftor/ivacaftor alone. These modulators have shown improvements in quality of 
life, reduced pulmonary exacerbations and variable improvement FEV1 in those with 
CF (Elborn, 2020). These drugs have revolutionised the treatment of CF, which is 
likely to evolve over the next decade as modulator treatment is more widely 
implemented.  
Lung cilia are bathed in airway surface liquid, the depth and composition of which is 
regulated by the CFTR. Airway surface liquid possesses a mucus component that traps 
inhaled particles, and, therefore, mucus clearance is an essential component of the 
lung’s innate defence system against disease. The rate of mucociliary clearance is 
dependent on the rate of ciliary beating (Matsui, Davis, Tarran, & Boucher, 2000), as 
well as the hydration state of airway surface liquid/mucus (Kilburn, 1968; Puchelle, 
de Bentzmann, & Zahm, 1995; Spring, 1999). Mucus hydration is dependent on the 
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volume of liquid present on the airway surface, which is modified by active ion 
transport (Spring, 1999). 
In CF, the volume of airway surface liquid is depleted, resulting in the cilia being less 
efficient at moving particles and mucus (Boucher 2007). Specifically, abnormalities 
in ion transport, including a reduction in chloride secretion and increased sodium 
absorption, coupled with low airway surface liquid, results in abnormally viscous 
mucus secreted by the submucosal glands and epithelial cells (Cutting & Zeitlin, 
2012). In healthy people, the submucosal glands produce mucus in the form of strands, 
which initiate the movement of large particles, facilitating their removal from the 
airways (Fischer et al., 2019). However, in those with CF, the insufficient airway 
luminal liquid prevents the release of the mucus strands from the glands, leading to 
tethering of mucus to the gland ducts (Cantin, Hartl, Konstan, & Chmiel, 2015; 
Hoegger et al., 2014; Figure 2.2). The subsequent mucus build-up provides a rich 
environment for bacterial infections leading to chronic and persistent 
bronchopulmonary infections such as Pseudomonas aeruginosa (P.aeruginosa), 
Staphylococcus aureus, and Burkholderia complex. These infections lead to chronic 
airway and systemic inflammation, destruction of tissue and respiratory insufficiency 







Figure 2.2 Chest computed tomography showing individuals with A) healthy lungs 
and B) cystic fibrosis lungs, showing peribronchial thickening and mosaic attenuation 
due to small airway disease. 
 
A decline in lung function due to recurrent vicious cycles of lung infection, 







those with CF, (Dinwiddie, 2000). Indeed, even before symptom onset in CF, 
pulmonary inflammation and infection are often present, although what manifests first 
is still unclear (Khan et al. 1995; Balough et al. 1995; Armstrong et al. 1997; Stoltz et 
al. 2015). As CF progresses, lung function deteriorates (Holford, 2013), as reflected 
by changes in forced expiratory volume in one second (FEV1), which has been 
suggested to be predictive of mortality in CF (Sanders & Goss, 2013). A recent 
systematic review found that the relationship between the decline in FEV1%predicted 
and age was not static or directly proportional, but a non-linear dynamic and time-
varying relationship. Specifically, the highest, and most stable, lung function was 
evident between 5-10 years of age, with the steepest decline in FEV1%predicted from 
11 to 15 years of age, with a continued, albeit less rapid, subsequent decline up to 30 
years of age (Harun, Wainwright, Klein, & Hennig, 2016). In those > 30 years of age, 
FEV1%predicted was shown to be relatively stable (Harun et al., 2016).  
Lung function remains the single most important predictor of survival in CF, with 
those exhibiting an FEV1 of <30% predicted reportedly having 50% increased risk of 
mortality (Kerem, Reisman, Corey, Canny, & Levison, 1992). However, more recent 
research utilising UK CF registry data found that 50% of individuals with an FEV1 
below 30% predicted lived > 5.3 years, a 4.1 year increase from 1990 (Elborn, Shale, 
& Britton, 1991; George et al., 2011). This discrepancy could be attributed to 
improved pharmacological treatments, the comprehensive multidisciplinary CF care 
now part of the treatment routine or the eradication of P.aeruginsosa (Stephenson et 
al., 2015). It is also pertinent to note that reduced exercise capacity has been shown to 
predict both mortality and an increased risk for hospitalisation, independent of lung 
function (Pérez et al. 2014; Pianosi et al. 2005; Nixon et al. 1992). Therefore, these 
interstudy discrepancies may also reflect the growing recognition of the importance of 
physical activity (PA) and exercise promotion in the treatment strategies of those with 
CF. 
Interestingly, sex may influence disease progression and prognosis in those with CF, 
with females suggested to demonstrate a higher mortality rate than their male 
counterparts (Corey & Farewell, 1996; Marshall et al., 2005; Morgan et al., 1999; 
Sweezey & Ratjen, 2014). Demko et al. (1995) demonstrated that females with CF 
acquired chronic P.aeurginosa at an earlier age (median of 9.5 years) in comparison 
to males (median of 11.2 years) and had a more rapid decline in lung function after 
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P.aeruginosa colonisation. Moreover, females have shown a more rapid decline in 
FEV1%predicted during adulthood in comparison to males (Harun et al. 2016). In 
youth, girls with CF have a lower peak capacity than boys with CF at the same age 
(Orenstein & Nixon, 1991), which may be of relevance as aerobic capacity is an 
important predictor of survival in this population (Nixon et al., 1992). Sex differences 
have also been reported in body composition in those with CF. Specifically, females 
have a higher risk of an abnormal BMI (Harness-Brumley et al., 2014), with impaired 
nutritional status evident in CF girls aged 8 years, compared to CF boys whose BMI 
remain close to the WHO normative reference values up to the age of 10 years (Boёlle 
et al., 2012). Moreover, the effect of a low lean body mass appears to differ according 
to sex, with deleterious consequences only evident in females when they were below 
the 50th percentile, whereas, in males, any decline in lean body mass is reported to be 
associated with worse pulmonary function (Sheikh et al., 2014). However, several 
reports have refuted the continued presence of a gender gap in CF outcomes, 
suggesting that improved airway clearance therapies have narrowed the gender bias 
(Harun et al., 2016; Sanders et al., 2014), yet a recent study found that male sex was 
associated with better survival at diagnosis, but only in ΔF508 non-homozygotes 
(Keogh et al., 2018). If a gender gap is evident, it has been postulated that this may be 
predominately related to a differential effect of sex hormones on inflammation and 
nutritional status in CF (Sweeney & Ratjen, 2014). Indeed, oestrogen has been 
implicated as a hormone that decreases airway surface liquid on the bronchial 
epithelial cells, thereby enhancing mucus viscosity (Harness-Brumley et al., 2014; 
Nick et al., 2010). Furthermore, oestrogen has been shown to promote P.aeruginosa 
from a nonmucoid to mucoid form that is more pathogenic and drug resistant (Assael, 
2002; Verma, Bush, & Buchdahl, 2005). Further research is needed to further 
understand the interrelationships between sex, disease severity, aerobic fitness, and 
lung function. 
Forty years ago, CF was almost exclusively a paediatric disease but now more 
paediatric patients are surviving to adulthood with the life expectancy having 
increased from <5 years of age in 1972 to 47 years in 2017 (Stephenson, Stanojevic, 
Sykes, & Burgel, 2017). With this ever-increasing adult population, the individual 
psychological and physiological burden of living with a chronic illness has led to 
increases in CF-related comorbidities, such as pulmonary disease, renal disease, 
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metabolic bone disease, CF-related diabetes, cancers, drug allergies and toxic effects, 
and complications associated with lung transplantation (Elborn, 2016; Plant, Goss, 
Plant, & Bell, 2013; Ronan, Elborn, & Plant, 2017). Therefore, interventions that 
could help combat these comorbidities and improve overall health are paramount. 
2.1.3 Pharmacological and Non-Pharmacological Interventions for those with 
Obstructive Pulmonary Disease   
Respiratory diseases are leading causes of death and disability in the world (Forum of 
International Respiratory Societies [FIRS], 2012), with an estimated 1 billion people 
suffering from either acute or chronic respiratory conditions (Wang et al., 2016). 
Medical advancements have increased the length and QoL in those suffering from 
respiratory disease, however, changing lifestyles, manifestations of disease, new types 
of infections and changing environments have created new challenges (FIRS, 2012).  
Medical treatment for respiratory diseases often incorporates a comprehensive 
approach aiming to reduce symptoms, improve QoL and prevent exacerbations, which 
are associated with worsening outcomes. Some standard pharmacological treatments 
for respiratory disease include: (i) airway clearance techniques involving either a 
physical or mechanical means to manipulate airflow to aid in the mobilisation of 
secretions and facilitate evacuation by coughing, helping to prevent further 
inflammation and infection (Volsko, 2013); and (ii) bronchodilators, which are short- 
or long-acting beta-2 agonists that aim to relax the smooth muscle of the airway, 
allowing better airflow for a period, however consistent use of beta-2 agonists for 
extended periods reduces their efficacy due to the downregulation of the beta-2 
receptor in the airways (Kim & Story, 2016); and (iii) inhaled Corticosteroids which 
are often used in combination with long-acting beta-2-agonists to reduce the risk of 
exacerbation and improve lung function and health status (Tashkin & Strange, 2018). 
For respiratory disease, treatment is individualised and based on the availability of 
existing drugs, disease severity, patient preferences, drug interactions, and 
comorbidities (Fernandes et al., 2017). 
Medical advancements have brought considerable costs that have threatened the 
financial health of many nations (FIRS, 2012). Specifically, the total cost of 
respiratory disease in the European Union exceeds €380 billion (Gibson et al., 2013). 
Therefore, non-pharmacological management must be utilised to reduce 
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pharmacological costs. Indeed, non-pharmacological therapy has been shown to 
provide symptomatic improvements and better QoL in those with chronic respiratory 
conditions (Safka & McIvor, 2015). There is a vast range of non-pharmacological 
treatment methods for those with chronic respiratory conditions. Popular non-
pharmacological treatment options include: (i) oxygen therapy, which is a widely used 
treatment method for patients with advanced respiratory disease and is used for the 
relief of symptoms and prolongation of survival (Gibson et al., 2013); (ii) smoking 
cessation to halt the progression of lung function decline and has been shown to have 
a mortality benefit, however, the rates of success of current smokers maintaining a 
smoke-free lifestyle remains low (Safka & McIvor, 2015); (iii) physiotherapy is the 
most popular non-pharmacological treatment of respiratory diseases. It is particularly 
helpful as an aid for clearing bronchial secretions. There are a variety of physiotherapy 
techniques used including postural drainage and forced expiration, which can be 
completed regularly at home (Gibson et al., 2013); (iv) pulmonary rehabilitation (PR) 
that focuses on exercise capacity, muscular strength, nutrition, education and 
psychological health has been shown to be successful in a range of respiratory disease 
(Gibson et al., 2013). Given the multi-faceted nature of PR it often requires input from 
occupational therapists, physiotherapists, dietitians, physicians, specialist respiratory 
nurses and smoking cessation counsellors  (Hill, Vogiatzis, & Burtin, 2013). However, 
more research is required in order to evaluate the benefits of PR in respiratory diseases 
other than COPD while understanding the optimal schedule and the maintenance of 
benefits on a long-term basis (Gibson et al., 2013). 
2.2 Physical Activity and Exercise for Cystic Fibrosis and Non-Cystic Fibrosis 
Bronchiectasis  
 
PA is defined as any bodily movement produced by the skeletal muscles, resulting in 
a substantial increase in energy expenditure above resting, while exercise is defined 
as regular participation to improve physical performance, cardiovascular function or 
muscle strength, or any combination thereof (Caspersen, Powell, & Christenson, 
1985). There are several challenges to exercise prescription and PA promotion in 
patients with chronic respiratory conditions, due in part to the heterogeneity of 
exertional symptoms and the high prevalence of comorbidities in patients (Crisafulli 
et al., 2008). Despite these challenges, PA and exercise in chronic respiratory 
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conditions has been shown to decrease dynamic hyperinflation and exertional 
dyspnoea, improve exercise tolerance, enhance quality of life, reduce disease 
exacerbations and augment patients’ ability to perform tasks of daily living (Burr, 
Davidson, Shephard, & Eves, 2012; Eves & Davidson, 2011).  
 
Both PA and exercise have been shown to positively impact health and well-being in 
those with CF. Specifically, increasing PA and exercise result in higher exercise 
capacity, and consequently longer survival (Nixon et al., 1992), an improved sense of 
well-being (Orenstein, Nixon, Ross, & Kaplan, 1989) and greater 
education/employment capabilities (Frangolias, Holloway, Vedal, & Wilcox, 2003) in 
both children and adults with CF. Additionally, higher levels of habitual PA amongst 
CF individuals are associated with a slower rate of decline in lung function (Wilkes et 
al. 2007) and bone mineral density (Wilkes et al. 2008).  
 
Although exercise and PA are currently recommended as part of the standard CF care 
(Boas 1997; Bradley & Moran 2008; Shoemaker et al. 2008; Rand & Prasad 2012; 
Wheatley et al. 2011; Cerny 2013; LeBlanc & Lands 2014), there is little guidance on 
the optimal type or dose required to achieve beneficial outcomes, with PA promotion 
in CF clinics limited to informal discussion and generic PA advice (Swisher et al., 
2015; Shelley et al., 2018). Current guidelines recommend that healthy children and 
young people aged 5-17 years should accumulate at least 60 minutes of moderate-
vigorous physical activity (MVPA) daily, the majority of which should be aerobic 
(World Health Organisation, 2019). For adults aged 18-64 years, 150 minutes of 
moderate physical activity (MPA), or at least 75 minutes of vigorous physical activity 
(VPA) throughout the week, is recommended (World Health Organisation, 2019). For 
young children with CF who have little disease-related limitations to their PA, the 
guidelines recommended by WHO for their healthy peers are deemed appropriate, 
though patients will need individually tailored PA and exercise prescriptions that are 
frequently re-evaluated as the disease progresses (UK CF Trust, 2020).  
 
A significant proportion of those with bronchiectasis have shown marked decreases in 
their exercise tolerance and PA levels (Burtin and Hebestreit, 2015; Pehlivan et al., 
2019). Additionally, the bronchiectasis population have demonstrated largely inactive 
lifestyles, with few meeting the recommended PA guidelines (Bradley et al., 2015). 
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While the benefits of a PR, exercise and PA has been well documented in other 
respiratory diseases such as COPD, there is limited studies investigating how these 
effect bronchiectasis (José et al., 2017; Ong, Lee, Hill, Holland, & Denehy, 2011). 
Improvements in exercise capacity and HRQoL have been reported following PR in 
bronchiectasis (Ong et al., 2011; Mandal et al., 2012; Lee et al., 2014, 2017; Patel et 
al., 2019). Indeed, one study showed maintained improvements in physiological and 
psychological health at a 12-month follow-up (Ong et al., 2011), however, 
contrastingly another study found improvements weren’t maintained at a 6-month 
follow-up (Lee et al., 2014). A major limitation of PR in bronchiectasis is the lack of 
long-term follow-up to determine whether improvements were maintained (Metersky 
& ZuWallack, 2019a). Further studies are needed to assess the impact of PA and 
exercise on bronchiectasis in both short- and long-term outcomes and whether a PR 
program is best for this population. 
 
2.2.1 Physical Activity for Children and Adolescents with Cystic Fibrosis 
 
There is little consensus regarding the PA in children with CF. Some have reported 
that, compared to their healthy peers, children with CF aged 6-17 years old engage in 
lower volumes of habitual PA (Aznar et al., 2014; Nixon, Orenstein, & Kelsey, 2001). 
Indeed, Aznar et al. (2014) reported that as little as 2.1% of children with CF meet the 
government guidelines of at least 60 minutes of MVPA every day. Nonetheless, the 
same children demonstrated higher levels of total and light PA. Conversely, other 
research has found no significant differences in PA between CF children and their 
healthy peers (Jantzen et al., 2016; Mackintosh, Ridgers, Evans, & McNarry, 2018; 
Selvadurai et al., 2004). These variations could be attributed to methodological 
inconsistencies such as a failure to account for maturity, disease severity or the relative 
intensity of PA, thereby limiting inter study comparisons. Specifically, it could be 
argued that the relative intensity for children and adolescents with CF could be greater, 
than in their healthy counterparts (Mackintosh et al., 2018). Therefore, “light” 
intensity PA for healthy population may actually be moderate intensity for those with 
CF and subsequently of more benefit to their health (Mackintosh et al., 2018). Such 
differences in the energy expenditure associated with absolute accelerometery 
intensities can only be resolved through the development of disease-specific cut-points 
(Bianchim et al., 2020). These issues associated with the appropriate interpretation of 
41 
 
the intensity and volume of PA are likely to be further exacerbated by the reliance on 
15 second epochs in previous studies (Aznar et al., 2014; Jantzen et al., 2016). Given 
the sporadic nature of children’s PA (Bailey et al., 1995), with high-intensity bouts 
suggested to typically last only 3 seconds and 95% to last less than 15 seconds (Bailey 
et al., 1995; Baquet, Stratton, Van Praagh, & Berthoin, 2007), using such long epochs 
may have potentially miscategorised VPA as MPA. Finally, questionnaire-based 
studies (Selvadurai et al., 2004) raise concerns regarding validity in chronic 
conditions, such as CF, due to their susceptibility to several forms of bias (Jantzen et 
al., 2016; Ruf et al., 2012).  
 
A study in CF found that self-reported PA levels peaks at the age of 10 years (Collaco 
et al., 2014), with lower levels of PA levels not subsequently reversed with increasing 
age (Cox et al., 2016). Furthermore, in accordance with healthy populations, the PA 
of girls with CF declines to a greater extent than their male counterparts following the 
onset of puberty (Wilkes et al., 2007). Indeed, Schneiderman-Walker and colleagues 
(2005) found that lower PA levels in girls with CF aged 7-17 years were associated 
with a steeper decline in FEV1 over a 2-year period, while higher levels of habitual PA 
were associated with a slower rate of decline, irrespective of sex (Schneiderman et al., 
2014). It is important, however, important to note the relatively high FEV1 of the 
participants within Schneiderman and colleague’s (2014) study, which may confound 
the generalisability of the findings to the wider CF population. Collaco and colleagues 
(2014) emphasised the importance of developing PA habits at a young age, as when 
the disease progresses in severity, it in itself becomes a direct cause hypoactivity 
(Williams & Stevens, 2013). Indeed, being as active as possible in early childhood is 
essential, especially in youth with CF, as the ability to engage in activities of daily 
living, improved body image and self-esteem as well as perceptions of wellness, 
acceptance and resilience are secondary QoL related outcomes associated with PA 
(Enright, Chatham, Ionescu, Unnithan, & Shale, 2004; Moola, Faulkner, & 
Schneiderman, 2012; Selvadurai et al., 2002; Stanghelle, Hjeltnes, Bangstad, & 
Michalsen, 1988). However, a self-selection bias whereby those with milder disease 
are most likely to take part in exercise and PA research is a fundamental limitation of 




Whilst the PA levels of those with CF remain to be conclusively elucidated, numerous 
factors that could influence PA levels in the CF population could be attributed to the 
treatment burden. Those with CF are required to attend regular clinic appointments, 
comply with drug therapy and physiotherapy sessions, and may miss school due to 
pulmonary exacerbations and/or increased illness (Williams & Stevens, 2013). 
Therefore, the burden of treatments and lung disease may reduce the opportunity for 
those with CF to be active on a regular basis (Williams & Stevens, 2013). Furthermore, 
parental overprotection, child fears, lack of understanding of the disease by teachers, 
self- or peer-imposed social isolation (Shields, Synnot, & Barr, 2012), as well as the 
perception of “no time to play” (Moola et al., 2012), could also contribute potential 
inactivity in children with CF.   
 
A commonly cited barrier to PA in those with CF are CF-specific concerns, such as 
coughing and poor perceptions of body image (Withers, 2012). Studies of adolescents 
have shown that adolescent girls have greater public self-consciousness compared to 
boys (Rankin, Lane, Gibbons, & Gerrard, 2004) and experience more strains and 
poorer treatment adherence (Patterson, Wall, Berge, & Milla, 2009). Adolescent girls 
have a greater need to fit in with their peers, reporting embarrassment with activities 
that are disdained by their peers (Allgood-Merten, Lewinsohn, & Hops, 1990; 
Christian & D’Auria, 1997; Rankin et al., 2004). Indeed, adolescent’s behaviours are  
increasingly influenced by significant others; social support from healthy peers could 
promote their QoL, adaptive psychological adjustments, and in some cases, greater 
treatment adherence (Helms, Dellon, & Prinstein, 2015). Specifically, social support 
has been shown to be protective for psychological well-being in youth with CF 
(Graetz, Shute, & Sawyer, 2000), with family support in particular being associated 
with greater treatment adherence (Collins, O’Loughlin, & Henry, 1998; Patterson, 
1985), as well as better health outcomes (Patterson, Budd, Goetz, & Warwick, 1993). 
Future research is needed to determine how peer relationships influence health and 
behaviour over time and the possible mediators and moderators of these effects in CF 
(Helms et al., 2015).  
 
It is imperative to ascertain the interests and abilities of children and adolescents with 
CF in order to ensure long-term adherence to a physically active lifestyle (Hebestreit 
et al. 2010). A recent study by Shelley et al (2018) found that PA monitoring is a 
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potential clinical tool for promoting physical PA in young people with CF, whilst 
allowing an individualised approach to activity prescription. Indeed, one study has 
shown that free-choice in PA is correlated with maximal aerobic capacity (Hebestreit 
et al., 2006), suggesting that the mode of PA may not be as influential as choosing 
activities in which the adolescent will agree to engage in. Furthermore, better 
treatment adherence in youth with CF has been attributed to family support (Collins 
et al., 1998; Patterson, 1985), resulting in better physical health outcomes (Patterson 
et al., 1993).  
2.2.2 Physical Activity for Non-Cystic Fibrosis Bronchiectasis  
Despite the strong evidence that adherence to PA guidelines is associated with health 
benefits and reduced mortality in chronic disease populations (Arne et al., 2009; 
O’Donovan et al., 2010), studies investigating the impact of PA on bronchiectasis are 
scarce (Bradley et al., 2015; Wilson et al., 2016). In other respiratory conditions such 
as COPD and CF, PA has been strongly related to mortality and lung health 
(Schneiderman et al., 2014; Waschki et al., 2011). Previous research has found that 
those with bronchiectasis have reduced PA and exhibit significantly lower walking 
distances (Cakmak et al., 2016; José et al., 2018) and fitness measured through 
intermittent shuttle walk test (ISWT) distance (704 ± 204.30 m vs 909 ± 200.58 m, p 
= 0.016) compared to healthy controls (Cakmak et al., 2016). Significant correlations 
have been observed between PA and FVC, FEV1, ISWT and dyspnea in bronchiectasis 
(José et al., 2018). Furthermore, pulmonary function, dyspnea, ISWT and long-term 
oxygen therapy were also identified as independent factors associated with PA (José 
et al., 2018). Bradley et al. (2015) used accelerometers in 55 bronchiectasis 
participants and found that only 11% of patients met the PA guidelines. Average daily 
time spent being sedentary was 634 ± 77 minutes, with time spent in LPA and MVPA 
being 207 ± 63 and 25 ± 20 minutes, respectively (Bradley et al., 2015). However, the 
utilisation of pedometers in José et al. (2018) and Cakmak et al. (2016), and the 
omission of comparing week and weekend day step count data, limits the accuracy of 
the PA levels presented. A recent study found that low PA levels and high sedentary 
time at baeseline were associated with a higher risk of hospitalisation as a result of 
bronchiectasis exacerbation (Alcaraz-Serrano et al., 2020). Alcaraz-Serrano et al. 
(2020) concluded that these findings needed to be validated in future studies but 
recommended that PA and sedentary behaviour should be incorporated into disease 
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severity scores. However, no other studies have considered the impact of 
Bronchiectasis and its range of clinical characteristics (disease severity, exercise 
capacity, HRQoL and symptoms) on sedentary behaviour and PA, thus their 
importance remains to be elucidated (Bradley et al., 2015). Indeed, more research is 
needed within this population to identify the need for PA interventions and how to 
tailor these to this population. 
 
2.2.3 Exercise for Children and Adolescents with Cystic Fibrosis  
 
Aerobic exercise, defined as any activity that uses large muscle groups, can be 
maintained continuously, and is rhythmical in nature (Wahid et al., 2016), is the 
recommended form of exercise by most CF centres as it is the most studied mode of 
exercise within this population (Hebestreit et al., 2015). The maintenance, or 
improvement, of pulmonary function and aerobic capacity, thereby slowing down the 
annual rate of decline in FEV1 and V̇O2peak, are vitally important given that they are 
both strong predictors of survival (Hebestreit et al., 2019; Nixon, Orenstein, Kelsey, 
& Doershuk, 1992; Pianosi, LeBlanc, & Almudevar, 2005). Furthermore, in a large 
cohort of adolescent CF patients, an acceleration of lung function decline was found 
in early adulthood (Vandenbranden et al., 2012). This decline was attributable to 
adolescents who exhibited early-stage lung disease (FEV1 ≥ 70%). This finding is 
consistent with previous research, whereby a higher baseline lung function was a risk 
factor for FEV1 decline in children and adolescents with CF (Konstan et al., 2007). 
Therefore, it is intuitive that any intervention that can positively impact these health 
outcomes would potentially enhance patient prognosis. Nonetheless, it is still 
unknown whether exercise training can improve survival in this population (Williams 
& Stevens, 2013). However, it is noteworthy that several mechanisms such as 
pulmonary, cardiac and peripheral skeletal muscle dysfunction, contribute to the 
reported limitation in exercise capacity in those with CF (Saynor et al., 2020; Aljamed 
& Lands, 2012). Ventilatory dysfunction in CF may contribute to exercise intolerance 
due to deleterious changes in lung function, dead space ventilation, respiratory muscle 
function, ventilatory reserve, and ventilatory control (Shei et al., 2019). Furthermore, 
muscle abnormalities including muscle weakness, mitochondrial dysfunction and 
altered muscle metabolism could also contribute to exercise intolerance (Gruet et al., 
2016; Werkman et al., 2016; Gruet et al., 2017). Whilst the mechanisms of exercise 
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intolerance in CF is often complex and interdependent (Huzelbos et al., 2015; Jiang et 
al., 206; Gruet et al., 2017), it has been postulated that age-related progressions in 
disease severity may be integral to the decrements annually observed (Shei et al., 
2019). Despite this, several studies have demonstrated that those with CF can tolerate 
aerobic exercise and improve aerobic capacity (Radke et al., 2017).  
In children and adolescents with CF, a significant psychosocial barrier is parental 
overprotection (Moola, Faulkner, Kirsh, & Schneiderman, 2011). Termed the 
“vulnerable child syndrome,” parents with children with a chronic illness may worry 
excessively about their child’s health and their capacity to undertake exercise (Wilkes 
et al., 2009). Indeed, parents of children with CF expressed concerns about their 
child’s participation in vigorous play or sports (Nixon et al., 2001). Parents are critical 
to health-related behaviour change by either facilitating or hindering their child’s 
engagement (Golan, 2006). Processes such as role modelling and observational 
learning mean children adopt their parents practices and their beliefs and attitudes, 
therefore strongly influencing youth’s PA and exercise (Moola et al., 2011). To 
enhance PA and exercise, processes such as dialogue about exercise in the home, 
availability of exercise equipment and access to facilities, are vital. Furthermore, 
interventions that involve parents are more applicable to the nuances of participants’ 
local environments and more likely to have benefits for all family members (Moola et 
al., 2011; Nader et al., 1989). Minimising the perceived barriers to exercise in CF, 
emphasising how exercise can modulate the disease process, and optimising 
motivators, are likely to influence the success of any program (Abu-Hasan, 
Armstrong, Andersen, Weinberger, & Nixon, 2010; Prasad & Cerny, 2002). 
 
During the last decade, the importance of exercise as an essential element in the 
treatment of CF has grown. Thus, exercise has been incorporated into many treatment 
regimens, with exercise capacity used as an outcome variable in many intervention 
studies (Schmidt et al., 2011). Additionally, it has been stated that aerobic capacity 
correlates with QoL measures, and changes in aerobic capacity are associated with 
changes in the QoL (Hebestreit et al., 2006). However, QoL remains an under-utilised 
assessment tool regarding the impact of PA and exercise in CF. In children, Selvadurai 
et al (2002) reported significant improvements in QoL at a one-month follow-up of an 
aerobic exercise programme. However, no significant improvements in QoL were 
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reported in the resistance or control group (Selvadurai et al., 2002). Specifically, 
improvements in QoL were only reported where V̇O2peak significantly increased 
(Selvadurai et al, 2002). This is consistent with previous research that found that QoL 
correlated more strongly with changes in aerobic fitness than changes in pulmonary 
function (Orenstein et al., 1989). These improvements in QoL may be related to the 
suggested influence of physical exercise training on anxiety, depression and feelings 
of well-being in CF (Hebestreit et al., 2014).  
 
Overall, there is a lack of research determining the psychological benefits of PA and 
exercise within youth with CF. As the complexity of treatment evolves with the ageing 
CF population, QoL could be negatively impacted due to the increased burden (Gee et 
al., 2005). With research emphasising the importance of cardiopulmonary exercise 
testing in not only providing important clinical information regarding the impact of 
disease, but the impact of the disease on patients QoL (Williams & Stevens, 2013), it 
is important that future exercise and PA interventions utilise psychological parameters 
to understand the full impact that PA and exercise can have on the well-being and QoL 
in CF patients.  
 
2.2.4 Exercise for Non- Cystic Fibrosis Bronchiectasis  
 
Exercise is important for those with bronchiectasis and is a critical component of PR 
(Spruit et al., 2013). The rationale for PR and exercise training within the 
bronchiectasis population is based on evidence that muscle weakness and physical 
inactivity may play a role in disease progression and therefore impact HRQoL, 
frequency of infectious exacerbations and the ability to mobilise secretions (Burtin & 
Hebestreit, 2015). Minimising inflammation and infection, addressing structural lung 
damage and optimising airway clearance are paramount for managing bronchiectasis 
(Polverino et al., 2017). Therefore, current guidelines recommend PR for those with 
bronchiectasis with the aim of improving exercise tolerance and HRQoL within this 
population (Pasteur, Bilton, Hill, & British Thoracic Society Bronchiectasis non-CF 
Guideline Group, 2010).  
 
A recent systematic review incorporating four trials with 164 bronchiectasis patients 
concluded that 8 weeks of supervised PR and exercise training initiated short-term 
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improvements in exercise capacity and HRQoL, with the maintenance of these 
improvements being challenging (Lee et al., 2017). High-intensity exercise training 
incorporated into a PR programme was effective in improving ISWT distance and 
endurance capacity (Newall, Stockley and Hill, 2005), whilst a standard eight-week 
supervised PR programme showed improvements in ISWT and 6MWT distances, 
though these were not sustained at 6 or 12 months (Lee et al., 2014). Furthermore, the 
eight-week PR programme did not impact cough-related QoL, mood or the frequency 
of acute exacerbations compared to the control group (Lee et al., 2014). However, the 
reduced exacerbation frequency should be interpreted with caution due to the reduced 
proportion of patients who attended the 12-month follow-up. A cohort of 108 
bronchiectasis participants showed that males, baseline FEV1/FVC >70% and greater 
than two exacerbations in the previous year, were independent predictors of PR 
efficacy in terms of improvement in 6MWD (Zanini et al., 2015).  
 
Although the evidence suggests that PR and exercise training is beneficial for those 
with bronchiectasis, numerous questions remain to be addressed (O’Neill, O’Donnell, 
& Bradley, 2019). Specifically, the timing of referral in relation to the stage of disease 
that patients may experience the most benefits remains to be elucidated. Furthermore, 
many patients with bronchiectasis are older adults and frail with orthopaedic risks 
(Bellelli et al., 2016), therefore exercise training within this population could be 
associated with risks of cardiac comorbidities, exercise-induced hypoxemia and 
haemoptysis (Burtin & Hebestreit, 2015). Overall, further research is required to 
investigate the effects of both short-and long-term exercise, at varying intensities, to 
determine the impact on the physiological and psychological health of those with 
bronchiectasis. 
 
The clinical profile associated with bronchiectasis results in increased anxiety, 
depression, reduced HRQoL and impaired exercise tolerance (Martínez-García et al., 
2005b; Olveira et al., 2013). Indeed, sputum production, breathlessness and 
exacerbations have been found to be the key determinants of QoL in bronchiectasis, 
with P.aeruginosa and nontuberculous mycobacteria having the highest burden on 
(Polverino et al., 2018). A recent study including 8,389 bronchiectasis patients (58% 
female) found that women living with the condition are significantly more affected in 
physical, emotional and social functioning aspects of their lives than their male 
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counterparts (Finch et al., 2017). This has implications for tailoring care and suggests 
further research is warranted to determine the sex-specific impact of bronchiectasis. 
 
It has been found that patients with bronchiectasis who experience frequent 
exacerbations, experienced more hospitalisation, higher symptom burden and poorer 
QoL (Visser et al., 2019). As mortality rates and burden increases in adults with 
bronchiectasis (Roberts & Hubbard, 2010), more high-quality research in key areas is 
needed (Welsh, Evans, Fowler, & Spencer, 2015). Conflicting evidence and limited 
longitudinal research in bronchiectasis means the effect of PR interventions, and 
indeed PA’s impact on HRQoL remains to be elucidated. Therefore, further research 
is imperative given that general well-being, mental health and the overall impact of 
disease on their activities of daily living will affect compliance to medical therapy and, 
ultimately, morbidity and mortality (de Bruyne, Eg, & Thavagnanam, 2017; Quittner 
et al., 2014). 
 
2.2.5 Medicalisation of Physical Activity and Exercise 
 
“Prescribed exercise” draws PA into the medical paradigm and shifts the focus of 
exercise culture to a clinical context. The medicalisation of sport is the process 
whereby ‘a problem is defined in medical terms, defined using medical language, 
understood through the adoption of a medical framework, or “treated” with a medical 
intervention’ (Conrad, 1992; p211). However, the majority of evidence-based practice 
in the health sector fails to consider the patient perspective (Rand, Dunn, Slade, 
Upadhyaya, & Sheehan, 2019). Furthermore, the need for new supplementary methods 
to evaluate treatment results and health status, aside from basing the evaluation of an 
intervention’s and/or treatment’s effectiveness against an objective biomedical goal, 
draws in patients’ own opinions of their general well-being (Mainz, Kristensen, & 
Bartels, 2015). It is therefore important to ensure that evidence-based sports medicine 
such as “prescribed exercise” integrates three key aspects: (i) research-based 
knowledge; (ii) clinical expertise; and (iii) patient values (Hallinan & Jackson, 2008). 
When structured PA, thereby exercise, is implemented in a treatment regimen, there 
is a possibility that the desire for PA is replaced by the focus on clinical health and 
illness. Furthermore, when the patient’s own motivation is not the driving force, and 
when PA is prescribed and orientated towards medical parameters, the participant can 
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become distanced from their own treatment (Hallinan & Jackson, 2008). It is therefore 
essential that both short-and long-term perspectives are obtained from patients and 
considered in the form of feelings, thoughts and values about exercise in relation to 
their own lifestyle. Motivating people to take responsibility for their own health as 
well as a ‘responsibility-giving’ process (Hallinan & Jackson 2008), could potentially 
result in a more sustainable and well-adhered intervention and/or treatment regimen.  
 
2.2 Respiratory Muscle Training 
 
An alternative method to traditional exercise interventions and/or pulmonary 
rehabilitation in those with a chronic respiratory condition is respiratory muscle 
training (RMT). RMT was first investigated in the late 1960s and research in both 
clinical and athletic populations has rapidly expanded over the last 30 years. 
Specifically, Delhez et al. (1966) conducted the first RMT programme in a clinical 
population, concluding that increases in inspiratory muscle strength may reduce the 
potential for the respiratory muscles to limit ventilatory work. Further research 
observed that five weeks of RMT, using repeated static inspiratory manoeuvres, 
improved mean inspiratory pressure (MIP) by 55% (Leith & Bradley, 1976). 
Additionally, Leith and Bradley (1976) found that volitional hyperpnoea training at 
rest improved maximal sustainable ventilatory capacity by 18%, thereby 
demonstrating that known strength-training principles can be applied to the respiratory 
muscles. The home-based, time-efficient nature of respiratory muscle training makes 
it an attractive alternate to hospital or community-based interventions. Furthermore, 
advancements in RMT devices mean clinicians and researchers can monitor 
adherence, effort and health remotely, reducing burden on health care practitioners 
and patients alike.  
2.3.1 Training the Respiratory Muscles 
 
Respiratory muscles are morphologically and functionally similar to skeletal muscles 
and therefore respond to training stimuli in the same manner, with improvements in 
strength and endurance reported following training (Romer & Polkey, 2008). These 
key principles to elicit training adaptations in skeletal muscles are well recognised, 
with suggestions that similar principles may be relevant to RMT, (i.e. overload, 
specificity and reversibility; Faulkner, 1985). Indeed, RMT utilises restricted airflow 
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breathing exercises to increase the mechanical load on the external intercostal muscles 
and diaphragm. The increased load engendered by RMT provides a stimulus to elicit 
a hypertrophic response (Enright et al., 2004).  
 
Training methods for the respiratory muscles can be divided into resistive, and 
endurance, training (McConnell, 2013). Resistance training is where the muscles are 
subjected to an external load and can be split into three further categories: (i) 
inspiratory flow resistive loading; (ii) inspiratory threshold loading; and (iii) 
expiratory threshold loading. Inspiratory flow resistive loading requires inspiration via 
a variable diameter orifice whereby, for a given flow, the smaller the orifice, the 
greater the resistive load (Figure 2.3). Flow-resistive loading specifically targets the 
inspiratory muscles, in which the effect on the inspiratory muscle force-velocity curve 
is solely dependent on flow rate and the amount of resistance. Inspiratory threshold 
loading requires individuals to produce a negative pressure sufficient to overcome a 
threshold load, thereby initiating inspiration (Figure 2.4). This results in the inspiratory 
muscles primarily performing an isometric contraction until the threshold valve opens 
to allow inspiratory flow, after which the contraction becomes isotonic (Dixit & 
Prakash, 2014). 
 
Figure 2.3 Respiratory resistance device (PFLEX; Respironics Inc; Pittsburgh, PA, 
USA). Adapted from Wu et al., (2017).  
 
Finally, expiratory pressure threshold loading requires individuals to produce an 
expiratory pressure sufficient to overcome a positive pressure load, and thereby initiate 
expiration. The ventilatory response to expiratory loading is hypothesised to depend 
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on the compensatory reflexes and the impedance of the respiratory systems (Kimoff, 
Cheong, Cosio, Guerraty, & Levy, 1990; Milic-Emili & Zin, 2011). Indeed, a typical 
acute response includes slowing of expiratory flow and lengthening of expiratory time, 
such that breathing frequency and minute ventilation decrease (Milic-Emili & Bishop, 
1979). Endurance training, specifically voluntary isocapnic hypernoea training, 
requires participants to maintain high target levels of ventilation for up to 30 minutes. 
To prevent hypocapnia (a state of reduced carbon dioxide in the blood), participants 
re-breathe through a dead space. Training sessions are usually completed at ~60-90% 
of maximum voluntary ventilation (MVV), three to five times per week (McConnell, 
2013). 
 
Figure 2.4 Respiratory threshold loading device (Threshold Inspiration Muscle 
Training; Respironics Inc; Pittsburgh, PA, USA). Adapted from Wu et al., (2017). 
 
Neural adaptations have been shown to occur over the first four weeks of a strength 
training intervention (Brown et al., 2017; Ramsay et al., 1990), with both adults and 
children exhibiting a learned response (Larson et al., 1993) and increased frequency, 
and improved co-ordination, of neuromuscular firing (Astrand & Rodahl, 1986; 
Ozmun, Mikesky, & Surburg, 1994). Any improvements beyond four weeks are 
considered to be morphological adaptations (Folland & Williams, 2007), which 
incorporate increases in the oxidative capacity, the capillary bed of the muscle and 
muscle fibre hypertrophy (Komi & Hakkinen, 1991). Indeed, research has suggested 
that, akin to skeletal muscles, inspiratory muscles can adapt according to the stress 
placed on them (Boutellier, Büchel, Kundert, & Spengler, 1992). A recent review 
(Shei, 2018) on RMT highlighted that seven key effects of RMT. Specifically, RMT: 
(i) decreases the inspiratory muscle motor drive while preserving pressure generation 
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(Huang, Martin, & Davenport, 2003); (ii) promotes hypertrophy of the diaphragm and 
increases the proportion of type I fibres and size of type II fibres in the external 
intercostal muscles (Downey et al., 2007; Enright, Unnithan, Heward, Withnall, & 
Davies, 2006); (iii) attenuates the respiratory muscle metaboreflex (Witt, Guenette, 
Rupert, McKenzie, & Sheel, 2007); (iv) decreases the rating of perceived 
breathlessness or rate of perceived exertion (McConnell, 2009; Sheel, 2002); (v) 
improves respiratory muscle economy (Turner et al., 2012); (vi) reduces the work of 
breathing (Held & Pendergast, 2014); and (vii) improves respiratory muscle endurance 
(Sales et al., 2016). It is plausible that these mechanisms are linked, however, how 
these factors interact and their subsequent impact on exercise performance is, at 
present, not well understood (Shei, 2018).  
 
2.3.2 Respiratory Muscle Training in Healthy Populations 
 
Inspiratory muscle fatigue has been suggested to compromise exercise performance in 
healthy individuals (Mador & Acevedo, 1991; Verges, Boutellier, & Spengler, 2008), 
possible due to impaired blood flow to the working muscles via the respiratory muscle 
metaboreflex, resulting in the acceleration of fatigue development in these muscles 
(Wüthrich, Notter, & Spengler, 2013). It is hypothesised that during exhaustive 
endurance exercise the changes in locomotor muscle blood flow have an important 
effect on O2 transport to the working locomotor muscles and, subsequently, on their 
fatigability (Scano, Grazzini, Stendardi, & Gigliotti, 2006). RMT has been shown to 
reduce the development of respiratory muscle fatigue (Romer & McConnell 2003; 
Verges et al. 2008) and blood lactate concentration during exercise (Brown, Sharpe, 
& Johnson, 2008). This is due to increased uptake and metabolism of lactate by the 
trained respiratory muscles (Spengler et al. 1999; Romer & McConnell 2003; 
McConnell & Sharpe 2005; Brown et al. 2008) and sympathetic activation by reducing 
sympathetic, and increasing parasympathetic, modulation (Ferreira et al., 2013; 
McConnell & Lomax, 2006; Witt et al., 2007). A recent systematic review of RMT in 
healthy participants included a detailed analysis of 46 original RMT studies (Illi, Held, 
Frank, & Spengler, 2012).  Specifically, Illi et al. (2012) found that respiratory muscle 
performance improved to a similar extent irrespective of fitness levels, with no effect 
of fitness with regards to improvements in MIP, MEP or respiratory muscle endurance. 
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Furthermore, inspiratory and expiratory strength training did not differ in their effect 
on improving exercise performance (Illi et al., 2012). 
 
In healthy populations, a minimum training intensity with an overload of 20-40% of 
peak power has been recommended (Chatham et al., 1999). However, whilst a load of 
20-40% would increase power, it is postulated that it may be below the recommended 
optional intensity, which is consistent with strength and endurance training (Faulkner, 
1985). To gain strength, training theory suggests intensities of 80-100% of maximum 
voluntary contraction, with a strength-endurance set ranging between 60 to 80%, and 
endurance at approximately 60% of peak (Newton & Karmer 1994). To ensure 
changes in load, constant maximal strength of contraction is needed to guarantee true 
overload is consistently applied through a training intervention (Dirix, Knuttgen, 
Tittel, International Olympic Committee., & International Federation of Sports 
Medicine., 1991). Incremental loading involving decreased rest periods between 
muscle contractions, thereby resulting in an increase in the efficiency of the aerobic 
response to loading by training in the pre-fatigued state, could be defined as 
overloading resulting in a high-density training programme (Acre, 1994). To be able 
to exhibit a training effect, frequency, duration and intensity of RMT must be carefully 
considered. Pardy and Rochester (1992) found a significant positive relationship 
between the percentage increase in MIP and relative magnitude of the IMT load. 
Therefore, it could be postulated that relative to an individual’s inspiratory muscle 
strength, the higher the load the greater the increase in strength achieved (Ernesto 
Crisafulli, Costi, Fabbri, & Clini, 2007). 
 
2.3.3 Respiratory Muscle Training in Clinical Populations  
 
Impairment in respiratory muscle function can significantly interfere with 
performance of daily activities in those living with a respiratory disorder (Charususin 
et al., 2018). Inspiratory muscles are used to generate airflow. Specifically, when 
inspiratory muscles contract, the changes in intrathoracic pressure allow air to enter 
lungs; conversely, when they relax air exits the respiratory system. However, if 
additional effort is required, the alveolar to atmosphere pressure gradient is altered and 
ventilatory demand increased (Gea, Casadevall, Pascual, Orozco-Levi, & Barreiro, 
2012). A muscle may not be defined as ‘weak’ in absolute terms, however, if the 
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demands that are placed on it are excessive then it is rendered ‘weak’ functionally. For 
example, in pulmonary fibrosis patients, respiratory muscle strength may be 
considered normal, but if the intrinsic inspiratory load is elevated this results in 
functional weakness that then manifests as reduced inspiratory muscle endurance 
(Hart et al., 2002). The majority of RMT research has been completed in those with 
COPD. Patients with COPD often exhibit respiratory muscle weakness and reduced 
muscle endurance, due to chronic mechanical loading of the inspiratory and expiratory 
muscles (Orozco-Levi, 2003). RMT has been shown to improve inspiratory muscle 
strength, endurance, exercise capacity, dyspnoea and QoL in those with COPD 
(Geddes, O’Brien, Reid, Brooks, & Crowe, 2008; Gosselink et al., 2011; Shoemaker 
et al., 2008). Although RMT has the potential to enhance respiratory muscles, its 
clinical use for those with respiratory conditions remains largely inconclusive.  
 
2.3.3.1 Bronchiectasis  
 
High levels of fatigue and dyspnoea are common features of bronchiectasis (Ozalp et 
al., 2012; Inal-Ince et al., 2014; de Carmargo et al., 2018), the causes of which are 
often multifactorial. However, the key contributors to dyspnoea include altered 
respiratory mechanics and insufficient gas exchange (Ozalp et al., 2012). Previous 
research has identified an expiratory flow limitation in people with moderate-to-severe 
bronchiectasis due to increased dynamic hyperinflation (Koulouris et al., 2003; Ozalp 
et al., 2012).  
Given that non-CF bronchiectasis has commonality in pathology with COPD, and 
RMT shows significant benefits to those with COPD (Geddes et al., 2008; Gosselink 
et al., 2011; Shoemaker et al., 2008), RMT could be a potential treatment strategy to 
improve both physiological and psychological health for those with non-CF 
bronchiectasis. Three studies have investigated IMT in bronchiectasis (Liaw et al., 
2011; Newall et al., 2005; Ozalp et al., 2019), with equivocal results. Specifically, 
Newall et al. (2005) found that adding an eight-week moderate-intensity (MIP 30-
60%) IMT intervention 15 minutes, two times a day, to an exercise training 
programme (PR-IMT) produced significant improvements in respiratory muscle 
strength, exercise capacity and health status, which was maintained three months after 
training cessation (Newall, Stockley and Hill, 2005). This is in contrast to the sham 
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IMT group, whose increase in exercise performance was not maintained, suggesting 
an additive effect of IMT in the PR-IMT group (Newall, Stockley and Hill, 2005). 
Contrastingly, a sole  IMT intervention (30% MIP increasing by 2cmH2O each week) 
for 30-minutes daily, five days a week for eight weeks found increases in both 
inspiratory (39%) and expiratory respiratory muscle strength (44%), but had no 
significant effect on respiratory function, QoL or walking capacity (Liaw et al., 
2011a). Most recently, a high-intensity programme involving IMT three days a week 
for eight weeks at 30% MIP and an exercise to rest ratio of 2:1, found both MIP and 
MEP increased by 43.53% and 11.67%, respectively (Ozalp et al. 2019). Additionally, 
Ozalp et al. (2019) found IMT increased exercise capacity, respiratory muscle 
endurance and reduced dyspnoea in patients with non-CF bronchiectasis. However, it 
is important to acknowledge the near-normal lung function (Newall et al. 2005; Ozalp 
et al. 2019) and relatively young age of participants in studies to date (Liaw et al. 2011; 
Ozalp et al. 2019), making IMTs applicability in those suffering from more severe 
symptoms difficult to ascertain. Bronchiectasis is associated with rising hospitalisation 
rates, resulting in growing healthcare utilisation (Seitz et al., 2010, 2012) and 
economic burden (Joish, Spilsbury-Cantalupo, Operschall, Luong, & Boklage, 2013; 
Ringshausen et al., 2013). Considering the economic and physical burden, increased 
dyspnoea and reduced exercise tolerance of tidal expiratory flow limitation in those 
with bronchiectasis (Koulouris, Retsou, Kosmas, Dimakou, Malagari, 
Mantzikopoulos, Koutsoukou, Milic-Emili, & Jordanoglou, 2003), there is an urgent 
need for cost-effective interventions irrespective of disease severity, to allow the 
identification of those who would benefit the most from IMT. 
 
2.3.3.2 Cystic Fibrosis 
 
Due to airway obstruction, respiratory muscles in those with CF are subject to an 
increased load (Reilly et al., 2011). Hyperinflation, because of gas trapping puts those 
with CF on the upper, flattened portion of the pressure-volume curve, causing an 
increase in the elastic work of breathing and causing the development of intrinsic 
positive end expiratory pressure (Reilly et al., 2011). Therefore, an imposing load is 
needed to overcome each breath due to increased airway resistance (Hart et al., 2002). 
Furthermore, a reduction in inspiratory muscle length and altered geometry on account 
of hyperinflation reduces the ability of the inspiratory muscles to generate negative 
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pressure (Polkey et al., 1996). This imbalance between ventilatory load and capacity 
of the respiratory muscles in those with CF is exemplified by inefficient breathing 
patterns (Hart et al., 2011) and exercise intolerance (Almajed & Lands., 2012). 
Preventing deterioration in pulmonary function has led to a substantial increase in life 
expectancy for those living with CF. As respiratory dysfunction is the major cause of 
morbidity in CF and associated with approximately 80 to 95% mortality (Lyczak, 
Cannon, & Pier, 2002), interventions that not only improve pulmonary function but 
associated health outcomes, would be extremely beneficial. Research regarding the 
impact of IMT in CF is scarce, with the limited number of studies adopting different 
training protocols and outcome measures, thereby limiting interstudy comparisons. 
 
The optimal duration and length of IMT to elicit beneficial improvements in health in 
CF remains unknown. It is hypothesised in normal strength training programmes that 
the optimal frequency of training is three times a week, with maintenance achieved by 
continued training one or two times per week (Fleck, 1994; Wernbom, Augustsson, & 
Thomee, 2007). However, there is little consensus within the literature, with 
considerable inter study variations in the frequency, intensity and duration of IMT 
interventions. It is therefore perhaps unsurprising that the outcomes vary between 
studies. Specifically, while de Jong et al. (2001) found improvements in respiratory 
muscle endurance following a five times a week IMT protocol at 20-40% MIP for 20 
minutes, others have reported improvements in strength, but not endurance, following 
daily IMT for 30 minutes at 60% MIP for 10 weeks (Clanton, 1993) or twice daily for 
15 minutes at 60% MIP (Asher et al, 1982). Low-intensity training has been shown to 
result in improvements in inspiratory muscle endurance, with inspiratory muscle 
strength targeted by high-intensity training (Celli, 1995; Reid & Samrai, 1995). This 
may explain the influence observed by de Jong et al. (2001) on inspiratory muscle 
endurance, although it is worth noting that a 30% maximal capacity IMT programme 
conducted two times a day for six weeks also reported improvements in respiratory 
muscle endurance, with additional improvements in FVC and PIMAX (Amelina et al., 
2006). Furthermore, Enright et al. (2004) conducted a high-intensity inspiratory 
muscle-strength-training programme three times a week for eight weeks (80% MIP), 
which elicited improvements in MIP (19%), respiratory muscle endurance, lung 
function and psychological status. The improvements elicited in both endurance and 
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strength in Amelina et al. (2006) and Enright et al. (2004) could be attributed to the 
frequency of training, with shorter and less fatiguing sessions, leading to higher 
average training intensities, thereby eliciting neural adaptations and, consequently, 
increased strength gains (Andersen et al., 2012).  
 
In children, 50-60% MIP once a day for 10 weeks elicited improvements in inspiratory 
muscle strength, vital capacity, total lung capacity and exercise tolerance (Sawyer & 
Clanton 1993). An eight-week, two times a day for 15 minutes IMT programme 
combined with a ‘whole strength’ training programme improved V̇O2peak, inspiratory 
and whole-body strength (Santana-Sosa et al., 2014). However, the specific influence 
of IMT is not possible to differentiate as there were no participants who solely 
completed the IMT programme. Furthermore, the failure to demonstrate improved 
exercise tolerance could be attributed to the scheduling of IMT sessions after aerobic 
training (Santana-Sosa et al., 2013), which could mean respiratory muscles may not 
have recovered sufficiently to gain the maximal benefit of IMT. Whilst an IMT 
protocol for children conducted twice per day, on five days across the week, for eight 
weeks, improved respiratory muscle endurance, the intensity was unknown and there 
were no changes in exercise endurance, lung function, QoL or CF clinical score (Biele 
et al., 2017). This could be attributed to the age difference, with CF adults tending to 
have more advanced lung disease than the young population in. Furthermore, Sartori 
et al. (2008) conducted the intervention over 12 weeks, in contrast to the eight weeks 
utilised in Biele et al. (2017) study, highlighting the importance of attributing the 
appropriate training length for specific outcomes. Finally, exercise performance could 
have been limited by factors other than, or in addition to, ventilatory performance. 
RMT may only be minimally affected, if at all, by airway obstruction, thereby 
inducing dynamic hyperinflation and/or breathing reserve resulting in limited exercise 
tolerance (Bieli et al., 2017; Williams et al., 2014).  
 
Adherence to therapies in the CF population are often attributed to time constraints 
and burden of care (Bregnballe, Schiøtz, Boisen, Pressler, & Thastum, 2011; George 
et al., 2010). RMT protocols can be quite physically demanding which could results 
in non-compliance in CF participants. Table 2.1 summarises the literature involving 
respiratory muscle training in CF. For CF adults, complex daily medications, airway 
clearance routines, nutritional monitoring, PA, physiotherapy and clinical visits are 
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part of their daily routine (Flume et al., 2007; Yankaskas, Marshall, Sufian, Simon, & 
Rodman, 2004). The resultant treatment burden coupled with balancing family, work, 
education and other responsibilities, pose continuous challenges in this population. 
Indeed, adherence to antibiotic treatment is highest (80-95%), nebulized medications 
and pancreatic enzymes is moderate (65-80%), and vitamin therapy, dietary changes, 
exercise and physiotherapy is lowest (40-55%; Kettler et al., 2002). Therefore, in an 
era of increasing number of additive therapies in CF, determining the effects of RMT 
in this population is imperative due to its time-efficient nature and the possibility it 
could replace more time-consuming treatments. Indeed, in clinical populations, long-
term adherence to therapeutic exercise regimens may be influenced by patient 
attributes and environmental factors (Buckworth & Dishman, 1999; Franklin, 2000; 
Schneider, 1995). Therefore, understanding what type of RMT intervention children 
and adults with CF would be willing to participant in, and the factors that influence 
their adherence to an intervention, has become increasingly important. Such 
understanding can potentially provide better adherence to interventions and 
improvements in health outcomes and QoL, as well as guiding the development of 
future interventions (Kettler et al., 2002). 
 
As long-term survival in CF has increased significantly in the past 25 years, patient-
related outcomes and HRQoL are regarded with equal importance to medically 
beneficial therapies (Royce & Carl, 2011). However, only three RMT studies have 
included HRQoL as an outcome measure (Bieli et al., 2017; Chatham et al., 1997; 
Enright et al., 2004). The chronic respiratory disease questionnaire (CRQD) is the 
most commonly used disease specific measurement tool, which evaluates four 
domains considered important to individuals with chronic airflow obstruction: 
dyspnoea, mastery, fatigue and emotion (Chauvin, Rupley, Meyers, Johnson, & 
Eason, 2008). Utilising the CRQD, Chatham et al. (1997) reported significant 
improvements (p < 0.01) between groups in two parameters of mastery and emotion 
when working at 80% of maximal effort; however, Enright et al. (2004) found no 
significant differences in CRQD scores between groups working at 20% of maximal 
effort. Nonetheless, Enright et al. (2004) found that anxiety and depression scores 
decreased in the 80% IMT group, with no changes in the 20% or control group. It 
could be postulated that higher-intensity IMT could result in greater reductions in 
anxiety, depression and QoL, however more IMT studies need to investigate the 
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effects of differing intensities of IMT on psychological factors. Furthermore, Biele et 
al. (2017) found no differences in HRQoL between treatment groups using the cystic 
fibrosis questionnaire (CFQ). When adopting the CF clinical score (CFCS), which 
indicates overall symptom severity, no significant difference was reported between 
groups at baseline or post-intervention (Biele et al., 2017). Given that the CF 
population in Biele et al. (2017) were 9-18 years old, their condition and lung function 
were likely more stable, the CFCS and CFQ may not be sensitive enough to observe 
small treatment effects. Indeed, the CFCS was developed for patients experiencing 
pulmonary exacerbation, thereby limiting its usefulness in stable CF participants 
(Kanga, Kuhn, Craigmyle, Haverstock, & Church, 1999). However, there is currently 
no alternative scoring system in CF for short-term changes in symptoms. HRQoL is 
an essential measure that is needed to prioritise the various therapeutic interventions 
that are available for those with CF, not only to provide longevity, but meaningful 
QoL (Royce & Carl, 2011). Furthermore, the external validity of the studies reported 
may also be limited by the under-use of assessing dyspnoea and exercise capacity. 
These measures are important to consider for further interventions as previous 
research in healthy individuals have found after RMT individuals’ perceptions of 
breathlessness and maximal capacity has improved (el-Manshawi, Killian, Summers, 
& Jones, 1986; Romer, McConnell, & Jones, 2002), which could be extremely 
beneficial in the CF population. Alternatively, akin to most interventions, RMT seems 
to have responders and non-responders (Guenette et al., 2006) and, therefore, an effect 
may not be observed in all participants and could be better prescribed on a patient-by-














     Table 2.1 Respiratory muscle training protocols in cystic fibrosis participants. 
 
Author Mode Age (years) Sample Size Intensity Frequency Duration  Length Outcome 
Asher et al.  
(1982) 






Threshold TG 11.46 ± 
2.45 








Chatham et al. 
(1997) 





de Jong et al.  
(2001) 
Threshold Group mean 
19 ± 5.5 
n=9 TG 
n= 8 CG 











Enright et al.  
(2004) 
Flow Group mean 




80% MIP 6 sets of 6 
reps 







Amelina et al. 
(2006) 
Threshold UNKNOWN n=10 TG 
n=10 CG 










21.36 ± 6.6 n=24 UNKNOWN 30 mins 4 sessions 
over 3 months 












Ozaydin et al. 
(2010) 
 13.18 ± 2.65 n=14 TG 
n=14 CG 
30 – 80% 
MIV 




Threshold 9-12 n=10 TG 








40% of ‘new’ 
MIP 















trend in QoL 
Giacomodonato 












9-18  n=22 UNKNOWN 10-15 mins 2x per day 
5 days a week 









MIP: mean inspiratory pressure, MVV: maximum voluntary ventilation, mins: minute, TG: treatment group, CG: control group, IMS: 
inspiratory muscle strength, IME: inspiratory muscle endurance, VC: vital capacity, TLC: total lung capacity, FVC: forced vital capacity 
RMF: respiratory muscle function, PIMAX: inspiratory muscle strength, SPIMAX: sustained inspiratory muscle strength, TR: diaphragm 




The maintenance of respiratory muscle strength and endurance, and its subsequent 
effects on lung function, are of vital importance for those with CF and bronchiectasis. 
Indeed, PA and exercise have been shown to be essential prescriptions in the 
management of health and well-being in those with CF and bronchiectasis. However, 
RMT, and specifically IMT, is a cost-effective and time-efficient treatment strategy, 
which has the potential to positively impact both physiological and psychological 
health in CF and bronchiectasis. Nonetheless, interpretation of research to date is 
hampered by differing study protocols, designs, lack of psychosocial outcomes and 
specific (i.e., children) population-based interventions. Further research is therefore 
warranted to understand the true extent of the impact of IMT on various health 
outcomes in those with CF and bronchiectasis. It is also essential to gather the views 
and opinions of participants across the lifespan and disease severity, as well as of the 
multidisciplinary team, to understand the key barriers and facilitators to adherence, 
thereby enabling individually tailored strategies and ultimately aiding adherence to 





















3.1 Ethical Approval 
 
Ethical approval for all studies was granted by the North West – Liverpool Central 
Research Ethics Committee, REC reference 16/NW/0764. Local NHS Research and 
Development Committees at each individual hospital site also approved all 
experimental procedures.  
 
3.2 Infection Control and Patient Safety during Exercise 
 
In accordance with standard clinical practice, segregation was ensured during any 
visits relating to the research study at outpatient clinics. All equipment was sterilised 
following each use using appropriate bactericidal wipes; data collection rooms were 
cleaned and ventilated following each patient. PrO2 devices were also coded to ensure 
that any device was not given to another CF or bronchiectasis participant.   
 
All participants were closely monitored for any significant development of symptoms, 
such as severe discomfort, shortness of breath or abnormally high heart rate during 
exercise testing and the recovery period. Oxygen saturation (SpO2) was measured 
during functional exercise capacity field tests as per The British Thoracic Society 
guidelines (Hardinge et al., 2015). Medical personnel were aware when testing was 
taking place and were available in the surrounding area in case of any adverse 
symptoms during or following exercise. If participants did experience any severe or 
persistent symptoms during testing, a respiratory physician would have provided a 




Body mass (Seca 220; Hamburg, Germany) and stature (Seca 220; Hamburg, 
Germany) were measured to the nearest 0.01 kg and 0.01 m, respectively and body 
mass index was calculated (Equation 3.1). Waist and hip circumference were 
measured to the nearest 0.01 m at the narrowest point between the bottom of the ribs 
66 
 
and iliac crest, and widest point around the hips, respectively, using anthropometric 
tape (Seca Ltd., Birmingham, UK). Participants were required to remove their 
footwear and wear minimal clothing.  
𝐵𝑀𝐼 =





3.4 Lung and Respiratory Function Measurements 
 
Bronchiectasis and CF are characterised by chronic airflow limitation; therefore, 
spirometry remains essential to diagnose and assess the severity of the respiratory 
disease. Specifically, spirometry provides measures of forced vital capacity (FVC), 
forced expiratory volume in 1s (FEV1), FEV1/FVC and peak expiratory flow (PEF). 
FEV1/FVC ratio is the gold standard to identify airway limitation, with severity 
assessed by FEV1 (Vestbo et al., 2013). In CF and bronchiectasis, FEV1 decline has 
been consistently associated with morbidity and mortality, as well as greater risk of 
pulmonary exacerbations, hospitalisations and colonisation of Pseudomonas 
aeruginosa (Guan et al., 2016; Kosorok et al., 2001; Onen et al., 2007; Sanders et al., 
2014). Furthermore, PEF has been identified as an important predictive value for 
determining acute exacerbations, hospitalisations and the risk of death in those with 
chronic respiratory disease (Iglesia et al., 2005). Spirometry indices, specifically 
FEV1, have been shown to be an important primary endpoint in clinical trials to assess 
the efficacy of new therapies (Mayer-Hamblett, Ramsey, & Kronmal, 2007; 
VanDevanter & Konstan, 2012). 
 
FVC, FEV1, FEV1/FVC and PEF were assessed using a portable spirometer (Micro1, 
MicroRPM, Numed, Sheffield, UK), which is validated in children (>6 years; Jat, 
2013) and adults (Miller et al., 2005). Participants were directed to breathe in as deeply 
as possible, place their lips tightly around a ‘single-use’ antibacterial mouthpiece and 
blow out as hard and as fast as possible into the mouthpiece until no air is left to exhale. 
Instructions for children included prompts such as “sucking on a straw” for deep 
inspiration and “blowing out birthday candles” for a forceful expiration (Jat, 2013). 
Spirometry is an invaluable screening test of general respiratory health, which allows 
the monitoring and assessment of therapeutic interventions, as well as how disease 
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course affects lung function (Miller et al., 2005). As such, spirometry is an extremely 
beneficial tool in clinical research. The interclass correlation coefficients (ICCs) for 
FEV1, FVC, FEV1/FVC and PEF are 0.99 (CI; 0.97, 0.99), 0.98 (0.96, 0.99), 0.86 
(0.66, 0.94), 0.98 (0.96, 0.99), respectively, demonstrating excellent repeatability 
within this thesis. 
 
The development of symptoms and functional limitations associated with respiratory 
disease are highly associated with the respiratory muscles (Moran, Piper, Elborn, & 
Bradley, 2010). Inspiratory muscle weakness can potentially lead to a disparity 
between muscle load and capacity, consequently producing higher levels of dyspnoea, 
reduced exercise capacity and the promotion and development of hyperventilation and 
respiratory failure (Gibson, 1995; Moxham, 1991; Troosters et al., 2005). Conversely, 
a reduction in expiratory muscle strength can adversely impact the efficiency of 
coughing, thereby affecting removal of secretions from the airways (Arora & Gal, 
1981; Troosters et al., 2005). Previous research has shown significant reductions in 
respiratory muscle strength during exacerbations in CF (Naon, Hack, Shelton, 
Gotthoffer, & Gozal, 1993), with a reduction in respiratory muscle strength shown to 
contribute to respiratory problems in spontaneous breathing in bronchiectasis 
(BTS/ACPRC, 2009). Consequently, the assessment of both maximal inspiratory 
pressure (MIP) and maximal expiratory pressure (MEP) and sustained maximal 
inspiratory pressure (SMIP) are useful to monitor changes in disease over time and to 
determine the impact of interventions (Moran, Piper, Elborn, & Bradley, 2010). 
MIP and MEP were assessed using a portable electronic respiratory pressure meter, 
with a 2 mm leak to prevent glottal closure (MicroRPM, Carefusion 232 Ltd, 
Hampshire, UK), reported to be are valid in individuals older than 6 years 
(Laveneziana et al., 2019).To measure MIP, participants were asked to seal their lips 
firmly around the ‘single-use’ antibacterial mouthpiece. They were then instructed to 
exhale slowly, until they felt they had no air left in their lungs (to residual volume), 
and then inhale maximally for more than one second against the resistance of the gauge 
(ATS/ERS, 2002). To determine MEP, participants were required to inhale as much 
as possible and then exhale maximally for more than one second against the resistance 
of the gauge (ATS/ERS, 2002). Furthermore, MIP and MEP allow a simple 
assessment of respiratory muscle strength in a clinical setting (ATS/ERS, 2002) and 
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have been found to be suitable to evaluate changes within participants (Laveneziana 
et al., 2019). Measurements of both MIP and MEP had an excellent test-retest 
reliability in this thesis of ICC = 0.90 (0.77, 0.96) and 0.93 (0.84, 0.97), respectively. 
The PrO2Fit (Design Net, Smithfield, USA; Figure 3.2) requires participants to inspire 
through a manometer from residual volume to total lung capacity, whilst sustaining 
that breathe for as long as possible (Formiga et al., 2018). Due to the nature of this 
test, the PrO2Fit can provide measures of MIP, sustained maximal inspiratory pressure 
(SMIP) and inspiratory duration (ID). Both SMIP and ID reflect pressure-generating 
and endurance capacity from residual volume to total lung capacity (Cahalin & Arena, 
2015). SMIP and ID are emerging measure across several populations (Cahalin et al., 
2016; Formiga, Campos, & Cahalin, 2018), correlating with a number of physiological 
measures, including pulmonary function, functional exercise capacity, breathlessness 
and health-related quality of life measures (Chatham, Baldwin, Griffiths, Summers, & 
Enright, 1999; Gething, Williams, & Davies, 2004; Mickleborough, Nicholas, 
Lindley, Chatham, & Ionescu, 2010).  
 
For all lung function measurements, a minimum of three clinically ‘acceptable’ 
manoeuvres were performed, with a minimum rest period of 30 seconds between each 
attempt to minimise respiratory fatigue. The best of three consistent exhalations was 
recorded and values were deemed acceptable if the reported values did not exceed the 
next greatest by 10% or 10 cm H20. Strong verbal encouragement was given 
throughout all assessments and they were performed in line with recommendations by 
the British Thoracic Society (BTS, 1994) and the American Thoracic 
Society/European Respiratory Society (2002).  
 
3.5 Measures of Functional Exercise Capacity  
The gold standard of exercise testing is cardiopulmonary exercise testing (CPET), 
however it is costly, needs highly specialised equipment and technical expertise to 
supervise and interpret (Urquhart, 2011). Field tests are low-cost, requiring minimal 
equipment and act as a surrogate of measuring exercise capacity. However, field 
walking tests are often volitional and submaximal, lacking precise measure outcomes 
(Urquhart, 2011). Despite this, both the six-minute walk test (6MWT) and intermittent 
shuttle walk test (ISWT) have been shown to be valid and reliable measures of 
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functional exercise capacity that are responsive to change in chronic respiratory 
diseases (Holland, Spruit, & Singh, 2015). Additionally, field tests can be used as 
predictors of survival and hospital re-admission (Singh et al., 2014).  
 
Participants were required to wear comfortable clothing and appropriate walking shoes 
and to have refrained from vigorous exercise within two hours of the test 
commencement. All subsequent testing visits occurred, where possible, at the same 
time of day to minimise intra-day variability, associated with bronchodilator use (Um, 
Yoo, Young, Sung, & Shim, 2007). Ambulatory oxygen testing was supplied to 
participants if their haemoglobin saturation (SpO2) decreased by more than 4%, or fell 
below 90%. Ambulatory oxygen was then provided if it was shown to be beneficial as 
per The British Thoracic Society home oxygen guidelines (Hardinge et al., 2015). 
Those participants who already used ambulatory oxygen were reassessed to ensure it 
remained adequate. At rest, and immediately following test cessation, measures of 
SpO2, heart rate, dyspnoea, fatigue and blood pressure were taken. 
 
3.5.1 Six-Minute Walk Test  
 
The 6MWT is a practical self-paced test of walking capacity. Participants are required 
to walk as far as possible in six minutes along a 10 metre corridor (ATS/ERS, 2002). 
Participants were permitted to slow down their pace, and to stop and rest if necessary. 
Patients were verbally encouraged using standard phrases as per the ERS/ATS 
Technical Standard (Holland et al., 2014). The main outcome measured is walk 
distance (6MWD) in metres, that is strongly related to measures of peak exercise 
performance and moderately related to PA in daily life (Singh et al., 2014). A change 
in 6MWD of 30 metres or more is considered to be clinically important (Holland, 
Spruit, & Singh, 2015). 
 
3.5.2 Intermittent Shuttle Walk Test  
 
The ISWT is an externally paced maximal exercise test, controlled with pre-recorded 
series of beeps, where the speed of walking increases with each level (Noonan & Dean, 
2000; Singh, Morgan, Scott, Walters, & Hardman, 1992; Thomson et al., 2015). A 
course of 10 metres in length, with two markers inset of 0.5 metres from either end 
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was utilised. Participants were required to walk around the cones to avoid abrupt 
changes in direction (Singh et al., 1992).  The test was terminated when the participant 
could no longer continue or keep with the required pace. The test was terminated when 
either: (i) the patient indicated that they were unable to continue; (ii) the operator 
determined the participant was not fit to continue; or (iii) the operator assessed the 
patient was unable to sustain the speed and cover the distance prior to the beep 
sounding, defined as the participant being more than 0.5 metre away from the come 
when the beep sounds on a second successive 10 metre length (Singh et al., 1992; 
Thomson et al., 2015). The maximal duration of the test was 20 minutes. The number 
of lengths walked in metres was calculated with lower ISWT distance associated with 
poor survival and risk of hospitalisation in those with chronic respiratory diseases 
(Emtner, Arnardottir, Hallin, Lindberg, & Janson, 2007; Williams et al., 2012). 
 
3.6 Cardiopulmonary Exercise Testing with Supramaximal Verification 
 
CPET provides a global assessment of the integrative exercise responses, involving 
the pulmonary, cardiovascular and skeletal muscle systems (Weisman et al., 2003). 
CPETs are a relatively non-invasive, dynamic physiological overview of both 
submaximal and peak exercise responses, providing relevant information for clinical 
decision making for assessing the effectiveness of intervention strategies (Weisman et 
al., 2003). Although a large range of measures can be ascertained from CPET, 
obtaining the maximal oxygen consumption (V̇O2max) is of particular importance in 
clinical populations as it defines the limitations of the cardiopulmonary system 
(Balady et al., 2010). Indeed, V̇O2max represents the highest physiologically attainable 
value, whereas V̇O2peak is defined as the highest value attained during exercise and 
represents a participant’s exercise tolerance (Day, Rossiter, Coats, Skasick, & Whipp, 
2003). V̇O2max is defined by the Fick equation, as the product of cardiac output and 
arteriovenous oxygen difference ([C (a - v) O2]; Equation 2) and is recognised as the 
gold standard for cardiorespiratory fitness and the best index of aerobic capacity 






 V̇O2𝑚𝑎𝑥  =   (HR × SV) × [C (a − v)𝑂2]     
Equation 3.2 
 
Exercise testing is an valuable investigative tool for the clinical management in those 
with a chronic respiratory condition (ERS, 1997; Roca & BJ, 1997; Weisman et al., 
2003). Indeed, V̇O2max is an indicator of prognosis (Nixon et al., 1992; Pianosi et al., 
2005), quality of life (de Jong et al., 1997; Verhage et al., 2010) and risk of 
hospitalisation for exacerbations (Pérez et al., 2014) in chronic respiratory conditions. 
 
Participants were asked to refrain from eating at least two hours before testing and to 
avoid strenuous exercise for at least 24 hours prior to the CPET (ERS Task Force, 
1997). Following familiarisation, exercise was performed on a cycle ergometer 
(ViaSprint 150P; ViaSys Healthcare, Hoechberg, Germany). A cycle ergometer was 
chosen as it is less prone to introduce movement or noise artefacts into measurements 
and the work rate can be easily quantified (Weisman et al., 2003). Cycle ergometry 
has therefore been identified as the preferable mode of exercise in respiratory 
conditions. After a three-minute warm-up (10 W), participants completed an 
incremental ramp test with work rate determined based on information regarding the 
individual’s PA, clinical status and familiarity with cycling (Radtke et al., 2019). 
Consequently, resistance was increased at a predetermined rate ranging from 10 to 
25Wˑ-1, ensuring a test duration of ~ 8-12-min (Saynor, Barker, Oades, & Williams, 
2013a, 2013b). Ramp protocols on cycle ergometers have been shown to represent a 
higher correlation between oxygen consumption (V̇O2) and workload compared to 
step, thereby reducing the error in predictive metabolic cost in individual workloads 
(Myers et al., 1991). Participants were required to maintain a cadence of ~70-80 
revolutions per minute (rpm) until volitional exhaustion, defined as a drop-in cadence 
of >10 rpm for five consecutive seconds, despite strong verbal encouragement. Peak 
workload (Wpeak) was recorded upon exhaustion.  Following completion of the CPET, 
a five-minute warm-down (10 W) followed by a 10-minute seated recovery was 
undertaken (Saynor et al., 2013a, 2013b). Supramaximal verification (Smax) of  
maximum rate of oxygen consumption (V̇O2max) was then performed, whereby a three-
minute baseline (10 W) preceded a ‘step transition’ to a constant work rate equivalent 
to 110% of peak power output (Saynor et al., 2013a, 2013b). This work rate was 
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maintained until voluntary exhaustion. A five-minute active recovery at 10 W was 
utilised following test cessation. Cardiopulmonary exercise testing with supramaximal 
verification has been shown to be a safe and valid measure of V̇O2max in children, 
adolescents and adults who span the spectrum of CF disease severity (Causer et al., 
2018) and the European Respiratory Society (ERS) supports its usage in other chronic 
lung diseases (Radtke et al., 2019). 
Breath-by-breath pulmonary gas-exchange data were collected continuously during 
the incremental exercise tests (MetaMax 3B, Cortex Medical, Germany). Participants 
wore a facemask and breathed through an impeller turbine assemble (Jaeger Triple V, 
Hoechberg, Germany). The inspired and expired gas volumes were continuously 
sampled at 100 Hz. The V̇O2max was taken at the highest moving average measured 
over 15 seconds prior to exhaustion. The gas exchange threshold (GET) was 
determined as the V̇O2max at which there was a non-linear increase in carbon dioxide 
production (V̇CO2) relative to V̇O2max and an increase in minute ventilation 
(V̇E)/ V̇O2max without an increase in V̇E/V̇CO2. The intraindividual day-to-day 
variation in measuring V̇O2max is variable in itself, with previous research finding  
children and adults with no known cardiopulmonary pathology or impairment showing  
an ~4-6%  (Jones, 1988; Shephard, 1984), or no variation (De Mendonça & Pereira, 
2008; Garrard & Emmons, 1986). However, day-to-day variation is thought to be 
higher than those with pulmonary disease with a variation between 6% and 10% 
reported in those with COPD (Brown, Fischer, Stansbury, & Light, 1985; Noonan & 
Dean, 2000). Indeed, children with CF, a 9% intra-participant coefficient of variation 
has been reported (Saynor et al., 2013b), though to the author’s knowledge no indices 
are available for intraindividual variation in bronchiectasis. Variation could be 
attributed to biological aspects, equipment measurement error or patient motivations 
(Schaun, 2017). Despite this, the MetaMax 3B has been shown to reliable and valid 
method of pulmonary gas analysis (Polese et al., 2015; Macfarlane & Wong, 2012), 
with an excellent test-retest reliability within this thesis (ICC = 0.99 (0.97, 1.0)). 
Subjective ratings of perceived exertion (RPE) were recorded every minute during the 
CPET (Borg and Dahlstrom, 1962; Borg, 1998; Borg and Linderholm, 2009). The 
Borg scale has been shown to be valid and reliable method of recording exhaustion in 
children (Roemmich et al. 2006; Marinov et al. 2007), adults (Shariat et al., 2018; 
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Shinya Yamauchi, 2013) and during V̇O2max testing (Eston, Faulkner, Mason, & 
Parfitt, 2006; Eston, Lamb, Parfitt, & King, 2005). 
 
3.7 Handgrip Strength Test 
 
There are four key hand dynamometer instruments: strain, mechanical, pneumatic and 
hydraulic. Whilst strain dynamometers are expensive and can be heavy, mechanical 
instruments have limited reproducibility in grip force measurements due to calibration 
problems and pneumatic devices can be influenced by the hand size of the participant 
due to its dependency on surface area over which the force is applied (Roberts et al., 
2011). In contrast, hydraulic handgrip dynamometers are portable, economic and have 
a large amount of normative data available in both healthy and obstructive lung 
disease, making it the most suitable instrument for the interventions utilised within 
this thesis (Roberts et al., 2011). 
 
Handgrip strength (HGS) is a validated measures of peripheral muscle function, which 
has been shown to be correlated with lung function in those with CF (M. P. Smith et 
al., 2018; Wells et al., 2014) and a strong determinant of exercise capacity in those 
with chronic lung disease (Rik Gosselink, Troosters, & Decramer, 1996). In 
bronchiectasis HGS was independently associated with the six-minute walk test 
distance (Ozalp et al., 2012) Handgrip strength was measured using a hand 
dynamometer (Takei 5401, Tokyo, Japan), with the grip distance altered to suit each 
individual participant to ensure fingers and palm were completely clasped around the 
handle. The Takei 5401 dynamometer has been shown to have good validity and 
reliability, and higher precision than other dynamometers, with systematic bias of 0.49 
kg and reliability analyses of 0.02 kg (España-romero, 2010; Cadenas-Sanchez et al. 
2016). Participants were asked to stand upright with the arm naturally extended 
straight, pointing to the floor, and squeeze as hard as they could. A total of four 
measurements were taken (two from each hand), alternating hands each time and the 
best value from each hand was recorded in kilograms. The best value from each hand 
was recorded in kilograms. Of importance, hand dominance was recorded given that 
research has found a 10% difference in strength between dominant and non-dominant 
hands (Hepping, Ploegmakers, Geertzen, Bulstra, & Stevens, 2015). Verbal 
encouragement was given throughout the test. The same hand dynamometer was used 
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throughout the study to ensure reliability (ICC = 0.92, (0.82,0.97)) and to minimise 
systematic error.  
 
3.8 Inspiratory Muscle Training Protocol 
 
The PrO2Fit (Design Net, Smithfield, USA; Figure 3.1) is a flow resistive device, 
requiring participants to breathe through a 2mm leak, present to prevent glottal 
closure. The PrO2 fit has several psychologically and physiologically appealing 
characteristics such as live biofeedback, monitoring of adherence remotely, auditory 
and visual support via an app, increasing work-to-rest ratio, as well as being home-
based and being easy to alter the IMT parameters. Due to the specific PrO2 software 
being able to correct and adjust airflow, and therefore inspiratory muscle power, a very 
accurate workload is provided (Chatham et al. 2009; Enright & Unnithan 2011; 
Enright et al. 2004; Ionescu et al. 1998). This correction and adjustment results in a 
constant workload being imposed on the inspiratory muscles and therefore is 
equivalent to the inspiratory force throughout all inspirations (Cahalin et al., 2013). 
Thus, the PRO2fit provides a workload that is isokinetic-like, yielding consistent work 
throughout all inspiration (Cahalin et al., 2013). Compared to other forms of IMT 
testing or training, the diagnostic and rehabilitation attributes of isokinetic work in the 
peripheral muscles has been observed to be superior (Chatham, 2000; Chatham, 
Baldwin, Griffiths, Summers, & Enright, 1999; Chatham et al., 1994). The reliability 
and validity of measurements from PrO2Fit have only been reported in patients COPD 







Figure 3.1. A PrO2Fit inspiratory muscle training device. 
75 
 
Training was performed three times a week, with at least 24 hours separating training 
sessions, over eight weeks. In adults and children, neural adaptations have been found 
to occur in the first four weeks of a strength training intervention (Brown et al., 2017; 
Ramsay et al., 1990), with any improvements beyond four weeks considered 
morphological (Folland & Williams, 2007). Indeed, previous IMT studies have found 
eight weeks to be sufficient in producing significant physiological and psychological 
adaptation in bronchiectasis (Liaw et al., 2011; Newall, Stockley, et al., 2005; Ozalp 
et al., 2019) and CF (Chatham et al., 1997; Enright et al., 2004; Santana-Sosa et al., 
2014). Furthermore, a similar IMT protocol produced significant improvements in 
MIP, SMIP, vital capacity, total lung capacity, physical work capacity and diaphragm 
thickness, as well as reductions in anxiety and depression scores (Enright et al., 2004). 
To improve the respective components of strength, strength endurance and endurance 
intensities of 80-100%, 60-80% and approximately 60% of maximum voluntary 
contraction are required (Newton & Karmer, 1994). A significant positive relationship 
between percentage increase in MIP and relative magnitude of IMT load (Rochester, 
1991), suggests that the higher the load, the greater the relative inspiratory muscle 
strength increase (Ernesto Crisafulli et al., 2007). Therefore, the three SMIP 
measurements were recorded at the start of each training session and the highest 
sustainable profile was selected automatically and redrawn by the computer as a 
training template equating to 80% of the maximum pressure profile (Figure 3.2). This 
ensures that a true, real-time 80% target is provided for that day, facilitating an 
individualised and progressive nature of training (Cahalin & Ross, 2015).  
 
Inspiratory training manoeuvres were repeated using a regime of six repetitions across 
six levels. During each set of inspirations, the rest time between repetitions was 
progressively reduced from 60 seconds to 45, 30, 15, 10 and finally 5 seconds. If at 
any point the participant failed to achieve a least 80% of the computer-generated 
template, the test would terminate. All training sessions were uploaded automatically 










Figure 3.2 PrO2Fit app showing example training template equal to 80% of an 
individual’s maximum pressure profile.  
Participants were given full training on the PrO2Fit device and guided on how to set 
up and navigate the app to complete a training session. Training was also given to 
ensure participants were completing an appropriate inspiratory manoeuvre. To begin 
with, participants were coached without the device to ‘empty’ their lungs slowly and 
with control and then inspire by ‘sucking’ in the air hard and fast. When they were 
comfortable with this procedure, they were then given the PrO2Fit device to practice 
undergoing a SMIP manoeuvre with the app. Participants were encouraged to practice 
and ask any questions until they were comfortable with the training regime. 
 
3.9 Physical Activity Levels 
 
PA is defined as any bodily movement generated by the contraction of skeletal muscles 
that raises energy expenditure above resting metabolic rate, and is characterised by a 
modality, frequency, intensity, duration and context of practice (Caspersen et al., 
1985). Sedentary behaviour is defined as any waking behaviour characterised by an 
energy expenditure ≤ 1.5 metabolic equivalents (METs), while in a seated, reclined or 
lying posture (Sedetary Behaviour Research Network, 2012; Tremblay et al., 2017). 
The validity and reliability of self-reported questionnaire-derived physical activity 
levels have been questioned as they are susceptible to bias and subsequently over- or 
under-estimate PA and sedentary time (Jantzen et al., 2016; Ruf et al., 2012). Direct 
measures, such as accelerometery, can provide accurate information regarding the 
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quantity, intensity and pattern of PA and have been shown to be well tolerated in 
clinical populations (Bassett, John, & Bassett, 2010).   
 
Participants wore an ActiSleep+ (ActiGraph LLC, Pensacola, FL) accelerometer for 
seven consecutive days (Aznar et al., 2014; Mackintosh, Ridgers, Evans, & McNarry, 
2018; Watz, Waschki, Meyer, & Magnussen, 2009), on their right mid-axillary line at 
the level of the iliac crest, which assesses acceleration in the vertical, antero-posterior 
and mediolateral axes. A high sampling frequency of 100Hz was chosen to prevent 
the loss of vigorous data processing that occurs at lower frequencies (e.g. default 
30Hz; Deenik, 2019). Hip placement of the ActiSleep+ was chosen due to its optimal 
close location to the centre of mass, therefore reflecting movement of the whole body 
(Rosenberger et al., 2013; Westerterp, 1999). Furthermore, better classification of 
activities into sedentary and light and moderate-to-vigorous PA have been reported 
from hip placement (Rosenberger et al., 2013). Additionally, a self-report log 
accompanied the monitors to record if and why the ActiSleep+ was removed (i.e 
water-based activities) and a PA log (type, duration), allowing for cross examination 
of the data (ActiGraph, 2012). ActiSleep+ has been shown to be valid and reliable for 
PA measures in healthy paediatric (Kinder et al., 2012) and adult populations (Aadland 
& Ylvisåker, 2015; Cellini, Buman, Mcdevitt, Ricker, & Mednick, 2013), as well as 
those with CF (Ruf et al., 2012) and bronchiectasis (O’Neill et al., 2017).  
 
Data was downloaded and analysed using ActiLife Software 6 (ActiGraph v6.10.4; 
Pensacola, FL). One second epochs with sustained periods of at least 20 minutes at 
zero counts were considered non-wear time to ensure accurate assessment of PA 
intensity (Catellier et al., 2005). To be included for analyses, participants were 
required to have worn the ActiSleep+ for ≥ 9 hours∙day-1, for at least three days 
(Mattocks et al., 2008), including one weekend day (Aadland, Andersen, Anderssen, 
& Kvalheim, 2013), which has been previously used in clinical populations (Ryan et 
al., 2015). PA is suggested to differ between weekdays and weekend days in children 
with CF (Aznar et al., 2014; Mackintosh, Ridgers, Evans, & McNarry, 2018) and in 
adults with chronic respiratory condition (Watz et al., 2009). It is, therefore, pertinent 
to analyse the type of day separately to gain further insight into PA levels in chronic 
respiratory populations. Currently, there is a lack of developed and validated age- and 
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population-specific cut-points for CF and bronchiectasis populations (Mackintosh, 
Ridgers, Evans, & McNarry, 2018; O’Neill et al., 2017). Cut point selection may be 
specifically relevant in chronic respiratory conditions, whose relative intensity of a 
given count rate could be argued to be higher than their healthy peers (Mackintosh et 
al., 2018). 
 
For children, Evenson et al. (2008) cut-points have been shown to be a valid and 
reliable measurement of activity intensity (sedentary: <100 counts∙min-1, light: 100-
2,295 counts∙min-1, moderate- to- vigorous 2,296-4,011 counts∙min-1 and vigorous: 
physical activity >4,012 counts∙min-1) in children and adolescents (Trost et al., 2011). 
In adults, Troiano et al. (2014) cut-points were used to determine activity spent at 
different intensity categories (sedentary: <99 counts∙min-1, light: 100-2,019 
counts∙min-1, moderate- to- vigorous 2,020-5,998 counts∙min-1, vigorous PA: >5,999 
counts∙min-1). Moderate and vigorous PA were summed to obtain moderate-to-




3.10.1 Cystic Fibrosis Questionnaire 
 
All participants completed the age-appropriate version of the cystic fibrosis 
questionnaire–revised (CFQ-R;  Modi & Quittner, 2003; Quittner et al., 2000), a 
disease-specific health-related quality of life (HRQoL) questionnaire designed to 
measure the physical, social and emotional impact of CF on participants. The CFQ-R 
was the first disease-specific patient reported outcome for CF patients and has 
demonstrated reliability, interval validity and clinical sensitivity (Gee, Abbott, 
Conway, Etherington, & Webb, 2000; Quittner, Buu, Messer, Modi, & Watrous, 2005; 
Quittner et al., 2012). Furthermore, a strong convergence between the CFQ-R scales 
and key health outcomes has been reported (Quittner et al. 2012). Quality of life 
dimensions, disease-related symptoms and overall health perceptions are assessed on 
Likert-type scales and scores are standardised on each scale ranging from 0 to 100. 
The CFQ-R child version consists of 35 items grouped into eight dimensions and the 
adolescent/adult version consists of 50 items grouped into 12 domains. Specific 
subscales include physical functioning, role functioning, energy/fatigue, 
psychological, emotional and social functioning, eating disturbances, body image, 
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respiratory symptoms, digestive symptoms, weight disturbance, treatment burden and 
subjective health perceptions. Higher scores on the subscales indicate a better HRQoL.  
 
3.10.2 Self-Determination Theory  
 
Self-determination theory (SDT) posits three universal psychological needs 
(autonomy, competence, and relatedness), suggesting that all three must be met to 
ensure ongoing satisfaction for people to maintain optimal performance and well-
being. Needs satisfaction is a questionnaire used to assess the degree to which people 
feel satisfaction regarding their three key needs (Deci & Ryan, 2000). SDT is the only 
theory of motivation and behaviours which emphasises the importance and assessment 
of autonomous self-regulation (Levesque et al., 2006). Autonomous or self-
determined functioning are differentiated by SDT as types of behavioural regulation. 
There are four different types of behavioural regulation: i) introjection, which refers 
to taking in an activity but not accepting it as one’s own; ii) identification, which refers 
to accepting the value of an activity as personally important; iii) integrated, which 
refers to integrating that identification with other aspects of one’s self and; iv) 
extrinsic, which refers to the external influence behind one’s choices (Ryan & Deci, 
2000). The treatment self-regulation questionnaire assesses participants’ perceptions 
as to the degree in which they perceive an intervention provides autonomy support 
(Williams, Rodin, Ryan, Grolnick, & Deci, 1998). Within SDT, competence is 
assumed to be one of the three fundamental psychological needs, therefore a person’s 
feelings of perceptions of competence towards an activity is theorised to be important 
as it facilitates people’s goal attainment, while providing a sense of need satisfaction 
from engaging in an activity at which they feel effective (Ryan & Deci, 1985). 
Therefore, employing a self-determination theory grounding (Ryan & Deci, 1985), all 
participants completed psychological measures of self-regulation, needs satisfaction 
and perceived competence in relation to IMT. These measures were taken at baseline 
and following initial evaluation tests were appropriate. All measures are validated for 
use with clinical populations and modifications of items to the specific context, as 










There are three fundamental types of research interviews: structured, semi-structured 
and unstructured. Structured interviews consist of a list of predetermined questions, 
with little to no variation and no scope for follow-up questions to answers that warrant 
further elaboration. They only allow limited participant responses and therefore are of 
little use when looking for in-depth discussion (Gill, Stewart, Treasure, & Chadwick, 
2008). In contrast, unstructured interviews are performed with little or no organised 
questions and do not reflect any preconceived ideas or theories (Legard et al., 2003) 
and therefore are at risk of interviewer bias (Saks & Allsop 2013). Semi-structured 
interviews are composed of several key questions that help define the areas to be 
explored and allows the interviewer or interviewee to diverge in order to pursue an 
idea or respond in more detail (Britten, 1999). The flexibility of this approach makes 
it advantageous in an intervention setting, allowing discovery and elaboration of 
information that is important to the participant that may not have been thought of by 
the research team (Gill et al., 2008). Interviews were conducted with individuals to 
allow comparison of responses between healthy and clinical populations, while also 
looking for consensus opinions among individuals with differing levels of health and 
ability (Carter & Wheeler, 2019) 
 
Children and adults were required to complete one, face-to-face, individual semi-
structured interview with follow-up questions. All questions were open-ended 
allowing interviewees the opportunity to explore their experiences and to expand on 
their thoughts, feelings and ventures in undertaking an IMT program (Dicicco-Bloom 
& Crabtree, 2006; Given, 2008). Clarification and/or elaboration was sought when 
required and themes were pursued as they arose. The language was adapted to ensure 
full understanding from younger children. Interviews were recorded and transcribed 




























Determination of Pulmonary Rehabilitation Efficacy in those with 
Respiratory Disease 
Aims Findings 
To determine the effectiveness of PR in 
various respiratory disease and 
investigate the influence of sex, and 
socioeconomic status and their 
interaction on adherence  
 
Traditional PR is a supervised program that incorporates exercise training, health 
education, and breathing techniques for those with lung conditions or problems. 
However, PRs applicability and effectiveness in other respiratory diseases other 




Determination of Pulmonary Rehabilitation Efficacy in those 
with Respiratory Disease 
McCreery, J.L., Mackintosh, K.A., Duckers, J., Lines, T., Chamberlain, J., Jones, M., 
McNarry, M.A. (2019). P21 Influence of attendance rate on pulmonary rehabilitation 
in those with respiratory disease. Thorax, 74: A100. 
4.1 Introduction 
Pulmonary rehabilitation (PR), first defined by the American College of Chest 
Physicians Committee in 1974, is a comprehensive multi-faceted intervention tailored 
to individual needs. Specifically, PR includes education, behaviour change and 
exercise training components, all of which are intended to improve physical and 
psychological health (Spruit et al., 2013). In chronic obstructive pulmonary disease 
(COPD), PR has been shown to relieve dyspnoea and fatigue and improve health-
related quality of life (HRQoL). Moreover, PR has been shown to significantly 
improve exercise capacity in those with COPD, while enhancing the sense of control 
that individuals have over their condition (McCarthy, 2015). Indeed, given the strength 
of evidence,  the Cochrane Airways Editorial stated that no further research is required 
regarding the benefits of PR in those with COPD (McCarthy, 2015). However, the 
applicability of PR to other respiratory conditions, and the factors that influence its 
effectiveness, largely remains unresolved. 
Evidence suggests that PR is feasible, safe and possibly effective for those with a 
variety of respiratory diseases (Rochester, Fairburn, & Crouch, 2014). Specifically, 
PR has been associated with improvements in HRQoL, exercise capacity, clinical 
symptoms and/or exacerbations in both restrictive lung diseases (Naji et al., 2006), 
including idiopathic pulmonary fibrosis (Jastrzȩbski et al., 2006), and obstructive lung 
diseases, such as bronchiectasis (Lee et al., 2017; Patel et al., 2019) and asthma 
(Schultz et al., 2017). However, many of these studies are characterised by small 
participant numbers due to poor participant uptake and a large dropout rate  (Steiner 
et al., 2017), with suggestions that the high treatment burdens associated with some of 
these respiratory diseases may preclude such patients from adhering to a regular 
combined exercise and education programme (Metersky & ZuWallack, 2019). Steiner 
et al. (2017) suggested that socioeconomic status (SES) may also be a key contributor. 
It is also pertinent to note that even in studies that have reported beneficial effects of 
83 
 
PR, the magnitude of these effects is generally considerably smaller than those elicited 
in those with COPD. It therefore appears that PR may not be transferable from COPD, 
potentially due to the composition of the PR programme being unsuitable for the 
specific, and highly varied, aetiologies of different chronic respiratory diseases 
(Holland, Wadell, & Spruit, 2013). However, considerable inter-study heterogeneities 
in the specific composition of the PR programme precludes the determination of 
whether the inter-condition differences in effectiveness are due to these 
methodological variations, adherence or disease-specific factors. 
Biological sex is a potent determinant of disease aetiology and progressions; in 
comparison to their male counterparts, females with COPD have been shown to have 
significantly higher degrees of dyspnoea, lower disease-related HRQoL, poorer 
exercise performance and function, and poorer psychological status (De Torres et al., 
2005; Martinez et al., 2007; Watson et al., 2004). However, despite such differences, 
PR guidelines do not vary by sex. This may be because little is known regarding 
whether there is a sex-specific response to PR, whereby males and females respond to 
a different extent or in a different manner (Robles, Brooks, Goldstein, Salbach, & 
Mathur, 2014). Nonetheless, research has suggested that women elicit significantly 
greater improvements in dyspnoea, and functional health status in response to PR, 
whereas men have engendered greater increases in exercise capacity (de Torres, 
Casanova, de Garcini, Jaime, & Celli, 2007; de Torres et al., 2006; Watson et al., 
2004).  
Overall, the benefit of PR in respiratory diseases beyond COPD remains equivocal. 
Therefore, the primary aim of the present study was to ascertain the relative 
effectiveness of a standardised PR programme according to respiratory disease. The 
secondary aim was to determine the influence of sex and SES, and their interaction 
with adherence, on effectiveness. 
4.2 Methods 
A retrospective analysis was conducted on all patients enrolled at a university 
outpatient PR programme in South Wales between 2011 and 2019. A total of 1,284 
participants who had a primary respiratory diagnosis: (COPD (n= 878), asthma (n= 
39), interstitial lung disease (ILD; n= 211), COPD/Asthma (n=79) and bronchiectasis 
(n= 77)) were included in the current analyses. Patients were referred to PR if they 
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met the eligibility and exclusion criteria outlined by The British Thoracic Society 
(Bolton, Bevan-Smith, Blakey & et al., 2013). Values of forced expiratory volume in 
one second (FEV1) and forced vital capacity (FVC) were measured using spirometry 
in line with the European Respiratory Society Taskforce guidelines (Miller et al., 
2005). Predicted values for pulmonary function were determined according to Cotes 
et al. (2009). Anthropometric measures of height (m), body mass (kg), and BMI 
(kg·m2) were taken. The program content and delivery remained consistent over the 
period included within this study. All patients with a primary diagnosis of respiratory 
disease, who were referred to the PR programme, irrespective of whether they had 
secondary concomitant conditions, were included in this study. Given that some 
patients participated in the PR programme more than once over the specified period, 
only data from the initial engagement were included.  
4.2.1 Pulmonary Rehabilitation Programme 
The outpatient PR programme was multidisciplinary, including input from 
occupational therapists, physiotherapists, dietitians, physicians, specialist respiratory 
nurses and a smoking cessation counsellor. Patients were requested to attend the 
rehabilitation unit three days per week, for six weeks. Each session lasted 
approximately two hours and consisted of educational activities, exercise, and mental 
well-being sessions. Educational activities, which were delivered for approximately 
40 minutes at the start of each session, focused primarily on patients’ understanding 
of their pulmonary pathophysiology, behavioural change and anxiety management and 
how to integrate rehabilitation into their daily lives. Further discussions were aimed at 
the mechanisms of breathlessness and how to identify and cope with breathless 
episodes, as well as methods of chest clearance, the type and use of pulmonary 
medicines and the importance of exercise and nutritional status. 
Beyond education, an individually prescribed 30-minute exercise training programme 
consisted of upper- and lower-body exercises. An upper-body, mixed-apparatus circuit 
consisting of weights or elastic resistance bands, was used, with patients completing 
as many repetitions in a two minute period as possible on each apparatus. Step-ups, 
treadmill and self-paced cycle exercise were used for the lower-body. Specifically,  
patients were required to walk for as long as possible on the treadmill at 80% of their 
maximum walking speed, derived from the shuttle walk test (Singh, Morgan, Scott, 
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Walters, & Hardman, 1992), rating their breathlessness on a modified Borg scale 
(Borg, 1998). Once the patient was comfortable, increases in either speed or incline 
on the treadmill and resistance on the bike, were continued until the target of three-to-
five out of ten on the Borg Scale was achieved. During the initial exercise test, if 
patient’s haemoglobin oxygen saturation (SpO2) decreased by more than 4% or fell 
below 90%, they were offered ambulatory oxygen testing. If shown to be beneficial, 
ambulatory oxygen was subsequently provided and used as per The British Thoracic 
Society home oxygen guidelines  (Hardinge, Annadale, Bourne, & et al, 2015). If 
patients already used ambulatory oxygen, they were reassessed to ensure it remained 
adequate and titrated if indicated. The final component of the PR programme involved 
stress management and relaxation to promote the patients’ mastery and control over 
their illness. Throughout the PR programme, individuals were encouraged to set goals 
and focus on specific needs in activities of daily living or specific physiotherapy 
advice. Additionally, patients were offered dietary advice, with those with a body mass 
< 20 kg·m-2 advised on formal supplementation and those > 25 kg·m-2 on weight loss 
techniques.  
4.2.2 Clinical Outcomes  
The primary anthropometric outcome was considered free fat mass (FFM; kg) 
assessed using Tanita bio-impedance scales (Tanita TBF-300MA). Depending on 
patient ability, the intermittent shuttle walk test (ISWT) or the six minute walk test 
(6MWT) were used, to estimate cardiorespiratory fitness levels. The ISWT is a 
progressive 10 metre walking test with audio cues indicating change of speed and 
progression to the next level (Singh et al., 1992; Noonan & Dean, 2000). The test was 
terminated when patients were unable to cover the distance in time for the beep, or if 
they exhibited breathlessness, reached 85% of their maximum heart rate or there were 
any obvious signs or symptoms of distress. For the 6MWT, the distance covered, along 
a 10 metre corridor , in six minutes was used to asses performance capacity (ATS/ERS, 
2002). Patients were able to rest within the six minutes if necessary. Finally, handgrip 
strength was measured using a hand dynamometer (Takei 5401, Tokyo, Japan), with 
grip distance altered to suit each individual patient. Patients were instructed to stand 
upright with the arm straight down by their side pointing to the floor and squeeze as 
hard as they could. Two repetitions were performed on each hand and a combined 
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overall average was calculated from both right- and left-hand results (Jeong et al., 
2017; Roberts et al., 2011).  
To determine the impact of the patient’s condition on their overall health, daily life 
and perceived well-being, the St George’s Respiratory Questionnaire (SGRQ) was 
used (Jones, Quirk, Baveystock, & Littlejohns, 1992). The SGRQ has three 
components focusing on symptoms (frequency and severity), activities (that cause or 
are limited by breathlessness) and impact (social functioning, psychological 
disturbances resulting from airway disease). The SGRQ yields a total score out of 100, 
with higher scores indicative of more severe limitations. Internal consistency 
reliability, assessed with Cronbach’s alpha (Cronbach, 1951), was 0.85 for the overall 
SGRQ scale and 0.81, 0.78 and 0.80 for symptoms, activity and impact subscales, 
respectively. The Hospital Anxiety and Depression Scale (HADS) was used to assess 
the symptom severity of anxiety disorders and depression (Snaith, 2003). The HADS, 
a valid and reliable measure (Snaith, 2003), is a 14-item questionnaire on a scale of 0 
(no anxiety/depression) to 21 (maximum anxiety/depression); scores greater than eight 
indicate clinically relevant anxiety and depression. Cronbach’s reliability coefficient 
was 0.82 and 0.74 for HADS anxiety and depression, respectively. 
4.2.3 Index of Multiple Deprivation 
The Welsh Index of Multiple deprivation (WIMD; www.wimd.gov.wales ), a measure 
of relative deprivation for areas in Wales was used to assess SES.  The WIMD 
incorporates eight separate domains and weights of deprivation (income [22%], 
employment [22%], health [15%], education [14%], access to services [10%], 
community safety [5%], physical environment [5%] and housing [7%]). The overall 
index is constructed from a weighted sum of the deprivation score for each domain. 
The weighted score reflects the importance of the domain as an aspect of deprivation, 
and the quality of the indicators available for that domain. WIMD ranks all areas in 
Wales from 1 (most deprived) to 1,909 (least deprived). Patient postcodes were used 
to obtain deprivation data pertaining to the area in which the patient lived at the time 
of their enrolment on the PR programme. 
4.2.4 Statistical Analysis 
A general linear model with univariate analysis was used to determine the relationship 
of the differing respiratory groups between variables at baseline. To account for the 
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repeated and correlated nature of data, linear mixed-effects models were used to 
determine the influence of, and interaction between, respiratory disease percentage 
attendance, overall deprivation score, sex, and walk test distance in each respiratory 
disease compared to COPD. All condition combinations were entered into one model, 
with a covariate (SGRQ activity domain) added to subsequent adjusted models to 
determine their effect. Statistical analyses were performed using statistical package 
STATA.13 (StataCorp 2001. Statistical Software: College Station, TX: Stata 
Corporation). All data are presented as means ± SD and statistical significance was 
accepted when p ≤ 0.05.  
4.3 Results 
There were significant differences in age, FEV1%predicted, FVC, FFM, BMI and SES 
between respiratory groups at baseline (p <0.001; Table 4.1). COPD patients had the 
lowest FEV1% predicted (47.0 ± 20.0) and highest FVC (2.5 ± 3.9 l), with those with 
COPD/Asthma having the highest BMI (30.8 ± 5.6 kg·m2). Those with ILD had the 
highest FEV1% predicted (79.6 ± 20.6), and FFM (52.7 ± 9.9 kg), while bronchiectasis 
patients had the lowest FVC (2.0 ± 0.5l), FFM (45.1 ± 7.8 kg) and BMI (25.9 ± 5.0 
kg·m2). SES was highest in the bronchiectasis group (1,136.0 ± 650.6) and lowest in 














       Table 4.1. Baseline characteristics according to respiratory disease.  
 
 
COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease;  BMI, body mass index; FFM, free fat mass; FEV1, forced vital 
capacity in 1 second; FEV1%pred, forced vital capacity in 1 second percentage predicted; FVC, forced vital capacity; FVC%pred, forced vital 
capacity percentage predicted; SES, socioeconomic status.*p <0.05. 
 
 Total 
n = 1,268 
COPD 
n = 881 
Asthma 
n = 39 
Bronchiectasis 
n = 77 
ILD 
n = 192 
COPD/Asthma 





Age 68.2 ± 9.7 67.5 ± 9.5 70.0 ± 10.1 69.8 ± 10.8 72.1 ± 9.8 64.4 ± 9.7 0.000* 
Sex Male  680 456  13  18  113  27   
Sex Female 663 422 26 59 98 52  
Height (m) 1.7 ± 0.9 1.6 ± 9.5 1.7 ± 0.1 1.6 ± 0.1 1.7 ± 0.1 1.6 ± 0.3 0.899 
FFM (kg) 50.0 ± 11.0 49.6 ± 10.7 48.8 ± 9.4 44.8 ± 6.8 52.9 ± 10.1 51.7 ± 11.4 0.000* 
BMI (kg·m2) 28.0 ± 6.8 28.0 ± 6.6 29.1 ± 5.6 25.9 ± 5.0 28.4 ± 5.7 31.2 ± 5.6 0.000* 
FEV1 (l) 1.51 ± 0.6 1.5 ± 2.2 1.23 ± 0.5 1.3 ± 0.4 1.9 ± 0.5 1.3 ± 0.5 0.940 
FEV1 %pred 54.9 ± 21.2 48.1 ± 0.1 54.6 ± 18.0 61.9 ± 23.5 79.6 ± 20.6 56.4 ± 20.2 0.000* 
FVC (l) 4.5 ± 0.9 2.6 ± 6.9 2.4 ± 0.9 2.0 ± 0.5 2.4 ± 0.7 2.4 ± 0.7 0.154* 
FVC %pred 76.8 ± 22.4 76.0 ± 20.2 71.1 ± 18.1 79.3 ± 20.8 78.3 ± 21.5 81.3 ± 21.7 0.168 
SES 899.4 ±654.9 810.8 ± 637.4 782.1 ± 588.5 1,136.0 ± 650.6 870.2 ± 609.1 1,126.7 ± 679.8 0.000* 
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Table 4.2. Changes pre-and post -pulmonary rehabilitation in physiological and psychological measurements across differing 
respiratory diseases.  
 
 Total 
n = 1,284 
COPD 
n = 878 
Asthma 
n = 39 
Bronchiectasis 
n = 77 
ILD 
n = 211 
COPD/Asthma 
n = 79 
                                                                                                               SGRQ 
Symptom 57.4 ± 22.7* 57.4 ± 23.0* 68.3 ± 17.7* 58.0 ± 18.0 51.3 ± 21.6 61.6 ± 21.5 
Activity 77.7±15.5* 79.3 ± 16.3* 85.5 ± 11.3 67.3 ± 17.4* 75.1 ± 16.9 77.9 ± 18.4* 
Impact 37.7 ±16.2* 37.6 ± 16.7* 36.1 ± 17.0* 32.6 ± 14.6* 35.7 ± 15.3* 36.5 ± 16.3* 
Total 52.5 ± 14.0*  53.4 ± 14.9* 54.4 ± 11.6* 47.3 ± 13.3* 50.1 ± 13.6* 53.3 ± 15.3* 
         HADS    
Anxiety  6.3 ± 3.8* 6.4 ± 4.0* 7.2 ± 4.1 6.1 ± 4.0* 5.0 ± 3.3* 7.2 ± 4.3* 
Depression  4.3 ±3.4* 4.5 ± 3.4* 4.5 ± 3.4* 3.6 ± 3.0* 3.8 ± 2.9* 4.3 ± 3.5* 
          Strength    
HGS 26.2 ±9.4* 25.7 ± 8.9* 26.3 ± 8.3 21.5 ± 6.9 27.6 ± 9.6 25.7 ± 9.9 
   Exercise Capacity     
6MWT (m) 221.3 ± 79.3* 
(n = 356) 
220.5 ± 80.6* 
(n = 282) 
246.7 ± 77.6 
(n = 10) 
243.6 ± 91.3* 
(n = 16) 
237.3 ± 84.3* 
(n = 26) 
192.4 ± 59.3 
(n = 16) 
ISWT (m) 
 
212.7 ± 95.8* 
(n = 650) 
213 ± 87.5* 
(n = 456) 
181 ± 62.3* 
(n = 23) 
231.7 ± 91.6* 
(n = 42) 
223.5 ± 104.3* 
(n = 78) 
224.9 110.3* 
(n = 38) 
COPD, chronic obstructive pulmonay disease; ILD, interstitial lung disease; HADS, hospital anxiety and depression scale; SGRQ, St Georges 




Irrespective of condition, there were significant sex differences at baseline, with 
females having a higher BMI (28.3 ± 6.9 kg·m2; p = 0.017), and higher anxiety levels 
(9.6 ± 4.7; p< 0.001), in comparison to males (27.3 ± 5.9 kg·m2 and 8.1 ± 4.6, 
respectively). In contrast, males had significantly higher FFM (57.8 ± 9.8 kg; 
p<0.001), HGS (31.5 ± 8.1kg; p< 0.001) and walking distance (161.9 ± 81.0 m; p 
<0.001), in comparison to females (42.5 ± 6.5 kg, 18.9 ± 5.2 kg, 144.6 ± 74.9 m, 
respectively). Post PR, a number of these differences were ameliorated, but significant 
differences still occurred between sexes, with females still demonstrating a higher 
BMI (28.5± 5.6 kg·m2; p = 0.03) and higher anxiety levels (6.9 ± 3.9; p <0.001), 
compared to their male counterparts (27.5 ± 6.0 kg·m2 and 5.7 ± 3.9, respectively). 
Males continued to have significantly higher HGS (32.4 ± 7.6 kg; p <0.001), FFM 
(57.5 ± 9.6 kg; p <0.001) and walking distance (226.5 ± 93.0 m; p <0.001) in 
comparison to females (19.8 ± 5.6 kg, 42.6 ± 6.5 kg, 204.1 ± 86.0 m, respectively; 
Table 4.3). Those with a low SES exhibited significantly higher levels of anxiety, 














Table 4.3. Pre- and post-pulmonary rehabilitation in physiological and psychological outcome measurements between and withing 
females and males, irrespective of disease.  
 PRE POST 
Parameters Male Female Male Female 
  Anthropometrics   
FFM (k) 27.4 ± 6.9 28.5 ± 6.9* 27.4 ± 5.9 28.5 ± 6.9* 
BMI (kg·m2) 57.5 ± 9.6 42.8 ± 6.4* 57.3 ± 9.6 42.7 ± 6.2* 
                                                     SGRQ  
Symptom 65.0 ± 20.9 66.3 ± 21.1 57.3 ± 22.3 58.7 ± 22.6 
Activity 83.8 ± 15.6 84.9 ± 14.8 76.6 ± 17.2 79.0 ± 16.8 
Impact 47.7 ± 17.6 50.0 ± 18.4 37.3 ± 16.7 36.6 ± 16.4 
Total 61.4 ± 14.9 63.3 ± 15.3 52.4 ± 15.0 53.1 ± 14.8 
HADS                                                     HADS  
Anxiety  7.8 ± 4.5 9.4 ± 4.6* 5.8 ± 3.9 6.9 ± 3.9* 
Depression  7.4 ± 3.9 7.7 ± 3.7 4.6 ± 3.5 4.2 ± 3.2 
                                                     Strength  
HGS 31.7 ± 7.8 18.8 ± 5.1* 32.3 ± 7.7 19.8 ± 5.5* 
           Exercise Capacity    
6MWT (m) 182.2 ± 76.5 155.4 ± 69.8* 235.5 ± 82.3 210.2 ± 73.7* 
ISWT (m) 153.7 ± 79.5 142.6 ± 201.7* 221.1 ± 97.1 201.7 ± 93.2* 
SGRQ, St George’s Respiratory Questionnaire; HADS, hospital and anxiety scale; FFS, free fat mass; BMI, body mass index; HGS, handgrip 






There was a significant interaction between attendance and exercise capacity (p 
<0.001), irrespective of disease. When compared to COPD, PR was shown to be 
effective across all disease types in both physiological and psychological parameters 
(Table 4.4). There was a significant improvement in exercise capacity following PR, 
irrespective of disease. Males had a significantly higher exercise capacity at both 
baseline and post PR. 
Overall, there was 70.5% average adherence (number of sessions completed) across 
the programme, with COPD (84%), asthma (85%) and bronchiectasis (75%), having 
the highest adherence rates, and fibrotic lung disease (54%) the lowest. All 
participants, irrespective of disease, were categorised into four groups: did not attend 
(n = 133), low adherence (<33% sessions; n = 130), moderate adherence (33-66% 
sessions; n = 134) and high adherence (>66% sessions; n = 950). SES had a significant 
















Table 4.4 Linear mixed models with random effects looking at chronic respiratory conditions compared to chronic obstructive 
pulmonary disease and the impact of sex, time, attendance and deprivation to a pulmonary rehabilitation programme.  
Coefficients Estimate SE z 95% Confidence Intervals p-value 
Asthma -5.64 25.85 -0.22 -56.31 45.03 0.270 
ILD 14.26 14.29 1.00 -13.75 42.27 0.318 
COPD/Asthma 4.53 16.80 0.27 -28.39 37.45 0.787 
Bronchiectasis 26.45 14.24 1.86 -1.47 54.36 0.063 
       
Male 26.31 7.07 3.72 12.45 40.45 0.000* 
Time 58.84 3.99 14.76 51.02 66.65 0.000* 
Attendance 41.89 2.09 20.05 37.80 46.00 0.000* 
SES 0.01 0.004 2.15 0.001 0.02 0.026* 









4.4 Discussion  
The aim of this retrospective study was to ascertain the relative effectiveness of PR to 
enhance physiological and psychological health according to respiratory disease. 
Overall, in comparison to COPD, patients were similarly able to adhere to, and benefit 
from, a six-week PR programme, irrespective of the specific respiratory disease. 
However, SES was found to have a significant impact on attendance to PR.  
The United Kingdom (UK) has a higher morbidity and mortality associated with 
respiratory disease compared to other western countries (Chung et al., 2002; 
Salciccioli et al., 2018). It is therefore paramount to identify effective treatment 
strategies that can address this problem, with one potential strategy being PR. The 
effectiveness of PR has been well documented (McCarthy, 2015), however, relatively 
little is known about the utility and feasibility of PR in other respiratory diseases.  In 
contrast to previous studies, which appear to suggest a lower magnitude of effect in 
other respiratory diseases, the current results found a similar degree of improvement, 
irrespective of disease. Specifically, whilst functional capacity and HRQoL have been 
reported to be improved by PR in various respiratory conditions, including asthma 
(Conemans et al., 2018), bronchiectasis (Metersky and ZuWallack, 2019) and in those 
with pulmonary fibrosis (Gomes-Neto et al., 2018), there has been little consistency 
in the PR programmes implemented, limiting comparisons and interpretations. 
Moreover, such inter-study discrepancies, may reflect the specific physiological and 
psychological effects of each condition, or indeed the requirement for a tailored 
education component. Future research is therefore warranted to determine whether PR 
needs to be tailored to disease-specific needs. Specifically, the optimal duration, 
frequency and intensity of PR has yet to been identified, with current guidelines 
recommending a programme of three times a week for eight weeks to gain beneficial 
improvements. However, the current study elicited training effects in a six-week 
program, irrespective of disease. Poor uptake and adherence remain a significant 
challenge to rehabilitation and there is a need for robust, well designed, trials to 
explore the overall effectiveness of PR, as well as exploring exacerbations post PR 
(Candemir, Kaymaz, & Ergun, 2017). Furthermore, improvements in exercise 
capacity and HRQoL from PR have been shown to diminish over time, therefore 
sustaining these enhancements is fundamental to ensure long-term well-being in those 
with a respiratory disease (Lee & Holland, 2014). 
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Accessibility to PR services for patients in the UK is variable, with over 37% of 
patients waiting more than three months (Steiner et al., 2015). However, despite what 
these waiting list suggests, the rate of attendance to PR is reported to be approximately 
50%, with 40% of those assessed for PR failing to enrol on or complete treatment 
(Garrod et al., 2006; Fischer et al., 2009; Keating, Lee and Holland, 2011; Steiner et 
al., 2015). Conversely, adherence to the PR reported within this retrospective study 
was substantially higher, with 70.5% of patients reporting high attendance, defined as 
>66% of sessions completed. Key reasons cited for poor compliance to large-scale PR 
programmes include a lack of resources, geographical distance from treatment centres 
and the time of scheduled classes (Steiner et al., 2015). Furthermore, working patients 
have been shown to be particularly disadvantaged as classes are often delivered during 
the traditional working day (Steiner et al., 2015; Bourne et al., 2017). Indeed, one of 
the reasons for the high adherence in our patient group could be their geographical 
closeness to the hospital, with the average travel time being 18 minutes. Qualitative 
studies have found that barriers to adherence in PR for those with COPD, include a 
lack of perceived benefit by patients, convenient transport, personal determination and 
physical health (Keating, Lee and Holland, 2011; Oates et al., 2017). Conversely, Guo 
and Bruce (2014) and Oates et al (2018) found that building patient confidence through 
motivational and supportive staff, access, evidence of tangible results and recognising 
and adjusting issues of readiness were all facilitators to participation in PR for those 
with COPD. However, whether these barriers and facilitators are also applicable to 
those undertaking PR with other respiratory diseases remains to be elucidated.  
Health disparities are common in those with respiratory disease, with lower 
socioeconomic groups up to 14 times more likely to have a respiratory disease 
(Pleasants, Riley, & Mannino, 2016; Sahni, Talwar, Khanijo, & Talwar, 2017; 
Schraufnagel et al., 2013). Furthermore, the prevalence and impact (e.g., risk of 
hospitalisations) of COPD is inversely associated with SES in many countries 
(Prescott, Lange, & Vestbo, 1999), including the UK (Gershon, Dolmage, Stephenson, 
& Jackson, 2012). Similarly, asthma severity and frequency of hospitalisations are 
negatively related to SES (Sahni et al., 2017). In accord with a recent study (Steiner et 
al., 2017), the present study found that those living in a more socially deprived area 
had poorer attendance to the PR program. It was also noted that, at baseline, those with 
a lower SES had higher anxiety levels, well-being (SGRQ total score) and dyspnea. 
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Symptoms of anxiety have been shown to manifest in a variety of ways, including 
dyspnea, with patients with COPD describing their understanding of dyspnea as an 
experience related to anxiety and emotional functioning (Tselebis et al., 2016). A 
systematic review concluded that PR is beneficial in reducing anxiety, by providing 
active distraction from worrying thought patterns, increasing self-efficacy, and 
providing a meaningful mastery experience, with regular social content and support 
(Coventry & Hind, 2007; Tselebis et al., 2016). Educating patients on breathing 
control exercises during PR teaches them to recognize and control their dyspnea, 
increasing confidence, control and autonomy (Lorig et al., 1999). Indeed, in line with 
previous research (Wadell et al., 2013), improvements in anxiety post PR in the current 
study were shown to significantly correlate with improvements in overall health, daily 
life and perceived well-being (SGRQ total score). However, anxiety may manifest in 
physical symptoms during the course of a PR program, and it is therefore essential that 
patients are treated on an individual basis (Tselebis et al., 2016). The paradox that 
currently exists in PR is that those most likely to benefit, are least likely to adhere or 
participate (Fischer et al., 2007; Robertson, 2010). Therefore, understanding the 
impact of an individual’s SES on adherence is paramount to improving outcomes for 
those with respiratory conditions. It is, however, important to note that SES in the 
current study (e.g., WIMD) was calculated based on home postcode at the time of PR 
enrolment, which is a reflection of the whole local area within which there is likely to 
be considerable variation in individual levels of deprivation.  
 
There is a growing body of evidence that suggests that alternative strategies to 
conventional PR needs to be considered for lower SES patients to improve overall 
adherence. Specifically, the British Thoracic Society guidelines highlight the need for 
fundamental research on the optimal structure of PR and to improve accessibility 
(Bolton et al., 2013). Home-based PR could be an effective strategy in those with 
lower SES. Indeed, a recent study in 459 COPD patients found that a once-weekly, 
home-based PR for eight weeks was effective, regardless of SES (Grosbois et al., 
2019). Furthermore, research found no significant differences when comparing the 
effects of online and conventional PR programmes on all outcomes measured 
following a six-week intervention (Bourne et al., 2017). However, it is important to 
acknowledge that this was a single-centre study and the applicability across different 
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providers and regions remains to be determined. Future multi-centered studies are 
therefore warranted. Whilst home-based PR may facilitate greater PR programmes in 
the UK, methods to offer remote supervision, provide home-based exercise 
equipment, as well as patient selection, need careful consideration (Bolton et al., 
2013). 
Congruent with previous research (Haggerty, Stockdale-Woolley, & ZuWallack, 
1999; Verrill, Barton, Beasley, & Lippard, 2005), the current study found that females 
had poorer fitness, irrespective of disease or time-point, in comparison to their male 
counterparts. Reduced walking capacity, as a proxy measure for fitness, may imply 
progressive deterioration and thereby increase prevalence of morbidity and mortality 
(Awotidebe et al., 2017). Salciccioli et al. (2018) found that mortality trends for men 
in the UK are similar to EU15+ countries, yet women in the UK have a significantly 
greater mortality with respect to obstructive respiratory disease. Furthermore, the 
current results showed sex differences post PR in handgrip strength and anxiety, but 
no difference in depression or overall health, daily life and perceived well-being 
(SRGQ total score). However, a systematic review (Robles et al., 2014) reported that 
some studies showed no gender differences in PR, concluding that sex-related 
responses to PR remains unclear. Such contradictory evidence could be attributed to 
differing PR programs, settings and outcome assessments. Therefore, the impact of 
sex-related differences on the efficacy of PR remains to be fully elucidated; further 
research is therefore needed to ascertain such outcomes and the underlying needs 
associated with sex and respiratory diseases. Such research is warranted to enable the 
modification of traditional training methods to align with specific patient needs.  
4.5 Conclusion 
In conclusion, this retrospective study highlights the applicability of PR to a variety 
of respiratory disease, while highlighting the clinical importance of participants 
adhering to, and engaging in, a PR program. Further prospective studies are warranted 








Determination of Pulmonary Rehabilitation Efficacy in those with 
Respiratory Disease 
Aims Findings 
To determine the effectiveness of PR in 
various respiratory disease and 
investigate the influence of sex, and 
socioeconomic status and their 
interaction on adherence  
Pulmonary rehabilitation (PR) is 
applicable to a variety of respiratory 
diseases. Sex differences occur at 
baseline and post-PR. Low 
socioeconomic status has a negative 
















Assessing the Perceptions of a POWERBreath Inspiratory Muscle Training 
Intervention in Children with Cystic Fibrosis and their Multidisciplinary Team 
Aims Findings 
Ascertain the views and opinions of 
inspiratory muscle training from 
children with CF and their 
multidisciplinary team 
 
To investigate the feasibility of alternate Pulmonary Rehabilitation strategies in 
those with a chronic respiratory condition, a short, home-based inspiratory muscle 
training intervention was undertaken. Children with Cystic Fibrosis and their 
multidisciplinary team were asked their thoughts and feelings on undertaking 
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Cystic Fibrosis (CF) is the most common, inherited, life-shortening condition in the 
UK (Jeffery et al., 2017). Despite recent advances in pharmacological interventions 
(Wainwright et al., 2015), the median life expectancy remains around 40 years (Jeffery 
et al., 2017). Characterised by recurrent respiratory infections, breathlessness, cough, 
and gastrointestinal complications, CF is a multi-system disease requiring many hours 
of daily therapy (Sawicki, Sellers, & Robinson, 2009). With no current cure, the 
development or refinement of treatment strategies that increase or maintain quality of 
life (QoL), exercise capacity and respiratory function are paramount for the well-being 
of people with CF.  
 
Inspiratory Muscle Training (IMT), which utilises restricted airflow breathing 
exercises to increase the mechanical load on the external intercostal muscles and 
diaphragm, is a subject of research interest. The increased muscular load engendered 
by IMT provides a stimulus to elicit a hypertrophic response (Enright et al., 2004), 
similar to that observed in response to strength training in limb muscles (Reid, Geddes, 
O’Brien, Brooks, & Crowe, 2008). Significant improvements in respiratory muscle 
endurance (Asher, Pardy, Coates, Thomas, & Macklem, 1982; De Jong et al., 2001), 
respiratory muscle strength and vital capacity (Sawyer & Clanton, 1993), have been 
reported in patients with CF who have undertaken IMT, and there is some evidence 
for a positive effect on lung function and QoL (Enright et al., 2004). Despite the 
potential benefits of IMT, there is a lack of consensus regarding its routine use in 
clinical practice due to significant variations in study protocols, small sample sizes 
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and lack of psychosocial outcome measures (Houston, Mills, & Solis-Moya, 2013; 
Reid et al., 2008). Specifically, only two studies report psychosocial health as an 
outcome, reporting that anxiety and depression scores decreased in an IMT group that 
trained at 80% of their maximal effort (Enright et al., 2004), and a trend towards an 
improved QoL with a combined IMT, ‘whole muscle’ training programme (Santana-
Sosa et al., 2014). Regardless of potential efficacy, many treatment strategies are 
limited by participant’s perceptions of, and thus adherence to, the intervention. Indeed, 
a common barrier to adherence cited by many adolescents with CF is the 
embarrassment of taking their treatments in front of other people (Rand & Prasad, 
2012; Selvadurai et al., 2004). This suggests the potential utility of home-based 
interventions, such as IMT, that may increase adherence to treatments in adolescents 
with CF. However, no studies are presently available regarding the perceptions, 
opinions or recommendations of participants, or indeed of a MDT, concerning IMT. 
Furthermore, the mean age of participants in IMT studies is approximately 18.5 years 
(Hilton & Solis-Moya, 2018b). With average life expectancy around 45.1 years, the 
participants in these studies are effectively middle aged and therefore further research 
in the younger CF population is warranted (Carr, Cosgriff, & Rajabzadeh-Heshejin, 
2015). This lack of evidence makes it difficult to establish the overall efficacy of IMT 
as a therapeutic strategy for adolescents with CF (Houston et al., 2013).  
 
Therefore, the aim of this study was to ascertain the views of children, and their 
respective CF MDT, in relation to IMT following a four-week training programme.  
 
5.2 Methods 
Five children (11-14 years), were included if they met the following criteria: (a) took 
part in the pilot study of IMT conducted by Swansea University; (b) had a confirmed 
diagnosis of CF or were a matched control; (c) absence of any additional non-CF 
illness and/ or disease; and (d) voluntarily participated and provided written informed 
parental consent and child assent. The MDT participants (two physiotherapists; one 
respiratory physician) were eligible for inclusion if they provided clinical care for 




5.2.1 Inspiratory Muscle Training 
The IMT intervention consisted of participants undertaking 30 inspirations, twice a 
day, for 28 consecutive days using a POWERbreath Plus device (POWERbreath Plus 
LF Level 1, Gaiam Ltd. E & OE, UK). A progressive approach was adopted, whereby 
participants initially trained at a load of 40% of their  baseline PImax, increasing to 50% 
during weeks three and four (Santana-Sosa et al., 2014a). All procedures and protocols 
utilised in this study were approved by the local NHS committee (13/LO/1907). 
 
5.2.2 Qualitative Protocol – Interviews 
Children and MDT members took part in individual semi-structured interviews with 
follow-up questions. A semi-structured interview includes a series of pre-determined 
but open-ended questions, thereby allowing the interviewer to follow topical 
trajectories in the conversation as well as providing the interviewee freedom to express 
their views in their own terms (Dicicco-Bloom & Crabtree, 2006; Given, 2008). 
Children’s interview questions were related to their thoughts and opinions of IMT. 
MDT’s interview questions were centred around their opinions of IMT, responses 
from patients, and IMT reflections and recommendations. All interviews were 
conducted by one investigator (JM). Sample interview questions are presented in 














Table 5.1. Example Interview Questions 
 
 
5.2.3 Data Analysis 
All interviews were transcribed verbatim by one author (JM) and analysed 
thematically (Braun & Clarke, 2014), using a manual approach. One author (JM) read 
and familiarised the transcripts and an initial list of codes were developed to organise 
the data to identify and develop themes from them (Fereday & Muir-Cochrane, 2006) 
A cross-examination of thematic data was undertaken by the research team in reverse, 
Interview Topic Examples 
Children Inspiratory Muscle 
Training (IMT) 
What did you like and 
dislike about the training 
device? 
  What made it 
easy/difficult to do the 
training programme? 
 Future How would you react if 






What is your opinion of 
the IMT device? 
  How did the patients 
respond to the IMT 
device? 
 Future What do you think about 
the National Health 
Service adopting an IMT 
intervention as a 
treatment? 
  What recommendations do 
you have for interventions 




tracing verbatim quotations back to transcripts to ensure that the developed themes 
were grounded in the original data (Tobin & Begley, 2004). To ensure methodological 
rigour, themes and verbatim quotations were then reviewed by three authors to ensure 
findings were worthy of attention and to offer alternative interpretation of the data 
(Boddy et al., 2012; Mackintosh, Knowles, Ridgers, & Fairclough, 2011). This process 
continued until an acceptable consensus had been reached by the group.  
 
5.3 Results 
Five children (n=3 boys) and 3 MDT’s (two physiotherapists; one respiratory 
physician) completed the interviews. All interviews were semi-structured and lasted 
between 30-40 minutes. Example verbatim quotes and frequency counts have been 
added to provide further context. Four themes emerged from the interviews: (i) 
acceptability; (ii) facilitators; (iii) barriers and; (iv) recommendations.  
 
5.3.1 Acceptability  
Feedback from all participants was very positive regarding acceptability of the 
intervention. The MDT noted children’s enthusiasm and all of the children reported 
enjoying the IMT intervention: 
“I felt really excited [to do IMT] I just wanted to have a go at.” [Girl; n = 5] 
With patients even suggesting they would like to take part in future interventions: 
“I was pretty sad I didn’t have to do it again. I’d happily do it again.” [Girl; n = 4] 
Children reported good participation and adherence to the IMT intervention due to the 
ease of implementation: 
“Like it was easy you just do it [IMT] at home. You don’t have to go anywhere 
specific or special. You could just do it in your bedroom if you wanted.” [Girl; n = 
2] 
And the ease of integration into daily routine; 
“I got into it…I feel like I’ve always don’t it. When you get up in the morning, you 
normally eat your breakfast, get ready for school, do IMT and then quickly leave 
the house for the bus.” [Girl; n = 5] 
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Most importantly, children expressed enthusiasm and enjoyment: 
“I really enjoyed it, I got into it…I feel like I’ve always done it” [Boy; n = 4] 
Furthermore, all children perceived IMT to have a positive effect on their ability when 
partaking in physical activity (PA): 
“For some reason, I don’t know how, but they [lungs] almost felt like, almost got 
stronger. You could just breathe more freely…I could keep running for longer, I 
didn’t have to stop and take deep breaths as much as normal.” [Girl; n = 5] 
Children also indicated reduced embarrassment associated with completing the 
treatment at home:  
 
“I like it [using the device at home] cause of not having all the constant questions. 
I don’t like, well, I don’t mind answering questions when people do ask [about CF], 
but like I am not getting caught up in it all the time in school with my friends.” [Boy; 
n = 2] 
The CF care team also reported positive feedback from their patients and high 
adherence: 
“They would have all liked to have kept the IMT device and carried on. In fact one 
of the patients subsequently went out and bought one and uses it as part of their 
routine.” [Female Physiotherapist; n = 3] 
Akin to the children’s perceptions, CF care team members believe that the IMT 
training schedule fitted well around children’s home and school schedules: 
“From a practical point of view I think that fitted well. All feedback seemed to 
confirm that.” [Female Physiotherapist; n = 2]. 
5.3.2 Facilitators  
Unsurprisingly, the MDT highlighted the importance of family, specifically parental 
influence, with “sporty families” being labelled as easier to motivate to undertake an 
intervention and exercise: 
“If you’ve a sporty family its easier…Families will support them [children] most of 
the families were very keen on IMT. You have to get the families on board.” [Female 
Physiotherapist; n = 3] 
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Not only are family facilitators influential, but peer facilitators are key, especially for 
children. The MDT highlighting the importance of children with CF being seen as 
equal to their peers: 
“It is very important to both keep them healthy and also to keep them in their peer 
group, you know at school and during sports activities. They need to be able to keep 
up with the rest of their class, so it is very, very important…A psychological benefit 
of being able to keep up with their peer group.” [Female Physiotherapist; n = 3] 
5.3.3 Barriers  
Although it seemed the intervention was well adhered to and enjoyed thoroughly by 
all participants, barriers were nonetheless highlighted, although predominantly by the 
MDT rather than the children. The MDT highlighted the following main barriers to 
implementation of IMT: 
5.3.3.1 Cost 
The clinical care-team highlighted cost to be a major barrier in implementing IMT 
within the local National Health Service (NHS) framework: 
“Obviously there is a cost implication as there is no money in the NHS for any of 
these things.” [Female Respiratory Physician; n = 3] 
Furthermore, there is a reliance on charitable income to fund airway clearance 
equipment: 
“Cost would be a big thing and whether it was a benefit to patients” [Female 
Respiratory Physician; n = 3] 
However, it was accentuated that if IMT proved to be successful the cost should be 
met: 
“If it is proven to be beneficial they [the NHS] are more likely to get it. If it’s proven 
to be beneficial and improve lung function compared to the cost of some of the drugs 
they [the NHS] might pay for it.” [Female Physiotherapist; n = 3] 
5.3.3.2 Burden 
People with CF have a high treatment burden involving daily physical therapy coupled 
with medication. Incorporating IMT into an already busy treatment schedule was a 
concern raised by the MDT: 
106 
 
“It’s yet another thing for us to ask them to do, because they do have quite a large 
treatment burden…so that would be the biggest con, a time thing” [Female 
Physiotherapist; n = 3] 
This concern was also echoed by one of the children: 
“It was extra work to do with everything else that I have to do.” [Boy; n = 2] 
Yet, one of the MDT had a solution whereby an IMT program could be viable within 
a CF patient’s treatment schedule: 
“Obviously you don’t want it to be too much of a burden. Deciding whether it is 
better than other parts of their treatment and other part of their Physio and then 
substitute it [IMT] in could be an option.” [Female Respiratory Physician; n = 1] 
5.3.3.3 Family 
Converse to families being deemed as facilitators, a physiotherapist reflected on 
previous cases whereby children’s divorced parents have had a negative impact on 
children’s participation levels in activities: 
“The parents have divorced and the girl lives with mum. The mum has a full-time 
job and mum didn’t push any after school clubs, dad was the one that did it 
previously. So that created a big barrier.” [Female Physiotherapist; n = 1]. 
5.4.7 Recommendations  
Participants were requested to comment on any changes they would make to the device 
and protocol. The children reported no changes, whereas the care team had numerous 
suggestions to improve future interventions. One of the main changes the care team 
suggested was the importance of knowing whether participants were adhering to the 
intervention: 
“I don’t know if you can measure compliance, but it would be good if it [IMT] can 
tell us how much they actually did.” [Female Respiratory Physician; n = 1] 
To ensure future would adherence to IMT protocols and make the intervention 
attractive to children it was suggested: 
“Young people like to have their smart phones and apps, visual feedback in a piece 
of electrical equipment, that is probably the way forwards.” [Female Respiratory 
Physician; n = 2] 
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Implementing a competitive element was also highlighted as important additions in 
future interventions: 
“Feedback so they know how well they are doing. They are quite competitive so if 
they know the others are doing it, they’ll be more motivated.” [Female 
Physiotherapist; n = 2] 
Contrastingly, despite reporting that a three-times a day intervention fitted well into a 
child’s routine, the MDT suggested a more time efficient intervention to reduce the 
burden on patients: 
“Three times a day would be a problem, it [IMT] would have to be something regular 
to get them into a routine.” [Female Respiratory Physician; n = 3] 
5.5 Discussion  
The aim of this study was to ascertain the views of children and the CF care team in 
relation to an IMT intervention, thereby providing population-specific evidence to 
inform future interventions. Results indicate that all the children enjoyed the home-
based intervention, whilst the CF care team raised concerns regarding cost, and 
treatment burden. Overall, these results provide important insights regarding future 
IMT interventions, building upon the limited literature available regarding the opinions 
of patients, respiratory physicians and physiotherapists. 
IMT in CF patients has been reported to improve endurance and strength of the 
inspiratory-muscles, as well as exercise capacity (Reid et al., 2008). Previous research 
has shown that increases in exercise capacity are associated with improved 
psychosocial status in patients with chronic pulmonary disease (Lacasse et al., 2001). 
Additionally, a recent study found that aerobic fitness was positively associated with 
health-related quality of life (HRQoL) in patients with CF, underlining the importance 
of good physical fitness (Hebestreit et al., 2014). Whether greater perceived ability to 
be physically active has the potential to influence psychosocial health and QoL in 
patients with CF is unknown.  
The perceived improvement in physical ability reported by participants could be due 
to the good adherence to the IMT programme. This is in contrast to previous reports 
that adherence to treatment in CF is sub-optimal (Jones, Curley, Wildman, Morton, & 
Elphick, 2015). This discrepancy could be a result of our participant’s MDT, the age 
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of our participants and the small numbers involved in the study. Adherence levels 
amongst people with CF tend to decline with increasing age (Arias, Bousoño, & Díaz, 
2008). In younger children treatment responsibility often lies with parents or guardians 
resulting in greater adherence. As adherence was a self-reported by participants in this 
study, it may have been over-or under-estimated and is subsequently subject to risk of 
bias (Prince et al., 2008). Key factors that influence adherence include family 
environment, stigma, embarrassment among peers and relationship with their MDT 
(Jones et al., 2015). Indeed, the interview findings presented here reflect a MDT that 
actively encourage patients to make their own choices about treatment decisions and 
are open to trialling new or novel interventions such as IMT. 
  
With a reduced exercise capacity and low daily PA levels potentially impacting on CF 
patient’s psychological and physiological health, parental and family involvement in 
PA is extremely important when encouraging children to meet recommended PA and 
exercise guidelines (Edwardson & Gorely, 2010), which can be translated to IMT 
interventions. Healthy children with physically active parents are over five times more 
likely to be active than children whose parents are inactive (Hood et al., 2000), which 
correlates with reports from the MDT that an active “sporty family” is essential 
regarding children’s participation levels. In addition to this, children’s moderate-to-
vigorous-physical-activity (MVPA) levels have been shown to correlate with their 
parent’s (Fuemmeler, Anderson, & Mâsse, 2011), with family cohesion and parent-
child joint PA predicting higher levels of MVPA (Ornelas, Perreira, & Ayala, 2007). 
Adversely, divorced parents can have a negative impact on child’s PA levels when the 
main parental facilitator becomes less involved (Dempsey, Kimiecik, & Horn, 1993); 
this impact of divorced parents was highlighted by the MDT.  
 
In addition to families, peer support is influential in determining activity-related self-
esteem and therefore treatment behaviours (Coleman & Sykes, 2017). School-aged 
children with CF report concerns of appearing “different” than their peers (D’Auria, 
Christian, & Richardson, 1997), and our participants voiced that they like to keep their 
condition separate from their friendships at school. This is in accordance with research 
in which children and adolescents with CF attempted to conceal their disease and 
symptoms to appear “normal” to their peers (Christian & D’Auria, 1997). As the 
perspectives of peers are critical to social acceptance it is essential that children with 
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CF are not defined by their disease but have their own identity. The time-efficient 
nature of IMT provides the capacity for self-directed therapy that does not detract from 
time spent with peers, which may increase adherence.  
 
Despite the ease of implementation, good adherence and enjoyment reported by 
participants, the MDT were more reserved with regards to their enthusiasm for an IMT 
intervention, with reservations relating to cost and treatment burden. Nevertheless, the 
team expressed an interest in investigating the potential of a longer-term IMT 
intervention to provide a clearer evidence-base on the impact on psychological and 
physiological health in CF patients. The main concern voiced by the care team, as well 
as the children with CF, was the potential burden it may have on patients in terms of 
their time and current treatments. Reports that a patient with CF can spend a mean of 
108 minutes per day on a wide range of CF therapies, regardless of age or disease 
severity (Sawicki, Sellers, & Robinson, 2009), highlights the importance of 
establishing the feasibility of time-efficient therapies, such as IMT. The CF care team 
also recommended that future IMT interventions incorporated technology, including 
the ability to monitor adherence objectively to reduce risk of bias, linking to smart 
phones and providing visual feedback. With smartphone ownership increasing, its 
usability for future interventions is highlighted by its accessibility, real-time 
assessment, adherence monitoring, visual feedback and adjustability to the user 
(Griffiths, Lindenmeyer, Powell, Lowe, & Thorogood, 2006). Increasing patient and 
MDT engagement in intervention design has the potential to improve health outcomes, 
better patient care and lower costs (Berwick, Nolan, & Whittington, 2008), and, 
furthermore, is essential in improving quality of health care and efficacy, which is 




In conclusion, the data revealed consistent themes relating to IMT amongst children 
with CF and their MDT. This preliminary study has highlighted the ease of 
incorporating an IMT programme into the lives of CF patients, who reported 
noticeable perceived improvements to their physical ability after only four-weeks of 
IMT. These preliminary results suggest that an IMT intervention may be well accepted 
by young patients with CF. This study has also emphasised the importance of 
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gathering views and opinions of patients and their care teams to ensure good adherence 
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Aims Findings 
Ascertain the views and opinions of 
inspiratory muscle training from 
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Heart Rate Variability in Children with Cystic Fibrosis: A Pilot Study 
Aims Findings 
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Chapter Five showed that a short home-based IMT intervention is feasible and 
acceptable for children with CF. Those with CF have an impaired gas exchange 
resulting in an increased sympathetic activation. IMT could potentially decrease 
respiratory muscle oxygen demand and ventilatory-perfusion mismatch, resulting 
in decreased respiratory fatigue and increased function capacity. Therefore, 
Chapter Seven aimed to ascertain whether IMT could improve HRV, lung 




Effects of a POWERBreathe Inspiratory Muscle Training 
Intervention on Heart Rate Variability in Children with Cystic 
Fibrosis: A Pilot Study 
McCreery, J.L., Mackintosh, K.A., McNarry, M.A. (2020). Effects of inspiratory 
muscle training on heart rate variability in children with cystic fibrosis: A pilot study. 
Journal of Science in Sport and Exercise. 
6.1 Introduction  
Cystic Fibrosis (CF) is the most common, inherited, life-shortening condition among 
Caucasians, with an estimated population of 10,469 in the UK alone (Charman, 
Connon, Cosgriff, Lee, & Carr, 2018).  It is a multisystem disease affecting the 
respiratory, gastrointestinal, reproductive tract and sweat glands (Goetzinger, 2018). 
In addition to respiratory dysfunction, cardiac damage may also be present in those 
with CF, with primary symptoms including dyspnoea, tachycardia and tachypnoea 
(Florêncio et al., 2013). Such symptoms may be attributed to β-2 agonist use, with 
hypoxemia potentially exacerbating cardiac autonomic dysfunction (Florêncio et al., 
2013).  
In those with CF, the autonomic nervous system may be influenced by the interaction 
between cardiac and pulmonary dysfunction (Florêncio et al., 2013). Heart rate 
variability (HRV) provides an insight to the autonomic nervous system and can 
provide an early indication of damage to the cardiac system (Vanderlei, Pastre, Hoshi, 
Carvalho, & Godoy, 2009) and increased risk of cardiac mortality (Taskforce, 1996). 
However, whether CF is associated with derangements in autonomic nervous system 
function is equivocal, with some reporting similar sympathovagal function during a 
six-minute walk test (6MWT: Florêncio et al., 2013), whilst others found higher 
sympathetic (Resqueti et al., 2012) and/or lower parasympathetic tone in children with 
CF at rest and during recovery (Florêncio et al., 2013). In adults with CF, further 
derangements in autonomic functions have been reported that have yet to be 
demonstrated in children with CF which may reflect age-related modulations and/or 
the progression of the disease itself (McNarry and Mackintosh, 2016). Alternatively, 
or additionally, the apparent age-related differences may reflect differences in fitness 
(Hautala et al. 2010) or the impact of medication (Sammito & Bocklemann, 2016). 
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Irrespective of the mechanisms for these differences, it is suggested that deleterious 
adaptations in HRV are associated with an increased risk of cardiovascular 
complications (Pivatelli et al., 2012). Therefore, improving HRV in those with CF is 
paramount to their physiological and psychological health.  
Inspiratory muscle training (IMT), a breathing exercise that aims to strengthen the 
respiratory muscles by using a restricted airflow breathing technique to increase the 
load placed upon the intercostal muscles and diaphragm, has been shown to stimulate 
a hypertrophic response (Enright et al., 2006). In adults with hypertension and 
diabetes, IMT has been shown to significantly enhance cardiac autonomic modulation 
in comparison to unloaded IMT (Ferreira et al., 2013; Kaminski, Schaan, da Silva, 
Soares, & Lago, 2015). Furthermore, a respiratory muscle feedback and breathing 
retraining program in adults with CF elicited significant improvements in forced 
expiratory volume in 1 second (FEV1) and mean expiratory flow during forced vital 
capacity (FVC) compared to an age and severity matched control group (Delk, 
Gevirtz, Hicks, Carden, & Rucker, 1994). In children with CF, IMT increases 
inspiratory muscle strength (IMS; Santana-Sosa et al. 2014; Sawyer and Clanton 
1993), vital capacity, total lung capacity and exercise tolerance (Sawyer and Clanton 
1993), as well as respiratory muscle endurance (Bieli et al., 2017). In healthy 
individuals and those with heart failure, improvements in respiratory muscle function 
following a 12-week IMT are associated with an enhanced metaboreflex activation 
threshold, resulting in decreased cardiac sympathetic output at rest (Dall’Ago et al. 
2006; HajGhanbari et al. 2013; Witt et al. 2007). However, whether similar beneficial 
adaptations to automatic nervous system (ANS) control following IMT are observed 
in those with CF remains to be elucidated.  
In addition to potential physiological adaptations, IMT has also been suggested to 
elicit positive benefits on quality of life (QoL; De Jong et al., 2001), anxiety and 
depression in CF adults (Enright et al., 2004). Little data is available in children with 
CF, but a weak correlation between HRV and QoL has been observed in healthy 
children and adolescents, with suggestions that a stronger correlation would be evident 
in chronically ill children (Seifert, Calaminus, Wiener, & Cysarz, 2014). Interventions 
that simultaneously promote improvements in lung function and QoL are highly 




Therefore, the aim of this study was to ascertain the effects of IMT on cardiac 
autonomic control (HRV), lung function and QoL in children with CF compared to 
their healthy counterparts.  
6.2 Methods 
Five CF and five matched control participants aged 10.4 ± 1.2 years (40% boys) were 
recruited from a CF unit in South Wales, from a local school and through University 
staff emails, respectively. Participants were recruited on the basis of meeting the 
following criteria: (i) documented clinical features of CF as well as an abnormal sweat 
test (sweat sodium and chloride 60 mmol.l-1); (ii) absence of any additional known 
illness/or disease in CF patients or absence of any known illness or disease in healthy 
controls; and (iii) voluntary participation and consent to comply with the study 
protocol. Ethical approval was obtained from the Bromley National Health Service 
Research Ethics Committee (REC reference: 13/LO/1907) and written informed 
assent and consent were obtained from participants and their parents/guardian, 
respectively. Participants were required to attend two testing visits in total (baseline 
and post-intervention), which both took place within a week before the first or after 
the last IMT session.  
Participants were supplied with their own personal POWERbreathe Plus device 
(POWERbreathe Plus LR Level 1, Gaiam Ltd. E & OE, UK) and undertook a 
familiarisation session to ensure they were comfortable with the training and device. 
Participants were encouraged to practice breathing technique and ask any questions 
until they were comfortable with the regime, which involved 30 breaths twice a day, 
for 28 consecutive days. The device resistance was determined by the participants 
baseline strength index. Specifically, the first two weeks of the training programme 
were performed at 40% of participant’s pre-IMT maximal strength index, with the 
remaining two weeks at 50%.  
6.2.1 Anthropometrics  
Anthropometrical characteristics were measured according to standard procedures 
pre- and post-intervention. Specifically, body mass was measured to the nearest 
0.01kg (Seca 899 flat scale, Seca, UK), stature and sitting stature were measured to 
the nearest 0.01m (Seca portable stadiometer, Seca, UK). Waist and hip circumference 
were measured to the nearest 0.01m using a non-elastic anthropometric tape (Seca Ltd, 
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Birmingham, UK) at the narrowest point between the bottom of the ribs and the iliac 
crest and around the widest point of the buttocks (WHO, 2008). Maturity offset was 
calculated using the equations developed by Moore et al. (2015; Table 6.1). 
Table 6.1. Participant characteristics of children Cystic Fibrosis and their 
healthy peers. 
 Total CF Healthy 
Controls 
Age (yrs) 10.4 ± 1.2 10.8 ± 1.2 10.0 ± 1.1 
Mass (kg) 40.3 ± 7.3 43.9 ± 3.6 36.7 ± 8.2 
Stature (m) 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 
BMI (kg·m-2) 18.3 ± 2.1 19.6 ± 1.4 16.9 ± 1.8 
Maturity Offset (y) -1.9 ± 1.1 -1.9 ± 0.9 -1.9 ± 1.3 
W:H (cm) 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.2 
Strength index 
(cmH20) 
51.7 ± 12.4 57.9 ± 1.1 46.8 ± 15.0 
Flow rate (l·s) 2.9 ± 0.8 3.4 ± 0.1 2.5 ± 0.9 
Volume (l) 1.1 ± 0.6 1.4 ± 0.7 0.9 ± 0.4 
Mean ± SD.  BMI, body mass index; CF, cystic fibrosis; W:H, waist-hip ratio. 
 
6.2.2 Heart Rate Variability 
Participants were required to wear an ActiHeart (Actiheart4, Camntech Ltd, 
Cambridge, UK) recording at 126 Hz for three consecutive days. The ActiHeart, which 
has high intra-and inter-instrument reliability and demonstrates good validity (Brage, 
Brage, Franks, Ekelund, & Wareham, 2005), comprises of two standard ECG 
electrodes adhered at V1 or V2 positions and approximately 10cm away on the left 
side at V4 or V5. This specific placement ensures a better signal to noise ratio, free 
from movement artefacts and with higher ECG amplitudes (Brage et al., 2005). At 
least two complete 24-hour RR recordings were used to obtain HRV parameters which 
were subsequently averaged. The analogue signal from the ActiHeart was band-pass 
filtered (10-35 Hz) and processed by a real time QRS-detection algorithm. The RR 
data also underwent visual examination in order to verify the accuracy of the data prior 
to subsequent analysis. When the RR interval(s) was anomalous, the RR data points 
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were removed from the data set. Indices of HRV were derived from the frequency 
domain (very low frequency (VLF; 0.017 to 0.04 Hz), low frequency (LF; 0.04 to 0.15 
Hz), high frequency (HF; 0.15 to 0.4 Hz ) power, (LF:HF ratio) according to the 
guidelines of the Task Force (1996) and presented as relative values. Prior to the 
frequency domain analysis procedures RR interval data were re-sampled using a 
sampling frequency of 2 Hz and then linearly de-trended and windowed in consecutive 
one-minute segments; the power spectral density of each segment was then calculated 
using the Welch periodogram method, using short-term Fourier transformation and a 
50% overlap between adjacent segments. 
6.2.3 Respiratory Strength Measurements 
Inspiratory muscle function and capacity were measured using the POWERbreathe K5 
(HaB International Ltd, UK). The K5 was programmed with the participant’s age, 
stature, mass and sex, and, following a familiarisation session, three maximal 
inspiratory efforts were performed. Inspiratory volume (l), flow (l·s-1) and strength 
index (cmH2O) were recorded and the average calculated across all three tests (Table 
6.1).  
6.2.4 Cystic Fibrosis Questionnaire  
All participants completed the age-appropriate version of the cystic fibrosis 
questionnaire-revised (CFQ-R; Modi and Quittner, 2003; Quittner et al., 2000), a 
disease-specific patient reported outcome designed to measure the physical, social and 
emotional impact of CF on a 4-point Likert, true-false or frequency scale. The CFQ-
R child version consists of 35 items grouped into the following categories: (i) physical 
symptoms (6); (ii) emotional functioning (8); (iii) social functioning (7); (iv) body 
image (3); (v) eating disturbance (3); (vi) treatment burden (3); (vii) respiratory (4); 
and viii) digestive symptoms (1). Those participants aged 6-11 years undertook an 
interviewer-administered version of the CFQ-R, whilst 12-year olds completed the 
self-report version. Control participants were excluded from treatment specific 
questions and their overall score was made relative to account for the reduced number 
of questions completed. Moreover, parent/guardians completed a 44-item CFQ-R 
questionnaire based on their perceptions of their child’s QoL. Raw scores from the 
CFQ-R Child and Parent/guardian questionnaires were standardised to a 0-100 scale, 
with a higher score indicative of a higher HRQoL. For the respiratory symptom 
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domain, the minimal clinically important difference (MCID) was defined as a change 
of 4.0 points (Quittner et al., 2009).  
6.2.5 Statistical Analysis 
Between group characteristics and anthropometrics were compared at baseline using 
an independent t-test. A repeated measures ANOVA was used to analyse lung function 
and HRV in response to the IMT intervention and their interaction with disease status. 
The MCIDS were calculated using distribution-based methods. Specifically, changes 
in HRV and lung function from baseline to follow-up were calculated as 0.5 multiplied 
by SD of baseline. Scores are shown as the proportion of individuals whose scores 
exhibited a clinically meaningful increase or decrease, in lung function or HRV of  ≥ 
0.05 SD. Effect size was calculated using the mean change in scores divided by the 
SD of  baseline scores (Copay, Subach, Glassman, Polly, & Schuler, 2007). For 
interpreting effect sizes, Cohen (1988) has proposed the following benchmarks: 0.2 
(small), 0.50 (moderate) and 0.80 (large). A moderate effect size is considered a 
clinically important effect (Guyatt, 1987). Pearson’s correlation coefficients were used 
to assess the relationship between CFQ-R domains, HRV and lung function, with 
Cronbach’s Alpha used to measure internal consistency within the questionnaires 
(Cronbach, 1951). Internal consistency was good for CF children (α = 0.83-0.98), CF 
parents (α = 0.92-0.95), control children (α = 0.72-0.79) and adequate for control 
parents (α = 0.55-0.59). For the CFQ-R, change scores were calculated to established 
MCID scores in the paediatric CF population (Modi et al., 2010; Quittner et al., 2009). 
All data was analysed using a statistical software package (IBM SPSS, Version 25.0) 
and is presented as mean ± SD. Statistical significance was accepted as p < 0.05. 
6.3 Results  
6.3.1 Lung Function 
There was no significant difference in lung function between those with and without 
CF at baseline. IMT elicited increases in lung function, irrespective of group. 
Specifically, in those with CF, S.Index and flow rate significantly increased by 18.3% 
and 18.1%, respectively, whilst in the healthy children, S.Index and flow increased by 
31% and 57%, respectively (Table 6.2). In contrast, there was not a significant 
intervention effect on volume in either group. All CF participants exhibited a large 
clinically meaningful increase in S.Index (d = 8.0) and flow (d = 9.9), but only 25% 
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showed a clinically meaningful increase in volume which was associated with a small 
effect size (d = 0.3). When the absolute magnitude of change was considered, the 
healthy children demonstrated greater increases in flow rate (1.0 ± 1.0 vs. 0.6 ± 0.3 
l·m-1; p<0.05) and S.Index than those with CF (14.8 ± 11.3 vs 10.5 ± 4.0 l·m-1; 
p<0.05).  
Table 6.2. Lung function variables pre- and post- the inspiratory muscle training 
intervention in children with CF and healthy controls. 
Mean ± SD. S.Index: Strength index. *p<0.05. 
 
6.3.2 Heart Rate Variability  
At baseline, frequency domain measures were not significantly different between 
those with CF and their healthy peers. A repeated measures ANOVA with a 
Greenhouse-Geisser correction determined that frequency domain indices did not 
differ significantly between time-points. Specifically, while IMT in those with CF was 
associated with an increase in VLF (1.7%) and HF (1.8%) and a reduction in LF (-
1.6%) and LF:HF (-0.15%) post-intervention, these were not statistically significant. 
However, changes in VLF exhibited a moderate clinically meaningful decrease (d = 
0.6), while other HRV parameters exhibited small to trivial clinical effect in CF (Table 






















 Cystic Fibrosis 




100% 0% 8.0 




100% 0% 9.9 
Volume 1.4 ± 0.8 1.6 ± 0.6 0.2 ± 0.4 25% 0% 0.3 
 Control 






60% 25% 0.9 
Flow 2.5 ± 1.1 3.5 ± 0.4 1.0 ± 0.9 60% 0% 1.0 
Volume 0.9 ± 0.5 1.0 ± 0.3 0.2 ± 0.4 40% 20% 0.4 
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and an increase in LF (0.7%) and HF (2.1%) were observed post-IMT but were 























Table 6.3.  Relative frequency domain indices of HRV pre-and post- the inspiratory muscle training intervention in children with CF and 
healthy controls. 
HRV Indices Baseline Post Mean 
Change 









 Cystic Fibrosis 
VLF (%) 20.2 ± 0.8 21.9 ± 5.9 -0.1 ± 1.5 25% 75% 0.6 
LF (%) 59.7 ± 3.4 58.1 ± 3.3 1.8 ± 9.5 25% 50% -0.002 
HF (%) 20.2 ± 5.1 22.0 ± 4.0 -1.6 ± 3.9 25% 25% 0.04 
LF:HF (%) 3.2 ± 0.8 3.4 ± 0.6 -0.2 ± 10.1 25% 50% -0.2 
 Control 
VLF (%) 18.6 ± 3.0 15.9 ± 1.5 -0.3 ± 0.3 25% 50% -0.8 
LF (%) 59.6 ± 4.8 60.3 ± 1.8 -2.8 ± 4.0 0% 25% -0.3 
HF (%) 21.7 ± 2.6 23.8 ± 2.5 0.7 ± 3.8 75% 25% 1.0 
LF:HF (%) 2.9 ± 0.5 2.6 ± 0.3 2.1 ± 1.1 0% 50% -0.5 
 Mean ± SD. VLF, very low frequency; LF, low frequency; HF, high frequency; LF:HF, low to high frequency ratio.
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6.3.3 Cystic Fibrosis Questionnaire  
There was no significant difference in HRQoL over time, irrespective of disease status. 
However, 62.5% of the population increased their HRQoL post-intervention. At 
baseline, the CFQ-R respiratory domain demonstrated a weak negative correlation 
with S.Index ( r= -0.29) and flow ( r= -0.23) and a weak positive correlation with 
volume (r= 0.24). After the intervention, the respiratory domain of the CFQ-R showed 
a strong negative correlation with S.Index (r = -0.85; p = 0.008) and flow (r = - 0.84; 
p = 0.009). The respiratory symptom domain change score indicated that CF 
participants perceived clinically meaningful improvements (6.3). 
Similar to their children, parent/guardian’s perceptions of their child’s HRQoL did not 
differ between time-points. The CF group showed no significant difference in 
perceived HRQoL between child and parents at baseline (child: 88.9 ± 7.5%; parent: 
90.9 ± 7.7%) or post-intervention (child: 89.3 ± 8.8%; parent: 90.7 ± 8.4%). 
6.4 Discussion  
 
The main finding of this pilot study was that IMT elicited clinically meaningful 
improvements in S.Index and flow rate, indicative of improvements in IMS 
irrespective of health status. Whilst the mechanistic basis of these changes in lung 
function remains to be elucidated, there were some indications of changes in 
parasympathetic modulation, although these were not significant and a clinically 
meaningful decrease in sympathetic modulation. In line with the changes in lung 
function, IMT elicited a perceived improvement in the respiratory symptom domain 
in CF participants. Overall, the current study provides preliminary indications that the 
benefits of IMT should be considered to extend to cardiovascular, as well as 
respiratory, function, and highlights that further work is warranted to ascertain the 
potential therapeutic benefits of IMT for children with CF. 
  
The significant improvements in S.Index following the 4-week IMT intervention are 
congruent with previous research in adults (Asher et al. 1982; De Jong et al. 2001; 
Enright et al. 2004; Sawyer and Clanton 1993) and children with CF (Asher et al., 
1982). Indeed, Asher et al. (1982) found significant improvements in IMS and 
endurance following a 4-week training programme of 15 mins twice per day, in 
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children and adults with CF. However, in contrast to the present study, Asher et al. 
(1982) used a substantially higher training intensity of 80% maximal inspiratory 
pressure (MIP). Similarly, Sawyer and Clanton (1993) reported improvements in IMS 
following a protocol involving 60% MIP, 30 mins a day for 10 weeks and de Jong et 
al. (2001) noted improvements in inspiratory muscle endurance following training at 
20-40% MIP for 20 mins, five days a week for 6-weeks. Although the optimal training 
intensity, duration and frequency clearly remains to be elucidated, research suggests 
that the specific combination used may influence the specific respiratory parameters 
effected. Specifically, it appears that low intensity training elicits improvements in 
inspiratory muscle endurance whilst high-intensity training influences IMS (Reid and 
Samrai 1995). Interestingly, in accord with whole body strength training regimens, it 
has been suggested that during the first four weeks IMT predominantly induces neural 
adaptations (Brown et al., 1997; Ramsay et al., 1990), with any improvements 
thereafter considered to be largely related to morphological adaptations (Folland & 
Williams, 2007). Therefore, given the 18% clinically meaningful improvement in 
S.Index observed in the current study, it could be postulated that 40% MIP is the 
minimum intensity required to elicit significant benefits in IMS. However, it appears 
that a longer duration and/or greater resistance may be required to elicit changes in 
lung volume. Indeed, Enright et al. (2006) found significant improvements in lung 
volume at 80% MIP resistance, but not 20% MIP; this study extends this finding to 
suggest that greater than 40% MIP is required. The current findings highlight the 
importance of tailoring the resistance to the desired outcome, whilst being cognisant 
that lower resistances are likely to be associated with better long-term adherence and 
perceptions of feasibility and enjoyment (McCreery, Mackintosh, Cox, & McNarry, 
2018).  
 
Inspiratory muscle training engendered clinically meaningful improvements in flow 
rate in those with CF (18.1%) but not in their healthy counterparts. This may be 
attributable to the slightly, albeit not significantly, lower values at baseline in those 
with CF, given that baseline “fitness” is broadly associated with the magnitude of 
response to training interventions (Rossman et al., 2014). However, this finding may 
also reflect a better adherence to the IMT protocol in those with CF. Whilst 
measurement of adherence was beyond the scope of the present study, those with CF 
have been reported to enjoy and perceive the benefits of IMT for their health 
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associated with CF (McCreery et al., 2018). An improved flow rate has been 
associated with greater capacity for gas exchange due to more time available for 
alveolar emptying (McCaffree, and Gray, 1981), while reduced respiratory comfort 
has been attributed to decreases in inspiratory flow rate (Manning and Schwartzstein, 
1995). Therefore, it could be hypothesised that improving inspiratory flow rate may 
enhance the efficiency of the respiratory system and feelings of discomfort. Indeed, in 
chronic obstructive pulmonary disease (COPD), IMT has been shown to enable deeper 
breaths and higher inspiratory flows, reducing inspiratory effort and dyspnoea scores 
(Dacha et al., 2017). However, whether this is similarly applicable in those with CF 
requires further investigation. 
 
This is the first study to investigate the influence of IMT on HRV in CF despite the 
inextricable associations and interrelations between cardiovascular and respiratory 
systems (Pinsky, 2005; Yasuma and Jun-ichiro, 2004). At rest, the CF group had a 
higher LF:HF, suggested to be indicative of a higher sympathetic activity (Bartur et 
al., 2014) and in accord with previous studies (Florêncio et al. 2013; McNarry and 
Mackintosh 2016). Although the exact mechanisms underpinning this CF-related 
adaptation remain inconclusive at this time, such findings could be attributed to 
alterations in respiratory patterns (Pöyhönen, Syväoja, Hartikainen, Ruokonen, & 
Taka, 2004), differences in participant age and its interaction with disease progression 
(McNarry and Mackintosh, 2016), higher work of breathing (Heindl et al., 2001) or, 
indeed, differences in the levels of catecholamines, between those with and without 
CF (Zouhal, Jacob, Delamarche, and Gratas-Delamarche, 2008). Whilst the decrease 
in LF and LF:HF in the CF group following IMT was not significant, the clinically 
meaningful decrease in VLF could result in a reduction in the sympathetic tone relative 
to parasympathetic tone (Silva et al., 2013). Previous research has suggested that 
inspiratory muscle fatigue increases the metaboreflex, which increases peripheral 
sympathetic activity; improving respiratory muscle function by IMT may therefore 
increase fatigue resistance and lessen sympathetic outflow (Ferreira et al., 2013). 
However, this remains speculative given the lack of power associated with this pilot 
study. Nonetheless, the current results are similar to previous IMT studies in healthy 
adults that reported 8-weeks IMT, 20 minutes a day at 30% MIP increased S.Index 
and HF and decreased LF (Ferreira et al., 2013), with others reporting the same 
protocol was associated with an increased lung volume and QoL (Mello et al., 2012). 
124 
 
However, the studies of Ferreira et al. (2013) and Mello et al. (2012) were of a longer 
duration and in older populations with cardiothoracic complications which may 
explain the significant improvements in cardiac function. Previous research has shown 
that respiratory patterns alter autonomic cardiovascular modulation, especially with 
respect to HF (Taskforce, 1996), which could explain the increase in parasympathetic 
modulation observed in the current study. Further studies should seek to determine the 
acute HRV response during, and following, IMT. 
 
Inspiratory muscle training may improve oxygen supply by augmenting tidal volume, 
leading to a reduction in chemoreflex activity and, consequently, decreased 
sympathetic nerve discharge (Bernardi, Porta, Gabutti, Spicuzza, and Sleight, 2001; 
Rodrigues et al., 2013). According to previous research in healthy adults, inspiratory 
loads lower than 60% of MIP do not engender diaphragm fatigue as the metaboreflex 
of the inspiratory muscles is not activated and therefore sympathetic tone is not 
increased (Callegaro, Ribeiro, Tan, and Taylor, 2011). Reduced lung function is 
related to sympathetic overactivity in those with bronchiectasis and COPD, suggesting 
an increased cardiorespiratory risk (Rached et al., 2015). Therefore, if IMT has the 
potential to improve HRV, it may improve lung function in those with CF, or vice 
versa.  
 
In accord with some (Bieli et al., 2017), but not all (Enright et al., 2006), previous 
studies, IMT had no significant impact on QoL. However, it is important to 
acknowledge that Enright et al. (2006) researched adults who may have had more 
severe impairments in lung function, and thus QoL, and improvements may therefore 
be more likely to be evident following IMT given the lower baseline. In children, the 
CFQ may also lack the sensitivity to reveal small treatment effects in stable patients, 
but no alternative scoring system for short-term changes in symptoms and clinical 
findings is currently available (Biele et al. 2017). Alternatively, this discrepancy may 
be related to the length of the intervention, indicating that longer interventions are 
needed to induce significant improvements in QoL in children (Hebestreit et al., 2010; 
Schneiderman-Walker et al., 2000). Despite this, the change in the respiratory domain 
scores, while not statistically significant, was clinically meaningful post IMT. 
Furthermore, the respiratory domain, S.index and flow were significantly correlated 
following IMT. A recent systematic review reported that lung function was 
125 
 
consistently associated with respiratory symptoms within the CFQ-R and should be 
considered an important outcome measure in CF (Habib et al., 2015). However, there 
is limited research regarding the relationship between QoL and IMT, with HRQoL 
remaining an underutilised tool that should be more widely incorporated into future 
IMT research. 
 
Whilst there are numerous strengths, it is important to consider certain limitations in 
the interpretation of this study. We acknowledge the controversy that surrounds 
interpretation of HF, LF and LF:HF (Hayano and Yuda, 2019),  however, HRV is a 
non-invasive tool that provides prognostic insight into global cardiovascular health 
(Reyes del Paso et al. 2013; Task Force 1996; Wilson et al. 2017). The small sample 
size limits our statistical power and a larger study is required to ratify our findings. 
Given the challenges of obtaining large sample sizes of participants with CF (Modi et 
al., 2010), the application of MCID suggests whilst our results are statistically 
significant, they were also clinically meaningful, highlighting the potential impact of 
IMT within the CF population (Beaton, Boers, and Wells, 2002). The short duration 
of our intervention may also be perceived as a limitation, although it also increases the 
ecological validity of the findings as it more closely replicates how IMT may be used 
as an adjunct therapeutic strategy. Indeed, individual responses to exercise training are 
highly variable and distinguishing patients with- and without-significant, and 
clinically relevant training responses is a key factor in the identification of effective 
interventions, ensuring a patient-centred approach. Furthermore, the consideration of 
intervention fidelity, adherence and the factors that underpin these, which were not 
assessed in the present study, must be considered in future studies wishing to 
investigate the potential therapeutic role of IMT in those with CF. 
 
6.5 Conclusion 
In conclusion, four weeks of IMT led to clinically significant increases in IMS and in 
the respiratory symptom domain, while potentially having important influences on the 
autonomic nervous system in those with CF. Overall, preliminary indications suggest 
that IMT could be considered to benefit respiratory and cardiovascular function in 





Effects of a POWERBreathe Inspiratory Muscle Training Intervention on 
Heart Rate Variability in Children with Cystic Fibrosis: A Pilot Study 
Aims Findings 
Investigate the effects of inspiratory 
muscle training on cardiac autonomic 
control, lung function and quality of life 
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Effects of an Eight-Week, Pro2Fit Inspiratory Muscle Training Programme 
on the Physiological and Psychological Health of Children with Cystic 
Fibrosis 
Aims Findings 
Determining the influence of inspiratory 
muscle training on physiological and 
psychological health and the efficacy of a 




In combination, Chapters Five and Six highlighted that inspiratory muscle 
training is feasible and effective in children with CF. Considering the qualitative 
feedback from the multidisciplinary team, the physiological findings and current 
literature on inspiratory muscle training, a decision to change the device and 
training protocol was taken. The Pro2Fit was chosen for its ability to monitor 
adherence remotely and the live bio-feedback element with interactive app, which 
was hypothesised to improve training adherence. A training protocol of 80% 
maximal inspiratory pressure, three times a week for eight weeks, with an eight-




The Effects of an Eight-Week PrO2Fit Inspiratory Muscle 
Training Programme on the Physiological and Psychological 
Health of Children with Cystic Fibrosis 
7.1 Introduction 
Cystic Fibrosis (CF) is an autosomal recessive disorder, caused by a genetic mutation 
in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene 
(O’Sullivan & Freedman, 2009). The encoded CFTR protein functions as a chloride 
channel, with mutations in the gene causing abnormalities in chloride transport across 
epithelial cells on mucosal surfaces (Rowe & Clancy, 2006). Whilst CF is a multi-
system disease (Ratjen & Döring, 2003; Rowe, Miller, & Sorscher, 2005), it primarily 
affects lung function, with the main cause of mortality being respiratory failure (Bhatt, 
2013). The progressive decline in respiratory function has been attributed to 
inflammatory-mediated airflow obstruction but inspiratory muscle weakness may also 
play a key role (Sovtic, Minic, Markovic-Sovtic, & Trajkovic, 2018). Such inspiratory 
muscle weakness is potentially exacerbated by higher ventilatory demands, increased 
airway resistance, and a higher minute ventilation due to ventilation-perfusion 
mismatch (Pinet et al., 2003). Furthermore, hyperinflation, induced by the airflow 
obstruction in those with CF, sub-optimally shortens the operating length of the 
inspiratory muscles, contributing to a mechanical disadvantage (Sharma et al., 2001). 
Strategies to address inspiratory muscle weakness, which may potentially increase 
exercise tolerance (Pastré et al., 2014), quality of life (QoL; Zemanick et al., 2010) 
and even life expectancy (Cohen-Cymberknoh et al., 2011), are therefore of vital 
importance for those with CF. 
 
One potential strategy to enhance inspiratory muscle strength is inspiratory muscle 
training (IMT). Specifically, IMT increases the load placed on the intercostal muscles 
and diaphragm, using a restricted airflow breathing technique to stimulate a 
hypertrophic response (Enright, Unnithan, Heward, Withnall, & Davies, 2006). IMT 
has been shown to improve physiological and psychological health in those with 
respiratory conditions, including an improved inspiratory muscle function (Geddes, 
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Reid, Crowe, O’Brien, & Brooks, 2005; Gosselink et al., 2011; Hoffman et al., 2019; 
McConnell, Romer, & Weiner, 2005), a reduction in dysnpoea (Geddes et al., 2005; 
Gosselink et al., 2011; McConnell et al., 2005), improved exercise tolerance (Geddes 
et al., 2005; Gosselink et al., 2011; McConnell et al., 2005) and an enhanced QoL 
(Geddes et al., 2005; Gosselink et al., 2011; Hoffman et al., 2019). However, in CF, a 
recent Cochrane review and meta-analysis concluded that there was insufficient 
evidence to conclude whether IMT has a beneficial effect on exercise tolerance and 
lung function (Hilton & Solis-Moya, 2018). Nonetheless, significant improvements in 
respiratory muscle strength (Asher, Pardy, Coates, Thomas, & Macklem, 1982; Bieli, 
Summermatter, Boutellier, & Moeller, 2017; De Jong, Van Aalderen, Kraan, Ko Ter, 
& Van Der Schans, 2001) and vital capacity (Sawyer & Clanton, 1993) have been 
reported following IMT in those with CF. However, in accord with the conclusions of 
Houston et al. (2018), findings should be considered with caution given the lack of 
methodologically rigorous studies and the range of training techniques and protocols 
used, which are known to exert divergent effects on the respiratory system (Larribaut 
et al., 2018), likely contributing to the equivocal findings (Bieli et al., 2017).  
 
To date, there has been an almost exclusive focus on the effect of IMT in middle-aged 
populations, with little known regarding the utility of IMT in youth with CF. Findings 
in adults with CF are unlikely to be applicable to youth given the substantially different 
treatment strategies used in each age group and their consequences for disease 
progression and experiences (Shei, Dekerlegand, Mackintosh, Lowman, & McNarry, 
2019).  Indeed, significant physiological and psychosocial age-related differences may 
affect the plasticity and response to IMT (Shei, Dekerlegand, Mackintosh, Lowman, 
& McNarry, 2019). Whilst Santana-Sosa et al. (2014) investigated the effects of IMT 
in young children, it was combined with a whole-body exercise protocol, precluding 
the identification of the effects of IMT per se. More recently, a four-week IMT 
program was reported to be well-adhered to, and enjoyed by, children with CF 
(Chapter 5; McCreery, Mackintosh, Cox, & McNarry, 2018), although the short 
duration prevents conclusions being drawn regarding the efficacy of this intervention. 
In light of the progressive decline in lung function that manifests from early 
adolescence (Welsh et al., 2014), the potential role of IMT as an effective tool to delay, 
or indeed ameliorate, the rate of progression warrants further investigation.  
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Therefore, the aim of this study was to ascertain the influence of an eight-week, home-
based, IMT programme on the physiological and psychological health and wellbeing 
of youth with CF. Given that sustainability and long-term adherence is paramount to 
real-world interventions, the secondary aim of this study was to determine the uptake 
and efficacy of a reduced-volume IMT programme to maintain any beneficial effects 
over a subsequent eight weeks.  
 
7.2 Methodology  
CF participants who were 8-18 years of age, characterised by a diagnosis that had been 
confirmed by an abnormal sweat chloride test (sweat chloride > 60 mmol·L-1 > 100 
mg sweat) and were categorised as clinically stable for six months preceding 
enrolment to the study were recruited from a paediatric CF Clinic in Wales. Ethical 
approval was granted by the North West – Liverpool Central Research Ethics 
Committee, (reference 16/NW/0764) and written informed consent and assent were 
obtained from parents/guardians and participants, respectively. Participants were 
required to attend two testing visits in total, one at baseline and one post-intervention 
(week 8). A third visit was required at week 16 for those participants who agreed to 
the eight-week IMT top-up. 
 
7.2.1 Inspiratory Muscle Intervention  
The PrO2Fit (Design Net, Smithfield, USA) is a flow-resistive device, requiring 
participants to breathe through a 2 mm leak, to prevent glottal pressure. Training was 
performed three times a week on non-consecutive days, with at least 24 hours 
separating training sessions, over eight weeks. Three sustained maximal inspiratory 
pressure (SMIP) measurements were recorded at the start of each training session; the 
highest sustainable profile was selected automatically and redrawn by the computer as 
a training template equal to 80% of the maximum pressure profile.  
 
Inspiratory training manoeuvres were repeated using a regime of six repetitions per 
level (six levels in total) performed at 80% of the SMIP. During each set of 
inspirations, the rest time between repetitions was progressively reduced from 60 
seconds to 45, 30, 15, 10, and, finally, 5 seconds. If at any point the participants failed 
to achieve at least 80% of the computer-generated template, the test would 
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automatically terminate. The participants were re-assessed prior to each training 
session to ensure the work performed during the incremental training on that day was 
relative to their current maximal effort. All training sessions were uploaded 




Body mass (Seca 220; Hamburg, Germany) and stature (Seca portable stadiometer, 
Seca, UK) were measured to the nearest 0.1 kg and 0.01 m, respectively. Waist and 
hip girth were measured to the nearest 0.01 m using an anthropometric tape (Seca Ltd., 
Birmingham, UK); measurements were taken at the narrowest point between the base 
of the ribs and the iliac crest for waist circumference and the widest point around the 
hips for hip girth. Waist-to-hip ratio (WHR) was subsequently calculated.  
 
7.2.3 Lung Function and Respiratory Strength Measurements 
Forced vital capacity (FVC) and forced expiratory volume in 1-second (FEV1) were 
assessed using a portable dry wedge spirometer (Micro Medical, MicroRPM, UK), 
according to the British Thoracic Society standards (1994), by an experienced 
respiratory physiotherapist. Each participant was required to complete three consistent 
inspirations and exhalations, with the best score being taken. All parameters were 
expressed as the percentage predicted for age, stature and gender (British Thoracic 
Society, 1994). For mean inspiratory pressure (MIP), the participant was instructed to 
exhale slowly and completely, seal their lips firmly around the mouthpiece, and then 
“pull in hard, like you are trying to suck up a thick milkshake” (Castile & Davis, 2012; 
Sachs, Enright, Stukovsky, Jiang, & Barr, 2009). Conversely, to measure mean 
expiratory pressure (MEP), participants were instructed to inhale slowly and 
completely, seal their lips firmly around the mouthpiece, and exhale as hard as possible 
(Castile & Davis, 2012; Vitacca et al., 2006). 
 
7.2.4 Handgrip Strength Test 
Handgrip strength (HGS), which has been shown to correlate with lung function 
(Smith et al., 2018; Wells et al., 2014) and upper extremity strength (Bohannon 1998) 
in CF participants, has been identified as a valid measure of peripheral muscle 
function. HGS was measured using a hand dynamometer (Takei 5401, Tokyo, Japan), 
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whereby participants were asked to stand upright with the arm naturally extended 
straight, pointing to the floor, and squeeze as hard as they could for 10 seconds. A total 
of four measurements were taken (two from each hand), alternating hands each time, 
with the overall mean result calculated. Verbal encouragement was given throughout 
the test. 
 
7.2.5 Physical Activity Analysis 
The ActiSleep+ monitor (ActiGraph LLC, Pensacola, FL), shown to be valid and 
reliable in paediatric populations (Kinder et al., 2012; Ruf et al., 2012), was placed on 
the right iliac crest and worn 24 hours a day, for seven consecutive days. The monitors 
were set to sample at 100 Hz. Participants were asked to log whether, and for how 
long, they removed the monitor (e.g. for water-based activities). 
 
7.2.6 Cardiopulmonary Exercise Testing with Supramaximal Verification Bout 
Following familiarisation, each participant completed an incremental ramp test on a 
cycle ergometer (ViaSprint 150P; ViaSys Healthcare, Hoechberg, Germany) to 
volitional exhaustion. After completing a three-minute warm-up at 10W, the resistance 
was progressively increased at a fixed rate based on height (<120 cm, 10 W∙min-1; 
120-150 cm, 15 W∙min-1; >150 cm, 20 W∙min-1). Participants were required to 
maintain a cadence of 70-80 revolutions per minute (rpm) throughout the test, with the 
test terminated when the cadence decreased by >10 rpm for five consecutive seconds, 
despite strong verbal encouragement. Following completion of the cardiopulmonary 
exercise testing (CPET), a five-minute active cool-down, followed by a 10-minute 
seated recovery was provided. A supra maximal (Smax) verification of V̇O2max was then 
performed, whereby a three-minute baseline at 10 W was followed by a ‘step 
transition’ to a constant work rate equivalent to 110% of the peak power output (Wpeak) 
achieved during the initial cycle ergometer test (Saynor et al., 2013a, 2013b). 
Participants were required to maintain this workload until voluntary exhaustion. 
During the incremental exercise tests, continuous breath-by-breath pulmonary gas 
exchange data was collected (MetaMax 3B, Cortex Medical, Germany). Participants 
were required to wear a facemask, breathing through an impeller turbine assemble 
(Jaeger Triple V, Hoechberg, Germany), were gas volumes were continuously 





All CF participants completed an age-appropriate version of the Cystic Fibrosis 
Questionnaire – Revised (CFQ-R; Modi & Quittner, 2003; Quittner et al., 2000), a 
disease-specific health-related quality of life (HRQOL) questionnaire designed to 
measure the physical, social and emotional impact of CF on participants. Quality of 
life dimensions, disease-related symptoms and overall health perceptions were 
assessed on Likert scales, with scores standardised on each scale ranging from 0 to 
100. The CFQ-R child version consists of 35 items grouped into eight dimensions, 
whereas the adolescent version consists of 50 items grouped into 12 domains. Specific 
sub-scales include physical functioning, role functioning, energy/fatigue, 
psychological, emotional and social functioning, eating disturbances, body image, 
respiratory symptoms, digestive symptoms, weight disturbance, treatment burden, and 
general health perceptions. Higher scales on subscales indicate better HRQoL. For the 
respiratory symptom domain, the minimal clinically important difference (MCID) was 
defined as a change of 4.0 points (Quittner et al., 2009).  
Employing self-determination theory (Williams, Deci & Ryan, 1999), all participants 
completed psychological measures of self-regulation, need satisfaction and perceived 
competence, in relation to IMT. Following a stem question (“Why do you exercise?”), 
participants responded to each item on a five-point Likert scale ranging from 1 (not 
true for me) to 5 (very true for me). These measures were taken at baseline and at post-
intervention by using the Behavioural Regulation Questionnaire (BREQ-3; Wilson, 
Rogers, Rodgers, & Wild, 2006), which is valid and reliable in children (Markland & 
Tobin, 2004; Sebire, Jago, Fox, Edwards, & Thompson, 2013; Crciun & Rus, 2012; 
Wilson, Rogers, Rodgers, & Wild, 2006). Psychological needs satisfaction was 
measured by using four single-item indicators to assess perceived competence in 
undertaking IMT (“I feel confident in my ability to complete IMT regularly”). 
Participants responded to each item on a scale ranging from 1 (not at all true) to 7 
(very true). All measures are validated for use with clinical populations and 
modifications of items to the specific context are permitted (Ng et al., 2012; G C 
Williams et al., 1985). 
 
7.2.8 Interviews  
Children were invited to complete a face-to-face, semi-structured interview 
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following the eight-week intervention. If participants failed to complete the 
intervention, they were still invited to take part in an interview to ascertain their 
perceptions. The interviewer (JMC) asked open-ended questions, seeking 
clarification or elaboration when required. Questions were centred around their 
experience with IMT, recommendations for future use, and more generic opinions of 
physical activity (PA) and exercise. The language used was tailored to be age-
appropriate and ensure full understanding from younger children. Interviews were 
audio recorded and transcribed verbatim. 
 
7.3 Data Analysis 
 
7.3.1 Cardiopulmonary Exercise Testing and Supramaximal Verification  
V̇O2 and carbon dioxide production (V̇CO2) were interpolated to 15-second averages 
and peak values taken as the highest moving average V̇O2 measured over 15-seconds. 
The gas exchange threshold (GET) was determined as the V̇O2 at which there was a 
non-linear increase in V̇CO2 relative to V̇O2 and an increase in minute ventilation 
(V̇E)/ V̇O2 without an increase in V̇E/V̇CO2 (Beaver, Wasserman, & Whipp, 1985). 
Given the within participant variability of V̇O2max in children and adolescents with CF 
(Saynor et al., 2013a), peak V̇O2 was considered maximal if the V̇O2 peak achieved 
during  Smax did not exceed that achieved during the ramp-test by ≥ 9% (Causer et al., 
2018).  
 
7.3.2 Physical Activity Analysis 
Accelerometery data was downloaded using ActiLife (v6.10.4; ActiGraph) and 
processed into 15-second epochs. Evenson et al. (2008) cut-points were selected due 
to their acceptability across a range of intensities and ages and have been shown to 
methodologically rigorous (Trost, Loprinzi, Moore, & Pfeiffer, 2011). Non-wear time 
was defined as sustained periods of 20 minutes or more of consecutive zero counts 
(Catellier et al., 2005), with a valid wear time defined as ≥ 9 hours per day, for at least 
three days (Mattocks et al., 2008), including one weekend day (Aadland et al., 2013), 
which has previously been used in clinical populations (Mackintosh et al., 2018). 
Children were required to have worn the ActiSleep+ monitor for at least three days 
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with one weekend day, which has been shown to have a reliability coefficient of 0.7 
(Mattocks et al., 2008b). 
 
7.3.3 Content Analysis 
To extend existing knowledge and theory, interview data was analysed via content 
analysis, in which a deductive and inductive approach was adopted (Hsieh & Shannon, 
2005). All interviews were transcribed verbatim by JMC, using a manual approach 
(Braun & Clarke, 2014), with line-by-line coding on each transcript, which were then 
placed within the relevant overarching category (i.e. experience of undertaking IMT, 
competitiveness, mastery, goals, motivations for adherence and top-up period and 
future suggestions). Similar and/or opposing codes were then organised into themes 
which provided a detailed account of the children’s experience (i.e. factors effecting 
adherence, feedback loop and future improvements). To ensure methodological rigour, 
all authors reviewed the data to verify findings were logical and to offer alternative 
interpretations of data (Boddy et al., 2012; Mackintosh et al., 2011). This process 
continued until an acceptable consensus had been reached. 
 
7.4 Statistical Analysis  
All data was analysed using IBM SPSS (IMB Corp, Version 25.0. Armonk, New York: 
IBM Corp) and presented as mean ± SD, unless stated otherwise. Statistical 
significance was accepted as p < 0.05. A one-way repeated measures ANOVA was 
used to analyse any differences in lung function, V̇O2max, questionnaire results and 
HGS, in response to the IMT intervention from baseline to eight weeks and following 
the eight-week top-up period. Pearson’s correlation coefficients were used to assess 
the relationship between CFQ-R domains, V̇O2max, HGS and lung function. To 
determine whether IMT had a clinically significant effect, MCIDS were calculated 
using changes in lung function, HGS and V̇O2max from baseline to follow-up as 0.5 
multiplied by the baseline SD. The effect size was calculated using the mean change 
score divided by the baseline SD, utilising the benchmarks of  0.2 (small), 0.50 
(moderate) and 0.80 (large; Cohen, 1988). Scores are shown as the proportion of 
individuals whose scores exhibited a clinically meaningful increase or decrease, in 
lung function of ≥ 0.05 SD, with a moderate effect size considered a clinically 




7.5 Results  
Five participants aged 11.0 ± 2.2 years (60% male) with mild CF (FEV1/FVC = 86.4 
± 8.0%) took part in the eight-week IMT intervention (Table 7.1). All of the 
participants also subsequently agreed to take part in the eight-week top-up period, 
however, only three were able to be retested due to COVID-19. On average, 
participants completed 89% of IMT training sessions in the first eight weeks, and 84% 
in the eight-week top-up period. 





7.5.1 Physical Activity  
All children fulfilled the wear time criteria for valid accelerometery. There were 
similar levels of PA across the intensity spectrum, irrespective of weekday or weekend 
day in this cohort (Table 7.2). Overall, 40% of children with CF met the current 
government guidelines for MVPA (60 min·day-1), with greater activity achieved 
during weekdays (60% ≥ 60 min·day-1) than weekend days (20% ≥ 60 min·day-1; Table 
7.2). 
Table 7.2. Physical activity levels across one week in children with cystic fibrosis. 
 Overall Weekday Weekend 
Physical Activity Levels 
Sedentary time (min·day-1) 914.5 ± 387.5 850.3 ± 425.5 1100.6 ± 136.8 
LPA (min·day-1) 149.6 ± 80.5 140.3 ± 83.6 176.6 ± 67.1 
MPA (min·day-1) 29.7 ± 18.6 30.2 ± 19.4 28.5 ± 17.02 
MVPA (min·day-1) 56.1 ± 37.5 57.9 ± 38.7 51.0 ± 35.4 
VPA (min·day-1) 26.4 ± 19.6 27.7 ± 19.7 22.5 ± 19.6 
LPA, light physical activity; MPA, moderate physical activity; MVPA, moderate-to-vigorous 




Characteristics Total (n= 5) 
Age (years) 11.00 ± 2.2 
Sex (Girl/Boy) 2/3 
Height (cm) 137.6 ± 11.7 
Body Mass (kg) 31.7 ± 7.8 
Body Mass Index (kg·m-2) 16.5 ± 1.6 
Waist-to-Hip Ratio (cm) 0.9 ± 0.1 
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7.5.2 Lung Function  
After eight weeks of IMT, MIP, MEP and PEF significantly increased by 49.9% (p = 
0.04), 12.5% (p = 0.03), 14.1% (p = 0.001), respectively (Figure 7.1). Despite showing 
trends for improvement in FEV1, FEV1%predicted, FVC %predicted and FEV1/FVC 
after eight weeks, these were not statistically significant. 80% of CF participants 
exhibited a large clinically meaningful increase in MIP (d = 2.0), MEP (d = 1.0) and 
ID (d = 1.0) and moderate clinically meaningful increases in SMIP (d = 0.7), while 
FEV1 (d = 0.3),  FEV1%predicted (d = 0.4), PEF (d = 0.4) and FEV1/FVC (d = 0.4) 
showed small clinically meaningful increases. There was a significant correlation 
between MIP and PEF (r = 0.879, p = 0.05) and FEV1/FVC (r = 0.926, p = 0.02). 
There were no significant differences in lung function between eight and eight-week 
top-up period, despite showing continued trends for improvement in all lung function 
parameters (Table 7.3). However, despite not being statistically significant, a large 
clinically meaningful improvement was seen in MEP (d = 2.3), moderate clinically 
meaningful improvement in SMIP (d = 0.8), and a small clinically meaningful 
improvement was exhibited in MIP (d = 0.3), ID (d = 0.2) and FEV1/FVC (d = 0.3) at 












































Figure 7.1. Changes in A) MIP, mean inspiratory pressure; B) MEP, mean 
expiratory pressure and C) PEF, peak expiratory flow, over the first eight weeks of 
the inspiratory muscle training intervention in children with cystic fibrosis. Grey 
bars represent mean group response with standard deviation bars. Overlaid lines 











7.5.3 Handgrip Strength 
There were no statistical or clinically significant changes in HGS following eight 
weeks or eight-week top-up of IMT (Table 7.3). However, HGS showed a clinically 
significant increase between eight and 16 weeks (d = 0.6). Furthermore, HGS was 
strongly correlated with FEV1 (r = 0.920; p = 0.01) and FVC (r = 0.903, p = 0.04) 
post-IMT. 
7.5.4 Exercise Capacity  
V̇O2max significantly increased by 3.1 ± 2.4 ml·kg-1·min-1 after eight weeks, with a 
decrease of 1.3 ± 0.8 ml·kg-1·min-1 from the initial eight weeks to the eight-week top-
up of IMT. However, the V̇O2max was still 7.9 ± 8.4 8 ml·kg-1·min-1 higher than 
baseline. There was no significant difference between V̇O2max and supramaximal V̇O2.  
Despite the changes in V̇O2max being statistically significant, only 20% of children 
exhibited a small clinically meaningful improvement in V̇O2max (d = 0.3) following 
eight-week IMT intervention. V̇O2max significantly correlated with FEV1 post-IMT (r 
= 0.902, p = 0.036). There were no statistical or clinically significant changes in Wpeak 
following the initial eight weeks or eight-week top-up period (Table 7.3).
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Table 7.3. Effect of an eight-week inspiratory muscle training intervention and a subsequent eight-week top-up period on lung function, 
exercise capacity and handgrip strength in children with cystic fibrosis.
Parameters Baseline 
(n = 5) 
8-weeks 

































MIP (cmH2O) 58.4 ± 19.1 97.2 ± 26.7* 80% 0% 2.0 115 ± 17.4 33% 0% 0.3 
MEP (cmH2O) 57.0 ± 7.7 64.6 ± 9.5* 80% 0% 1.0 85.3 ± 24.2 67% 0% 2.3 
FEV1 (l) 1.8 ± 0.6 2.0 ± 0.6 40% 0% 0.3 2.2 ± 0.5 0% 33% -0.1 
FEV1 
%predicted  
61.0 ± 11.8 65.2 ± 7.9 40% 0% 0.4 62.3 ± 5.5 0% 33% -0.9 
FVC (l) 2.2 ± 0.6 2.2 ± 0.6 20% 0% 0.04 2.4 ± 0.7 33% 33% -0.2 
FVC 
%predicted  
72.4 ± 10.0 73.6 ± 9.0 20% 20% 0.1 55.7 ± 13.7 0% 33% -1.7 
PEF (L·min-1) 289.0 ± 109.6 332.8 ± 117.3* 40% 0% 0.4 366.0 ± 67.7 0% 67% -0.3 




35.7 ± 10.7 38.7 ± 10.8* 20% 0% 0.3 43.6 ± 6.1 0% 100% -0.1 
 
Wpeak 101.6 ± 40.5 88.0 ± 14.8 0% 0% 0.03 103.5 ± 34.6 0% 0% 0.02 
Handgrip Strength 





7.5.5 Questionnaires  
The total CFQ-R score improved, on average, by 6%, though this was not significant 
(p = 0.06). Whilst there was a trend for improvements in each domain, only the 
physical functioning domain showed a significant increase of 8.2% (p = 0.02) 
following eight weeks of IMT. Similarly, from the initial eight weeks to the eight-
week top-up, total CFQ-R and the physical function, emotional, eating disturbance 
and respiratory domains increased, albeit not significantly (Table 7.4). 
There was no significant difference following eight weeks of IMT in children’s 
motivation (BREQ) or on their autonomy, competence or relatedness to exercise 
(Table 7.4). However, participants exhibited a significant improvement in their 







MIP, mean inspiratory pressure; MEP, mean expiratory pressure; SMIP, 
sustained maximum inspiratory pressure PTU, pressure time uni, s, seconds; 
FEV1, forced expiratory volume in 1-second; FVC, forced vital capacity; PEF, 
peak expiratory flow; V̇O2max, maximal oxygen consumption; Wpeak, peak power output. 
*Significance p <0.05. 
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 Table 7.4. Psychological parameters pre- and post- eight weeks of an inspiratory muscle training intervention  
    95% Confidence Interval 
of the Difference 
 
 Baseline 8 Weeks Cohen’s 
d 
Lower Upper p 
 CFQR 
Total 85.2 ± 4.9 89.9 ± 5.3 -0.9 -11.4 2.1 0.064 
Physical functioning 91.1 ± 8.4 98.9 ± 2.5 -1.3 -15.6 0.1 0.026* 
Emotional 78.3 ± 3.5 87.5 ± 7.2 -0.9 -21.5 3.2 0.054 
Eating disturbances 82.2 ± 24.3 88.9 ± 24.8 -0.3 -33.6 20.2 0.500 
Treatment 95.6 ± 9.9 95.6 ± 9.9 0 0 0 1.000 
Social functioning 69.5 ± 21.7 81.0 ± 8.9 -0.3 -47.1 24.2 0.395 
Body 100 ± 0.1 95.6 ± 9.9 0 -7.9 16.8 0.374 
Respiratory 85.0 ± 16.0 85.0 ± 16.0 0 -24.2 11.8 1.000 
Digestive 80.0 ± 18.3 86.7 ± 18.3 -1.0 -25.2 11.8 0.500 
 BREQ 
Intrinsic Motivation 4.3 ± 0.8 4.2 ± 0.7 0.5 -0.4 0.7 0.391 
Introjected Motivation 2.1 ± 0.8 2.3 ± 0.9 -0.3 -1.1 0.7 0.585 
Identified Motivation 4.6 ± 0.5 4.1 ± 0.6 2.6 0.2 0.8 0.098 
Extrinsic Motivation 3.1 ± 0.9 2.7 ± 0.8 0.6 -0.8 1.6 0.423 
 Psychological Needs Satisfaction 
Autonomy 3.8 ± 0.6 3.6 ± 0.6 0.2 -1.3 1.7 0.707 
Competence 3.6 ± 0.5 3.4 ± 0.2 0.4 -0.6 1.0 0.465 
Relatedness 4.4 ± 0.6 4.2 ± 0.6 0.5 -0.4 0.8 0.337 
 Perceived Competence in undertaking IMT 
























7.5.6 Qualitative Experiences  
A summary of key themes derived from the children’s interviews are shown in Table 
7.5. All children reported good autonomy and high competency when undertaking the 
training, attributing this to the simplistic nature of the intervention: 
“It was quite simple and easy to use…I could do it easily on my own” [P1] 
Good participation and excellent adherence to the training sessions was noted, with 
children highlighting the home-based nature of the training as a positive: 
“I liked being able to use it at home, it meant we didn’t have to go somewhere to use 
it” [P3] 
Furthermore, children reported perceived improvements in their physical ability, 
highlighting this as a critical motivating factor which also contributed to the high 
adherence in this cohort: 
“I think that [noticing improvements in physical ability] made me want to do it as 
well, I could actually see the changes” [P1] 
Another critical motivating factor that promoted adherence was the live, real-time 
biofeedback they received from the app on their training progress. Indeed, the real- 
time feedback was highlighted as one of the main positives from the intervention, with 
children stating that their motivation and effort during each session would have been 
diminished without the app: 
“I think it [feedback from the app] made it more entertaining cause you could see 
how you were doing visually…I wouldn’t have worked [as hard] without the 
feedback” [P2]. 
The feedback provided by the app increased the children’s determination and drive to 
set goals in order to beat their previous score:   
“You are constantly trying to beat it [previous score]. I like that about it [the training 
programme], it didn’t just show nothing…I said ‘alright I’m going to beat it’ and I 
did it properly!” [P3]. 




“I’m happy I’ve done it…It’s quite strange to say you have something three times a 
week that helped [lung function] and it helped my fitness, so I think it was worth 
it!” [P1] 
With regards to future IMT interventions, children discussed their enjoyment of using 
an app-based training programme and suggested ways in which their experience could 
be enhanced. Specifically, the ability to compete against others in a virtual group-
based training session rather than completing the session individually was suggested: 
“If it was multiplayer, so you were against other people would be really fun!” [P2] 
Feeding into the children’s competitive nature, the ability to gain extrinsic rewards 
from training to enhance motivation and drive to succeed was also suggested: 
“Maybe if you got to the top of the leader board you could get gems to buy 
different themes for the app…To get people to try harder to get higher [on the 
leader board] because they want that theme.” [P3] 
Table 7.5. Key themes derived from interviews with children regarding their 







Factors affecting adherence Autonomy and competency 
Convenience of being home-based 
Perceived physical improvements 
Feedback loop Motivational  
Competitive nature  
Goal setting 
Positive affect 
Future improvements Game-based element 
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7.6 Discussion  
The present study found that an eight-week, three times a week, IMT intervention 
elicited clinically meaningful improvements in respiratory muscle strength and 
exercise capacity, as well as significantly improving the physical function domain of 
the CFQ-R. Furthermore, an eight-week top-up period induced additional large 
clinically meaningful improvements in MIP and the respiratory domain of the CFQ-
R. These improvements were associated with excellent adherence, with children 
reporting being motivated and having perceived competence to undertake IMT. These 
findings therefore suggest that IMT could be a highly beneficial intervention for youth 
with CF, with only ~20 minutes, three times per week for eight weeks leading to 
clinically meaningful adaptations in important health markers that can subsequently 
be maintained by only one session per week. 
Respiratory muscle weakness is hypothesised to contribute to the development of 
chronic respiratory insufficiency (Adler & Janssens, 2019) due to increased work of 
breathing, contributing to dyspnoea, ventilatory inefficiency and exercise intolerance 
in CF (Dekerlegand et al., 2015). Indeed, early childhood represents a critical time in 
CF during which the disease may progress asymptomatically and aggressive 
intervention is of high importance to prevent pulmonary deterioration (Vilozni et al., 
2016). The current study exhibited large clinically meaningful improvements in MIP 
after eight weeks of IMT, with smaller clinically meaningful additional effects after 
16 weeks. These findings largely agree with previous research whereby significant 
improvements have been found for MIP, despite differing training protocols (Asher et 
al., 1982; Sawyer and Clanton, 1993; Santana-Sosa et al., 2014). More specifically, 
whilst both earlier interventions were implemented at 60% MIP, Asher et al. (1982) 
incorporated training daily, two times per day, for four weeks (9% improvement in 
MIP), whereas Sawyer and Clanton. (1993) consisted of training daily, once per day 
for 10 weeks (13% improvement in MIP). However, despite the lower intensities 
utilised by Asher et al. (1982) and Sawyer and Clanton. (1993) eliciting improvements 
in MIP, the magnitude of improvement was considerably greater in the current study 
(50% improvement in MIP). This supports the hypothesis that high-intensity 
respiratory training influences inspiratory muscle strength, with greater intensities 
associated with greater improvements (Reid & Samrai, 1995). It is also pertinent to 
note that the current intervention only required participants to complete the IMT three 
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times per week rather than every day, considerably reducing the participant burden 
and making IMT a more sustainable and feasible long-term intervention than the 
earlier protocols reported. 
To our knowledge, no previous research has found significant improvements in MEP 
or PEF in children with CF following an IMT intervention. However, IMT enhanced 
MIP, MEP and reduced airflow obstruction due to an increased PEF in children with 
asthma (Lima et al., 2008). Although IMT does not directly load the expiratory 
muscles, it could be hypothesised that the improvements in MEP and PEF are 
attributable to stronger inspiratory muscles which enable a greater expansion of the 
thorax (de Medeiros, Fuzari, Rattesa, Brandão, & de Melo Marinho, 2017). This 
greater expansion may subsequently result in a larger elastic recoil. Furthermore, 
strong expiratory muscles, as suggested by increased MEP and PEF, have been shown 
to improve the ability to generate and maintain expiratory force for coughing 
(Mancopes, Smaoui, & Steele, 2020), which, given that coughing is a natural defence 
mechanism for airway clearance, would be of benefit to the CF population. Indeed, 
weak or ineffective coughing can result in secretion retention, infection and 
deterioration of lung function (Ramos, Krahnke, & Kim, 2014). Although the 
exploration of cough and cough flow/volume index, which provides an insight into the 
degree of respiratory impairment, was beyond the scope of this study, IMT has been 
shown to increase sputum production in adults with CF (Chatham et al., 1997). The 
improved MEP and PEF in the current study is therefore an important finding which 
should be explored in depth in future studies.  
Despite the significant improvements in respiratory muscle strength, no significant 
improvements were evident in pulmonary function. Specifically, in accord with 
previous research in CF (Asher et al., 1982; Sawyer and Clanton, 1993; Jong et al., 
2001; Albinni et al., 2004), there was no significant differences in FEV1 or FVC 
following eight or 16 weeks of IMT. However, Amelina et al. (2006) found significant 
improvements in FEV1 (48% to 51%) and FVC (65% to 68%) at 30% of maximal 
effort for 10-15 minutes, twice a day for six weeks in adults with CF. However, it is 
pertinent to note that adults with CF have more severe inspiratory muscle function 
impairments compared to children (Enright, 2001), and therefore may be more 
sensitive to adaptations at lower intensities compared to children. 
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The current study highlighted that a top-up period of IMT once a week was not only 
able to maintain the improvements obtained in the first eight weeks, but engendered 
further improvements, resulting in a small and large clinically meaningful 
improvement in MIP and MEP, respectively. This is line with traditional strength 
training programmes that suggest the optimal frequency of a training programme is 
three times a week, with maintenance achieved by continuing once or twice per week 
for up to 12 weeks (Fleck, 1994; Wernbom et al., 2007). Improvements beyond four 
weeks of a strength training protocol are considered to be morphological adaptations, 
including increased capillary beds and muscle fibre hypertrophy (Folland & Williams, 
2007; Komi & Hakkinen, 1991). Indeed, increases in the proportion of type I fibres 
and size of type II fibres have been found following a five week IMT intervention in 
adults with chronic obstructive pulmonary disease (Ramírez-Sarmiento et al., 2002). 
It could, therefore, be speculated that the top-up period was sufficient to maintain the 
earlier structural remodelling of the inspiratory muscles, which could explain the 
maintained functional improvements. 
Given that V̇O2max is a key predictor mortality in CF patients (Nixon et al., 1992; 
Pianosi et al., 2005; Vendrusculo, Heinzmann-Filho, Piva, Marostica, & Donadio, 
2016; Ward, White, Rowe, Stiller, & Sullivan, 2013), our findings of an improved 
exercise capacity post IMT are of clinical relevance. Indeed, children with CF over 8 
years of age with a V̇O2max of < 32 ml·kg
-1·min-1 have 60% increased mortality rate 
(Pianosi et al., 2005). Although participants in the current study had an average V̇O2max 
of 36 ml·kg-1·min-1 at baseline, higher than the aforementioned high-risk category 
threshold, eight weeks of IMT still significantly increased their V̇O2max. Whilst 
Santana-Sosa et al. (2014) reported a 5.4 ml·kg
-1·min-1 significant improvement in 
V̇O2max  following an eight week IMT intervention in children with CF, their IMT was 
combined with whole body strength training; the lack of an IMT-only group precludes 
the differentiation of the effect attributable to IMT per se. 
It is also noteworthy that only 73% of participants completed all the sessions in the 
‘whole body’ training intervention of Santana-Sosa et al. (2014), compared to the 89% 
in the current study, suggesting that IMT alone is more tolerable than a ‘whole body’ 
exercise training programme in children with CF. Therefore, a home-based, less 
intensive and more time efficient IMT intervention can exhibit similar improvements 
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in aerobic capacity to traditional exercise training interventions. Of note, the lack of 
association between the exercise gains and MEP in the current study contradicts the 
association between MEP and the six-minute walk distance previously reported in 
children with CF (Cunha et al., 2006; Gambazza et al., 2018). This discrepancy may 
be related to inter-study differences in the measurement of exercise capacity.  
Impairments in lung function are associated with a decreased HRQoL in CF (Abbott, 
Hurley, Morton, & Conway, 2013; Wen et al., 2019) but little is known regarding the 
influence of IMT on HRQoL. In the current participants, CFQ-R increased by 6% after 
eight-week IMT intervention, with a continued trend for further improvements 
following the eight week top-up period. Furthermore, the physical functioning 
domain, which has been shown to be an independent predictor of survival in CF 
(Abbott et al., 2009), showed a significant 9% increase after initial eight week 
duration. This is in accord with the qualitative comments in the current study, as well 
as earlier studies (Chapter 5; McCreery et al., 2018), which highlighted that children 
perceived improvements in physical ability as a result of the IMT intervention. 
Interestingly, the respiratory symptom domain exhibited clinically meaningful 
improvements after 16 weeks of IMT, suggesting that longer interventions may be 
needed to elicit significant improvements in other CFQ-R domains in children 
(Hebestreit et al., 2010; Schneiderman-Walker et al., 2000). The clinically meaningful 
and significant improvements in perceived physical function and respiratory symptom 
domains highlight the potential for IMT to have a positive impact on individual’s 
HRQoL. This is especially pertinent in children with CF as QoL has been shown to 
deteriorate in those greater than 12 years of age due to increased disease severity (van 
Horck et al., 2017). 
The improvement in physiological and psychological parameters highlighted in this 
study could be related to the high adherence reported. IMT has previously been shown 
to be feasible and acceptable within this population (Chpater 5; McCreery et al., 2018), 
yet this is the first study to monitor adherence to IMT remotely and objectively. In the 
current study, an average adherence of 87% was reported throughout the 16 weeks, 
which is 37% higher than adherence typically reported for traditional treatments in 
children with CF (Modi & Quittner, 2006). This high adherence may be related to the 
home-based and time-efficient nature of the training which was stated as a positive by 
the children. Alternatively, or additionally, the high adherence may be attributed to 
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the positive perceptions of IMT by children who cited a sense of ‘fun’ and 
‘enjoyment,’ along with an enhanced autonomy and mastery, while undertaking IMT, 
all of which are important factors for long-term engagement (Denford, Van Beurden, 
O’Halloran, & Williams, 2020; Teixeira, Carraça, Markland, Silva, & Ryan, 2012). 
Indeed, this is consistent with self-determination theory which suggests motivation for 
an activity is either intrinsic or extrinsic (Deci & Ryan, 1985). 
The feelings of intrinsic motivation reported by children could be related to the live 
biofeedback provided by the app. The positive and significant improvements in 
perceptions of competency in the children within this study orient individuals towards 
the possibility of success, allowing children to adopt mastery-oriented goals (Morris 
& Kavussanu, 2008). Indeed, mastery-oriented goals have been found to be positively 
predicted by perceived competence, which, in turn, has been shown to be positively 
associated with PA and exercise effort (Kinoshita, MacIntosh, & Sato, 2019). If 
training is deemed too complicated to understand, or perceived as too stressful, it may 
diminish compliance to treatment (Taylor, 1991). The simplistic nature of the current 
intervention, coupled with the feedback loop, is therefore likely to be advantageous 
for intrinsic motivation while simultaneously influencing positive affect and effort. 
However, despite children voicing improved mastery and autonomy, these self-
determination parameters were not significant, which could be a result of the short-
intervention duration or small sample size, with previous research highlighting that 
longer intervention durations are needed to elicit significant changes in self-
determination (Teixeira et al., 2012).  
Despite the numerous strengths within this study, there are certain limitations to 
consider. The small sample size limits statistical power and therefore the interpretation 
of the data. However, the application of MCID allows for additional patient-orientated 
insights, and enables studies to be adequately powered with fewer participants (Beaton 
et al., 2002; Modi et al., 2010). Indeed, considering whether findings are clinically 
meaningful is arguably more important in terms of driving future treatment decisions 
(Ranganathan, Pramesh, & Buyse, 2015). Another limitation is the lack of a control 






In conclusion, IMT elicited clinically meaningful and significant benefits to 
respiratory muscle strength, exercise capacity and physical and respiratory function 
domains of the CFQR after eight weeks. Furthermore, a once-a-week top-up period 
was able to maintain or show trends for improvements in respiratory muscle function 
parameters. This current study has also highlighted how IMT alone can elicit similar 
benefits for aerobic capacity as more intensive and time-consuming traditional ‘whole 
body’ training interventions. The feedback element of the training programme was 
discussed as a positive by all children, leading to increased adherence, feelings of 
mastery, competency and autonomy while undertaking IMT. The combined 
quantitative and qualitative components provide a unique insight into patient 
perceptions conveying the feasibility and acceptability of IMT to improve 






































Effects of an Eight-Week, Pro2Fit Inspiratory Muscle Training Programme 
on the Physiological and Psychological Health of Children with Cystic 
Fibrosis 
Aims Findings 
Determining the influence of inspiratory 
muscle training on physiological and 
psychological health and the efficacy of a 
16-week top-up period. 
Inspiratory muscle training elicited 
improvements in respiratory muscle 
strength, exercise capacity and 
physical functioning domain of the 
CFQ-R. The 16-week top-up period, 
maintained improvements in 
respiratory function 
Effects of a High-Intensity, Pro2Fit Inspiratory Muscle Training Programme 
on the Physiological and Psychological Health in Adults with Bronchiectasis 
Aims Findings 
To investigate the influence of  
inspiratory muscle training on 
physiological and psychological health 
and evaluate participants adherence and  
ascertain their views and opinions of IMT. 
 
To ascertain whether IMT is effective in other respiratory disease, the same IMT 
intervention was implemented in adults with bronchiectasis. This population was 
chosen as bronchiectasis shares a similar pathophysiology with CF and the 
median age of bronchiectasis diagnosis is 61.8 years. 




The Effects of a High-Intensity PrO2Fit Inspiratory Muscle 
Training Intervention on the Physiological and Psychological 
Health in Adults with Bronchiectasis 
8.1 Introduction  
Bronchiectasis is a chronic pulmonary disease characterised by airflow obstruction 
due to the destruction of elastic tissue and smooth muscles of the bronchial walls 
(Onen et al., 2007; Ozalp et al., 2012), arising from a vicious cycle of transmural 
infection and inflammation (Cole, 1986). Primary symptoms include cough, excessive 
secretions, dyspnoea, exercise intolerance and fatigue (Koulouris, Retsou, Kosmas, 
Dimakou, Malagari, Mantzikopoulos, Koutsoukou, Milic-Emili, & Jordanoglou, 
2003; Newall, Stickley, & Hill, 2005). These symptoms may, at least in part, be 
attributable to the respiratory muscle weakness also reported in those with 
bronchiectasis (Liaw et al., 2011; Moran, Piper, Elborn, & Bradley, 2010; Newall, 
Stickley et al., 2005), which may lead to discord between respiratory muscle load and 
capacity (Ozalp et al., 2019). Indeed, decreased respiratory muscle strength is 
associated with less productive coughing and decreased removal of airway secretions 
(Moran et al., 2010; Troosters et al., 2005). Effective strategies to target and resolve 
respiratory muscle weakness are therefore needed for those with bronchiectasis. 
Inspiratory Muscle Training (IMT), utilising a restricted airflow breathing technique, 
has often been used as an adjunct to traditional pulmonary rehabilitation (PR) 
programmes in chronic obstructive pulmonary disease (COPD), leading to greater 
improvements in exercise capacity than PR in isolation (Wanke et al., 1994; Weiner, 
Azgad, & Ganam, 1992). However, whether similar benefits are elicited by IMT in 
those with bronchiectasis is less clear. Specifically, whilst some report improvements 
in respiratory muscle strength and endurance, exercise capacity and social aspects of 
quality of life following IMT (Ozalp et al., 2019), others have reported beneficial 
effects to be limited to improvements in inspiratory and expiratory muscle strength 
(Liaw et al., 2011) or there to be no additional benefits to those associated with 
traditional PR in those with bronchiectasis (Newall, Stockley, et al., 2005). Further 
work is required to resolve these equivocal findings, which may be related to 
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considerable methodological differences, such as with regard to the intensity, 
frequency or duration of the IMT used. Indeed, in those with COPD, interval-based, 
high-intensity IMT has been shown to elicit greater improvements in respiratory 
muscle function than low-to-medium intensity protocols (Hill et al., 2006; Sturdy et 
al., 2003). Alternatively, or additionally, these discrepancies may reflect inter-study 
differences in participant adherence to the IMT protocol, however, no studies have 
reported adherence, limiting further conclusions.  
The long-term nature of bronchiectasis means patients must cope with the debilitating 
nature of their disease over the course of their lives. Indeed, patients with 
bronchiectasis have reported reduced quality of life and increased symptoms of 
anxiety and depression (Martínez-García, Perpiñá-Tordera, Román-Sánchez, & Soler-
Cataluña, 2005; O’leary et al., 2002). Feelings of anxiety have been associated with 
patients’ perceptions of their health and well-being, whereas, in contrast, depression 
is suggested to be linked to exercise impairment and breathlessness (O’leary et al., 
2002). Therefore, interventions that improve both patient perceptions and exercise 
capacity, whilst relieving symptoms of breathlessness, are of paramount importance 
to the psychological health of patients with bronchiectasis.  
Pulmonary rehabilitation has been recommended for those with bronchiectasis, 
however, patient perceptions on the effects of PR are limited (Hoffman, Assis, 
Augusto, Silveira, & Parreira, 2018). Sinnerton and Gillen (2009) found 
improvements in physical and psychological health post-PR, with enhanced 
confidence and patients being less dependent on medical resources. However, 
exacerbations, transport difficulties and lack of motivation were highlighted as 
barriers to participation in, and adherence to, PR (Sinnerton & Gillen, 2009). In a 
qualitative study evaluating patient perceptions of home-based IMT in chronic lung 
disease, Hoffman et al. (2018) found that IMT had a positive impact on activities of 
daily living, mobility and breathlessness, with patients becoming more confident in 
managing their disease.  Therefore, investigating patient perceptions and motivations 
to participate in an intervention, in conjunction with determining its physiological and 




Therefore, the aim of the current study was to determine the physiological and 
psychological effect of an eight-week home-based IMT intervention in adults with 
bronchiectasis. The secondary aim was to evaluate participants’ adherence to the IMT 
protocol and their experiences and perceptions of this type of pulmonary rehabilitation 
programme. 
8.2 Methods 
Ten clinically stable bronchiectasis patients, diagnosed by clinical history including 
high-resolution tomography, pulmonary functions tests, cough, shortness of breath and 
exertional dyspnoea, were recruited from an outpatient clinic in South Wales. Eight 
healthy participants were recruited from University networks and were required to 
have no pulmonary or respiratory conditions that may impair exercise capacity. Ethical 
approval was granted by the North West – Liverpool Central Research Ethics 
Committee (reference 16/NW/0764) and written informed consent was obtained from 
all participants. Participants were required to attend a testing session at baseline and 
one following the eight-week intervention. For participants who agreed to do an eight-
week IMT top-up, a third visit was required at week 16. 
8.2.1 Inspiratory Muscle Training Intervention 
The PrO2Fit device (PrO2 Health Incorporated, Rhode Island, USA), was chosen due 
to its ability to provide biofeedback, remote adherence monitoring and its capacity for 
greater IMT workloads throughout the full range of inspiration using a decreasing rest 
period between breaths (Cahalin et al., 2013). Participants were required to breathe 
through a 2 mm leak from residual value to total lung capacity, while sustaining that 
breath for as long as possible (Formiga et al., 2018). Prior to completing the 
intervention, participants were given an ~30-minute training session on how to use the 
device and the inspiratory manoeuvre technique. 
Participants completed high-intensity IMT three times per week, with at least 24 hours 
between sessions, for eight weeks. After the eight weeks, participants were given the 
option to complete a further eight weeks during which they were asked to complete 
IMT once a week. All sessions were performed at home. At the start of every IMT 
sessions, participants completed a maximal manoeuvre to determine their sustained 
maximal inspiratory pressure (SMIP), with the subsequent IMT requiring participants 
to achieve 80% of this SMIP throughout each inspiratory effort. Inspiratory duration 
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was also measured for each breath. Each IMT session involved up to six blocks of six 
inspirations, with the rest between inspirations in each block progressively decreasing 
from 60 seconds to 45, 30, 15, 10, and, finally, 5 seconds. If participants failed to 
achieve 80% SMIP, the training session was automatically terminated. 
8.2.2 Anthropometrics 
Physical characteristics including body mass (Seca 220; Hamburg Germany) and 
stature were measured to the nearest 0.1 kg and 0.01 m, respectively, with body mass 
index (BMI) subsequently calculated. Waist and hip circumference were measured to 
the nearest 0.01 m using an anthropometric tape (Seca, UK) at the narrowest point 
between the base of the ribs and the iliac crest for waist circumference, and the widest 
point around the hips for hip girth. Waist-to-hip ratio (WHR) was subsequently 
calculated. 
8.2.3 Physiological Measures 
Parameters of respiratory function forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), FEV/FEV1 and peak expiratory flow (PEF) were assessed 
in a sitting position using a portable spirometer (Micro1, MicroRPM, UK), measured 
according to the European Respiratory Society Task Force guidelines (Miller et al., 
2005). Respiratory muscle strength was measured using a portable electronic mouth 
pressure device (Micro Medical MicroRPM, UK), with mean inspiratory pressure 
(MIP) measured at residual volume and mean expiratory pressure (MEP) determined 
at total lung capacity. Each participant was required to complete three maximal 
inhalations and exhalations; differences greater than 10% or 10 cm H2O required an 
additional effort, with the best inspiration and exhalation selected for subsequent 
analysis. FEV1 and FVC were also expressed as the percentage predicted for age, 
stature and gender (Miller et al., 2005; Quanjer et al., 2012). 
As peripheral muscle strength has been reported to be associated with respiratory 
muscle strength in those with bronchiectasis (Ozalp et al., 2012), handgrip strength 
(HGS) was measured using a hand dynamometer (Takei 5401, Tokyo, Japan). 
Participants were required to stand upright, with the arm naturally extended and 
pointing to the floor, and to squeeze as hard as they could for five seconds, while 
verbal encouragement was given. A total of four measurements were taken (two from 
each hand) and the mean result calculated.  
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If able, participants were asked to complete an incremental ramp test on a cycle 
ergometer (ViaSpint 150P; ViaSys Healthcare, Germany) to volitional exhaustion. 
Following a three minute warm-up at 10 W, the resistance was progressively increased 
at 10 W·min-1. Participants were required to maintain a cadence ~60-70 revolutions 
per minute (rpm) throughout the test, with the test terminated when the cadence 
decreased by > 10 rpm, despite strong verbal encouragement. Subjective ratings of 
perceived exertion (RPE) were recorded every minute (Borg and Dahlstrom, 1962; 
Borg, 1998; Borg and Linderholm, 2009). Subsequently, participants completed a 
supramaximal validation bout at 110% of peak power output achieved during the 
initial cycle ergometer test. Breath-by-breath pulmonary gas-exchange data were 
collected continuously during the incremental and supramaximal exercise tests 
(MetaMax 3B, Cortex Medical, Germany). Participants were required to wear a 
facemask, breathing through an impeller turbine assemble (Jaeger Triple V, 
Hoechberg, Germany), with gas volumes and flow rates continuously sampled at 100 
Hz.  
 
Participants were asked to wear an ActiSleep+ (ActiGraph LLC, Pensacola, FL) tri-
axial accelerometer, measuring at 100 Hz on their right mid-axillary line at the level 
of the iliac crest, 24 hours a day for seven consecutive days. The ActiSleep+ has been 
shown to be valid and reliable for physical activity (PA) in adult populations (Aadland 
& Ylvisåker, 2015; Cellini et al., 2013). Additionally, participants completed a self-
report log to record whether, and indeed why, the ActiSleep+ was removed (i.e. water-
based activities). Troiano et al. (2014) cut-points were used to determine time spent in 
each intensity (sedentary: < 99 counts∙min-1; light: 100-2,019 counts∙min-1; vigorous, 
> 5,999 counts∙min-1). Time spent in moderate and vigorous PA was summed to obtain 
moderate-to-vigorous PA (MVPA; 2,020-5,998 counts∙min-1).  
 
8.2.4 Psychological measurements 
Employing self-determination theory (Williams, Deci & Ryan, 1999), all participants 
completed questionnaires to assess treatment self-regulation and perceived 
competence in relation to IMT, following the initial eight-week intervention. 
Specifically, the 15-item treatment self-regulation questionnaire was utilised to assess 
reasons for completing IMT regularly (i.e. “The reason I would undertake IMT is 
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because I feel that I want to take responsibility for my own health”). The treatment 
self-regulation questionnaire has three subscales: autonomous regulation, controlled 
regulation and amotivation. Perceived competence was measured using four single-
item indicators (i.e. “I feel confident in my ability to undertake IMT regularly”). Both 
questionnaires were answered using a Likert scale ranging from one (not at all true) to 
seven (very true) and are validated for use within clinical populations (Ng et al., 2012).  
 
Finally, participants were invited to complete a face-to-face, semi-structured interview 
following the eight-week intervention. If participants failed to complete the 
intervention, they were still invited to take part in an interview to ascertain their 
perceptions and barriers to completing the intervention. The interviewer (JMC) asked 
open-ended questions, seeking clarification or elaboration when required. Questions 
were centred around their experience with IMT, recommendations for future use and 
more generic opinions of PA and exercise. Interviews were audio recorded and 
transcribed verbatim. 
 
8.3 Data Analysis  
8.3.1 Cardiopulmonary Exercise Testing and Supramaximal Verification 
Oxygen consumption (V̇O2) and carbon dioxide production (V̇CO2) were converted to 
15 -second averages. The highest moving average of V̇O2 measured over 15 -seconds 
was taken as the peak value. The gas exchange threshold (GET) was determined as 
the V̇O2 at which there was a non-linear increase in carbon dioxide consumption 
relative to V̇O2, with an increase in minute ventilation (V̇E)/V̇O2 without a concomitant 
increase in V̇E/V̇CO2 (Beaver et al., 1985). Peak V̇O2 was considered maximal if the 
V̇O2 peak achieved during the supramaximal verification did not exceed that achieved 
during the ramp test by ≥ 9% (Causer et al., 2018).  
8.3.2 Interview Analysis  
All interviews were transcribed verbatim by JLM, using a manual method (Braun & 
Clarke, 2014), with interview data analysed using an inductive and deductive approach 
via direct content analysis (Hsieh & Shannon, 2005). Transcripts were coded line-by-
line and then placed in a relevant overarching category. To ensure a detailed account 
of participants experiences, similar and/or opposing codes were then organised into 
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themes. An independent author (KAM) undertook a cross examination of the data to 
challenge the interpretations, ensuring methodological rigour and that findings were 
logical and to offer alternative interpretations (Boddy et al., 2012; Mackintosh et al., 
2011).  
 
8.3.3 Physical Activity Analysis 
PA data was downloaded and analysed using ActiLife Software 6 (ActiGraph v6.10.4; 
Pensacola, FL). Data was integrated into one second epochs, with sustained periods of 
at least 20 minutes of zero counts considered non-wear time (Catellier et al. 2005). To 
be included in the subsequent analyses, participants were required to have worn the 
ActiSleep+ for ≥ 9 hours∙day-1, for at least three days, including one weekend day, 
which has been previously implemented in clinical populations (Ryan, Forde, Hussey, 
& Gormley, 2015) and shown to have a reliability coefficient of 0.7 (Mattocks et al., 
2008). 
 
8.4 Statistical Analysis  
All data were analysed using IBM SPSS (IMB Corp, Version 25.0. Armonk, New 
York: IBM Corp) and are presented as mean ± standard deviation (SD) unless stated 
otherwise. Statistical significance was accepted as p < 0.05. A repeated measures 
ANOVA was used to determine the influence of IMT, and how this differed by group. 
Pearson’s correlation coefficients were used to assess the relationships between 
V̇O2max, HGS and lung function. The minimal clinically important difference (MCID) 
was calculated using distribution-based methods. Specifically, the baseline SD 
multiplied by 0.5 was used to determine whether IMT had a clinically significant effect 
on lung function, HGS and V̇O2max. The change score divided by the baseline SD score 
was used to calculate effect size, with Cohen's (1988) d thresholds used for 
interpretation (small = 0.2, moderate = 0.5 and large = 0.8).  
 
8.5 Results 
Fourteen adults with clinically stable bronchiectasis agreed to take part in the study. 
One patient withdrew due to an acute exacerbation, two withdrew due to the inability 
to use the device and one was unable to make the retesting visits. Due to the impact of 
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COVID-19, eight healthy participants could not be retested, but they were invited to 
take part in interviews. Overall, adherence to the IMT protocol was high, with 
bronchiectasis patients completing significantly more IMT sessions (95%) than the 
healthy participants (80%) during the first eight weeks. 
The healthy participants were younger than those with bronchiectasis who were 
characterised by a higher BMI at baseline (Table 8.1). Furthermore, healthy 
participants exhibited a higher MEP (p = 0.05), FEV1 (p = 0.002), FVC (p = 0.002), 
FVC %predicted (p = 0.03) and V̇O2max (p = 0.002; Table 8.2).  
 
Table 8.1. Baseline anthropometrics of adults with bronchiectasis and healthy 
participants. 






Age (years) 51.9 ± 17.2 64.5 ± 10.3 36.1 ± 8.5 <0.05* 
Sex (female/male) (5/13) (3/7) (2/6) 0.886 
Height (cm) 172.6 ± 10.9 169.5 ± 11.2 176.4 ± 9.7 0.183 
Weight (kg) 76.9 ± 16.8 81.2 ± 19.7 71.5 ± 11.2 0.238 
BMI (kg·m-2) 25.8 ± 5.5 28.3 ± 6.3 22.8 ± 1.8 0.024* 
WHR (cm) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.6 0.106 











Table 8.2. Effect of an eight-week inspiratory muscle training intervention in adults with bronchiectasis and healthy participants. 
Parameters Baseline 8-week Change from baseline mean 
 Bronchiectasis 
(n = 10) 
Healthy 
(n = 8) 
Bronchiectasis 
(n = 10) 
Healthy 
(n = 8) 
Bronchiectasis 
(n = 10) 
Healthy 
(n = 8) 
MIP  
(cmH2O) 
72.5 ± 44.5 95.3 ± 46.8 92.1 ± 50.8 125.9 ± 35.2 19.6 ± 18.9* 30.6 ± 29.3* 
MEP  
(cmH2O) 
65.7 ± 22.3 107.5 ± 56.8 68.9 ± 25.9 115.6 ± 49.5 3.2 ± 20.3 8.1 ± 28.3 
SMIP  
(PTU) 
407.2 ± 354.2 437.0 ± 206.0 473.4 ± 327.0 513.2 ± 238.0 66.1 ± 57.8* 
 








2.5 ± 0.6 3.8 ± 0.9 2.5 ± 0.6 3.8 ± 1.0 -0.01 ± 0.2 0.01 ± 0.3 
FEV1 %predicted 78.1 ± 15.8 90.6 ± 8.9 78.5 ± 15.5 90.9 ± 15.8 0.4 ± 11.7 0.3 ± 8.3 
FVC  
(l) 
3.2 ± 0.6 4.8 ± 1.2 3.2 ± 0.7 4.8 ± 1.2 -0.01 ± 0.2 0.02 ± 0.5 
FVC  
%predicted 
80.3 ± 11.9 93.8 ± 12.5 78.3 ± 10.4 94.8 ± 9.1 -2.0 ± 14.1 1.0 ± 7.8 
PEF  
(L·min-1) 
436.5 ± 127.3 547.4 ± 107.9 441.5 ± 105.0 557.6 ± 110.3 5.0 ± 49.7 10.3 ± 4.8* 





11.1 ± 2.6 39.7 ± 11.0 11.0 ± 2.2 44.3 ± 13.6 -0.1 ± 1.5 
 
4.6 ± 4.2*# 












MIP, mean inspiratory pressure; MEP, mean expiratory pressure; SMIP, sustained maximal inspiratory pressure; PTU, pressure time unit; ID, 
inspiratory duration; s, seconds; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; HGS, handgrip 




One bronchiectasis participant did not meet the wear-time criteria and was therefore 
removed from PA analysis. On weekdays, bronchiectasis participants spent more time 
sedentary and less time in VPA and MVPA compared to healthy participants, whilst, 



























Sedentary Time 1,095.4 ± 249.6 1,158.1 ± 181.1 1,033.0 ± 290.7 0.005* 
LPA 106.6 ± 46.3 106 ± 38.9 106.7 ± 52.8 0.981 
MPA 46.8 ± 25.6 46.0 ± 26.3 47.5 ±25.1 0.740 
MVPA 55.2 ± 32.1 51.4 ± 29.1 59.1 ± 34.6 0.186 
VPA 8.5 ± 16.8 5.4 ± 12.0 11.5 ± 20.1 0.043* 
Weekday, min·d-1 
Sedentary Time 1,102 ± 224.6 1,144.6 ± 196.7 1,007.0 ± 257.5 0.017* 
LPA 104.5 ± 44.1 102.1 ± 30.8 110.0 ± 53.1 0.442 
MPA 50.7 ± 24.5 48.0 ± 25.1 56.8 ± 22.4 0.121 
MVPA 59.0 ± 31.4 53.1 ± 27.4 72.8 ± 36.1 0.006* 
VPA 8.4 ± 16.2 5.0 ± 8.5 16.0 ± 25 0.034* 
Weekend, min·d-1 
Sedentary Time 1,064 ± 306.9 1,182.1 ± 1,153.9 947.6 ± 375.7 0.020* 
LPA 110.6 ± 52.3 109.1 ± 39.6 112.1 ± 63.6 0.867 
MPA 37.2 ± 26.0 36.6 ± 23.7 37.7 ± 28.8 0.901 
MVPA 47.0 ± 32.7 42.4 ± 27.7 51.6 ±37.2 0.218 
VPA 9.9 ± 19.4 5.8 ± 16.5 13.9 ± 21.7 0.407 
 
 




8.5.1 Effects of Inspiratory Muscle Training  
A repeated measures ANOVA with Greenhouse-Geisser correction showed eight 
weeks of IMT was associated with a main effect of time and group for MIP, SMIP and 
inspiratory duration, with a significant group-by-time interaction for PEF and V̇O2max 
(p < 0.05). Specifically, bronchiectasis and healthy participants exhibited significant 
increases in MIP (27% vs. 32%, respectively), SMIP (16% vs. 17%, respectively) and 
inspiratory duration (36% vs. 30%, respectively) after eight weeks of IMT. The 
healthy participants also exhibited further improvements in PEF and V̇O2max after eight 
weeks, which were not evident in the bronchiectasis group (Figure 8.1; Table 8.2). No 








































Figure 8.1. Changes in A) MIP, mean inspiratory pressure; B) SMIP, sustained 
maximal inspiratory pressure; C) PEF, peak expiratory flow and D) inspiratory 
duration over the eight weeks of an inspiratory muscle training intervention in adults 
with bronchiectasis and healthy controls. Grey columns represent the mean group 










MCID revealed that bronchiectasis patients exhibited small clinically meaningful 
improvements in MIP, SMIP and HGS (d = 0.4; d = 0.2; d = 0.2, respectively) and a 
moderate clinically meaningful improvement in inspiratory duration (d= 0.6) 
following IMT. There were no clinically meaningful improvements in any other 
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Lung Function  
MIP (cmH2O) 19.6 ± 18.9* 40% 0% 0.4 23.7 ± 27.5 0% 33% 0.5 
MEP (cmH2O) 3.2 ± 20.3 20% 10% 0.1 4.7 ± 4.1 0% 0% 0.2 
SMIP (PTU) 66.1 ± 57.8* 50% 0% 0.7 65.8 ± 57.6 0% 0% 0.2 
ID (s) 3.8 ± 4.0* 60% 0% 0.2 3.4 ± 4.1 0% 0% 0.1 
FEV1 (l) 0.01 ± 0.2 0% 0% 0.01 0.1 ± 0.1 0% 0% -0.1 
FEV1 
%predicted 
0.4 ± 11.7 30% 60% 0.02 7.0 ± 6.7 67% 0% 0.5 
FVC (l) 0.01 ± 0.2 10% 0% -0.02 0.1 ± 0.1 0% 0% -0.2 
FVC 
%predicted 
-2.0 ± 14.1 40% 40% -0.2 9.0 ± 13.1 33% 0% 0.9 
PEF (L·min-1) 5.0 ± 49.7 20% 10% 0.04 5.0 ± 9.5 0% 0% -0.04 
FEV1/FVC 2.1 ± 10.2 10% 0% 0.1 1.3 ± 1.5 0% 0% 0.1 












1.6 ± 3.3 10% 0% 0.1 -0.6 ± 0.6 0% 0% 0.1 
MIP, mean inspiratory pressure; MEP, mean expiratory pressure; SMIP, sustained maximal inspiratory pressure; PTU, pressure time unit; ID, 
inspiratory duration; s, seconds; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; HGS, handgrip 




Following the eight-week IMT intervention, MIP significantly correlated with FEV1 
(r = 0.667; p = 0.035) and FVC (r = 0.772; p = 0.009), whilst V̇O2max showed significant 
correlations with FEV1 (r = 0.693; p = 0.039) and FEV1/FVC (r = 0.795; p = 0.018) in 
those with bronchiectasis. Contrastingly, in the healthy participants, MIP correlated 
with MEP (r = 0.821; p = 0.012), whilst FEV1 was significantly correlated with FVC 
(r = 0.721; p = 0.044).  
Compared to healthy participants, those with bronchiectasis exhibited significantly 
higher levels of autonomy (4.9 ± 1.4 vs 2.1 ± 0.7; p < 0.01) and perceived competence 
(5.5 ± 1.3 vs 4.6 ± 1.1; p < 0.01), with lower levels of amotivation (1.4 ± 0.6 vs 4.3 ± 






























 Bronchiectasis Healthy Mean Difference SEM Lower Upper  
Treatment Self-Regulation 
Autonomous  4.9 ± 1.4* 2.1 ± 0.7 2.8 0.5 1.7 4.0 <0.01* 
Controlled 1.7 ± 0.7 1.5 ± 0.3 0.2 0.3 -0.4 0.8 0.411 
Amotivation 1.4 ± 0.6 4.3 ± 0.4* -2.9 0.3 -3.4 -2.4 <0.01* 
        
Perceived 
Competence 
5.5 ± 1.3* 4.6 ± 1.1 0.9 0.6 -0.31 2.1 0.128 
Table 5. Self-determination measures after eight weeks of inspiratory muscle training.  
 




8.5.2 Eight-Week Top-Up Period 
Five bronchiectasis and four healthy participants agreed to do a further eight-week top 
up period. Two bronchiectasis patients subsequently dropped out of the top-up period; 
one participant was going on vacation and the other had purchased their own PrO2 
and wanted to train more frequently. Two healthy participants also dropped out due to 
being unable to make the final testing visit. Adherence in those that completed the 
entire top-up period was 100% and 69% for bronchiectasis and healthy participants, 
respectively. 
There were no significant differences in respiratory muscle strength, lung function 
parameters, handgrip strength or exercise capacity between or within groups compared 
to the values following the initial eight weeks after the eight-week top-up period. 
8.5.3 Qualitative Experiences 
Key themes derived from the interviews with bronchiectasis and healthy participants 
are presented below. ‘B’ indicates quotes from bronchiectasis and ‘H’ from healthy 
participants. 
Relationship with Physical Activity and Exercise  
Positives 
Most bronchiectasis participants (80%) and all healthy participants (100%) 
highlighted a positive relationship with PA and exercise, citing experiences of both 
mental and physical enjoyment: 
“I love walking the dogs, because it gets you out into the open air… it is good for 
you mentally as well I think. It does make you feel better doesn’t it? You feel very 
virtuous when you’ve done some [PA].” [B10] 
“I like the freedom of it… I find it really helpful for my mental health. The 
knowledge that my body is capable of doing things. I like the sense of achievement.” 
[H1] 
Barriers to Exercise 
Symptoms associated with bronchiectasis were highlighted as the main barrier to 
exercise in this cohort of patients: 
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“Having this bronchiectasis limits the amount of physical activity and exercise I can 
do… I look forward to it [physical activity and exercise] mentally, but I am very 
much aware of my limitations very soon… I wish I could do a lot more walking and 
I would really enjoy that much more if I could.” [B3] 
With their condition impacting on their activities of daily living: 
“I’ve got to take my time on everything, but anything that’s up and down, I mean 
like the stairs, up is physical, but down is just as hard.” [B1]  
In line with the healthy participants, barriers such as enjoyment, weather, work and 
time constraints were also highlighted as reasons for being inactive: 
“I don’t enjoy it [physical activity], I haven’t got the time to do it. It’s time more 
than anything [that is a barrier], you come home from work and you’re tired, you 
don’t want to start doing exercises.” [B6] 
“Time is always the biggest one [barrier to exercise and physical activity]. It always 
is isn’t it? Time and mental sort of motivation… One of the downsides of my job is 
that I’m spending a lot of time sitting down. I’ve come from a previously very active 
job… to then go to a really sedentary job has been really hard and that’s really 
affected my activity.” [H5] 
Motivations to Exercise  
Despite these limitations and the barriers to PA and exercise, patients understood the 
importance of being physically active and also highlighted their bronchiectasis as a 
motivator to be active: 
“Since the diagnosis I realise I need to be more active in order to keep my lungs 
healthy and the sputum moving around... So, the more active you are the better it 
[bronchiectasis] is. I try to be a little bit more active, whereas before [diagnosis] I 
might have thought ‘I won’t do any exercise tonight’, I think ‘right I’ve got to do it 
because of the bronchiectasis’.” [B10] 
Another critical motivator was being healthy for family reasons: 
 “The idea, certainly with the grandchildren, is to be as fit as you can around them 
so that you can keep up with them! It has been quite physically demanding [looking 
after the grandchildren].” [B8] 
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In line with the bronchiectasis participants, healthy adults also highlighted an 
understanding of the importance of exercise: 
“The benefit [of exercising] is I know it is good for me. It’s probably the best drug 
in the world, if you could bottle it. I do it for my own health and that it makes me 
feel better about myself.” [H5] 
External Influences 
External influences to exercise also centred around health, implications of ageing and 
the impact a person’s health can have on others: 
 
“I think there is a moral obligation to exercise and at least remain healthy, because 
it matters to other people what happens to us. Obesity and smoking causes demand 
on the health service… problems just get worse as you get older and then it drags 
other people in because they have to look after you… It’s a drag on your friends and 
relatives and you have to consider the effect of your own decisions on other people.” 
[H9] 
 
Furthermore, the social aspect and the influences of others were also highlighted as an 
external motivator to exercise: 
 
“It depends who you hang around with. If you hang around with lots of sports 
people you tend to learn off your group. Whereas, if you haven’t got that social side 
to it, then maybe you won’t exercise as much.” [H1] 
 
Some healthy participants also discussed the pressures they feel to be active, citing 
external influences such as media, society pressures and weight control: 
 
“If I wasn’t particularly active, I think I would feel guilty. I don’t know if that is 
something that is put on me myself or more because of the media aspect… I’m 
probably going to have more health complications, probably going to be overweight. 
I don’t know if it is a societal thing or a personal thing [pressure to be active], but 




Inspiratory Muscle Training Intervention  
Enjoyment 
Bronchiectasis participants expressed ‘enjoyment’ of undertaking IMT and that it was 
something they ‘looked forward’ to doing due to the perception it could help their 
health: 
“I was looking forward to doing it, because I want to do anything that’s going to 
help. I’ve been so poorly with my chest this year that anything that will help, I will 
try.” [B2] 
Motivations 
Bronchiectasis patients discussed determination and motivation to do the training, due 
to the structure of the training programme: 
“I was determined, I wanted to do this [IMT]… the main reason is that it gives me 
that discipline, I am more than happy to follow a training programme and then the 
motivation followed ‘I will do this’.” [B3] 
Participants enjoyed the high-intensity nature of the training and discussed how the 
differing levels and reducing rest times were ‘challenging’ but motivated them to try 
harder: 
“They [decreasing rest times] were good. That really set a goal for you, you know. 
It was hard, but I was motivated to do it, it did push you a bit more!” [B1] 
“That made it harder at the time [levels and decreasing rest times]. I think it was 
good, it kept it more engaging… it kind of has a reward element to it, I suppose.” 
[H9] 
In contrast to bronchiectasis, while some enjoyed the IMT intervention, more healthy 
participants discussed having less motivation to complete training compared to regular 
exercise, due to the lack of intrinsic and extrinsic rewards: 
“Less motivated to do it [IMT] than I am to do exercise. I think once you’ve done 
exercise you feel good about it afterwards, you feel like you have achieved 
something. Whereas, after doing the PrO2 training, it just felt like something that I 
had to do, I had to get through, but no reward at the end.” [H1] 
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The reasons for this lack of motivation were due to participant’s perceived lack of 
improvements from undertaking IMT, with healthy participants suggesting that 
clinical populations or athletes may benefit from this style of training more: 
“I’m guessing you might get more significant results if someone sort of sedentary 
was using it. I don’t feel like it was helping me in anything other than being able to 
do the test better.” [H6] 
Accessibility 
The remote nature of the training programme was a positive for the participants as it 
allowed easy integration into their daily lives, with participants reporting that if it 
wasn’t home-based, they wouldn’t have taken part: 
“If I had to go somewhere to use it, I probably would not have done it… I would 
have had to have made more of an effort and having something small and portable, 
why would I want to go somewhere else with it?... Having it at home I can do it 
easily” [B4] 
Similarly, the convenience of being able to do it at home was also discussed by healthy 
participants as a positive of the intervention: 
“I think it’s better to have it at home than having it elsewhere, it would never have 
worked [training elsewhere]… It’s just convenient really, doing it at your own time 
at your own pace without anyone watching.” [H2] 
Healthy participants also discussed the ease of training and how easily it can be 
integrated into daily routine: 
“It’s quite portable and convenient as opposed to setting an hour of your day aside 
to physically go and do exercise… It’s a lot more flexible in terms of time of day or 
motivation. You can adapt to it quite well.” [H10] 
Feedback 
Another highlight of the training was the accompanying app and the live feedback 
loop it provided. All participants cited this as a critical motivating factor, while giving 
them a chance to set their own goals: 
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“You can set your goals then… I found having that sort of feedback was very 
helpful” [B7] 
“It [feedback] changed my behaviour for the better, I was aiming for something, I 
knew what I was meant to be doing. I think having that goal in mind helps the person 
try and exercise.” [H7] 
While it gave participants an opportunity to track their own progress, it also brought 
out the competitive nature of some participants: 
“It is nice to know how you are doing, but it’s also nice to have something to compete 
against. If somebody would have asked me before ‘are you competitive’? I would 
have said no, not really, but yes, in this instance I certainly am!” [B5] 
Participants also highlighted if they didn’t have this extrinsic motivation, they 
wouldn’t have trained or have been as motivated to try as hard as they perceived they 
did: 
“You wouldn’t have pushed yourself as much [if you didn’t have the visual 
feedback]” [B4] 
 “I wouldn’t have tried as hard because you don’t know how you’ve done. You 
wouldn’t be as motivated to try then.” [H2] 
However, healthy participants also discussed the negative aspects of the feedback 
element and how it could also potentially be demotivating: 
“Then I got really frustrated if I couldn’t get to the end.” [H4] 
Perceived Improvements 
Importantly, all bronchiectasis participants perceived an improvement in their physical 
ability and health after completing IMT, attributing this solely to the training 
programme: 
“I’m not doing anything different in my life other than using the device… Some of 
the things I do now, the recovery time after doing them is about half [the recovery 
time] was before. I have never got this far into a winter without a cold turning into 
a chest infection. My lungs aren’t producing the same levels of mucus as they 
177 
 
typically do which is a great improvement. Physically I’m feeling better, now that’s 
[IMT] got to be worth doing.” [B8] 
Activities of daily living were also perceived to be easier: 
“My stamina has got better I would say that, I was quite pleased with that actually. 
I found it easier walking up the stairs, I was fitter. It’s all hills round me and two 
months ago I wouldn’t have been able to do an hour [walk]… but now it’s ok!” [B1] 
Bronchiectasis participants also voiced the ability to expectorate sputum more easily, 
which they felt led to a decrease in recurrent respiratory infections: 
“What I like about it was that it helped me to clear a lot of sputum much better than 
the Acapella [an airway clearance device]… I haven’t had any infections, and this 
is my tenth week without antibiotics or infection. I think my record before was three 
weeks!... When you have bronchiectasis, as long as you can keep your lungs clear, 
happy days. That is the most important thing.” [B2] 
Some healthy participants (38%) also discussed perceived improvements post-IMT: 
I definitely think my lung capacity is improved… I decided to go for a little run and 
I was really shocked my breathing had improved… I definitely felt the benefit from 
it, which was surprising actually. I think it has definitely made a difference. I know 
a couple of friends of mine are quite jealous.” [H10] 
However, they could not be confident their perceived improvements were attributable 
to IMT alone: 
“There’s definitely been an improvement in my training over time, but I don’t know 
whether that was necessarily because of this device.” [H5] 
Future Improvements 
Adherence  
Despite the positives, participants did voice some areas they would like to improve. 
Specifically, some bronchiectasis patients, despite excellent adherence to the training 
programme, thought the training programme was ‘too long’ (30%): 
“Tiresome three times a week… it was getting to be a bit of a pain after eight 
weeks… Possibly if it could get condensed to fit into your lifestyle more.” [B4] 
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Which was also voiced by the healthy participants and would have potentially helped 
with adherence in this cohort (75%): 
“If you could condense it into a shorter training period, that would definitely help 
in making me complete more sessions.” [H5] 
Extrinsic Feedback 
Participants, irrespective of health status, suggested more extrinsic feedback to help 
with motivation, while also providing rewards: 
“I would have liked something like a smiley face or a ‘hip hip hooray! You’ve done 
it, well done’!” [B1] 
“I think from a sort of motivation point of view, it may sound silly, but just to have 
a ‘well done, that was better than last time, you’ve improved this much,’ ‘you’re 
nearly there, keep on going,’ and ‘you’re doing better than you have previously 
done.’ So, that would help motivate you.” [H6] 
Despite participants exhibiting goal setting, they would also like the app to provide 
tangible goals that they have to reach: 
“If it set you targets to achieve within a certain period. That would make it far more 
worthwhile.” [B4] 
“You could have a set target from the data… you know ‘can I get closer to the 
target’? Without targets, it was difficult to know what you could improve on or 
whether you were improving.” [H9] 
8.6 Discussion  
This study revealed that an eight-week, home-based IMT programme elicited 
significant and clinically meaningful increases in inspiratory muscle strength and 
endurance in both bronchiectasis and healthy participants, with healthy participants 
also significantly enhancing expiratory flow and exercise capacity. Whilst no 
additional adaptations were shown at 16 -weeks, doing IMT once per week was 
sufficient to maintain those benefits already elicited. These physiological benefits 
were enabled by a high adherence to the IMT protocol, with participants reporting that 
IMT was enjoyable and that they perceived health and well-being benefits. This 
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therefore suggests that IMT may represent an effective and palatable alternative to 
traditional pulmonary rehabilitation programmes in those with bronchiectasis.  
As bronchiectasis is associated with respiratory muscle weakness (Liaw et al., 2011; 
Moran et al., 2010; Newall, 2005), the clinically meaningful improvement in MIP 
observed after eight weeks of IMT in the current study is of clinical importance. 
Previous research found low intensity IMT (30% MIP) improved MIP by 39% 
(Newall, 2005), while a progressive overload-based IMT programme (20-70% MIP) 
elicited improvements of 44% (Ozalp et al., 2019). However, in contrast to the present 
study, both Newall. (2005) and Ozalp et al. (2019) found significant improvements in 
MEP of 44% and 12%, respectively. Indeed, whilst the present study found 
improvements in MEP, these were not statistically significant or clinically meaningful. 
Such discrepancies may be due to the small sample size in the present study, though it 
is noteworthy that these findings are in accord with Harver and colleagues (1989) who 
found that eight weeks of high-intensity IMT improved MIP, but not MEP, in 
individuals with COPD. As such the physiological effect of IMT on expiratory 
muscles remains unclear. It has, however, been hypothesised that inspiring against a 
resistance, as is the case in IMT, could increase the activation of the expiratory 
muscles by force extension, leading to an increase in MEP (Ozalp et al., 2019). 
Elsewhere, it has been postulated that increased inspiratory muscle strength results in 
better thorax expansion, enabling a greater elastic recoil, that could improve MEP and 
PEF (de Medeiros et al., 2017). Decreased expiratory muscle strength can have 
detrimental effects in bronchiectasis patients on their effectiveness of coughing and 
removal of airway secretions (Moran et al., 2010; Troosters et al., 2005), therefore, 
further research is required to determine the effect, and underlying mechanism, IMT 
has on respiratory muscle function.  
Lung function parameters were not affected by IMT in the present intervention. This 
is in line with previous research that found eight weeks of high intensity IMT increased 
MIP, but had no effect on FEV1 or FVC in those with COPD (Harver et al., 1989), CF 
(Enright, Chatham, Ionescu, Unnithan, & Shale, 2004) or bronchiectasis (Liaw et al., 
2011). Despite there being no significant improvements in respiratory function post-
IMT, MIP values were significantly associated with pulmonary function in those with 
bronchiectasis. It could therefore be postulated that those with inspiratory muscle 
weakness may suffer from more severe airflow obstruction and greater lung 
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hyperinflation. This is in accord with previous research that found a positive 
correlation between MIP and airflow limitation in a COPD population (Jamaati et al., 
2013; Nambiar, Ravindra, & Kumar, 2018; Tudorache, Oancea, & Mlǎdinescu, 2010).  
Both SMIP and inspiratory duration are emerging as key clinical markers across 
several populations (Cahalin & Ross, 2015; Formiga, Campos, & Cahalin, 2018), with 
suggestions that they are both superior markers of inspiratory performance than MIP 
(Severin, Arena, Lavie, Bond, & Phillips, 2020). In combination, they provide a more 
comprehensive assessment of identifiable characteristics of respiratory muscle 
weakness or fatiguability (Cahalin & Ross, 2015), while potentially providing greater 
ability to identify outcomes associated with mortality risk in individuals with COPD 
(Formiga et al., 2018). The significant improvements in SMIP and inspiratory duration 
exhibited post-IMT in the present study are therefore of particular interest. In COPD, 
greater SMIP is independently related to reduced airflow limitation, less dyspnoea and 
increased six minute walk test (6MWT) distance (Formiga et al., 2018). Like SMIP, 
increased inspiratory duration is reported to be associated with an increase in distance 
walked in 6MWT (Formiga et al., 2018). Therefore, the current improvements could 
be postulated to translate to meaningful enhancements in functional exercise capacity. 
Exercise intolerance is often reported in those with bronchiectasis, the basis for which 
is likely to be multifaceted and includes decreased ventilatory efficiency, altered 
respiratory mechanics, insufficient gas exchange, expiratory flow limitation and 
increased dynamic hyperinflation (Koulouris, Retsou, Kosmas, Dimakou, Malagari, 
Mantzikopoulos, Koutsoukou, Milic-Emili, & Jordanoglu, 2003; Ozalp et al., 2012). 
Furthermore, reduced exercise tolerance has been associated with increased 
depression (O’leary et al., 2002). In contrast to the healthy participants, IMT was not 
associated with any change in V̇O2max in those with bronchiectasis in the current study. 
Whilst this is congruent with some earlier studies (Liaw et al., 2011), others have 
reported significant improvements in intermittent shuttle walk test (ISWT) distance in 
a bronchiectasis population (Newall, 2005; Ozalp et al., 2019). It is pertinent to note 
that the IMT protocol in Newall et al. (2005) was combined with conventional exercise 
training so it is not possible to discern the independent effect of IMT. Nonetheless, 
these apparent discrepancies in the effect of IMT on exercise capacity are perhaps 
more likely to be attributable to the measure of exercise capacity within the studies. 
Specifically, the current cardiopulmonary exercise testing (CPET) derived values 
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provide an accurate measure of maximal exercise capacity, the clinical significance of 
which is increasingly evident with regards to predicting prognosis in numerous clinical 
conditions (Paolillo & Agostoni, 2017). However, the applicability of this measure to 
functional capacity and daily activities has been questioned (Houghton, Harrison, 
Cowley, & Hampton, 2002), with suggestions that measures such as the 6MWT 
distance may be more applicable to bronchiectasis due to its relatedness to everyday 
activity (Crapo et al., 2002). This notion is supported by the present study in which, 
despite exhibiting no significant difference in maximal exercise capacity, 
bronchiectasis patients reported perceived improvement in their physical ability to 
undertake activities of daily living. The discrepancies in the effect of V̇O2max are 
contradictory to what might be expected, given the well-established relationship 
between baseline fitness and the magnitude of change elicited by traditional exercise 
interventions (Vollaard et al., 2009). Therefore, it could be speculated that those with 
bronchiectasis could have different sites or mechanisms of exercise intolerance, that 
are perhaps less effected by IMT or require a greater dose, be that in terms of intensity, 
frequency or duration, for beneficial changes to be manifested. Therefore, future IMT 
studies should consider incorporating measures of functional capacity and assessing 
the effect of IMT on the underlying causes of functional capacity limitations.  
Although the value of patient involvement in clinical research is well established 
(Supple et al., 2015), few studies have specifically explored the opinions, experiences 
and/or needs of those with bronchiectasis (Dudgeon, Crichton, & Chalmers, 2018). 
Moreover, whilst Hoffman et al. (2018) found that individuals with chronic lung 
disease perceived IMT to be of benefit and to increase their confidence in their disease 
management, our understanding of patients’ motivations to complete IMT is limited. 
More specifically, no research has previously applied or examined motivation theories 
within this population. Importantly, IMT elicited high levels of intrinsic motivation in 
the bronchiectasis participants in this study, who endorsed and valued their 
involvement in the intervention, reporting satisfaction, interest and engagement. A 
critical motivating factor for participants desire to train was the live biofeedback, 
allowing the adoption of mastery orientated goals, which have been shown to be 
positively associated with effort in PA and exercise interventions (Kinoshita, 
MacIntosh & Sato, 2019). Furthermore, high levels of motivation were reflected in the 
increased levels of autonomy and perceived competence and low levels of amotivation 
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and controlled regulation in bronchiectasis compared to healthy participants. High 
levels of autonomy have been associated with positive health, behavioural and 
psychological outcomes, such as adherence to treatment regimens (Manganello, 
2008). Contrastingly, controlled forms of amotivation, as reported in the healthy 
group, have been linked to poorer adherence (Williams, Mcgregor, Zeldman, 
Freedman, & Deci, 2004). The differences in motivation between groups could explain 
the better adherence noted in bronchiectasis participants. Indeed, enjoyment, enhanced 
autonomy and competency are important factors for long-term adherence in clinical 
populations (Denford et al., 2020; Teixeira et al., 2012). Such high adherence to the 
IMT protocol in those with bronchiectasis is discordant to research utilising other 
treatment regimes in this population (McCullough et al., 2014). Adherence to such 
treatment programmes has also been associated with pulmonary exacerbations 
(McCullough et al., 2014), reinforcing the potential utility of IMT as a viable 
rehabilitation strategy for those with bronchiectasis.  
Previous research found that patients with bronchiectasis experience feelings of 
anxiety and fear of exacerbation (Dudgeon et al., 2018). Indeed, the main motivations 
for being physically active and to undertake IMT in our cohort were centred around 
the management of their bronchiectasis and their desire to improve their health. 
Patients reported perceived improvements in their physical ability, a better ability to 
expectorate sputum in comparison to using traditional methods, such as the Acapella® 
(Smiths Medical, Wampsville, New York), and a reduction in exacerbations during 
the intervention, which they attributed solely to IMT. Of importance, impaired 
clearance of sputum results in a vicious cycle of colonisation and infection of the 
bronchi with pathogenic organisms, dilation of bronchi, pulmonary exacerbations and 
further production of sputum (Patterson, 2005) and therefore the ability to remove 
sputum is a key finding. Indeed, this is congruent with previous research which found 
that training protocols incorporating ≥ 80% MIP are better at enhancing mucus 
transport, due to higher flow rate as a result of the higher pressure elicited (Kim, 
Iglesias, & Sackner, 1987). Conversely, previous research found that sputum clearance 
only increased with the Acapella®, which was preferred by patients compared to 
threshold IMT (Naraparaju, Vaishali, Venkatesan, & Acharya, 2010). However, it is 
pertinent to note that sputum clearance was self-reported in the present study, which 
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is subject to bias. Future IMT research should therefore utilise sputum volume 
measurements. 
Reductions in reported exacerbations as a result of the IMT intervention is also an 
important finding. Indeed, the economic burden of exacerbation in those with 
bronchiectasis resulting in hospitalisations is significant (Goeminne et al., 2019). 
Unsurprisingly, the convenience of being able to train at home was highlighted as a 
key enabler, particularly in a population with increasing treatment burdens (Chalmers, 
Aliberti, & Blasi, 2015). Therefore, the cost-effective, home-based nature of IMT 
could be advantageous in those with bronchiectasis. 
Despite numerous strengths, this study is not without its limitations. The lack of age- 
and sex-matched controls could explain the discrepancies in exercise capacity and, 
more specifically, the lack of perceived physical improvement in the healthy cohort. 
Indeed, the significantly younger healthy population mean such results should be 
interpreted with caution. Despite the recruitment of age- and sex-matched controls, 
the onset of COVID-19 precluded the completion of post-intervention testing. Finally, 
the relatively small sample size limits statistical power and interpretation of the data. 
However, the application of MCIDs enables studies to be adequately powered with 
fewer participants (Beaton et al., 2002; Modi et al., 2010), and has been highlighted 
as more important for future treatment decisions (Ranganathan et al., 2015). 
8.7 Conclusion 
In conclusion, an eight-week IMT programme significantly increased inspiratory 
strength, respiratory endurance, perceived competence and autonomy in those with 
bronchiectasis. Furthermore, bronchiectasis patients perceived an improvement in 
their physical ability and had high levels of intrinsic and extrinsic motivation to 
complete IMT. IMT, therefore, appears to be an effective and palatable tool to enhance 








Determination of Pulmonary Rehabilitation Efficacy in those with 
Respiratory Disease 
Aims 
Determine effectiveness of PR in 
various respiratory diseases. 
Investigate influence of sex and 
socioeconomic status and their 
interaction on adherence. 
Findings 
PR is applicable to variety of respiratory 
diseases. Sex differences occur at 
baseline and post-PR. SES has a 
negative effect on adherence. 
Assessing the Perceptions of a POWERBreathe Inspiratory Muscle 
Training Intervention in Children with Cystic Fibrosis and their 
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Aims 
Ascertain view and opinions of 
IMT from children with CF and 
their multidisciplinary team 
Findings 
Children enjoyed IMT and reported 
perceived improvement to physical 
ability. MDT suggested monitoring 
adherence in future interventions. 
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Aims 
Investigate the effects of IMT on 
cardiac autonomic control, lung 
function and waulity of life. 
Findings 
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CFQ-R and a reduction in sympathetic 
modulation. 
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Aims 
Determine the influence of IMT on 
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health and the efficacy of a 16-
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Findings 
IMT elicited improvements in 
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capacity and physical functioning 
domain of the CFQ-R. The 16-week 
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in respiratory function. 
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muscle strengths, respiratory endurance 
in those with bronchiectasis. 
Participants reported high levels of 
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The importance of physical activity (PA) and exercise is well-recognised and reported 
in children and adults with chronic respiratory conditions, however, adherence to 
pulmonary rehabilitation (PR) programmes is often poor. The purpose of this thesis 
was to investigate alternative, non-pharmacological strategies that aim to enhance the 
health and well-being in those with a chronic respiratory condition. This chapter will 
seek to synthesise the overall outcomes, strengths, limitations and future implications 
derived from the individual studies presented. 
9.1 Summary of Individual Study Findings 
Impaired respiratory function is associated with increased mortality and morbidity 
(Schünemann, Dorn, Grant, Winkelstein, & Trevisan, 2000). PA and exercise are 
known to improve physiological and psychological health, and reduce mortality and 
morbidity in numerous chronic conditions (United State Deaprtment of Health and 
Human Services, 1996). Consequently, PR is advocated as a strategy to improve 
physical and psychological health in those with chronic obstructive pulmonary disease 
(COPD) and there is emerging evidence for its application to other respiratory diseases 
(Holland et al., 2013). However, patients with respiratory diseases present a unique 
challenge for the appropriate prescription of PR due to the considerable heterogeneity 
in disease symptoms and the high prevalence of comorbidities (Crisafulli et al., 2008). 
Therefore, determining the benefit and efficacy of PR in respiratory diseases beyond 
COPD is of clinical importance and was the first aim of this thesis (Chapter 4). In 
accord with this aim, in a sample of 1,268 patients, PR was found to equally effective 
across five respiratory diseases. However, sex-related differences were apparent and 
low adherence was associated with a low socioeconomic background.  
Adherence to PR is essential in order to elicit the associated health benefits, however, 
the rate of attendance is generally low, with the primary reason for poor adherence 
suggested to be a lack of resources, geographical distance from treatment centres and 
the times of scheduled classes (Steiner et al., 2015). Therefore, home-based 
interventions are a potentially attractive option to overcome these barriers. Treatment 
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strategies are only effective in the real world if they are considered acceptable and 
palatable by participants. Therefore, Chapter 5 explored the experiences and 
perceptions of IMT in healthy controls and children with CF and their multi-
disciplinary team (MDT). Five children, two physiotherapists and one respiratory 
physician participated in semi-structured interviews, with data transcribed verbatim 
and thematically analysed. Four key themes emerged from the interviews: (i) 
acceptability; (ii) facilitators; (iii) barriers; and (iv) recommendations. Findings 
indicated that children enjoyed the home-based IMT intervention, reporting good 
adherence, while perceiving a benefit to their physical ability. The MDT had more 
reservations, specifically regarding the cost of devices and treatment burden. 
However, they did express interest in investigating longer-term IMT interventions that 
could provide feedback to patients as well as the ability to monitor adherence 
remotely.  
The aim of Chapter 6 was to pilot a home-based, inspiratory muscle training (IMT) 
intervention in children with cystic fibrosis (CF) and its potential effects on 
physiological and psychological health. Lung function, heart rate variability (HRV) 
and health-related quality of life (HRQoL) were assessed in ten participants (five CF) 
across a four-week intervention. Results indicated that IMT elicited increases in 
strength index and flow rate, while exhibiting a perceived improvement in respiratory 
symptoms, with indications of change in sympathetic modulation. Importantly, these 
results were clinically meaningful. These preliminary indications suggested that IMT 
could benefit respiratory, cardiovascular, and psychological health in children with 
CF. 
Following the feedback from participants and incorporating previous evidence, an 
IMT intervention was developed in order to establish the effect of IMT on the 
physiological and psychological health in children with CF. Chapter 7 examined the 
impact of an eight-week, home-based, IMT programme, incorporating three training 
sessions a week. A further eight-week top-up period, with training once a week was 
offered to participants to ascertain sustainability, long-term adherence and efficacy of 
a reduces-volume training programme. Physiological measures of lung function, 
handgrip strength (HGS), exercise capacity, sleep and PA were taken, as well as 
HRQoL and self-determination theory questionnaires. Participants were also 
interviewed to gather their perceptions of the training programme. Following eight 
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weeks of IMT, improvements in mean respiratory strength, exercise capacity and the 
physical functioning domain of the cystic fibrosis questionnaire (CFQ-R) were 
evident. After 16 -weeks, which all participants opted to do, lung function parameters 
showed continued trends for improvement, which were clinically meaningful for 
respiratory strength and forced expiratory volume in one second/forced vital capacity 
(FEV1/FVC). Furthermore, the respiratory symptom domain also showed a clinically 
meaningful improvement after 16 -weeks. Children reported high levels of autonomy, 
competency and positive affect and perceived physical improvements in their physical 
ability. They enjoyed the game-based nature of the app, highlighting the feedback 
provided by the app as a positive motivating factor. 
Finally, to ascertain the effects of IMT in another respiratory disease, Chapter 8 
investigated the same IMT intervention in adults with bronchiectasis. Similar 
physiological measures were taken, as in Chapter 7, with measures of perceived 
competence, treatment self-regulation and views of IMT also gathered from the 
bronchiectasis patients. Significant improvements in MIP, sustained maximal 
inspiratory pressure (SMIP) and inspiratory duration were evident after eight weeks, 
which were all clinically meaningful. No additional improvements in any parameter 
were exhibited after 16 -weeks of IMT, but importantly all parameters remained at the 
levels exhibited post-intervention (eight weeks) and did not return to baseline. 
Bronchiectasis patients exhibited high levels of autonomy and perceived competency 
and low levels of amotivation regarding their ability to undertake IMT compared to 
their healthy counterparts. Furthermore, bronchiectasis patients enjoyed the home-
based IMT intervention and perceived improvements to their physical ability, ability 
to undertake tasks of daily living, increased sputum clearance and a reduction in 
exacerbations. High levels of intrinsic and extrinsic motivation were also noted, with 
four participants going on to purchase their own devices following the intervention.  
9.2 General Discussion 
9.2.1 Feasibility of Pulmonary Rehabilitation in Chronic Respiratory Conditions 
PR has been extensively researched in COPD and found to be of physiological and 
psychological benefit in this population (McCarthy, 2015). However, its application 
to other respiratory diseases is still unclear, due to small numbers in studies as a result 
of poor participant uptake and large dropout rates (Michael C Steiner et al., 2017). In 
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this thesis, irrespective of the type of intervention, specific respiratory condition or 
age, the magnitude of beneficial effects was considerably smaller than those 
previously reported to be elicited in COPD participants. In contrast to previous 
research  (Kozu et al., 2011; Michael C Steiner et al., 2017), the retrospective analysis 
in Chapter 4 found similar beneficial effects from PR across respiratory diseases. 
Furthermore, adherence was much higher than reported in previous studies (Arnold, 
Bruton, & Ellis-Hill, 2006), with only 21% of participants categorised as non-attenders 
to PR. Due to the retrospective nature of this analysis, ascertaining the reasons for poor 
adherence was precluded and therefore more research is needed to understand patients’ 
perceptions of PR in respiratory conditions other than COPD. Indeed, it has been 
recommended that mixed-methods study designs are adopted in future research to 
understand the novel and complex responses to PR (Witcher et al., 2015). Despite this, 
evidence in COPD has suggested that the lack of adherence is primarily related to a 
lack of confidence and self-efficacy, low anticipation of benefits and accessibility to 
PR programs (Guo & Bruce, 2014). Due to the considerable variations of aetiologies 
that exist between chronic respiratory conditions, whether these barriers are also 
evident in other respiratory conditions is unclear.  
Chapter 4 also highlighted that socioeconomic status (SES) had an impact on 
adherence to PR. Lower SES groups are 14 times more likely to have a respiratory 
disease (Pleasants et al., 2016; Sahni et al., 2017; Schraufnagel et al., 2013) and 
therefore must be targeted to better improve adherence to PR. One potential strategy 
to rectify the adherence problem in low SES groups is home-based PR. Home-based 
PR has been shown to demonstrate effectiveness and equivalence to centre-based PR 
in COPD (Lahham et al., 2018), whilst also being feasible in those with bronchiectasis 
(Dal Corso et al., 2017). However, the ability to monitor patient adherence and effort 
remotely is a potential limitation of home-based PR. Indeed, in Chapter 5, the MDT 
highlighted the desire to be able to monitor patients remotely and track their progress 
to ensure engagement, while reducing the risk of reporting bias (Jantzen et al., 2016; 
Ruf et al., 2012b). 
Finally, sex differences were evident in Chapter 4, with females exhibiting poorer 
fitness and higher anxiety levels compared to males both pre- and post-PR. Despite 
sex being a potent determinate of disease aetiology and progression, PR guidelines do 
not vary by sex. Indeed, a systematic review  concluded that sex-related differences in 
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PR remain unclear (Robles et al., 2014). It is pertinent to note that The British Lung 
Foundation (2018) found a significant male bias in diagnosis of COPD and therefore 
more timely access to PR, with being female shown to be a predictor of non-adherence 
to PR in COPD  
In conclusion, Chapter 4 revealed the benefits to PR in a variety of respiratory 
diseases. However, it also highlighted the significant barriers that SES and sex can be 
to PR outcomes and adherence. As such, Chapter 4 suggested that future areas of 
interest should be to ascertain the impact of PR on differing respiratory conditions, 
while research needs to focus on the interaction of sex and SES on key mediators of 
outcome such as adherence. 
9.2.2 Inspiratory Muscle Training Intervention Evaluation 
The optimal training frequency, intensity and duration of IMT interventions in CF and 
bronchiectasis, is unclear (Martin-Valero et al., 2020; Shei et al., 2019). Studies range 
from 4-12 weeks with adaptations ranging across these time frames. However, neural 
adaptions are found to occur over the first four weeks of a strength training 
intervention (Brown et al., 2017; Ramsay et al., 1990), with morphological adaptations 
evidenced beyond this period (Folland & Williams, 2007). In Chapter 6, a four-week 
IMT programme of 30 breaths, for 15 minutes, twice a day, for 28 days at 40-50% 
MIP was implemented in children with CF. The improvements elicited in the pilot 
study were similar to those by Asher et al. (1982), who also found improvements in 
inspiratory muscle strength in children with CF, though they implemented the IMT at 
80% MIP intensity. Furthermore, participants in Chapter 6 cited the four-week 
programme as a feasible training schedule and reported good-adherence and 
enjoyment to the programme. Evidence from other IMT research in CF cited further 
physiological and psychological improvements in health using higher MIP intensities. 
Specifically, 60% MIP elicited improvements in respiratory muscle strength, 
endurance and some effect on exercise performance (Sawyer & Clanton, 1993a), 
whereas 80% MIP training protocols have elicited greater improvements in sputum 
clearance, respiratory muscle function and endurance, as well as reduced anxiety and 
depression (Chatham et al., 1997; Enright, Chatham, Ionescu, Unnithan, & Shale, 
2004). In bronchiectasis, 30% MIP produced improvements in respiratory muscle 
strength (Newall, 2005), whereas an increase to 60% MIP resulted in improvements 
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in respiratory muscle strength, exercise capacity and health status (Liaw et al., 2011; 
Ozalp et al., 2019). Previous research has found power increased at 20-40% MIP 
(Faulkner, 1985), strength at 80-100% MIP, with strength endurance adaptations at 
60-80% (Newton & Karmer 1994). Therefore, utilising previous research in these 
populations coupled with the feedback from MDT and participants in Chapter 6, an 
eight-week, three times a week, 80% MIP, with an eight-week, once a week 80% MIP 
top-up, IMT training intervention was designed in order to gain maximum 
physiological and psychological benefits, while being time-efficient.  
The training method utilised in Chapters 7 and 8 could provide further benefits over 
standard IMT. The PrO2Fit utilises a submaximal isokinetic-like training modality 
using a progressive work-to-rest ratio. Additionally, the ability to set a one-rep max 
relative to each individuals’ inspiratory muscle strength for each training session, 
enables an individualised and progressive training nature. This not only allows a 
constant velocity, but accommodates resistance during inspiratory muscle testing 
while taking into account the variable nature of disease in CF and bronchiectasis across 
time, making it appropriate and safe for impaired individuals (Chatham, 2000; 
Chatham et al., 1997; Enright et al., 2004; Ionescu et al., 1998). Traditional threshold 
IMT fixes the generation of pressure for each breath via a spring valve, allowing 
inspiration to occur when a set threshold is overcome and closes the valve when it is 
no longer achieved. In contrast, PrO2Fit provides a constant and accommodating 
resistance throughout the whole inspiration, enabling a greater MIP and inspiratory 
duration to be achieved in comparison to traditional IMT (Cahalin & Arena, 2015). 
Training loads associated with standard IMT are limited with workloads, with 
traditional threshold devices exhibiting a maximal resistance of ~42 cmH2O or less 
(Cahalin & Arena, 2015; Formiga et al., 2018). In contrast, the PrO2Fit allows a 
considerably higher level of inspiratory pressure (up to ~300 cmH2O), throughout a 
full inspiration (Cahalin & Arena, 2015; Formiga et al., 2018), allowing modulation 
of all aspects of muscle performance including strength, endurance and work capacity. 
Previous research has shown it is vitally important to fix the workload to fulfil the 
principle of overload, which is essential to the training outcomes in both skeletal 
muscle training and in IMT (Gosselink et al., 2011; Illi, Held, Frank, & Spengler, 
2012; Smart, Giallauria, & Dieberg, 2013), therefore, traditional IMT may be 
suboptimal compared with the PrO2Fit training modality.  
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Previous research in IMT in children with CF using traditional IMT devices have 
adopted training durations of two times a day, up to eight weeks (Asher, Pardy, Coates, 
Thomas, & Macklem, 1982; Bieli, Summermatter, Boutellier, & Moeller, 2017; 
Santana-Sosa et al., 2014). The training in Chapter 7 was only performed three times 
a week, yet still exhibited physiological improvements in respiratory muscle strength, 
exercise capacity and psychological improvements in physical functioning and the 
respiratory symptom domains of the CFQ-R, that were maintained in a 16-week top-
up period, training once a week. Improvements in MEP and PEF have not been 
reported post-IMT in CF, while the improvements in exercise capacity were 
comparable to more intensive and time-consuming interventions (Santana-Sosa et al., 
2014). Whilst in Chapter 8, bronchiectasis participants only exhibited improvements 
in MIP, respiratory endurance, perceived competence and motivational levels, the 16-
week top-up period was also efficient at maintaining benefits already elicited. The 
differences exhibited between CF and bronchiectasis could be attributed to the 
significant age difference and therefore physical ability of participants (McPhee et al., 
2016).  
In Chapter 5, the ability to monitor adherence and patient’s effort was highlighted by 
the MDT. Therefore, the PrO2Fit device was also chosen due to its live biofeedback 
and ability to remotely monitor adherence and effort. Often traditional methods of 
IMT do not provide live feedback on training, with participants highlighting in 
Chapters 7 and 8 that if they did not have the visual aid, they would consider training 
to be ‘boring’ and would be less likely to be motivated to adhere to, and comply with, 
IMT. Indeed, previous research has found biofeedback from isokinetic training to 
elicit greater testing and training results in clinical populations. (El Mhandi & 
Bethoux, 2013; Hammami et al., 2012). This thesis demonstrated the ability to monitor 
progress in training-elicited potential improvements in autonomy and both intrinsic 
and extrinsic motivation, as evidenced in Chapters 7 and 8. Furthermore, Chapters 
7 and 8 highlighted the perceived competence participants felt in completing IMT in 
the long-term, which could be related to the feedback provided by the app. Indeed, 
long-term compliance facilitated by effective training loads has been shown to be 
further facilitated by optimal feedback to participants in exercise programmes 
(Chatham, 2000; Chatham, Ionescu, Nixon, & Shale, 2004; Enright et al., 2004; 
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Enright, Unnithan, Heward, Withnall, & Davies, 2006; Hammami et al., 2012; Ionescu 
et al., 1998; Mickleborough, Nicholas, Lindley, Chatham, & Ionescu, 2010).   
In conclusion, the IMT intervention designed in this thesis is feasible, applicable and 
well-adhered to within CF and bronchiectasis populations. Furthermore, the intensity, 
duration and frequency are sufficient to attain physiological improvements in strength 
and endurance, psychological improvements in HRQoL, and enhance self-
determination measures. 
9.2.3 Participant Perspectives of Inspiratory Muscle Training Intervention 
The mixed-methods design of Chapters 7 and 8 allows a better understanding of the 
connections, or, contradictions, between qualitative and quantitative data (Shorten & 
Smith, 2017). Furthermore, the use of interviews provide participants with a strong 
voice and an opportunity to share their experiences across the intervention period, 
facilitating different avenues of exploration that enriches evidence and enables 
questions regarding intervention efficacy, feasibility and enjoyment to be answered 
more deeply (Wisdom & Creswell, 2013). To date, this is the first thesis to investigate 
patient and MDT perceptions of IMT in CF and bronchiectasis and implement these 
opinions into research design.  
Treatments in CF and bronchiectasis are highly prescribed, therefore gaining the views 
of patients in intervention research is essential in order to improve the quality of care 
and efficacy (Chalmers, Aliberti, & Blasi, 2015; Johnson, 2011). CF patients 
reportedly spend 108 minutes per day on a range of therapies, regardless of age or 
severity of disease (Sawicki, Sellers, & Robinson, 2009c). Bronchiectasis patients also 
have a high treatment burden, which has shown to impact compliance and adherence 
to prescribed treatments (Chalmers et al., 2015; McCullough et al., 2014). It is 
therefore a highly important finding that participants reported that a short eight-week, 
time-efficient IMT intervention was feasible and easily implemented into their daily 
routine. Both children and adults demonstrated high adherence to IMT, which was 
better than the adherence levels previously reported to treatment strategies within 
these cohorts (McCullough et al., 2014; Modi & Quittner, 2006). This improved 
adherence could be attributed to the app and the live biofeedback, with both children 
and adults exhibiting both intrinsic and extrinsic motivation, and low amotivation. The 
addition of feedback to an IMT intervention was highlighted by MDT in Chapter 5 
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and fed forward to the intervention design. Specifically, in bronchiectasis patients, 
previous research has highlighted that they want to feel in control of their symptoms 
and disease (Dudgeon et al., 2018), with patients reporting perceived competence in 
undertaking IMT in both short- and long-term interventions. Despite perceived 
competence not being significant in children with CF, interviews highlighted children 
felt competent, while reporting increased autonomy and mastery in undertaking IMT. 
Increased levels of autonomy has been associated with positive health, behavioural 
and psychological outcomes and is therefore important to long-term adherence and 
compliance to treatment interventions (Manganello, 2008). Children reported that the 
IMT device and app were easy to use, which is essential to adherence, as training that 
is deemed too complicated to understand, or perceived as too stressful, has been shown 
to reduce compliance in the CF population (Taylor, 1991). 
Children with CF and adults with bronchiectasis also perceived improvements in their 
physical functioning, attributing this to the inclusion of IMT into their daily routine. 
Despite not exhibiting quantitative improvements in their exercise capacity, 
bronchiectasis adults felt their ability to undertake activities of daily living improved, 
while children who significantly improved their exercise capacity, noticed 
improvements in their sporting abilities. Furthermore, bronchiectasis participants also 
reported increased sputum clearance and a reduction in pulmonary exacerbations. This 
was not reported by children with CF, potentially due to the near normal lung function 
and the overall good health of participants in Chapter 7. Further investigation is 
warranted on how this perceived improvement could affect patients’ anxiety and 
depression in the bronchiectasis population. Finally, the qualitative results in Chapter 
8 are in line with previous research in advanced lung disease, with  perceived improved 
breathlessness, mobility, breathing control and abilities in daily activities after eight 
weeks of IMT (Hoffman et al., 2018). Overall, the qualitative data has further 
strengthened the evidence of the quantitative data, and shown IMT to be well-adhered 
to, and enjoyed, in these patient populations. Research should continue to gain insights 






9.3 Thesis Strengths  
A major strength of the thesis is patient involvement in the design and implementation 
of IMT. In Chapter 5, the pilot study, views and opinions of patients were sought to 
help design the future IMT studies implemented within this thesis. Furthermore, the 
perceptions of IMT gathered from Chapters 7 and 8 highlight the feasibility and 
acceptability of IMT in both CF and bronchiectasis. The eight-week, three times a 
week, intervention period was deemed appropriate to fit into treatment schedules in 
these populations. Interview data presented in this thesis can help influence the design 
of future IMT interventions to ensure maximum patient recruitment and retention in 
studies. 
Interview analysis from Chapter 5 highlighted the MDTs desire to track adherence, 
progress and compliance to IMT objectively, to reduce the risk of patient reported 
bias. Indeed, objective adherence to IMT has not been reported previously in clinical 
populations and therefore is a major strength of both Chapters 7 and 8. The ability 
for the PrO2Fit to monitor adherence remotely allows reliability in assessing 
participants’ adherence to study protocol, while enabling dose-response to be 
effectively investigated (Formiga et al., 2018).  
Another novel feature of the PrO2fit is the visual feedback provided by the app, while 
also storing past training sessions. This not only enables participants to track their 
progress, but objective monitoring of home-based IMT from a distance by researchers 
and clinicians. This therefore reduces the supervision required for IMT to be 
efficacious. Indeed, Chapters 7 and 8 highlighted the perceived competency and 
autonomy reported by participants in undertaking the unsupervised training sessions. 
Furthermore, the live biofeedback induced feelings of mastery, with participants 
exhibiting goal-setting behaviour, increasing their motivation to train, which could be 
attributed to the high adherence reported in both chapters. The high adherence reported 
in Chapters 7 and 8 is another strength to this thesis, not least given the lack of 
adherence to usual treatments in both CF (Modi & Quittner, 2006) and bronchiectasis 





9.4 Thesis Limitations  
There are several limitations within this thesis, which should be acknowledged. 
Firstly, the small sample sizes within Chapter 5, 6, 7 and 8 limit the statistical power 
and therefore the ratification of the findings. A larger sample would have increased 
the generalisability of the findings, while allowing more in-depth analysis of IMT’s 
effectiveness across the age and disease severity ranges in CF and bronchiectasis. 
However, the findings within Chapters 6, 7 and 8 were supported by the application 
of minimal clinically important difference (MCID) calculations, allowing studies to 
be adequately powered with fewer participants (Modi et al., 2010), instead of relying 
solely on statistical significance (Beaton et al., 2002). It is important to consider 
whether there is a tendency in clinical studies to undervalue findings stemmed from 
small samples. Such bias towards larger sample sizes could inadvertently direct 
research interest and focus away from studies involving under-served and hard-to-
reach populations (Manganello, 2008).  
An additional limitation is the lack of age- and sex-matched controls in chapters 5, 6, 
7 and 8. Matching on factors such as age and sex improves study efficiency by 
enhancing statistical precision (Pearce, 2016). Furthermore, matched control groups 
would have aided in the assessment of efficacy and by discriminating outcomes found 
post-IMT from those caused by other factors, such as course the of disease, participant 
expectation or other treatments (Malay & Chung, 2012). Age- and sex-matched 
controls were recruited for Chapters 7 and 8, however, due to the onset of COVID-
19 they could not complete the intervention. 
Finally, the lack of longitudinal follow-up to determine whether the physiological and 
psychological improvements exhibited from IMT in Chapters 5, 7 and 8 were 
maintained, would have been beneficial.  Whilst improvements in physiological health 
were maintained during a top-up period in Chapters 7 and 8, whether these 
parameters were maintained in the long-term remains to be elucidated. Furthermore, 
one of the biggest concerns regarding utilising technology in a clinical setting is 
whether individuals will sustain their engagement with technology over time (Ledger 
& McCaffrey, 2014). The application of longer interventions and longitudinal follow-




9.5 Implications for Future Research 
The work completed in this thesis, alongside current and emerging literature, has 
developed several recommendations that should be considered for future research.  
9.5.1 Patient Involvement in Clinical Research 
As recruitment for clinical research studies is a major challenge (Anderson, Borfitz, 
& Getz, 2018; Tohid et al., 2017), Chapters 6, 7 and 8 suggest the importance of 
ascertaining the views and opinions of participants undertaking the research. 
Furthermore, to date, these are the first studies to investigate the perceptions of IMT 
in chronic respiratory conditions. Future studies should implement short-term pilot 
studies to ascertain patients’ perceptions of an intervention prior to long-term 
interventions. This will allow research to determine the feasibility and acceptability of 
an intervention, and simultaneously foster autonomy in providing input regarding the 
potential palatability of interventions, not least in terms of their frequency, intensity 
and duration. Indeed, compromising on the optimal intervention dose may be more 
effective if participants will adhere to it, than striving for the optimal dose that no 
participants will engage in. 
9.5.2 Determining Optimal Inspiratory Muscle Training Programmes 
As discussed in Chapter 2, research surrounding the optimal frequency, intensity and 
duration of IMT in clinical populations remains to be determined. Such uncertainty 
has arisen as a result of the, considerable inter-study variation resulting in equivocal 
results regarding the effect of IMT in CF and bronchiectasis. It is hypothesised that 
the individual participant variations in disease, age and underlying comorbidities are 
the cause of the varying effects of IMT. As the focus on the importance of patient-
centred clinical outcomes and the drive towards personalised/precision medicine 
continues to increase, it could be argued that IMT should be utilised on a case-by-case 
basis. Based on individual needs, protocols that aim to target the strength and/or 
endurance deficits, may in turn elicit optimal physiological and psychological benefits 





9.5.3 Implementing Respiratory Muscle Strength Measures into Standard Clinical 
Care 
Impairment of the respiratory muscles is a common finding in those with respiratory 
disease (Laghi & Tobin, 2003; ATS, 1999). Indeed, in respiratory disease, inspiratory 
muscle weakness may cause a disparity between muscle load and capacity, resulting 
in dyspnoea, reduced exercise capacity and the development of hypoventilation and 
respiratory failure (Moxham, 1991; Gibson, 1995; Trooster et al., 2005). Expiratory 
muscle weakness can impact on cough efficiency, affecting the removal of secretions 
from the airway, resulting in respiratory infection in those with a chronic respiratory 
condition (Arora & Gal, 1981; Irwin et al., 1998). However, diagnosis of respiratory 
muscle weakness is often delayed as standard screening protocols do not assess muscle 
strength (Parshall et al., 2012; Caruso et al., 2015). This is surprising given that the 
assessment of respiratory muscle strength may be clinically useful to monitor changes 
in disease over time, helping to identify risk of hypoventilation and determining the 
impact of interventions (Moran et al., 2010). Additionally, since the relationship 
between lung volumes and inspiratory muscle strength is non-linear (de Troyer et al., 
1980), mean inspiratory pressure (MIP) measurements can identify inspiratory muscle 
weakness earlier than would be possible based on changes in lung volumes (Caruso et 
al., 2015).  
To quantify respiratory muscle strength, volitional and non-invasive measures of MIP 
and mean expiratory mouth pressures (MEP) are the mostly widely accepted and 
commonly used methods (ATS/ERS, 2002). Importantly, the equipment is low-cost, 
low-complexity and portable, with the test being quick and easy to perform, which is 
essential in busy respiratory clinics (Caruso et al., 2015). Given the ease of testing and 
the valuable indices of MIP and MEP, the implementation of frequent respiratory 
muscle strength testing in standard clinical care would be advantageous to monitor 
health, disease progression and identify risks in chronic respiratory conditions. 
9.5.4 Prognostic Value of Handgrip Strength Testing 
Muscle dysfunction is a common manifestation in chronic lung diseases, secondary to 
multiple mechanisms, including, but not limited to, diet changes, systemic 
inflammation, reduced muscle repair, oxidative stress, drug use, aging, and muscle 
deconditioning (Lima et al., 2019). Muscle dysfunction may appear early in lung 
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impairment or manifest over time, resulting in PA limitations and a reduction in 
activities of daily living, resulting in deterioration of QoL (Chaves et al., 2007; Ziegler 
et al., 2007; Pleguezuelos et al., 2016). Loss of peripheral skeletal muscle mass and 
progressive decline in muscle strength (Blau et al., 2002) are caused by a reduction in 
ventilatory capacity, which promotes adaptive changes in skeletal muscle mass, 
therefore contributing to exercise intolerance in respiratory disease (Chaves et al., 
2007; Garcia et al., 2017).  
Handgrip strength (HGS) is a rapid, simple, cost-effective measure of upper limb 
muscle force and is an overall indicator of physical capacity (Lima et al., 2019). 
Moreover, HGS is not limited to assessing the upper limbs and has been found to be a 
good predictor of mortality, with various respiratory and cardiovascular co-
morbidities associated with reduced HGS (Leong et al., 2015). Several studies have 
evidenced a positive association between HGS and lung function in those with COPD 
(Martinez et al., 2017) and CF (Rovedder et al., 2019). Furthermore, HGS is correlated 
with six-minute walk distance in COPD (Kyomoto et al., 2019) and bronchiectasis 
(Ozalp et al., 2012), and absolute VO2peak in children with CF (Wells et al., 2014). 
Despite HGS prognostic value, it is infrequently used as a functional measure in those 
with respiratory disease, perhaps because it is often associated with a complex battery 
of tests (Martinez et al., 2017; Lima et al., 2019). Finally, HGS can serve as a test to 
identify those with poor upper limb strength that can be referred for more extensive 
exercise capacity testing, a health and disease monitoring process and a marker for 
intervention success in respiratory disease (Han et al., 2018). Therefore, the use of 
HGS tests in standard clinical care is warranted.   
9.5.5 Application of Inspiratory Muscle Training in Conjunction with Pulmonary 
Rehabilitation 
The efficacy of PR and IMT has been discussed throughout this thesis, however, the 
effects of both of these rehabilitation modalities in combination are worth 
consideration and further research. In COPD, IMT has been found to be an important 
adjunct to PR, with reduced respiratory muscle strength, resulting in greater 
improvements in exercise capacity than reported with PR in isolation (Wanke et al., 
1994; Weiner et al., 1992). These additional gains in exercise capacity may be related 
to the increase in inspiratory muscle strength at the end of the training programme, or 
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to the reduction in perceived dyspnoea during exercise (Weiner, Magadle, Berar-
Yanay, Davidovich, & Weiner, 2000). During exercise, the inspiratory muscles have 
demonstrated increased loading in both CF (Goetghebeur et al., 2002) and 
bronchiectasis patients (Koulouris, Retsou, Kosmas, Dimakou, Malagari, 
Mantzikopoulos, Koutsoukou, Milic-Emili, & Jordanoglu, 2003) due to tidal 
expiratory flow limitation, increased dyspnoea and reduced exercise tolerance. The 
consequences of expiratory flow limitation have also been well documented in COPD, 
where the combination of PR and IMT has been shown to be effective (Newall, 
Stockley, et al., 2005b). It can therefore be postulated that combined PR and IMT 
could possibly be effective in both CF and bronchiectasis due to similar disease 
pathologies (Schafer, Grise, Chandrasekaran, Chotirmall, & Hartle, 2018). 
In CF, there has been one reported study combing exercise training and IMT. Santana-
Sosa et al. (2014) combined IMT with aerobic and strength training exercises for four 
weeks. Children significantly increased their peak oxygen uptake, inspiratory and 
‘whole body’ muscle strength, while exhibiting a shift towards a healthier body 
composition (Santana-Sosa et al., 2014). Furthermore, inspiratory muscle and leg 
press strength were maintained after detraining, while a positive trend was noted in 
children’s HrQoL (Santana-Sosa et al., 2014). It could be hypothesised that the 
combination of central adaptations, such as the potential effect of IMT on maximal 
ventilatory capacity, coupled with the peripheral adaptations, higher leg muscle 
strength, and delayed fatigue during testing, could explain the improvement in peak 
oxygen consumption. Indeed, it was concluded that the evidence in Santana-Sosa et 
al. (2014) study supported the need to prescribe a ‘complete’ exercise intervention as 
early as possible, across disease severities and ages within the CF population. Despite 
these findings, this is the only study to date to investigate the combination of exercise 
and IMT in CF.  
In line with CF, only one study has reported the beneficial effects of combined PR and 
IMT training in bronchiectasis (Newall, Stockley, et al., 2005b). Exercise training 
sessions, incorporating treadmill walking, cycle ergometry and stair climbing, were 
combined with IMT across eight weeks. IMT increased respiratory muscle strength 
significantly, but did not provide immediate benefits beyond the effects of exercise 
training alone (Newall, Stockley, et al., 2005b). However, in the PR-IMT group 
improvements in both exercise capacity and health status observed, were maintained 
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three months after training cessation, whereas those in the PR-sham group were not 
maintained, highlighting the potential additive effect of IMT.  
 
Overall, both studies (Newall, 2005; Santana-Sosa et al., 2014) highlight that 
combined PR methodologies and IMT training are feasible and applicable within these 
populations. Whilst it is impossible to identify the specific influence of IMT in 
Santana-Sosa and colleagues (2014) study due to lack of sham IMT group, Newall et 
al. (2005) highlighted the potential additive effect of IMT long-term. However, both 
studies acknowledge the small sample sizes and the normal to mildly reduced 
inspiratory muscle strength at baseline in participants (Newall, Stockley, et al., 2005b; 
Santana-Sosa et al., 2014b). Indeed, it was argued by Newall et al. (2005) that the lack 
of additional benefit of IMT in conjunction with exercise training was due to the lack 
of functional weakness in their cohort, which has also been evidenced elsewhere 
(Larson et al., 1999). Furthermore, the optimal combination of exercise training and 
IMT needs to be investigated. Indeed, the high-intensity nature reported in Newall et 
al. (2005) may have induced the maximal attainable benefits in exercise capacity, 
therefore the addition of IMT may elicit no further benefit. Conversely, the addition 
of a strength training protocol utilised by Santana-Sosa et al. (2014) may have only 
elicited peripheral adaptions due to the increase in leg strength, thereby delaying 
fatigue during testing. Furthermore, the optimal intensity, duration and frequency of 
IMT in both populations still remains to be elucidated.  
 
In conclusion, while there is emerging evidence supporting the use of combined PR 
and IMT in both short- and long-term health outcomes, further research is warranted 
to investigate the optimal combination of training methods, across ages and disease 
severities in both CF and bronchiectasis populations.  
9.5.6 Potential Application of Inspiratory Muscle Training to Coronavirus Disease 
Coronavirus disease 2019 (COVID-19) is a global pandemic, causing significant 
damage to the lungs and airways, potentially leading to acute respiratory distress 
syndrome and, if severe enough, respiratory failure (Honce & Schultz-Cherry, 2019). 
Those who are at higher susceptibility of developing severe respiratory complications 
from COVID-19 include those who are obese, older age, and smoke, as well as those 
who suffer from cardiometabolic and lung diseases (Arentz et al., 2020; Livingston & 
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Bucher, 2020; Wu & McGoogan, 2020). There are also people who do not possess 
these characteristics that develop severe respiratory complications, and, as such, there 
are other factors that contribute to the risk of poorer outcomes from COVID-19 that 
are yet to be elucidated (Severin et al., 2020).  
Despite impaired respiratory muscle performance being considered rare (A. Rodrigues 
et al., 2017; Sclauser Pessoa et al., 2014), it is frequently evident in patients with 
poorer health characteristics, such as obesity and chronic respiratory condition 
(Severin et al., 2020). Indeed, a reduction in respiratory muscle strength, and changes 
in airway resistance and chest wall compliance, due to the increased demand imposed 
on the respiratory muscles, have been found in patients with chronic lung disease and 
obesity (ATS/ERS Statement, 2002; Laveneziana et al., 2019; Sood, 2009). Therefore, 
patients with these underlying complications that sustain an acute viral infection, such 
as COVID-19, can experience increased risk of respiratory failure, due to further 
imbalances between respiratory muscle-force-generating capacity and imposed 
demands required for breathing (Levine et al., 2008). 
Those who suffer from acute respiratory distress syndrome and respiratory failure 
require mechanical ventilation to unload the respiratory musculature, which has been 
demonstrated in COVID-19 (Severin et al., 2020). However, mechanical ventilation 
has been shown to adversely change the respiratory muscles, inducing rapid atrophy 
and profound weakness, resulting in ventilator-induced diaphragm dysfunction 
(VIDD; Berger et al., 2016; Vassilakopoulos, Zakynthinos, & Roussos, 1998). 
Evidence has shown VIDD results in unsuccessful weaning from mechanical 
ventilation due to lower diaphragm thickness (American Society of Anesthesiologists 
Task Force, 2012), and an imbalance between respiratory muscle-force-generating 
capabilities and demand imposed for spontaneous breathing (Martin et al., 2011; Purro 
et al., 2000; Sklar et al., 2020), causing increased risk of further complications 
(American Society of Anesthesiologists Task Force, 2012) .  
Those who are in poor health post-COVID-19 and at greater risk of a viral infection, 
may demonstrate respiratory muscle weakness and, therefore, be at an increased risk 
of poorer clinical trajectory, if acute respiratory distress syndrome continues (Severin 
et al., 2020). Therefore, respiratory muscle training, which improves respiratory 
muscle strength, exercise capacity, diaphragm thickness and dyspnoea in several 
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populations (Edwards, Maguire, Graham, Boland, & Richardson, 2012; R Gosselink 
et al., 2011; Illi et al., 2012; Pazzianotto-Forti, Mori, Zerbetto, & et, 2019; H. Souza, 
Rocha, Pessoa, & Al., 2014) may be of pertinence post-COVID infection. To date, no 
studies have investigated the impact of respiratory muscle training in those who have 
suffered a viral infection. However, a recent study found that just five days of a 
preoperative respiratory muscle training protocol significantly reduced pulmonary 
complications and time spent in hospital (Elkins & Dentice, 2015). Furthermore, in 
patients at risk of prolonged hospitalisation, four weeks of respiratory muscle training 
at 50% of MIP reduced hospital stay duration, mortality and risk of intubation 
(Nikoletou et al., 2016). In  patients that required mechanical ventilation, a respiratory 
muscle training invention improved weaning outcome, (Langer et al., 2015) and 
reduced post-operative respiratory conditions (Martin et al., 2011). Nonetheless, the 
role of respiratory muscle training to mitigate the effects of respiratory complications 
from viral infections has yet to be investigated. The current evidence of the apparent 
connection of impaired respiratory muscle performance, mechanical ventilation and 
respiratory complications, coupled with the strong evidence of the beneficial effects 
of respiratory muscle training, warrants further exploration regarding whether it can 
reduce the risk of severe complications during and or after a viral infection (Severin 
et al., 2020). 
9.5.7 The Fatigue Index Test (FIT) 
Respiratory muscle fatigue is the cause of the onset of ventilatory impairment, often 
accompanied by hypoxemia and hypercapnia (Tsukamoto, Maruyama, Kato, Uchida, 
& Kubo, 2019) and a major cause of respiratory failure in CF (Dunnink, Doeleman, 
Trappenburg, & de Vries, 2009) and bronchiectasis (Ozalp et al., 2019). Multiple 
measures, such as electrical or magnetic stimulation, have been employed to quantify 
respiratory muscle fatigue in chronic respiratory conditions, however, such testing is 
difficult, uncomfortable and time-consuming (ATS/ERS, 2002). The Fatigue Index 
Test (FIT) is a novel method of quantifying the propensity for inspiratory muscle 
fatigue in clinical practice (Formiga, Vital, Urdaneta, Campos, & Cahalin, 2019). The 





(𝑆𝑢𝑚𝑚𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐼𝑛𝑠𝑝𝑖𝑟𝑎𝑡𝑜𝑟𝑦 𝑃𝑜𝑤𝑒𝑟 𝑥 𝑇𝑜𝑡𝑎𝑙 𝐼𝑛𝑠𝑝𝑖𝑟𝑎𝑡𝑜𝑟𝑦 𝑇𝑖𝑚𝑒)
(𝑃𝑜𝑤𝑒𝑟500 ×  𝑇𝑖𝑚𝑒500)
 
Equation 9.1 
The FIT is based upon the parameters measured during a single inspiratory breath, 
where Power500 is equal to the power expended to inspire 500 ml of air and Time500 is 
the time to inspire 500 ml of air. The 500 ml is set a default because it is the equivalent 
of average resting tidal volume (Hallett & Ashurst, 2018). However, this baseline may 
need to be altered to reflect underlying lung volumes and health status (Chatham, 
2018). The FIT Score compares capacity in measurement of total single inspiratory 
breath work performed to demand the average tidal volume of 500 ml. Therefore, the 
FIT Score is related to propensity to inspiratory muscle fatigue and may be an indicator 
of approaching respiratory failure in chronic conditions. According to this equation, 
those presenting with greater MIP measured at residual volume will achieve shorter 
T500 times, which will result in a greater FIT score for a given total time, whereas a 
high MIP with rapid and acute fall of power output will result in a lower FIT Score 
and less endurance (Chatham et al., 1999). A recent study examined the relationship 
between the FIT Score and COPD-related outcomes (Formiga et al., 2019). A higher 
propensity to inspiratory muscle fatigue, as reflected by lower FIT Scores, was 
associated with more severe airflow obstruction, reduced functional exercise capacity, 
impaired HRQoL, increased symptomatology and greater risk of mortality in COPD 
(Formiga et al., 2019). Despite limited evidence, and no studies to date in other 
respiratory conditions, the FIT Score potentially promises a valuable and quick 
indicator of overall health in individuals with chronic respiratory disease. Further 
research is warranted and encouraged to gain insight into the FIT Score and its 









9.6 Overall Conclusion 
This thesis provides evidence that an alternative PR strategy, such as IMT, is an 
applicable, feasible, safe and time-efficient form of exercise that can improve 
physiological and psychological health in those with CF and bronchiectasis. The 
home-based nature, coupled with enjoyment and the ability to monitor progress, led 
to increased motivation and high adherence within our participant cohort. Whilst it is 
acknowledged that the small sample sizes may limit the generalisability the current 
findings to the wider CF and bronchiectasis population, this thesis provides a strong 
foundation to develop further investigations and interventions, drawing on the 
strengths of the IMT study protocol and patient feedback to help enhance future 
directions of IMT research. Indeed, this thesis presents evidence that IMT can be a 
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Information Sheets and Consent/Assent Forms 
 
 
Applied Sports Technology Exercise and Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
 
ADOLESCENT PARTICIPANT INFORMATION SHEET 
(Version 1, Date 17/10/2015) 
 
  
Project Title:  
Determining physical activity levels in young cystic fibrosis 
patients Contact Details:  
Dr Melitta McNarry          Dr Kelly Mackintosh  
Email:       Email:   
Telephone:         Telephone:   
  
Jessica McCreery  
Email:   
  
  
1. Invitation Paragraph  
Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy to take part.  If you are happy to take part, thank 
you.  If you prefer not to take part, this is not a problem and we thank you for thinking 




2. What is the purpose of the study?  
The four week program you completed before was to see whether 
making your muscles stronger, made life easier for you. What we would 
like to do is ask you some questions on how the training went, how you 
felt about using the resistive device and whether it made life easier for 
you. This will help us in future studies with children and adults with 
cystic fibrosis.  
  
3. Why have you been chosen?  
You have been asked if you would like to take part because you 
have completed a four week program with the resistive training 
device.  
  
4. What will happen to you if you take part?  
You will be asked to come to your normal Cystic Fibrosis Clinic at 
Singleton Hospital once. You will then be asked some questions 
on the four week program you completed. There is no right or 
wrong answer to these questions, all we want to know are your thoughts.  
  
5. What are the possible disadvantages of taking part?  
There may be some questions you are not sure on how to answer or need longer to think 
about, but that’s ok we will give you plenty of time to answer and help you as much as we 
can!  
  
6. What are the possible benefits of taking part?  
You will help us see whether this type of training is good for people with cystic fibrosis and 
whether it makes them feel better. This will help us make future studies better for people 
with cystic fibrosis. 
7. Will my taking part in the study be kept confidential?  
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  Any direct quotes used will be given a 
fake name so that no one will know who originally said it. After the study is finished, all 
private information will be deleted.   
  
8. What if I have any questions?  
If you have any questions, please contact us on the details at the beginning of this sheet. 
You can also ask one of the researchers when you come in to visit the Clinic.   
   
294 
 
Applied Sports Technology Exercise and 
Medicine Research Centre (A-STEM)  




PARENT/GUARDIAN PARTICIPANT INFORMATION SHEET  
(Version 1, Date 17/10/2015)  
  
Project Title:  
Determining physical activity levels in young cystic fibrosis patients  
  
Contact Details:  
Dr Melitta McNarry          Dr Kelly Mackintosh  
Email:       Email:   
Telephone:         Telephone:   
  
Jessica McCreery  
Email:   
  
1. Invitation Paragraph  
Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy for your child to take part.  If you are happy for 
them to take part, thank you.  If you prefer them not to take part, this is not a problem and 
we thank you for thinking about it.  Your child’s care will not be influenced if they do or do 
not decide to take part.  
  
2. What is the purpose of the study?  
The four week program that was completed before was to see 
whether making muscles stronger for people with cystic fibrosis, 
made life easier for them. The questions we will ask is about their 
feelings and views on how the training went, how they felt about 
using the resistive device and whether it made life easier for them. 
This will help us in future studies with children and adults with 




3. Why has your child been chosen?  
Your child has been asked if they have previously taken part in a 
four week resistive breathing study.  
  
4. What will happen to your child if they take part?  
They will be asked to come to their normal Paediatric Cystic 
Fibrosis Clinic at Singleton Hospital once. They will then be 
asked some questions based on their four week program which 
they previously completed. The questions will be solely centered on their opinions and 
experiences of the previous study. There is no right or wrong answers to these questions!  
  
5. What are the possible disadvantages of taking part?  
Your child may get stuck on a question or find it difficult to answer. We will give them as 
much help as we can and plenty of time to answer the questions. All questions will be 
catered towards children and their level of understanding.   
  
6. What are the possible benefits of taking part?  
The information gathered will help us determine whether this type of training is good for 
people with cystic fibrosis. It will also help us in future studies with children and adults with 
cystic fibrosis.  
  
7. Will my child taking part in the study be kept confidential?  
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  Any direct quotes used will be given a 
fake name so that no one can identify who originally said it. After the study is finished, all 
private information will be deleted.   
  
8. What if my child or I have any questions?  
If your child or you have any questions, please contact us on the details at the beginning of 
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UNDER 12 YEARS OLD INFORMATION SHEET CONTROL 
(Version 1.2, Date 09/03/2017) 
 Project Title: 
Investigating the influence of an Inspiratory Muscle Training program 




Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 






Thank you for being interested in our project. Please read this information 
sheet carefully and think about whether you are happy to take part.  If you are 
happy to take part, thank you.  If you prefer not to take part that is ok. If you 
have any questions, please contact us on the details at the beginning of this 
sheet. You can also ask one of the researchers when you come in to visit the 
Clinic.  
What is the purpose of this study? 
We want to see if we can make your breathing muscles stronger. To do this 
we will ask you to use a special device into which you breathe in and out. The 
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point of this study is to see if breathing through this device makes you feel 
better and able to exercise for longer afterwards. 
 
What will happen to you if you take part? 
You will be invited to attend 4 sessions. These will take place at Swansea 
University or Morriston Hospital, we can help cover cost of travel to these 
sessions. 
 
Each visit will take about 1.5 hours. During the first visit, we will 
show you all the equipment being used during the study and 
you can ask any questions you may have. After this, we will 
measure how tall you are when you are standing and sitting 
down and how much you weigh on a special machine (picture 
right). We will also measure your waist and hip size and see how 
strong your lungs are when you breathe in as hard as you 



























   

















Visit 1  
Ask any questions 
Get to know the equipment 
Take height and weight (Picture 1) 
How strong are you (Picture 2) 
Cycle as long as you can (Picture 3) 
Questionnaire 
Get to know the breathing device 
(Picture 4) 
Be given a monitor to measure how 
much you move (Picture 5) 
Picture 1 
Visit 2 (week 2) 
Return movement monitors 
Picture 3 
Visit 3 (week 4) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
 
Visit 4 (week 8) 
Take height and weight 
Cycle as long as you can 
Questionnaire 
One-to-one talk 
How strong are you? 
 
Visit 5 (week 16) 
Take height and weight 
Cycle as long as you can 








To measure how strong, you are you will be asked to squeeze a hand grip 
machine as hard as you can (picture 2). We will then ask you to cycle on the 
bike with a mask on that you breathe through and some stickers on your 
chest to see how fast your heart beats. While you cycle, it will get slowly 
harder and harder, like cycling up hill, and we will encourage you to keep 
going for as long as you can. 
 
Breathing Device 
You will then be given your own breathing device 
(picture on left), which you can link to your mobile 
or tablet through an app. This means you can track 
your progress during training and see how well you 
are doing!  
 
We want you to use this device three times a week, every week for 8 weeks. 
During these sessions, you will start each session by doing a maximum effort 
breath into the device. You should do this 
standing up and by blowing out all the air in 
your lungs and then taking the biggest breath 
in you possibly can as hard, fast and long as 
you can! After this, you will do sets of 6 
breaths at a time, with the time between each 
breath getting shorter as you keep going through each set. As you breathe in, 
you are trying to match the effort shown on the app (picture on right) all the 
way through the breath. You will find it gets harder and harder as you go 
through and we want you to try and get as far through the sets as you can each 
day. 
 
At the end of 8 weeks you can decide if you want to keep training for another 
8 weeks or stop, this is completely your choice.  
 
After wearing this monitor for a week you can send this monitor back to us. 
When you are wearing the monitor, you do NOT need to do anything 





At the end of 8 weeks you still sit down with one of the researchers and talk 
about your thoughts and feelings on the IMT program. There is no right or 
wrong answer to these questions, all we want to know are your thoughts. This 
chat will be recorded and what you say will be written down and then 
destroyed. 
 
If you are 10+ years old at one training session in weeks 1, 4 and 8 some 
questions will pop up on the IMT app for you to answer before and after your 
training sessions. There is no right or wrong answer to these questions, we just 
want to know how you are feeling on that day. Answers will be based on a 
scale: 
 
Please indicate how much each reason is true for you, using the following 
scale:  
 
1         2   3  4  5   6  7  
not at all         somewhat       very  
true              true                true 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little 
uncomfortable. The visits will take up some time, however we can time them 
at times that best suit you. The sticky pads that are stuck to your chest may 
be slightly uncomfortable when removed, but it’s just like removing a sticky 
plaster! You may find breathing against the resistance device strange at first 
but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 
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It might help us find ways to help children and adults with Cystic Fibrosis. 
Cystic Fibrosis is a disease that causes the body to make thick sticky slime 
which hurts a persons lungs. 
What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong 
during the study you will be asked to stop. We will get the doctors to check 
you to make sure you are ok and to see if you can continue or not. 
Will my taking part in the study be kept secret? 
All personal information collected will be kept completely secret. That is, only 
members of the research team will have access to it.  You will be given a 
special number so that no one knows who your results belong to. Interview 
recordings will be written up and then the audio recordings will be 



















Applied Sports Technology Exercise and 
Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of 
Engineering 
 
12- 15 YEARS OLD INFORMATION SHEET CONTROL 
(Version 1.2, Date 09/03/2017) 
 Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry   Dr Kelly Mackintosh 
Email:  Email:  






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy to take part. If you have any questions, please just 
ask one of the researchers or contact us in the details above. If you are happy to take part, 
thank you.  If you prefer not to take part, this is not a problem and we thank you for thinking 
about it.  
 
What is the purpose of this study? 
We think that if we make breathing muscles stronger, it might make everyday life easier. To 
make the breathing muscles stronger, we will ask you to use a special device into which you 
breathe in and out. The point of this study is to see if breathing through this device makes 
you feel better and able to exercise for longer afterwards. 
 
What will happen to you if you take part? 
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You will be invited to attend 4 testing sessions. (See Diagram below) These will take place 
at Swansea University or Morriston Hospital, we can help cover cost of travel to these 
sessions. 
 
Each visit will take about 1.5 hours. During the first visit, we will show you 
all the equipment being used during the study and you can ask any 
questions you may have. After this, we will measure how tall you are when 
you are standing and sitting down and how much you weigh on a special 
machine (picture right). We will also measure your waist and hip size and 
then see how strong your lungs are when you breathe in as hard as you 
possibly can! To measure how strong, you are you will be asked to squeeze 
a hand grip machine as hard as you can (picture 1). 
 
We will then ask you to cycle on the bike with a mask on that you breathe through and some 
stickers on your chest to see how fast your heart beats. While you cycle, it will get slowly 
harder and harder, like cycling up hill, and we will encourage you to keep going for as long 














































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
How strong are you? (Picture 1) 
Cycle as long as you can (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Given a monitor to measure how 
much you move (Picture 4) 
 
Visit 2 (week 2) 
Return movement monitors 
Picture 3 
Visit 3 (week 4) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
Picture 2 
Visit 4 (week 8) 
Take height and weight 
Cycle as long as you can 
Questionnaire 
One-to-one talk 
















You will then be given your own IMT device (picture on left), 
which you can link to your mobile or tablet through an app. 
This means you can track your progress during training and 
see how well you are doing!  
 
We want you to use this device three times a week, every week for 8 weeks. During these 
sessions, you will start each session by doing a maximum effort breath in to the device. You 
should do this standing up and blowing out all the air in your lungs and then taking the 
biggest breath in you possibly can as hard, fast and long as you can! After this, you will do 
sets of 6 breaths at a time, with the time between each breath 
getting shorter as you keep going through each set. As you 
breathe in, you are trying to match the effort shown on the 
app all the way through the breath (picture on right). You will 
find it gets harder and harder as you go through and we want 
you to try and get as far through the sets as you can each day. 
 
At the end of 8 weeks you can decide if you want to keep training for another 8 weeks or 
stop, this is completely your choice! 
 
Questionnaires 
At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
you to answer before and after your training sessions. There is no right or wrong answer to 
these questions, we just want to know how you are feeling on that day. Answers will be 
based on a scale: 
 
Please indicate how much each reason is true for you, using the following scale:  
 
Visit 5 (week 8 of top-up/detraining) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
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1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
 
At the end of 8 weeks you still sit down with one of the researchers and talk about your 
thoughts and feelings on the IMT program. There is no right or wrong answer to these 
questions, all we want to know are your thoughts. This chat will be recorded and what you 
say will be written down and then destroyed 
 
Monitors 
We will then give you a monitor to wear. The monitor shown in the picture on the 
right, will be worn on a belt around your waist but you will need to take it off when 
you shower or swim and write down how long you didn’t have it on for. After 
wearing the monitor for a week you can send it back to us. When you are wearing 
the monitor, you do not need to do anything differently. We just want you to do 
whatever you would normally do each day. 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little uncomfortable, 
however you will complete a warm-up and cool-down exercise before and after all exercise 
testing. We will give you some rest breaks and water will be available. Coming to the labs 
will take up some time, however we can schedule testing for times that best suit you. The 
sticky pads that are stuck to your chest may be slightly uncomfortable when removed, but 
it’s just like removing a sticky plaster! You may find breathing against the resistance device 
strange at first but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 
Any information that is gained from the research will help children and adults with cystic 
fibrosis and other scientists. Cystic Fibrosis is a disease that causes the body to make thick 
sticky slime which hurts a persons lungs. 
 
What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong during the study 
you will be asked to stop. We will get the doctors to check you to make sure you are ok and 
to see if you can continue or not. 
 
Will my taking part in the study be kept confidential? 
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All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  You will be given a unique number so 
that no one knows who your results belong to. Interview recordings will be written up and 





























Applied Sports Technology Exercise and Medicine Research Centre (A-
STEM) 
Sport and Health Portfolio, College of Engineering 
 
PARENT/GUARDIAN PARTICIPANT INFORMATION SHEET 
CONTROL 
(Version 1.2, Date 09/03/2017) 
Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy for your child to take part.  If you are happy for them 
to take part, thank you.  If you prefer them not to take part, this is not a problem and we 
thank you for thinking about it.  Your child’s care will not be influenced if they do or do not 
decide to take part. If you have any questions, please just ask one of the researchers or 
contact us in the details above. 
 
What is the purpose of this study? 
We think that if we make your child’s breathing muscles stronger, it might make their 
everyday life easier. This involves breathing through a resistive device to train your child’s 
muscles. After this your child may be asked to do another 8 weeks of training or stop. The 
aim of this study is to investigate 1) the effects of training the lung muscles on how your 





What will happen to your child if they take part? 
Your child will be invited to attend 4 testing sessions. These will take 
place at Swansea University or Morriston Hospital, we can help cover cost 
of travel to these sessions.  
 
Each testing visit will take approximately 1.5 hours. During the first visit, 
we will show your child all the equipment being used during the study 
and they can ask any questions they may have. We will measure their 
height, weight on a machine (picture right), waist and hip size. We will 
also measure their lung function to determine how strong their lungs are. 
To measure the strength of your child’s hand and forearm muscles they will be asked to 
complete a handgrip test (picture 1). 
 
We will then ask them to cycle on the bike with a mask (to measure oxygen and carbon 
dioxide levels) and chest stickers (to measure heart rate). While they cycle it will slowly get 








































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
Handgrip strength (picture 1) 
Bike Programme (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Physical Activity Tracker (Picture 4) 
 Visit 2 (week 2) 
Return Physical Activity Monitors 
 
Visit 4 (week 8) 










Visit 5 (week 8 of top-up/detraining) 






Visit 3 (week 4) 











Your child will then be given their own IMT device (picture on left), 
which can be linked to a mobile or tablet through an app. This 
means they can track their progress during training and see how 
well they are doing!  
 
IMT involves your child breathing through the device, which provides a resistance when they 
breathe. This makes their muscles work harder and therefore makes them stronger! We will 
ask them to do the training 3 times a week for 8 weeks. They will start each session by doing 
a maximum effort breath in to the device. This should 
be done standing up, blowing all the air out of their 
lungs and then inhaling through the device for as hard 
and as long as they can! After this, your child will do 6 
sets of breaths at a time, there are 6 levels in total and 
the time they have between each breath at each level 
reduces. As they breathe in, they are trying to match 
the effort shown on the app all the way through the breath (picture on right). Your child will 
find it gets harder as they go through and we want them to try and get as far through the 
sets as they possibly can each day.  
 
At the end of 8 weeks your child can decide if they want to keep training for another 8 weeks 




At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
your child to answer before and after their training sessions. There is no right or wrong 
answer to these questions, we just want to know how they are feeling on that day. The 
questionnaires will be centred around completing IMT and their health. Answers will be 
based on a points scale (like the one below): 
 
Please indicate how much each reason is true for you, using the following scale:  
 
1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
 
At the end of 8 weeks your child will sit down with one of the researchers and talk about 
their thoughts and feelings on the IMT program. There is no right or wrong answer to these 
312 
 
questions, all we want to know are their thoughts. This chat will be recorded and what they 
say will be written down and then audio recording will be destroyed 
 
At the end of the 8 weeks, your child will be given the option to continue training for another 
8 weeks or stop. This decision is entirely up to your child and their care will not be changed 
if they do or do not decide to continue training. 
 
Monitors 
We will then give your child a monitor to wear. The monitor shown in the picture 
on the right, will be worn on a belt around their waist but they will need to take it 
off when they shower or swim and write down how long they didn’t have it on for. 
After your child wears the monitor for a week they can send it back to us. When 
your child is wearing these monitors, they do not need to do anything differently. 
We just want them to do whatever they would normally do each day. 
 
What are the possible disadvantages of taking part? 
The bicycle test may make them feel tired and the mask may feel a little uncomfortable, 
however a warm-up and cool-down exercise will be completed before and after all 
exercise. Sufficient rest breaks will be provided and water readily available. Coming to the 
labs is a time commitment, however testing can be scheduled round times that suit you 
and your child best. The sticky pads that are stuck to their chest may be slightly 
uncomfortable when removed, but it’s just like removing a sticky plaster! They may find the 
breathing against a resistance strange at first but, like any exercise, the more they do it the 
more they will feel comfortable with it. The study and all the protocols within it are 
covered by Swansea University’s indemnity policy. 
 
What are the possible benefits of taking part? 
Knowledge that is gained from this research will contribute to the wider scientific 
community and possibly help children and adults with Cystic Fibrosis. 
 
What happens if something goes wrong? 
We don’t envisage any problems occurring, however if something does go wrong during 
the study your child will be asked to stop and checked by their medical team to determine 
whether they can continue or not. 
 
8. Will my child taking part in the study be kept confidential? 
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All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it. Your child will be given an individual 
code to ensure confidentiality and anonymity.  All audio recordings will be destroyed after 































Applied Sports Technology Exercise and Medicine Research Centre (A-
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Sport and Health Portfolio, College of Engineering 
 
 
UNDER 12 YEARS OLD INFORMATION SHEET CYSTIC FIBROSIS 
(Version 1.4, Date 09/03/2017) 
 Project Title: 
Investigating the influence of an Inspiratory Muscle Training program 




Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 
Telephone:     Telephone:  
 
Jessica McCreery 
Email:   
Telephone:     
 
Thank you for being interested in our project. Please read this information 
sheet carefully and think about whether you are happy to take part.  If you are 
happy to take part, thank you.  If you prefer not to take part that is ok!  Your 
care will not be changed if you do or do not decide to take part. If you have 
any questions, please contact us on the details at the beginning of this sheet. 
You can also ask one of the researchers when you come in to visit the Clinic.  
 
What is the purpose of this study? 
As you have Cystic Fibrosis we want to see if we can make your breathing 
muscles stronger. To do this we will ask you to use a special device into which 
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you breathe in and out. The point of this study is to see if breathing through 
this device makes you feel better and able to exercise for longer afterwards. 
 
What will happen to you if you take part? 
You will be invited to attend 4 sessions. These will take place at Swansea 
University or Morriston Hospital, we can help cover cost of travel to these 
sessions. 
 
Each visit will take about 1.5 hours. During the first visit, we will 
show you all the equipment being used during the study and 
you can ask any questions you may have. After this, we will 
measure how tall you are when you are standing and sitting 
down and how much you weigh on a special machine (picture 
right). We will also measure your waist and hip size and then 
see how strong your lungs are when you breathe in as hard as 



































   











Visit 1  
Ask any questions 
Get to know the equipment 
Take height and weight (Picture 1) 
How strong are you? (Picture 2) 
Cycle as long as you can (Picture 3) 
Questionnaire 
Get to know the breathing device 
(Picture 4) 
Be given a monitor to measure how 
much you move (Picture 5) 
Cough experiment 
Visit 2 (week 2) 
Return movement monitors 
Visit 4 (week 8) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
Questionnaire 
One-to-one talk 
Cough experiment Visit 5 (week 16) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
Cough experiment 
Visit 3 (week 4) 
Take height and weight 
Cycle as long as you can 










To measure how strong, you are you will be asked to squeeze a hand grip 
machine as hard as you can (picture 2). We will then ask you to cycle on the 
bike with a mask on that you breathe through and some stickers on your 
chest to see how fast your heart beats. While you cycle, it will get slowly 
harder and harder, like cycling up hill, and we will encourage you to keep 
going for as long as you can. 
Breathing Device 
You will then be given your own breathing device 
(picture on left), which you can link to your mobile 
or tablet through an app. This means you can track 
your progress during training and see how well you 
are doing!  
 
We want you to use this device three times a week, every week for 8 weeks. 
During these sessions, you will start each session by doing a maximum effort 
breath out into the device. You should do this 
standing up and by blowing out all the air in 
your lungs and then taking the biggest breath 
in you possibly can as hard, fast and long as 
you can! After this, you will do sets of 6 
breaths at a time, with the time between each 
breath getting shorter as you keep going through each set. As you breathe in, 
you are trying to match the effort shown on the app (picture on right) all the 
way through the breath. You will find it gets harder and harder as you go 
through and we want you to try and get as far through the sets as you can each 
day. At home, we also want you to be a scientist and do your own experiment! 
We want you to measure how much stuff you can cough up from your lungs 
after training. All you have to do is cough into a pot and weigh it on a set of 
kitchen scales! 
 
At the end of 8 weeks you can decide if you want to keep training for another 
8 weeks or stop. This is your choice and whatever choice you make your care 
will not be changed 
After wearing this monitor for a week you can send this monitor back to us. 
When you are wearing the monitor, you do NOT need to do anything 





At the end of 8 weeks you still sit down with one of the researchers and talk 
about your thoughts and feelings on the IMT program. There is no right or 
wrong answer to these questions, all we want to know are your thoughts. This 
chat will be recorded and what you say will be written down and then 
destroyed. 
 
If you are 10+ years old at one training session in weeks 1, 4 and 8 some 
questions will pop up on the IMT app for you to answer before and after your 
training sessions. There is no right or wrong answer to these questions, we just 
want to know how you are feeling on that day. Answers will be based on a 
scale: 
 
Please indicate how much each reason is true for you, using the following 
scale:  
 
1         2   3  4  5   6  7  
not at all         somewhat       very  
true              true                true 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little 
uncomfortable. The visits will take up some time, however we can time them 
at times that best suit you. The sticky pads that are stuck to your chest may 
be slightly uncomfortable when removed, but it’s just like removing a sticky 
plaster! You may find breathing against the resistance device strange at first 
but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 




What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong 
during the study you will be asked to stop. We will get the doctors to check 
you to make sure you are ok and to see if you can continue or not. If you are 
unhappy with anything that happens you can contact Dr McNarry (details 
above) or alternatively Professor Mike McNamee. 
 
Will my taking part in the study be kept secret? 
All personal information collected will be kept completely secret. That is, only 
members of the research team will have access to it.  You will be given a 
special number so that no one knows who your results belong to. Interview 
recordings will be written up and then the audio recordings will be 



















Applied Sports Technology Exercise and Medicine Research Centre (A-
STEM) 
Sport and Health Portfolio, College of Engineering 
 
12- 15 YEARS OLD INFORMATION SHEET CYSTIC FIBROSIS 
(Version 1.4, Date 09/03/2017) 
 Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy to take part. If you have any questions, please just 
ask one of the researchers or contact us in the details above. If you are happy to take part, 
thank you.  If you prefer not to take part, this is not a problem and we thank you for thinking 
about it.  Your care will not be changed if you do or do not decide to take part.  
 
What is the purpose of this study? 
As you have Cystic Fibrosis we think that if we make your breathing muscles stronger, it 
might make your everyday life easier. To make your breathing muscles stronger, we will ask 
you to use a special device into which you breathe in and out. The point of this study is to 
see if breathing through this device makes you feel better and able to exercise for longer 
afterwards. 
 
What will happen to you if you take part? 
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You will be invited to attend 4 testing sessions (See Diagram below). These will take place 
at Swansea University or Morriston Hospital, we can help cover cost of travel to these 
sessions. 
 
Each visit will take about 1.5 hours. During the first visit, we will show you 
all the equipment being used during the study and you can ask any 
questions you may have. After this, we will measure how tall you are when 
you are standing and sitting down and how much you weigh on a special 
machine (picture right). We will also measure your waist and hip size and 
then see how strong your lungs are when you breathe in as hard as you 
possibly can! To measure how strong, you are you will be asked to squeeze 
a hand grip machine as hard as you can (picture 1). 
 
We will then ask you to cycle on the bike with a mask on that you breathe through and some 
stickers on your chest to see how fast your heart beats. While you cycle, it will get slowly 
harder and harder, like cycling up hill, and we will encourage you to keep going for as long 








































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
How strong are you? (Picture 1) 
Cycle as long as you can (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Given a monitor to measure how 
much you move (Picture 4) 
Cough experiment 
Visit 2 (week 2) 
Return movement monitors 
Visit 4 (week 8) 
Take height and weight 
Cycle as long as you can 
Questionnaire 
One-to-one talk 
How strong are you? 
Cough experiment 
 
Visit 5 (week 8 of top-
up/detraining) 
Take height and weight 
Cycle as long as you can 
How strong are you? 
Cough experiment 
 
Visit 3 (week 4) 
Take height and weight 
Cycle as long as you can 












You will then be given your own IMT device (picture on left), 
which you can link to your mobile or tablet through an app. 
This means you can track your progress during training and 
see how well you are doing!  
 
We want you to use this device three times a week, every week for 8 weeks. During these 
sessions, you will start each session by doing a maximum effort breath in to the device. You 
should do this standing up and blowing out all the air in your lungs and then taking the 
biggest breath in you possibly can as hard, fast and 
long as you can! After this, you will do sets of 6 breaths 
at a time, with the time between each breath getting 
shorter as you keep going through each set. As you 
breathe in, you are trying to match the effort shown 
on the app all the way through the breath (picture on 
right). You will find it gets harder and harder as you go 
through and we want you to try and get as far through the sets as you can each day. At home, 
we also want you to be a scientist and do your own experiment! We want you to measure 
how much you can cough up from your lungs after training. All you have to do is cough into 
a pot and weigh it on a set of kitchen scales! 
At the end of 8 weeks you can decide if you want to keep training for another 8 weeks or 
stop. This is your choice and whatever choice you make your care will not be changed. 
 
Questionnaires 
At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
you to answer before and after your training sessions. There is no right or wrong answer to 
these questions, we just want to know how you are feeling on that day. Answers will be 
based on a scale: 
 
Please indicate how much each reason is true for you, using the following scale:  
 
1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
 
At the end of 8 weeks you still sit down with one of the researchers and talk about your 
thoughts and feelings on the IMT program. There is no right or wrong answer to these 
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questions, all we want to know are your thoughts. This chat will be recorded and what you 
say will be written down and then destroyed 
 
Monitors 
We will then give you a monitor to wear. The monitor shown in the 
picture on the right, will be worn on a belt around your waist but you 
will need to take it off when you shower or swim and write down 
how long you didn’t have it on for. After wearing the monitor for a 
week you can send it back to us. When you are wearing the monitor, 
you do not need to do anything differently. We just want you to do 
whatever you would normally do each day. 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little uncomfortable, 
however you will complete a warm-up and cool-down exercise before and after all exercise 
testing. We will give you some rest breaks and water will be available. Coming to the labs 
will take up some time, however we can schedule testing for times that best suit you. The 
sticky pads that are stuck to your chest may be slightly uncomfortable when removed, but 
it’s just like removing a sticky plaster! You may find breathing against the resistance device 
strange at first but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 
 Any information that is gained from the research will help other people with CF and other 
scientists! 
 
What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong during the study 
you will be asked to stop. We will get the doctors to check you to make sure you are ok and 
to see if you can continue or not. The University indeminity policy covers any adverse 
events. If you are unhappy with anything that happens during the study you can contact Dr 
McNarry (details above) or alternatively if you prefer to speak to someone independent, 
you can contact Prof Mike McNamee chair of the A-STEM Ethics committee.  
 
Will my taking part in the study be kept confidential? 
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  You will be given a unique number so 
that no one knows who your results belong to. Interview recordings will be written up and 






Applied Sports Technology Exercise and 
Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of 
Engineering 
 
PARENT/GUARDIAN PARTICIPANT INFORMATION SHEET 
CHILD CYSTIC FIBROSIS 
(Version 1.4, Date 09/03/2017) 
Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy for your child to take part.  If you are happy for them 
to take part, thank you.  If you prefer them not to take part, this is not a problem and we 
thank you for thinking about it.  Your child’s care will not be influenced if they do or do not 
decide to take part. If you have any questions, please just ask one of the researchers or 
contact us in the details above. 
 
What is the purpose of this study? 
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As your child has Cystic Fibrosis we think that if we make your child’s breathing muscles 
stronger, it might make their everyday life easier. This involves breathing through a 
resistive device to train your child’s muscles. After this your child may be asked to do 
another 8 weeks of training or stop. The aim of this study is to investigate 1) the effects of 
training the lung muscles on how your child feels and how well they exercise and 2) the 
subsequent effects of a detraining or top-up period. 
 
What will happen to your child if they take part? 
Your child will be invited to attend 4 testing sessions. These will take place 
at Swansea University or Morriston Hospital, we can help cover cost of 
travel to these sessions. 
 
Each testing visit will take approximately 1.5 hours. During the first visit, we 
will show your child all the equipment being used during the study and they 
can ask any questions they may have. We will measure their height, weight 
on a machine (picture right), waist and hip size. We will also measure their 
lung function to determine how strong their lungs are. To measure the 
strength of your child’s hand and forearm muscles they will be asked to 
complete a handgrip test (picture 1). 
 
We will then ask them to cycle on the bike with a mask (to measure oxygen and carbon 
dioxide levels) and chest stickers (to measure heart rate). While they cycle it will slowly get 





































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
Handgrip strength (picture 1) 
Bike Programme (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Physical Activity Tracker (Picture 4) 
Sputum production  
Visit 2 (week 2) 
Return Physical Activity Monitors 
 
Visit 4 (week 8) 











Visit 5 (week 8 of top-up/detraining) 






Visit 3 (week 4) 












Your child will then be given their own IMT device (picture on left), which can be linked to a 
mobile or tablet through an app. This means they can track their progress during training and 
see how well they are doing!  
 
IMT involves your child breathing through the device, which 
provides a resistance when they breathe. This makes their 
muscles work harder and therefore makes them stronger! We 
will ask them to do the training 3 times a week for 8 weeks. They 
will start each session by doing a maximum effort breath in to the device. This should be 
done standing up, blowing all the air out of their lungs and then inhaling through the device 
for as hard and as long as they can! After this, your child will do 6 sets of breaths at a time, 
there are 6 levels in total and the time they have between each breath at each level reduces. 
As they breathe in, they are trying to match the effort shown on the app all the way through 
the breath (picture on right). Your child will find it gets 
harder as they go through and we want them to try 
and get as far through the sets as they possibly can 
each day. At home, we want your child to do their own 
experiment. We ask if you and your child could take a 
measurement of their sputum production after 
exercise. All they have to do is cough into a pot and 
weigh and record the weight on a set of kitchen scales and dispose of it as your normally do. 
At the end of 8 weeks your child can decide if they want to keep training for another 8 weeks 




At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
your child to answer before and after their training sessions. There is no right or wrong 
answer to these questions, we just want to know how they are feeling on that day. The 
questionnaires will be centred around completing IMT and their health. Answers will be 
based on a points scale (like the one below): 
 
Please indicate how much each reason is true for you, using the following scale:  
 
1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
At the end of 8 weeks your child will sit down with one of the researchers and talk about 
their thoughts and feelings on the IMT program. There is no right or wrong answer to these 
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questions, all we want to know are their thoughts. This chat will be recorded and what they 
say will be written down and then audio recording will be destroyed 
 
At the end of the 8 weeks, your child will be given the option to continue training for another 
8 weeks or stop. This decision is entirely up to your child and their care will not be changed 
if they do or do not decide to continue training. 
 
Monitors 
We will then give your child a monitor to wear. The monitor shown 
in the picture on the right, will be worn on a belt around their waist 
but they will need to take it off when they shower or swim and 
write down how long they didn’t have it on for. After your child 
wears the monitor for a week they can send it back to us. When 
your child is wearing these monitors, they do not need to do 
anything differently. We just want them to do whatever they 
would normally do each day. 
 
What are the possible disadvantages of taking part? 
The bicycle test may make them feel tired and the mask may feel a little uncomfortable, 
however a warm-up and cool-down exercise will be completed before and after all 
exercise. Sufficient rest breaks will be provided and water readily available. Coming to the 
labs is a time commitment, however testing can be scheduled round times that suit you 
and your child best. The sticky pads that are stuck to their chest may be slightly 
uncomfortable when removed, but it’s just like removing a sticky plaster! They may find the 
breathing against a resistance strange at first but, like any exercise, the more they do it the 
more they will feel comfortable with it. The study and all the protocols within it are 
covered by Swansea University’s indemnity policy. 
 
What are the possible benefits of taking part? 
Knowledge that is gained from this research will contribute to the wider scientific 
community so you can help other people with CF. 
 
What happens if something goes wrong? 
We don’t envisage any problems occurring, however if something does go wrong during 
the study your child will be asked to stop and checked by their medical team to determine 
whether they can continue or not. The University indeminity policy covers any adverse 
events. If you are unhappy with anything that happens during the study you can contact Dr 
McNarry (details above) or alternatively if you prefer to speak to someone independent, 




Will my child taking part in the study be kept confidential? 
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it. Your child will be given an individual 
code to ensure confidentiality and anonymity.  All audio recordings will be destroyed after 



























Applied Sports Technology Exercise and Medicine Research Centre (A-
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16 YEARS PLUS INFORMATION SHEET CONTROL 
(Version 1.2, Date 09/03/2017) 
Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy to take part.  If you have any questions, please just 
ask one of the researchers or contact us in the details above. If you are happy to take part, 
thank you.  If you prefer not to take part, this is not a problem and we thank you for thinking 
about it. 
 
What is the purpose of this study? 
We think that if we make breathing muscles stronger, it might make everyday life easier. 
This involves breathing through a resistive device to train your muscles. The aim of this 
study is to investigate 1) the effects of training the lung muscles on how you feel and how 
well you exercise and 2) the subsequent effects of a detraining or top-up period. 
 
What will happen to you if you take part? 
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You will be invited to attend 4 testing sessions. These will take place at 
Swansea University or University Hospital, Llandough, we can help cover 
cost of travel to these sessions. 
 
Each testing visit will take approximately 1.5 hours. During the first visit, 
we will show you all the equipment being used during the study and you 
can ask any questions you may have. We will measure your height, weight 
on a machine (picture right), waist and hip size. We will also measure 
your lung function to determine how strong your lungs are. To measure 
the strength of your hand and forearm muscles you will be asked to complete a handgrip 
test (picture 1). 
 
We will then ask you to cycle on the bike with a mask (to measure your oxygen and carbon 
dioxide levels) and chest stickers (to measure your heart rate). While you cycle it will slowly 







































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
Handgrip strength (Picture 1) 
Bike Programme (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Physical Activity Tracker (Picture 4) 
 
Visit 2 (week 2) 
Return Physical Activity Monitors 
 
Visit 4 (week 8) 








Visit 5 (week 8 of top-up/detraining) 





Visit 3 (week 4) 












You will then be given your own IMT device (picture on left), which you can link to your 
mobile or tablet through an app. This means you can track your progress during training and 
see how well you are doing!  
 
IMT involves you breathing through the device, which provides 
a resistance when you breathe. This makes your muscles work 
harder and therefore makes them stronger! We will ask you to 
do the training 3 times a week for 8 weeks. You will start each 
session by doing a maximum effort breath in to the 
device. This should be done standing up, blowing all the 
air out of your lungs and then inhaling through the 
device for as hard and as long as you can! After this, you 
will do 6 sets of breaths at a time, there are 6 levels in 
total and the time you have between each breath at 
each level reduces. As you breathe in, you are trying to 
match the effort shown on the app all the way through the breath (picture on right). You will 
find it gets harder as you go through and we want you to try and get as far through the sets 
as you can each day.  
 
At the end of 8 weeks you can decide if you want to keep training for another 8 weeks or 
stop, this is completely your choice! 
 
Questionnaires 
At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
you to answer before and after your training sessions. There is no right or wrong answer to 
these questions, we just want to know how you are feeling on that day. Answers will be 
based on a scale: 
 
Please indicate how much each reason is true for you, using the following scale:  
 
1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
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At the end of 8 weeks you still sit down with one of the researchers and talk about your 
thoughts and feelings on the IMT program. There is no right or wrong answer to these 
questions, all we want to know are your thoughts. This chat will be recorded and what you 
say will be written down and then destroyed. 
 
Monitors 
We will then give you a monitor to wear. The monitor shown in 
the picture on the right, will be worn on a belt around your waist 
but you will need to take it off when you shower or swim and 
write down how long you didn’t have it on for. After wearing 
the monitor for a week you can send it back to us. When you are wearing the monitor, you 
do not need to do anything differently. We just want you to do whatever you would normally 
do each day. 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little uncomfortable, 
however you will complete a warm-up and cool-down exercise before and after all exercise 
testing. We will give you some rest breaks and water will be available. Coming to the labs 
will take up some time, however we can schedule testing for times that best suit you. The 
sticky pads that are stuck to your chest may be slightly uncomfortable when removed, but 
it’s just like removing a sticky plaster! You may find breathing against the resistance device 
strange at first but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 
 Any information that is gained from the research will help children and adults with cystic 
fibrosis and other scientists. 
 
What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong during the study 
you will be asked to stop. We will get the doctors to check you to make sure you are ok and 
to see if you can continue or not. 
 
Will my taking part in the study be kept confidential? 
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  You will be given a unique number so 
that no one knows who your results belong to. Interview recordings will be written up and 
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16 YEARS PLUS INFORMATION SHEET CYSTIC FIBROSIS AND BRONCHIECTASIS 
(Version 1.4, Date 09/03/2017) 
Project Title: 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 
quality of life in children and adults with Cystic Fibrosis. 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
   Email: 
 






Thank you for being interested in our project.  Please read this information sheet carefully 
and think about whether you are happy to take part.  If you have any questions, please just 
ask one of the researchers or contact us in the details above. If you are happy to take part, 
thank you.  If you prefer not to take part, this is not a problem and we thank you for thinking 
about it.  Your care will not be influenced if you do or do not decide to take part. 
 
What is the purpose of this study? 
As you have Cystic Fibrosis or bronchiectasis we think that if we make your breathing 
muscles stronger, it might make your everyday life easier. This involves breathing through a 
resistive device to train your muscles. The aim of this study is to investigate 1) the effects of 
training the lung muscles on how you feel and how well you exercise and 2) the subsequent 
effects of a detraining or top-up period. 
 
What will happen to you if you take part? 
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You will be invited to attend 4 testing sessions. These will take place at 
Swansea University or University Hospital, Llandough, or Glangwili 
Hospital we can help cover cost of travel to these sessions. 
 
Each testing visit will take approximately 1.5 hours. During the first visit, 
we will show you all the equipment being used during the study and you 
can ask any questions you may have. We will measure your height, weight 
on a machine (picture right), waist and hip size. We will also measure 
your lung function to determine how strong your lungs are. To measure 
the strength of your hand and forearm muscles you will be asked to complete a handgrip 
test (picture 1).  
 
We will then ask you to cycle on the bike with a mask (to measure your oxygen and carbon 
dioxide levels) and chest stickers (to measure your heart rate). While you cycle it will slowly 






































Visit 1  
Ask questions 
Get to know the equipment 
Take height and weight 
Handgrip strength (Picture 1) 
Bike Programme (Picture 2) 
Questionnaires 
Get to know the breathing device 
(Picture 3) 
Physical Activity Tracker (Picture 4) 
Sputum collection  
Visit 2 (week 2) 
Return Physical Activity Monitors 
 
Visit 4 (week 8) 









Visit 3 (week 4) 


















You will then be given your own IMT device (picture on left), which you can link to your 
mobile or tablet through an app. This means you can track your progress during training and 
see how well you are doing!  
 
IMT involves you breathing through the device, which provides a 
resistance when you breathe. This makes your muscles work 
harder and therefore makes 
them stronger! We will ask 
you to do the training 3 times a week for 8 weeks. You 
will start each session by doing a maximum effort 
breath in to the device. This should be done standing 
up, blowing all the air out of your lungs and then 
inhaling through the device for as hard and as long as 
you can! After this, you will do 6 sets of breaths at a time, there are 6 levels in total and the 
time you have between each breath at each level reduces. As you breathe in, you are trying 
to match the effort shown on the app all the way through the breath (picture on right). You 
will find it gets harder as you go through and we want you to try and get as far through the 
sets as you can each day. At home, we also ask if you could take a measurement of your 
sputum production after exercise. All you have to do is cough the sputum into a pot and 
weigh and record the weight on a set of kitchen scales and dispose of it as you normally do.  
At the end of 8 weeks you can decide if you want to keep training for another 8 weeks or 
stop. This is your choice and whatever choice you make your care will not be changed. 
 
Questionnaires 
At one training session in weeks 1, 4 and 8 some questions will pop up on the IMT app for 
you to answer before and after your training sessions. There is no right or wrong answer to 
these questions, we just want to know how you are feeling on that day. Answers will be 
based on a scale: 
 
Please indicate how much each reason is true for you, using the following scale:  
 
Visit 5 (week 8 of top-up/detraining) 







1         2   3  4  5  6  7  
not at all         somewhat                 very  
   true              true               true  
At the end of 8 weeks you still sit down with one of the researchers and talk about your 
thoughts and feelings on the IMT program. There is no right or wrong answer to these 
questions, all we want to know are your thoughts. This chat will be recorded and what you 
say will be written down and then destroyed. 
 
Monitors 
We will then give you a monitor to wear. The monitor 
shown in the picture on the right, will be worn on a belt 
around your waist but you will need to take it off when you 
shower or swim and write down how long you didn’t have 
it on for. After wearing the monitor for a week you can send 
it back to us. When you are wearing the monitor, you do not 
need to do anything differently. We just want you to do 
whatever you would normally do each day. 
 
What are the possible disadvantages of taking part? 
The bike exercise may make you feel tired and the mask may feel a little uncomfortable, 
however you will complete a warm-up and cool-down exercise before and after all exercise 
testing. We will give you some rest breaks and water will be available. Coming to the labs 
will take up some time, however we can schedule testing for times that best suit you. The 
sticky pads that are stuck to your chest may be slightly uncomfortable when removed, but 
it’s just like removing a sticky plaster! You may find breathing against the resistance device 
strange at first but, like any exercise, the more you do it the more you will feel comfortable 
with it.  
 
What are the possible benefits of taking part? 
 Any information that is gained from the research will help other people with CF and other 
scientists! 
 
What happens if something goes wrong? 
We don’t expect any problems to occur, but if something does go wrong during the study 
you will be asked to stop. We will get the doctors to check you to make sure you are ok and 
to see if you can continue or not. The University indeminity policy covers any adverse 
events. If you are unhappy with anything that happens during the study you can contact Dr 
McNarry (details above) or alternatively if you prefer to speak to someone independent, 




Will my taking part in the study be kept confidential? 
All personal information collected will be kept completely confidential. That is, only 
members of the research team will have access to it.  You will be given a unique number so 
that no one knows who your results belong to. Interview recordings will be written up and 





























GP Information Sheet  
(Version 1.2; Date – 07/03/2017) 
 
Research Study: Investigating the influence of an Inspiratory Muscle Training 





Your patient has been invited to participate in the above study because they have 
Cystic Fibrosis or bronchiectasis. 
 
The purpose of the study is to determine whether a home based inspiratory muscle 
training programme can improve lung function, physiological response to exercise 
and quality of life in both adults and children with Cystic Fibrosis and 
bronchiectasis. We have already completed a pilot study with children which was 
well received and we would now like to investigate a larger population to 
determine inspiratory muscle trainings effectiveness in progression from childhood 
to adulthood.  
 
Your patient has been assessed in their Cystic Fibrosis Unit at Singleton Hospital/ 
Llandough University Hospital Glangwili Hospital by their care team and is 
considered eligible to participate. He/she will be asked to attend Singleton 
Hospital/ Llandough University Hospital/ Glangwili Hospital or Swansea University 
Bay Campus on four occasions with the following occurring: 
 
Anthropometrics and Maximal Cardiopulmonary Exercise Test (CPET) 
Anthropometric data including age, height, body mass, sex and waist and hip 
circumference will be recorded. Patients’ resting pulmonary function 
measurements will also be recorded, including forced vital capacity (FVC), FEV1, 
Peak Expiratory Flow (PEF) using a flow-volume loop spirometer and will follow 
British Thoracic Society guidelines. Measures of respiratory muscle strength 
(maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)) will 




Participants will be familiarised with exercising on a cycle ergometer, maintaining a 
constant pedal rate [revolutions per minute (RPM)] at a given power output. The 
maximal CPET on a cycle ergometer has been demonstrated to be safe and effective 
for this population (e.g. Saynor et al., 2013a, 2013b, 2014a, 2014b, under review). 
Adjustments will be made to the seat, pedals and handlebars to insure maximum 
comfort for each individual patient and will be recorded for future visits. Prior to 
the test beginning heart rate, resting pulmonary gas measurements, heart rate 
variability and oxygen saturation will be measured. The intensity of exercise will be 
dependent on patients’ age, height, weight and health status. The test involves a 
maximal exercise test to voluntary exhaustion using an incremental ramp protocol 
on a cycle ergometer. It will be followed by a supramaximal verification test to 
exhaustion (Smax) following recovery from the ramp test.  
 
The test will begin with unloaded pedalling (0.W) for a baseline period of 3 minutes. 
Following, this the power output will increase incrementally (10-20 W.min-1) in a 
fixed interval based on height (10 W.min-1 <120cm; 15 W.min-1 120-150cm; 20 
W.min-1 >150cm), independent of sex. All participants will pedal at a cadence of 70-
80 rpm and be verbally encouraged to continue until voluntary exhaustion which is 
defined as volitional exhaustion or drop of pedal cadence by >10rpm despite strong 
verbal encouragement. A recovery period consisting of 5 minutes of unloaded 
pedalling (0W) will be followed by a 10 minute passive recovery, seated in an 
upright position. One further bout of supramaximal exercise will follow consisting 
of 3 minutes pedalling at 20 W and a ‘step’ transition to 110% of the peak power 
achieved during the ramp test. This will require patients to cycle at this intensity 
with a pedal rate of 70-80rpm until exhaustion, as defined above. Active recovery 
will follow with a power output of 20W. Throughout the testing patients will be 
observed by a researcher and a doctor will be present at all times. The CPET is 
relative for all patients and they have the right to stop the test whenever they 
want. 
 
Breath-by-breath changes in pulmonary gas exchange, ventilation, heart rate 
variability, HR and SpO2 will be recorded continuously during all exercise testing 
and recovery period. Subjective ratings of perceived exertion (RPE) and perceived 
dyspnoea (RPD) will also be obtained. Gas exchange responses will be interpolated 
to 1 second intervals and averaged every 15 seconds. HR will be determined on 
beat-by-beat basis and will be averaged every 15 seconds, HR variability will be 
monitored using an3 lead electrocardiogram (ECG) and impedance cardiography 
(ICG).  
 




Participants will be given their own personal Inspiratory Muscle Training device 
(PrO2 hand-held wireless device) to prevent cross contamination. The training 
programme will initially be 8 weeks with 3 training sessions a week, unsupervised in 
their own home. Before each session patients are asked to establish a 1 rep max 
(baseline) and they train based on 80% of that number. The programme consists of 
6 levels (A-F) with 6 inspirations at each level for a total of 36 breaths. At each level 
recovery times decrease (A=20s, B= 30s, C= 20s, D= 15s, E= 10s, F= 5s). The training 
programme takes approximately 20-30 minutes depending on the individual’s 
advancement through the training levels. Each patient baseline is reassessed every 
time they train, therefore they still work 80% of what they are capable on that day. 
At one training session in weeks 1, 4 and 8 participants will be requested to answer 
questions on feeling scale, arousal scale and profile of mood states before and after 
their IMT session. They will be prompted to complete these questions by the app 
and should take no longer than 10 minutes to complete. After 8 weeks of training 
participants will have the option to continue a top-up training for a further 8 weeks 
(1 IMT session a week) or undergo a detraining period where they will stop IMT and 
continue with their normal routine. This decision is entirely their choice and their 
decision will not influence their care or future participation in studies. 
 
In addition to the above measures, patients will undertake some psychological 
questionnaire measures on self-determination theory, quality of life, affective 
valence and one to on interviews to determine their thoughts and feelings on the 
intervention. Patients physical activity and sleep will also be monitored for 7 days 
using an accelerometer and ECG that is attached via the chest via two electrodes. 
None of these pose any risk to patients. 
 
Handgrip  
Handgrip strength is a validated measure of peripheral muscle function, which has 
been shown to be correlated to lung function in Cystic Fibrosis patients (Ziai et al, 
2014) and upper extremity strength (Bohannon, R.W. 1998). Handgrip strength will 
be measured using a hand dynamometer (Takei 5401, Tokyo, Japan). Subjects will 
be asked to stand upright with the arm naturally extended straight pointing to the 
floor and be asked to squeeze as hard as they can. A total of 4 measurements will 
be required (2 from each hand) alternating hands each time. Verbal encouragement 
will be given throughout and the device can be altered to suit the grip distance of 
each individual subject.  
 
Bioelectrical Impedance Analysis  
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Bioelectrical Impedance calculates body composition and free fat mass (FFM) 
measurements through a safe electrical signal being sent throughout the body. 
Recent studies have documented an association between FFM depletion and poor 
respiratory muscle strength or impaired pulmonary function (Enright et al, 
2007 and King et al, 2010).  
Patients height, weight, gender and age will be entered into the Bioelectrial 
Impedance Device (Tanita BC-418ma). Patients will then be asked to stand on the 
weighing platform with bare feet and asked to grasp the grips with both hands. 
Subjects will be required to empty their bowels, refrain from vigorous exercise or 
alcohol within 12 hours of BIA and be measured at least 2 hours after their last 
meal. Any patient on diuretic medications, pacemaker or any other medical 
electrical device implanted will not be able to undertake BIA.  
 
Sputum Clearance  
Patients will be supplied with a sterile pot and will be asked to rinse mouth and 
gargle with sterile water prior to collection. Patients will be instructed to cough 
deeply, then breathe deeply and cough deeply to produce sputum from the airway 
into a sterile pot. This pot will then be measured and the wet weight recorded. 
Patients can complete this in their home and measure with any set of scales. Their 
sputum can then be disposed with as they normally do.  
 
Outline of Visits 
Visit 1/baseline will be prior to exercise programme beginning. It will consist of 
incremental CPET, lung function, BIA, hand-grip strength and anthropometric 
measurements. CFQ and CFQ-child questionnaire, basic needs satisfaction scale, 
treatment self-regulation questionnaire, perceived competence scale and health 
care climate questionnaire. Patients will be given their own ActiHeart and 
ActiSleeps and IMT training device. Patients will also measure their sputum 
clearance in their home as a baseline sputum clearance pre IMT training. 
  
Visit 2/Week 1 will be 7 days later for patients to return their accelerometers. Week 
1 of IMT training, participants will complete the feeling scale, arousal scale and 
profile of mood states questions on the IMT app. Patients will also measure their 
sputum clearance in their home post exercise session.  
Visit 3/Week 4 will be at week 4 of the training programme and consist of the 
incremental CPET, BIA, handgrip strength and lung function measurements for 
reassessment. Participants will complete the feeling scale, arousal scale and profile 
of mood states questions on the IMT app and measure their sputum clearance in 
their home post exercise session. They will also complete basic needs satisfaction 
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scale, treatment self-regulation questionnaire, perceived competence scale and 
health care climate questionnaire. 
Visit 4/week 8 of the training programme participants will complete the feeling 
scale, arousal scale and profile of mood states questions on the IMT app and 
measure their sputum clearance in their home post exercise session. Following the 
end of the initial 8 weeks of training, participants will be retested in; incremental 
CPET, lung function measurements, BIA, handgrip strength, CFQ and CFQ-child 
questionnaires and interview measurements for assessment. They will also 
complete basic needs satisfaction scale, treatment self-regulation questionnaire, 
perceived competence scale and health care climate questionnaire. Patients will 
also make the decision to either continue a top-up period of training for a further 8 
week or detrain. 
Visit 5/Week 16 top-up/detraining participants will return for an incremental CPET, 
BIA, handgrip strength and lung function measurements for reassessment. Patients 
will also measure their sputum clearance in their home post exercise session.  
Your patient has been made aware that they are free to withdraw from the study at 
any point, without having to give a reason, and this will not affect their medical care 
or legal rights.  All data generated from this study will be treated with the strictest 
confidentiality and will not be used for any other purpose.   
Thank you for taking time to read the above information. If you have any questions 





Jessica McCreery, Dr Melitta McNarry,  Dr Kelly Mackintosh 
 
College of Engineering   
Swansea University   








Applied Sports Technology Exercise and Medicine 
Research Centre (A-STEM) 





PARTICIPANT ASSENT FORM 
(Version 1.2, Date: 05/12/2013) 
 
Project Title: 
Determining physical activity levels in young cystic fibrosis patients 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:     
 
Telephone:     Telephone:  
Please initial box 
 
1. I have read and understood the information sheet for this study and have  
been able to ask any questions I have. 
2. I know that it is my choice to take part and that I am can stop doing so                                          
at any time, without giving any reason, and without any problems. 
3. I understand that some of the information I give may be looked at  
by people at Swansea University or the hospital. I am happy for 
these people to see my results. 
4. I am happy for my GP to be informed that I am doing this study 
5. I understand that the interviews will be recorded and that the  
anonymized data from these interviews will be retained. 






 Name of Parent/Guardian            Date               Signature  
_____________________________ ______________          ________________________ 
Name of Person taking consent  Date          Signature  
_____________________________ _______________   ________________________ 



























Applied Sports Technology Exercise and Medicine Research Centre (A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
 
PARENT/GUARDIAN CONSENT FORM 
(Version 1.2, Date: 05/12/2013) 
Project Title: 
 
Determining physical activity levels in young cystic fibrosis patients 
 
Contact Details: 
Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 
Telephone:     Telephone:  
 
                    Please initial 
box 
 
1. I confirm that I have read and understood the information sheet dated 
05/11/2013 (version number 1.1) for the above study and have had  
 the opportunity to ask questions. 
 
2. I understand that my child’s participation is voluntary and that they are  
free to withdraw at any time, without giving any reason and without their  
medical care, school work or legal rights being affected. 
 
3. I understand that sections of any of data obtained may be looked at by  
responsible individuals from the Swansea University or from regulatory  
authorities where it is relevant to my child taking part in research.  I give  
permission for these individuals to have access to these records. 
 




        5.   I understand that the interviews will be recorded and that the  
anonymized data from these interviews will be retained. 
 





Name of Parent/Guardian            Date               Signature  
_____________________________ ______________          ________________________ 
Name of Person taking consent  Date          Signature  
_____________________________ _______________   ________________________ 

















Applied Sports Technology Exercise and Medicine Research Centre 
(A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
ADOLESCENT ASSENT FORM 





Investigating the influence of an Inspiratory Muscle Training program on lung function and 








Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 
Telephone:     Telephone:  
 
 
Please Initial Box 
1. I have read and understood the information sheet for this study 
and have been able to ask any questions I have 
 
2. I know that it is my choice to take part and that I can stop doing so at 
any time, without giving any reason, and without any problems. 
 
3. I understand that some of the information I give may be looked at by 
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people at Swansea University or the hospital. I am happy for these  
people to see my results 
 
4. I am happy for my GP to be informed that I am doing this study. 
 
 
5. I agree to take part in the above study, 
 
 
Name of Parent/Guardian            Date               Signature  
_____________________________ ______________          ________________________ 
Name of Person taking consent  Date          Signature  
_____________________________ _______________   ________________________ 




















Applied Sports Technology Exercise and Medicine Research Centre 
(A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
PARENT/GUARDIAN CONSENT FORM 





Investigating the influence of an Inspiratory Muscle Training program on lung function and 








Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 
Telephone:     Telephone:  
 
 
Please Initial Box 
1. I confirm I have read and understood the information sheet  
Dated 28/03/2016 (Version 1) for the above study and had  
the opportunity to ask questions. 
 
2. I understand that my child’s participation is voluntary and that they 
are free to withdraw at any time, without giving reason and without 




3. I understand that sections of any data obtained may be looked at by 
Responsible individuals from Swansea University or from regulating 
Authorities where it is relevant to my child taking part in research. I  
Give permission for these individuals to have access to these records. 
 
4. I am happy for my child’s GP to be informed of their participation in this 
Study. 
 




Name of Parent/Guardian            Date               Signature  
_____________________________ ______________          ________________________ 
Name of Person taking consent  Date          Signature  
_____________________________ _______________   ________________________ 
















Applied Sports Technology Exercise and Medicine Research Centre 
(A-STEM) 
Sport and Health Portfolio, College of Engineering 
 
ADULT CONSENT FORM 
(Version 1.2; Date – 05/02/2019) 
Project Title: 
 
Investigating the influence of an Inspiratory Muscle Training program on lung function and 







Dr Melitta McNarry     Dr Kelly Mackintosh 
Email:    Email: 
 
Telephone:      
 
 
Please Initial Box 
6. I confirm I have read and understood the information sheet  
Dated 28/03/2016 (Version 1) for the above study and had  
the opportunity to ask questions. 
 
7. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving reason and without 
my medical care, work or legal rights being affected. 
 
8. I understand that sections of any data obtained may be looked at by 
Responsible individuals from Swansea University or from regulating 
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authorities where it is relevant to my involvement in research. I  
give permission for these individuals to have access to these records. 
 
9. I am happy for my GP to be informed of my participation in this 
Study. 
 




Name of Parent/Guardian            Date               Signature  
_____________________________ ______________          ________________________ 
Name of Person taking consent  Date          Signature  
_____________________________ _______________   ________________________ 




















Questionnaires and Interview Questions 
 
 
Treatment Self-Regulation Questionnaire - Adults 
 
TSRQ (exercise/modified for IMT) The following question relates to the reasons why 
you would start to complete IMT regularly or continue to do so. Different people 
have different reasons for doing that, and we want to know how true each of the 
following reasons is for you. All 15 response are to the one question.  
 
Please indicate the extent to which each reason is true for you, using the following 
7-point scale:  
 
1         2   3  4  5  6  7  
not at all         somewhat                  very  




The reason I would complete IMT regularly is:  Likert Scale 
Number 
Because I feel that I want to take responsibility for my own 
health.  
 
 Because I would feel guilty or ashamed of myself if I did not 
complete the IMT regularly. 
 
Because I personally believe it is the best thing for my health.   
Because others would be upset with me if I did not.  
I really don't think about it.  
Because I have carefully thought about it and believe it is very 
important for many aspects of my life. 
 
Because I would feel bad about myself if I did not complete IMT 
regularly. 
 
Because it is an important choice I really want to make.  
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Because I feel pressure from others to do so.  
Because it is easier to do what I am told than think about it.  
Because it is consistent with my life goals.  
Because I want others to approve of me.  
Because it is very important for being as healthy as possible.  
Because I want others to see I can do it.  
I don't really know why.  
 
Perceived Competence - Adults 
 
Perceived Competence (Exercising Regularly/Modified for IMT) Please indicate the 
extent to which each statement is true for you, assuming that you were intending 
either to begin now a permanent regimen of exercising regularly or to permanently 
maintain your regular exercise regimen.  
 
In answering the questions, please use the following scale:  
       1         2   3  4  5  6  7  
not at all         somewhat                  very  
   true              true               true  
 
Question: Likert Scale 
Number 
I feel confident in my ability to complete IMT regularly.  
I now feel capable of completing IMT regularly.  
I am able to complete IMT regularly over the long term.  









BREQ - Physical activity among school age children.  
Why are you active?  
Boys and girls can be active by doing all sorts of things:  
• Exercise (walking, keep fit, gym)  
• Playing out, doing active things (like playing in the park)  
• Sports (like football, tennis, netball, swimming)  
The following pages have some reasons why you might be active.   
Please Highlight the Relevant Box 
I am active because...     
1.  
being active is fun  
Not true 








for me  
Very true 
for me  
2.  
it is important to me to do active 
things  
Not true 








for me  
Very true 
for me  
3.  
when I’m not active I feel bad  
Not true 








for me  
Very true 
for me  
4.  
other people say I should be  
Not true 








for me  
Very true 
for me  
5.  
I enjoy being active  
Not true 








for me  
Very true 
for me  
6.  
I value the benefits of being 
active  
Not true 








for me  
Very true 
for me  
7.  when I don’t do activity I feel 
bad about myself  
Not true 








for me  
Very true 
for me  
8.  if I’m not, other people will not 
be pleased with me  
Not true 








for me  
Very true 
for me  
9.  
I like being active  
Not true 








for me  
Very true 




in life it is important to be active  
Not true 








for me  
Very true 
for me  
11 . I want to show other people how 
good I am  
Not true 








for me  
Very true 
for me  
12 . 
other people pressure me to be 
active  
Not true 








for me  
Very true 





The next section has some sentences describing how people feel about BEING 
ACTIVE and DOING ACTIVE THINGS (like active games, playing out and doing 
sports).  Please read each sentence and tell us how like you each one is.   
 
25.  When it comes to being 







like me  
Sometimes 





like me  
15.  I can decide which 
activities and sports I 
want to do.  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
16.  I have a say in what 
activities and sports that I 
want to do  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
17.  I feel I am active because I 
want to be  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
18.  
I have to force myself to 
be active  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
19.  
I feel free when I’m active  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
20.  I have some choice in 
what activity and sport I 
want to do  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
21.  When it comes to playing 
active games, I think I am 
pretty good.  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
22.  I think I do well compared 
to other children  
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
23.  After working at a new 
activity for a while, I feel 




at all  
Not 
really 
like me  
Sometimes 





like me  
24.  I am happy with how 
good I am at doing active 
games.   
Not 
like me 
at all  
Not 
really 
like me  
Sometimes 





like me  
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26.  I can’t do physical 







like me  
Sometimes 





like me  
 
27.  I am included by others in 







like me  
Sometimes 





like me  
28.  








like me  
Sometimes 





like me  
29.  







like me  
Sometimes 





like me  
30.  Other children want me to 







like me  
Sometimes 





like me  
31.  








like me  
Sometimes 





like me  
32.  







like me  
Sometimes 









Perceived Competence (Exercising Regularly/Modified for IMT) Please indicate the 
extent to which each statement is true for you, assuming that you were intending 
either to begin now a permanent regimen of exercising regularly or to permanently 
maintain your regular exercise regimen.  
 
In answering the questions, please use the following scale:  
       1         2   3  4  5  6  7  
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not at all         somewhat                  very  
   true              true               true  
 
Question Likert Scale 
Number 
I feel confident in my ability to complete IMT regularly.  
I now feel able to complete IMT regularly.  
I am able to complete IMT regularly over the long term.  

























Cystic Fibrosis Questionnaire Revised – Children Ages 6 to 11 (Interviewer Format) 
 
This questionnaire is formatted for use by an interviewer.  Please use this format for 
younger children. For older children who seem able to read and answer the 
questions on their own, such as 12 and 13 year olds, use this questionnaire in its 
self-report format.    
  
There are directions for the interviewer for each section of the questionnaire.  
Directions that you should read to the child are indicated by quotation marks.  
Directions that you are to follow are underlined and set in italics.  
 
Interviewer:  Please ask the following questions  
A. What is your date of birth?  
Date  
   Day  Month  Year  
  
B. Are you?  
    
 Male  Female  
  
C. During the past two weeks, have you been on holiday or out of school for reasons NOT 
related to your health?  
    
 Yes  No  
  
D. Which of the following best describes your racial background?   
 White - UK  
 White - other  
 Indian/ Pakistani  
 Chinese/ Asian  
 African  
 Caribbean  
 Other [not represented above or people whose predominant origin cannot be determined/ 
mixed race]  
 Prefer not to answer this question  
 
What year are you in now at school?  
     (If summer, year you just finished)  
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 Reception  
 Year 1  
 Year 2  
 Year 3  
 Year 4  
 Year 5   
 Year 6  
 Year 7   
Interviewer: Please read the following to the child: “These questions are for 
children like you who have cystic fibrosis.  Your answers will help us 
understand what this disease is like and how your treatments help you.  So, 
answering these questions will help you and others like you in the future.” 
"For each question that I ask, choose one of the answers on the cards I’m 
about to show you."  Present the orange card to the child. "Look at this card 
and read with me what it says: very true, mostly true, somewhat true, not 
at all true." "Here’s an example:  If I asked you if it is very true, mostly true, 
somewhat true, not at all true that elephants can fly, which one of the four 
answers on the card would you choose?" Present the blue card to the child. 
"Now, look at this card and read with me what it says: always / often / 
sometimes / never." "Here’s another example:  If I asked you if you go to 
the moon always, often, sometimes, or never, which answer on the card 
would you choose?" Present the orange card to the child. "Now, I will ask 
you some questions about your everyday life." "Tell me if you find the 
statements I read to you to be very true, mostly true, somewhat true, or not 











Please tick the box indicating the child's response.  







all True  
  1. You were able to walk as fast as others ...........................................   
        
  2. You were able to climb stairs as fast as others ................................           
  3. You were able to run, jump, and climb as you wanted ...................           
4. You were able to run as quickly and for as long as others ..............   
5. You were able to participate in sports that you enjoy (e.g.,  
        
swimming, football, dancing or others) ...........................................   
  6. You had difficulty carrying or lifting heavy things such as books,  
        














20. You got together with friends a lot ................................................           
21. You stayed at home more than you wanted to ...............................           
22. You felt comfortable sleeping away from home (at a friend or 
family member’s house or elsewhere) ...........................................           
Children Ages 6 to 11 (Interviewer Format)  
   








all True  
23. You felt left out ..............................................................................           
24. You often invited friends to your house ........................................           
25. You were teased by other children ................................................           
26. You felt comfortable discussing your illness with others (friends, 
teachers) .........................................................................................   
        
27. You thought you were too short ....................................................           
28. You thought you were too thin ......................................................           
29. You thought you were physically different from others your age .           
30. Doing your treatments bothered you .............................................   
  
Interviewer: Present the blue card to the child again  
    Please tick the box indicating the child's response.  
  
        
 
Interviewer:   Present the blue card to the child.    
Please tick the box indicating the child's response.  
“And during these past two weeks, tell me how often”:  Always  Often  Sometimes  Never  
  7. You felt tired ..................................................................................           
  8. You felt mad ..................................................................................           
  9. You felt grouchy ............................................................................           
10. You felt worried .............................................................................           
11. You felt sad ....................................................................................           
12. You had trouble falling asleep .......................................................           
13. You had bad dreams or nightmares ...............................................           
14. You felt good about yourself .........................................................           
15. You had trouble eating ...................................................................           
16. You had to stop fun activities to do your treatments .....................           
17. You were forced to eat ...................................................................   
        
Interviewer:   Present the orange card to the child.  
"Now tell me if you find the statements I read to you to be very true, mostly true, somewhat 
true, or not at all true."  
Please tick the box indicating the child's response.  








all True  
18. You were able to do all of your treatments ....................................           


















20. You got together with friends a lot ................................................           
21. You stayed at home more than you wanted to ...............................           
22. You felt comfortable sleeping away from home (at a friend or 
family member’s house or elsewhere) ...........................................           
Children Ages 6 to 11 (Interviewer Format)  
   








all True  
23. You felt left out ..............................................................................           
24. You often invited friends to your house ........................................           
25. You were teased by other children ................................................           
26. You felt comfortable discussing your illness with others (friends, 
teachers) .........................................................................................   
        
27. You thought you were too short ....................................................           
28. You thought you were too thin ......................................................           
29. You thought you were physically different from others your age .           
30. Doing your treatments bothered you .............................................   
  
Interviewer: Present the blue card to the child again  
    Please tick the box indicating the child's response.  
  
        
 
“Tell me how often in the past two weeks”:   Always  Often  Sometimes  Never  
31.  You coughed during the day .................................................................        
32.  You woke up during the night because you were coughing .................        
33.  You had to cough up mucus ..................................................................        
34.  You had trouble breathing ....................................................................        
35.  Your stomach hurt.................................................................................    
    
  
Please make sure all the questions have been answered.  
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Cystic Fibrosis Questionnaire Revised – Children Ages 12 to 13 (Self Report Form) 
 
These questions are for children like you who have cystic fibrosis. Your answers will 
help us understand what this disease is like and how your treatments help you. So, 
answering these questions will help you and others like you in the future.  
  
Please answer all the questions. There are no right or wrong answers! If you are not 
sure how to answer, choose the response that seems closest to your situation.  
 
A. What is your date of birth?  
Date  
   Day  Month  Year  
  
B. Are you?  
    
 Male  Female  
  
C. During the past two weeks, have you been on holiday or out of school for reasons NOT 
related to your health?  
    
 Yes  No  
  
D. Which of the following best describes your racial background?   
 White - UK  
 White - other  
 Indian/ Pakistani  
 Chinese/ Asian  
 African  
 Caribbean  
 Other [not represented above or people whose predominant origin cannot be determined/ 
mixed race]  
 Prefer not to answer this question  
 
E.What year are you now in school? 
 Not in school 
 Year 6  
 Year 7  
 Year 8  
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 Year 9  
 Year 10   

















Please tick the box matching your response.  







all True  
  1. You were able to walk as fast as others ................................................................ 
        
  2. You were able to climb stairs as fast as others .....................................................         
  3. You were able to run, jump, and climb as you wanted .........................................         
  4. You were able to run as quickly and for as long as others ...................................   
5. You were able to participate in sports that you enjoy (e.g., swimming, football,  
        
dancing or others) ................................................................................................. 
  6. You had difficulty carrying or lifting heavy things such as books, your school  
        
bag, or a rucksack .......................................................................................... ....... 
Please tick the box matching your response.  
        
 And during these past two weeks, indicate how often:  
Always  Often  Sometimes  Never  
  7. You felt tired ................................................................................. ......................   
        
  8. You felt mad ......................................................................................................           






Please tick the box matching your response.  
And during these past two weeks, indicate how often:  
  Always  Often  Sometimes  Never  
16. You had to stop fun activities to do your treatments 
.........................................   
        
17. You were forced to eat 
.......................................................................................   
Please tick the box matching your response.  
        










18. You were able to do all of your treatments 
........................................................           
19. You enjoyed eating 
............................................................................................   
        
20. You got together with friends a lot 
....................................................................   
        
21. You stayed at home more than you wanted to 
...................................................           
22. You felt comfortable sleeping away from home (at a 
friend or family member’s house or elsewhere) 
..........................................................................   
        
23. You felt left out 
..................................................................................................   
        
10. You felt worried 
..................................................................................................   
        
11. You felt sad 
........................................................................................................   
        
12. You had trouble falling asleep 
...........................................................................           
13. You had bad dreams or nightmares 
...................................................................   
        
14. You felt good about yourself 
.............................................................................   
        
15. You had trouble eating 





Please tick the box matching your response.  
Let us know how often in the past two weeks:  Always  Often 
 Sometimes  
Never  
31.  You coughed during the day 
........................................................................................                  
32.  You woke up during the night because you were coughing 
........................................  
           
33.  You had to cough up mucus 
........................................................................................                 
34.  You had trouble breathing 
...........................................................................................  
                
35.  Your stomach hurt 
.......................................................................................................                  
  









24. You often invited friends to your house ............................................................           
25. You were teased by other children ....................................................................           
26. You felt comfortable discussing your illness with others (friends, teachers)          
27. You thought you were too short ........................................................................           
28. You thought you were too thin ..........................................................................           
29. You thought you were physically different from others your age .....................           
30. Doing your treatments bothered you .................................................................   





Cystic Fibrosis Questionnaire Revised – Adolescents and Adults (Patients 14 Years 
Old and Older) 
 
Understanding the impact of your illness and treatments on your everyday life can 
help your healthcare team keep track of your health and adjust your treatments.  
For this reason, this questionnaire was specifically developed for people who have 
cystic fibrosis.  Thank you for your willingness to complete this form.  
  
Instructions: The following questions are about the current state of your health, as 
you perceive it.  This  
 information will allow us to better understand how you feel in your everyday life.   
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Please answer all the questions. There are no right or wrong answers! If you are not 
sure how to answer, choose the response that seems closest to your situation.  
 
A. What is your date of birth?  
Date  
   Day 
 Month  Year  
B. What is your gender?  
 Male  Female  
C. During the past two weeks, have you been on holiday or 
out of school or work for reasons NOT related to your 
health?  
    
 Yes  No  
D. What is your current marital status?  
 Single/never married  
 Married  
 Widowed  
 Divorced  
 Separated  
 Remarried   
 With a partner  
E. Which of the following best describes your racial 
background?  
 White - UK  
 White - other  
 Indian/ Pakistani  
 Chinese/ Asian  
 African  
 Caribbean  
 Other [not represented above or people whose 
predominant origin cannot be determined/ mixed 
race]  
 Prefer not to answer this question  
F. What is the highest level of education you have        
completed?  
 Some secondary school or less  
 GCSEs/ O-levels  
 A/AS-levels  
 Other higher education  
 University degree  
 Professional qualification or post-graduate 
study   
  
  
G. Which of the following best describes your current work 
or school status?  
 Attending school outside the home  
 Taking educational courses at home  
 Seeking work   
 Working full or part time (either outside the 
home or at a home-based business)  
 Full time homemaker  
 Not attending school or working due to my 
health   
 Not working for other reasons  















Section II. Quality of Life  
 Please tick the box indicating your answer.  
  
During the past two weeks, to what extent have you had difficulty:  







 difficulty  
  1.  Performing vigorous activities such as running or playing sports .....................           
  2.  Walking as fast as others ...................................................................................           
  3.  Carrying or lifting heavy things such as books, shopping, or school bags ........           
  4.  Climbing one flight of stairs ..............................................................................           
  5.  Climbing stairs as fast as others .........................................................................   
  
        
During the past two weeks, indicate how often:  Always  Often  Sometimes Never  
  6.  You felt well .......................................................................................................          
  7.  You felt worried ..................................................................................................          
  8.  You felt useless ...................................................................................................          
  9.  You felt tired ............................................................................................... ........          
10. You felt full of energy .........................................................................................          
11. You felt exhausted .............................................................................. ................          
12. You felt sad .........................................................................................................          
 
Thinking about the state of your health over the last two weeks:      
13. To what extent do you have difficulty walking?  
1. You can walk a long time without getting tired  
2. You can walk a long time but you get tired  
3. You cannot walk a long time because you get tired quickly  
4. You avoid walking whenever possible because it’s too tiring for you  
14. How do you feel about eating?  
1. Just thinking about food makes you feel sick  
2. You never enjoy eating  
3. You are sometimes able to enjoy eating  
4. You are always able to enjoy eating  
15. To what extent do your treatments make your daily life more difficult?    
1. Not at all  
2. A little  
3. Moderately  
4. A lot  
 16. How much time do you currently spend each day on your treatments?  
1. A lot  
2. Some  
3. A little  
4. Not very much  
17. How difficult is it for you to do your treatments (including medications) each day?  
a. Not at all  
b. A little  
c. Moderately  
d. Very  
18. How do you think your health is now?  
a. Excellent  
b. Good  
c. Fair  











Please select a box indicating your answer.  
Thinking about your health during the past two weeks, indicate the extent 
to which each sentence is true or false for you.  
Very  Somewhat 





19.  I have trouble recovering after physical effort ......................................................          
20.  I have to limit vigorous activities such as running or playing sports ....................         
21.  I have to force myself to eat ..................................................................................         
22. I have to stay at home more than I want to ............................................................         
23. I feel comfortable discussing my illness with others .............................................         
24.  I think I am too thin ..............................................................................................         
25.  I think I look different from others my age ...........................................................         
26.  I feel bad about my physical appearance ..............................................................         
27.  People are afraid that I may be contagious ...........................................................         
28.  I get together with my friends a lot .......................................................................         
29.  I think my coughing bothers others ......................................................................         
30.  I feel comfortable going out at night.....................................................................         
31.  I often feel lonely ..................................................................................................         
32. I feel healthy .........................................................................................................  
33. It is difficult to make plans for the future (for example, going to college, getting  
















  Section III. School, Work, or Daily Activities  
 
  
Questions 35 to 38 are about school, work, or other daily tasks.  
35. To what extent did you have trouble keeping up with your schoolwork, professional work, or other daily activities during the 
past two weeks?   
1. You have had no trouble keeping up  
2. You have managed to keep up but it’s been difficult  
3. You have been behind  
4. You have not been able to do these activities at all  
36. How often were you absent from school, work, or unable to complete daily activities during the last two weeks because of 
your illness or treatments?  
              Always        Often                     Sometimes                   Never          
37. How often does CF get in the way of meeting your school, work, or personal goals?  
                   Always               Often                 Sometimes          Never        
38. How often does CF interfere with getting out of the house to run errands such as shopping or going to the bank?  





















Section IV. Symptom Difficulties  
  
 Please select a box indicating your answer.  
Indicate how you have been feeling during the past two weeks.   A great deal Somewhat  A little  Not at all  
39. Have you had trouble gaining weight? ......................................................          
40. Have you been congested? ........................................................................          
41. Have you been coughing during the day? .................................................          
42. Have you had to cough up mucus? ............................................................         
        Go to  
Question 
44 43.  Has your mucus been mostly:    Clear   Clear to yellow   Yellowish-green   Green with traces of blood    Don't 
know  
    
How often during the past two weeks:  Always  Often  Sometimes  Never  
44.  Have you been wheezing? .........................................................................         
45.  Have you had trouble breathing? ...............................................................         
46.  Have you woken up during the night because you were coughing? ..........         
47.  Have you had problems with wind? ..........................................................         
48.  Have you had diarrhoea? ...........................................................................         
49.  Have you had abdominal pain? ..................................................................         
50.  Have you had eating problems? .................................................................         
Please make sure you have answered all the questions.   
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Applied Sports Technology Exercise and Medicine Research Centre 
(A-STEM) 
Sport and Health Portfolio, College of Engineering 
Interview Questions – Study 3 
Version 1.1 
 
   
Thank you for agreeing to talk to me. Today we are going to have a chat about your 
thoughts and feelings on completing the four week programme with the 
Powerbreathe training device (show device). In this interview remember, there is no 
right or wrong answer and if you are confused or don’t understand the question just 
let me know. I have a terrible memory so I am going to record our interview so I can 
listen to it again later. Are you happy to go ahead?   
   
1. What do you think physical activity is?   
Follow-Up – What are your thoughts about doing that physical 
activity/exercise?   
Can you talk me through how much exercise you do weekly? 
(before School, after school, P.E. classes, weekends, clubs, how 
they get to school)   
 What do you like/not like about doing exercise?                          
             Think back to when you’re (insert example they have previously 
listed above), how do you feel during and after it?  
Both physically and mentally  
   
2. What do you think this is (show training device)?  
Follow-Up – Can you tell me how it works?   
How did you find using the device?   
            Where did you use it? (What did you like/dislike about using it there?) Places  
What did you like/not like about using the device?                     
       
   
3. How did you feel before starting your 30 breaths? How did it 
make you feel in the middle? How did you feel at the end of 
your 30 breaths?   
Follow-Up – How did your lungs feel during the training?   
                      How did you feel after finishing the exercise?   
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                      How did your lungs feel after finishing 
                      the 4 weeks of training?                 
   
4. Now I’m going to ask you about the training programme. 
Describe to me the steps you went through to complete the 
training programme?   
Follow-Up – Describe to me when in your day you completed 
                      your training?   
                      What made it easy/difficult to do the training 
                      programme?   
                      What changes, if any, did you notice if you didn’t 
                    do, the training?    
                    How did you find the length of the training 
                    programme?   
                    If you could suggest something to change, what 
                    would it be?    
 
5. Can you describe to me how you feel the Powerbreathe has 
changed how you are able to exercise?   
Follow –Up – How has the training programme effected your daily life?    
                     
6. What are your opinions on exercise now you have finished the 
programme?  
Follow-Up – How do you think the physical activity you do now has changed 
compared to/is different to before the programme?   
                      When training was completed after 4 weeks, how 
                      did this make you feel?   
  
7. Overall, what did you think of the training programme?   
Follow-Up – How do you think you’d react if you were asked to do this training 
programme again?   
   
8. Any other comments?   




Applied Sports Technology Exercise and Medicine Research Centre 
(A-STEM) 
Sport and Health Portfolio, College of Engineering 
Interview Questions 
25/05/2016 – Version 1.2 Study 4 & 5 
N.B. child version in orange 
Pre-Intervention 
*What are your opinions on doing physical activity/exercise? 
 *Do you enjoy doing physical activity – why/why not? 
 *Do you enjoy exercise – why/why not? 
(Physical Activity – anybody movement that works your muscles and requires more 
energy than resting (i.e. housework, dog walking, swimming, dancing) 
(Exercise – planned, structured and repetitive with the objective of improving or 
maintaining fitness (i.e. gym work, cycling, running) 
*What do you think about doing physical activity/exercise? 
 *What do you like about doing physical activity/exercise? 
 *What do you dislike about doing physical activity/exercise? 
*Why do you/do you not exercise? 
*What encourages you to exercise? 
*What prevents you from exercising? 
*Is exercising important to you? 
 *Why/Why not? 
*How much physical activity do you do in a week? (active job?) 
 * Broken down to - Before school, during school, P.E. lessons, after school, 
   weekends, clubs? 
*Think back to when you’re (insert example they have previously listed above), how 
do you feel during it? 
 *How do you feel before it? Why? 
 *How do you feel after it? Why? 
 *Is this always the same? Different? Why? 
 
During the Intervention 
 
< IMT Device and App > 
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*How did you find setting up the device with the app? 
           *Did you do this on your own, or did you have help? 
*What are your opinions on the app? 
            *How did you find using the app (easy/hard)? 
            *What are your opinions on the design/layout? 
            *What did you like/dislike about the colours and graphs on the app?  
 *What do you think about the feedback that the app provided? 
           *How well did you understand the information you got? 
           *How useful did you find it? 
           *How did it make you feel? 
          *How did it make you behave? 
<IMT Device> 
*What are your opinions on the IMT device 
            *What did you like about using it? Why? 
            *What did you dislike about using it? Why? 
*How did you find its usability?  
*How did you find using it, was it easy/hard? Why? 
*Where did you use it? 
           *What did you like about using it there? 
        *What did you dislike about using it there? 
        * What are your pros and cons of using it? 
 
<Exercise Programme> 
*How did you feel (physically, emotionally, mentally) before you began the 
training?  
*How did you feel (body, describe feelings, what were you thinking) before you 
began training 
       *How did you feel (physically, emotionally, mentally) during the training? 
       *How did you feel (body, describe feelings, what were you thinking) during the 
training? 
       *How did you feel (physically, emotionally, mentally) finishing the exercise 
session? 
      * How did you feel (body, describe feelings, what were you thinking) finishing 
the 
         exercise? 
      *Was it all of the exercise programme/ Just part of it/ which part? 
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     * Was there any changes in these feelings across time/ across the exercise? 
Why? 
*How did your lungs feel after finishing the 8 weeks of training, compared to the 
first week? 
*What was the highest level you got to? 
      *What did you think about the different levels? Why? 
      *What did you think about the decreasing rest times? 
      * How did you react? How did they make you feel? – Were there any changes? 
*When did you complete your training? 
      *What made it easy/difficult to do the training? 
      *What changes, if any, did you notice if you didn’t do the training? Good? Bad? 
Why? 
     *How did you find the length of the exercise session? 
 
<Top Up> 
*Why did you decide to continue training? 
More effect further tests effect 
*Did anyone influence your decision to continue?  
        *What did they say/do that influenced you? 
*What changes (physically) if any, did you notice when training decreased to once a 
week? 
*What changes, if any, did you observe from ending the first 8 weeks to the end of 
the top-up period? 
<Detraining> 
*Why did you decide to stop training?  
*Did anyone influence your decision to stop? 
          *What they say/do that influence you? 
*What changes (physically), if any, did you notice from the end of the 8 week of 
training to the 8 weeks of no training? 
*If you were given the option again, would you take the top-up period or would you 
stick with the detraining? Why? 
 
Post Intervention Reflections and Recommendations 
 
< Intervention > 
*What changes, if any, would you make to the design/layout of the app. Why? 
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               *What other feedback, if any, would you like to receive? 
*What changes, if any, would you make to the IMT device? Why? 
*What changes, if any, would you make to the IMT programme? Why? 
*What would have made you complete more of the exercise sessions? (If 
adherence was poor). What were the specific reasons for not completing the 
exercise on those days? 
*What would have made you do more training? 
*How has the training changed the way you are able to exercise? In what way? 
               *How the training effected your daily life? If so, can you explain how? 
*What are your opinions on the exercise now you have finished the programme? 
              *Has the amount of exercise you do now changed compared to before the 
programme? In what way. Why? If not any reason? 
*How did you feel when training was completed? Why? 
*How would you feel if you were asked to do this training programme again? 
*Would you like IMT to integrated into your treatment regime and why?  
*Would you like to continue doing more IMT and why? 



















Physical Activity and Sleep Logs 
 
 
Physical Activity Log - Child 
 
Activity – Tell us what type of activity you did on that day e.g. walking the dog, PE 
lesson, football practice. 
Length – Tell us how long you spent doing the activity e.g. 30 minutes 
Monitor – If you had to remove your monitor for anything e.g. water based 
activities, contact sports, please record how long you had your monitor off for. 
Sleep - Tell us time you went to bed, time you woke up and how long you slept for  
*Don’t forget to fill it in everyday and every week * 
 
Please Return Monitors To: 
Jessica McCreery 
Swansea University Bay Campus 

































       
  
 

























Physical Activity Log - Adults 
 
Activity – Tell us what type of activity you did on that day e.g. walking the dog, gym 
work (strength, cardio) football practice. 
Length – Tell us how long you spent doing the activity e.g. 30 minutes 
Monitor – If you had to remove your monitor for anything e.g. water-based 
activities, contact sports, please record how long you had your monitor off for. 
Sleep - Tell us time you went to bed, time you woke up and how long you slept for 
 
*Don’t forget to fill it in everyday and every week * 
 
Please Return Monitors To: 
Jessica McCreery 
Swansea University Bay Campus 














































Sleep Log-Adults (Week 1 Only) 
 














       
 
 
 
